WO2015124138A1 - Tumour-associated antigens and gene products in diagnosis and treatment - Google Patents

Tumour-associated antigens and gene products in diagnosis and treatment Download PDF

Info

Publication number
WO2015124138A1
WO2015124138A1 PCT/DE2015/000077 DE2015000077W WO2015124138A1 WO 2015124138 A1 WO2015124138 A1 WO 2015124138A1 DE 2015000077 W DE2015000077 W DE 2015000077W WO 2015124138 A1 WO2015124138 A1 WO 2015124138A1
Authority
WO
WIPO (PCT)
Prior art keywords
expression
nucleic acid
tumor
agent
tumors
Prior art date
Application number
PCT/DE2015/000077
Other languages
German (de)
French (fr)
Inventor
Dominik Kraus
Rainer Probstmeier
Jochen Winter
Original Assignee
Rheinische Friedrich-Wilhelms-Universität Bonn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102014002256.0A external-priority patent/DE102014002256A1/en
Priority claimed from DE102014011258.6A external-priority patent/DE102014011258A1/en
Application filed by Rheinische Friedrich-Wilhelms-Universität Bonn filed Critical Rheinische Friedrich-Wilhelms-Universität Bonn
Publication of WO2015124138A1 publication Critical patent/WO2015124138A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising an agent which detects or inhibits the expression or activity of a tumor-associated antigen, and a method for the treatment and diagnosis of a tumor disease.
  • tumor cells differ biologically significantly from their non-malignant cells of origin.
  • tumor development can be attributed to the formation of qualitatively or quantitatively altered molecular structures in the cancer cells.
  • tumor-associated antigens stems from the fact that the recognition of antigens on cells that promote neoplasm of tumors can cause the elimination of cancer cells by the immune system. Accordingly, a central goal of tumor immunology is to define these structures molecularly. The molecular structure of many antigens has long been unrecognized. Only after the development of suitable cloning techniques, such as cDNA expression libraries of tumors, was it possible to systematically identify tumor-associated antigens by analysis of the target structures. For this purpose, cDNA expression libraries were prepared from fresh tumor tissue and expressed recombinantly as proteins.
  • Elimination (as part of therapeutic procedures) of tumor cells allows. This task is therapeutically by a pharmaceutical
  • a composition for inhibiting or inhibiting expression of a tumor-associated antigen wherein the tumor-associated antigen has a sequence selected from a nucleic acid selected from the group consisting of:
  • nucleic acid comprising a nucleic acid sequence derived from the
  • nucleic acid which can be added to the nucleic acid under (a), (b) or (c)
  • tissue areas such as in the intestinal, Lung, kidney, bladder, gastrointestinal, skin, brain, bone, breast,
  • Thyroid, ovarian, pancreatic, prostate, liver, lymphatic tissue Thyroid, ovarian, pancreatic, prostate, liver, lymphatic tissue.
  • these genes can activate tumor cells and, in addition, tumor growth in other tissues.
  • the invention relates to the possibility of identifying
  • the tumor-associated antigens identified according to the invention relate in particular to acrosin, ACRBP, CATSPER1, CATSPER2, CATSPER4, CATSPERB, CATSPERD, CATSPERG, CRISP3, FER1 L5, FER1 L6, FOLR4, GGN, GGNBP2, IZUMO1, PSG1, PSG2, PSG5, ROPN1L, SPAG6 , SPAG8, SPAG17, CRISP1, CRISP2, DYSF, MMP15, MMP16, MMP17, MMP20, MYOF, OTOF, SED-1, ZAN, ZP1, ZP2, ZP3.
  • genes are described which are selectively expressed in tumor cells and represent tumor-associated antigens. These genes or their derivatives, in particular nucleic acids, are preferred targets for therapeutic
  • the therapeutic approaches may target an inhibition of the activity of the selectively expressed tumor-associated gene product.
  • a nucleic acid is preferably deoxyribonucleic acid (DNA) or ribonucleic acid (RNA).
  • Nucleic acids according to the invention comprise genomic DNA, cDNA, mRNA, recombinantly produced and chemically
  • a nucleic acid can be used according to the invention as
  • nucleic acid it is meant that single or multiple nucleotide substitution, deletion and / or addition are present in the nucleic acid.
  • the term comprises a chemical derivatization of a nucleic acid on a nucleotide base, on the sugar or on the phosphate.
  • derivative also includes nucleic acids containing non-naturally occurring nucleotides and nucleotide analogs.
  • isolated nucleic acid means according to the invention that the nucleic acid (i) has been amplified in vitro, for example by polymerase chain reaction (PCR), (ii) (iii) was purified, for example by cleavage and gel electrophoretic separation, or (iv) was synthesized, for example by chemical synthesis.
  • PCR polymerase chain reaction
  • isolated nucleic acid is one
  • a recombinant DNA molecule according to the invention is a vector, optionally with a promoter, which promotes the expression of a nucleic acid, e.g. a nucleic acid encoding an antigen associated with a tumor of the invention.
  • a promoter which promotes the expression of a nucleic acid, e.g. a nucleic acid encoding an antigen associated with a tumor of the invention.
  • vector is used in its most general meaning. Vectors are preferably replicated and / or expressed in the cell. Vectors include plasmids, phagemids or viral genomes.
  • RNA or of RNA and protein are used according to the invention in its most general meaning and includes the production of RNA or of RNA and protein.
  • antisense molecule or “antisense nucleic acid” as used in the invention refers to an oligonucleotide which is an oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide or modified oligodeoxyribonucleotide according to the invention
  • proteins and polypeptides described in this invention may be in a substantially purified state.
  • substantially purified means that the protein or polypeptide is substantially free of other substances present in nature or in vivo. Such proteins and polypeptides are used, for example, for the production of
  • Proteins and polypeptides described in accordance with the invention can be isolated from biological samples and can also be expressed recombinantly in a variety of pro- or eukaryotic expression systems.
  • the present invention relates in general to the use of tumor-associated antigens identified in accordance with the invention or of parts thereof, nucleic acids coding therefor or nucleic acids directed against the coding nucleic acids or of antibodies directed against the tumor-associated antigens identified in accordance with the invention or parts thereof are directed for therapy and diagnosis.
  • the usage can be single, but also combinations of several of these
  • Antigens, functional fragments, nucleic acids, antibodies, etc. in one embodiment, but also in combination with other tumor-associated genes and antigens for diagnosis, therapy and follow-up.
  • Preferred diseases for therapy and / or diagnosis are those in which there is a selective expression or also abnormal expression of one or more of the tumor-associated antigens identified according to the invention.
  • the invention also relates to nucleic acids and gene products which are expressed associated tumor cells and caused by altered processing, for example, in the transcription or translation of known genes.
  • nucleic acids comprise the sequences according to identification numbers corresponding to page "http://www.ncbi.nlm.nih.gov/nuccore/":
  • ACR Homo sapiens acrosin; NM_001097.2.
  • ACRBP Homo sapiens acrosin binding protein; NM_032489.2.
  • CATSPER1 Homo sapiens cation channel, sperm associated 1 1; NM_053054.
  • CATSPER2 Homo sapiens cation channel, sperm associated 2; NM_172095.2.
  • CATSPER4 Homo sapiens cation channel, sperm associated 4; NM_198137.1.
  • CATSPERB Homo sapiens catsper Channel auxiliary subunit beta; NM_024764.2.
  • CATSPERD Homo sapiens catsper Channel auxiliary subunit delta; NM_152784.3.
  • CATSPERG Homo sapiens catsper Channel auxiliary subunit gamma; NM_021185.4.
  • CRISP3 Homo sapiens cysteine-rich secretory protein 3; NM_001190986.1.
  • FER1 L5 Homo sapiens fer-1-like 5; NM_001113382.1.
  • FER1 L6 Homo sapiens fer-1 -like 6; NM_001039112.2.
  • FOLR4 Homo sapiens folate receptor 4, delta; NM_001199206.1
  • GGN Homo sapiens gametogenin
  • GGNBP2 Homo sapiens gametgenin binding protein 2; BC137491.1.
  • IZUM01 Homo sapiens izumo sperm-egg fusion 1; NM_182575.2
  • PSG1 Homo sapiens pregnancy specific beta-1-glycoprotein; NM_001184825.1
  • PSG2 Homo sapiens pregnancy specific beta-1-glycoprotein 2; NM_031246.3
  • PSG5 Homo sapiens pregnancy specific beta-1-glycoprotein 5; NM_002781.3
  • ROPN1 L Homo sapiens rhophilin associated tail protein 1 -like; NM_031916.4.
  • SPAG6 Homo sapiens sperm associated antigen 6; CR533552.1.
  • SPAG8 Homo sapiens sperm associated antigen 8; NM_172312.1.
  • SPAG17 Homo sapiens sperm associated antigen 17; NM_206996.2.
  • DYSF Homo sapiens dysferlin; GenBank: AF075575.1.
  • ZP1 Homo sapiens zona pellucida glycoprotein 1; NM_207341.2
  • ZP2 Homo sapiens zona pellucida glycoprotein 2; NM_003460.1.
  • ZP3 Homo sapiens zona pellucida glycoprotein 3; NM_007155.5 ..
  • MYOF Homo sapiens myoferlin (MYOF); GenBank: AF182316.1.
  • OTOF Homo sapiens otoferlin (OTOF); NM_004802.3.
  • MMP15 Homo sapiens matrix metallopeptidase 15; NM_002428.2.
  • MMP16 Homo sapiens matrix metalloproteinase 16; NM_005941.4 1.
  • MMP17 Homo sapiens matrix metalloproteinase 17; NM_016155.4.
  • MMP20 Homo sapiens matrix metalloproteinase 20; NM_004771.3.
  • SED1 secreted protein containing EGF repeats and discoidin / F5 / 8.
  • ZAN Homo sapiens zonadhesin variant 1 (ZAN); GenBank: AF332975.1
  • gene products comprise sequences according to (SEQ ID NO: 1 to 36) of the sequence listing.
  • the antigens are according to the invention as targets for the
  • a variety of mechanisms may be causative, such as the use of variable transcription sites, the use of additional exons, the mutation altered regulatory sequences or the
  • Proteins / antigens can act as molecular markers for both the detection of
  • Tumor cells are used as well as for the therapeutic targeting of tumors.
  • radioactive or non-radioactive isotopes, photosensitizers, nanoparticles, radionuclides, enzymes or antibodies can be used for the detection.
  • the diagnosis and / or treatment of tumor cells for example in blood, serum, bone marrow, sputum, bronchial lavage, elaboratesekreten and tissue biopsies can be carried out according to the invention, for example, after extraction of nucleic acids by PCR amplification.
  • all sequence-dependent are suitable
  • Detection systems In addition to the PCR, these are e.g. Microarray systems, Northern blot, RNAse protection assays (RDA) and others. All detection systems have in common that the detection on a specific hybridization with
  • tumor cells can also be carried out according to the invention by antibodies which recognize a coded specific epitope.
  • composition of the invention for inhibiting or inhibiting the expression of a tumor-associated antigen may further comprise an agent or agent which recognizes the tumor-associated antigen identified according to the invention and is preferably selective for cells having a
  • the agent may, in certain embodiments as a diagnostic or therapeutic agent, be the induction of cell death, the reduction of the
  • Cell growth causing damage to the cell membrane or the secretion of cytokines and preferably has a tumor-inhibiting activity.
  • the agent is an antisense nucleic acid that selectively hybridizes to the nucleic acid encoding the tumor-associated antigen.
  • the agent is an antibody that selectively binds to the tumor-associated antigen, in particular a complement-activating or toxin-conjugated antibody that selectively binds to the tumor-associated antigen.
  • an anti-cytokine antibody in particular an anti-cytokine antibody. It is also according to the invention.
  • the agent comprises a plurality of agents, each of which selectively recognizes different tumor-associated antigens, wherein at least one of the tumor-associated antigens according to the invention
  • the agent is an antisense nucleic acid that selectively hybridizes to the nucleic acid encoding the tumor-associated antigen.
  • the agent is an antibody that selectively binds to the tumor-associated antigen.
  • the agent comprises a plurality of agents each selectively inhibiting the expression or activity of various tumor-associated antigens, wherein at least one of the tumor-associated antigens comprises a tumor-associated antigen identified in accordance with the invention
  • Antigen is.
  • a monoclonal, a chimeric or humanized antibody, a fragment of a natural antibody, or a synthetic antibody can be used.
  • the antibodies may be coupled to a therapeutically or diagnostically useful agent.
  • Therapeutic agents may according to the invention taxines, alkylating agents, colchicines, vinca alkaloids such as vinblastine and vincristine, bleomycin,
  • Anticancer agents include anticancer agents, radioactive iodine-containing compounds, toxins, cytostatic or cytolytic drugs, etc.
  • aminoglutethimide for example, aminoglutethimide, azathioprine, bleomycin sulfate, busulfan, carmustine, chlorambucil, cisplatin, cyclophosphamide, cyclosporin, cytarabidine, dacarbazine, dactinomycin, daunorubin, doxorubicin, taxol, etoposide, fluorouracil, interferon- ⁇ , lomustine, mercaptopurine, methotrexate, mitotane, procarbazine HCI, thioguanine and high energy emitting radionuclides such as cobalt-60, as well as mixtures of these agents.
  • Diagnostic agents may include, but are not limited to, barium sulfate, locetamic acid, lopanoic acid, calcium ipodate, sodium diatrizoate, meglumine diatrizoate, metrizamide, sodium tylopanoate and radiodiagnostics for the
  • Computed tomography including positron emitters such as fluorine-18 and carbon-11, gamma emitters such as iodine-123, technitium-99m, iodine-131 and indium-111, Nuclides, in particular nanoparticles for nuclear magnetic resonance such as fluorine, gadolinium, iron oxide, etc. include.
  • An antisense nucleic acid contained in a pharmaceutical composition of the invention may comprise a sequence of 8-20 bases, preferably from the translated region of the transcript, with contiguous nucleotides from the nucleic acid encoding antigens associated with the invention identified according to the invention.
  • an ADCC-activating antibody or antibody will elicit further humoral or cellular immune responses
  • an anti-cytokine antibody either directly or through the
  • nucleic acid provided tumor-associated antigen on the surface of cells, wherein the binding preferably induces or prevents a cytokine secretion.
  • a pharmaceutical composition according to the invention can be a
  • Excipient may be selected from the group of saponin, GM-CSF, CpG nucleotides, RNA or a cytokine.
  • a pharmaceutical composition according to the invention is preferably used for the treatment of a disease, such as cancer, which is characterized by the selective expression or abnormal expression of a tumor-associated antigen.
  • a disease such as cancer
  • the term "disease” according to the invention relates to any pathological condition in which tumor-associated antigens are expressed or abnormally expressed.
  • cancer especially seminomas, melanomas, teratomas, gliomas, gastrointestinal, colorectal, pancreatic, cervical, nasal, ear (ENT), breast, prostate, uterine, ovarian and lung cancers, Seminomas, melanomas, teratomas, tumors of the nervous system (such as gliomas, meningiomas, neuroblastomas, medulloblastomas, schwannomas, neuroendocrine tumors), gastrointestinal, pancreatic, cervical, nasal, ear (ENT), bladder, breast, bone , Liver, kidney, prostate, uterus, ovarian, Pulmonary and thyroid tumors, lymphomas, as well as tumor types of the blood-forming system (leukemia, etc.).
  • the nervous system such as gliomas, meningiomas, neuroblastomas, medulloblastomas, schwannomas, neuroendocrine tumors
  • gastrointestinal, pancreatic, cervical, nasal, ear (ENT) bladder, breast,
  • the invention also relates to a method for the treatment or diagnosis of a disease characterized by the expression of one or more tumor-associated antigens, comprising the treatment of the administration of a disease
  • inventive pharmaceutical composition is provided.
  • the invention relates to a method for the treatment and / or diagnosis comprising a tumor disease
  • the antigen has a sequence selected from the group consisting of: a nucleic acid comprising a nucleic acid sequence derived from the
  • nucleic acid which under stringent conditions with the
  • nucleic acid which is degenerate with respect to the nucleic acid under (a) or (b), and
  • nucleic acid complementary to the nucleic acid of (a), (b) or (c),
  • Detecting the interaction of said agent with components of the sample comprising PCR, ELISA, Northern, Southern, Western blot, immunocytochemistry and immunohistology, MRI, CT, PET, LC / MS.
  • a biological sample is preferably isolated from patients who have or are suspected of having or are suspected to have cancer, the presence of the nucleic acid and / or the tumor-associated antigen and / or or a certain amount of a nucleic acid and / or of the tumor associated antigen, as an indication of a cancer or as a potential starting point for the development of cancer.
  • the method of diagnosis and / or treatment also includes the detection or determination of the amount of nucleic acid and / or the tumor-associated antigen. So it is possible to predict whether a metastasis of a
  • Cancer can be done. This is done by using PCR, ELISA, Northern, Southern, Western blotting, immunocytochemistry and immunohistology, MRI, CT, PET, LC / MS methods.
  • the detection of a nucleic acid using an oligo- or polynucleotide which hybridizes specifically to the nucleic acid carried out, wherein a selective amplification of the nucleic acid, for. B. by PCR amplification.
  • the method according to the invention relates to the treatment, diagnosis of a disease which is characterized by the expression of a tumor-associated antigen identified according to the invention, comprising the
  • RNA extraction From 500 ng total RNA was in a reaction mixture according to the
  • a first-strand cDNA synthesis was performed. Integrity and quality of the cDNA were checked by amplification in a 40-cycle PCR.
  • Hybridization temperatures were determined using the online tool "TM Calculator” (NEB) After 5 minutes at 95 ° C to activate the polymerase, 40 cycles of PCR (denaturation at 95 ° C for 15 s, hybridization temperature 65 ° C for 30 s and final elongation at 72 ° C for 30 sec.) 20 ⁇ of this reaction was separated on an ethidium bromide stained 2% agarose gel and analyzed.
  • Antisense 5 '-ATGGCCTGGGGGCTTTCTCTTC-3'
  • ACRBP Acrosine binding protein
  • Antisense 5 ' -GGAGCTCCTGCTGCTTCTCAGTC-3 ' cation channel, sperm associated 2 (CATSPER2):
  • Catsper Channel auxiliary subunit beta (CATSPERB):
  • Antisense 5 '-CTCCAGTTGACAGTAGCTGTAGTACGG-3'
  • Catsper Channel auxiliary subunit gamma (CATSPERG):
  • Cysteine-rich secretory protein 3 (CRISP3):
  • Fer-1-like 6 Fer-1 L6
  • Antisense 5 ' - ACAGTCTTCCCACCACTCCT -3 ' lzumo-1 (IZUM01)
  • Antisense 5 ' - GACCGTTAGGAAGGGTGCTC -3 '
  • PSG2 Pregnancy specific beta-1 glycoprotein 2
  • Antisense 5 -GTCTGGACCATAGAGGACATTCAGG-3 '
  • GGNBP2 Gametogenetin binding protein 2
  • ROPN1 L Rhophilin associated tail protein 1-like
  • Antisense 5 -TGG AGGTAACACCGGTATGTTCCC-3 '
  • Antisense 5 '-ACATCCAGGTCAGGCAGAGT-3' ZP 1 (zona pellucida glycoprotein 1)
  • Antisense 5 -G AAAGGGCATCCGTCTG ACA-3 '
  • ZP 2 (zona pellucida glycoprotein 2)
  • Antisense 5 ' -TTGGTTGGCGGAGGAATCTC-3 '
  • ZP 3 (Zona pellucida glycoprotein 3)
  • CRISP 1 Cysteine-rich secretory protein 1
  • CRISP 2 (Cysteine-rich secretory protein 2)
  • Antisense 5 -CAGGTCCTTCAGGGCTACAG-3 ' OTOF (Otoferlin)
  • SED-1 secreted protein containing EGF repeats
  • MMP 15 matrix metallopeptidase 15
  • Antisense 5 ' -TGCTCCCACACGCGGAAGGC-3 '
  • MMP 16 matrix metallopeptidase 16
  • MMP 17 matrix metallopeptidase 17
  • Antisense 5 -ACCAGCGCATGGCGTCGTCC-3 ' MMP 20 (matrix metallopeptidase 20)
  • Antisense 5 -TTAGCAACCAATCCAGGAACTAGAT-3 '
  • HL60 Birnia GD.
  • the HL60 cell line a model for human myeloid cell differentiation.
  • A549 Watanabe T, Miura T, Degawa Y, Fujita Y, Inoue M, Kawaguchi M, Furihata C. Comparison of lung cancer cell lines versus four histopathological subtypes with gene expression profiling using quantitative real-time PCR. Cancer Cell Int. 2010; 10: 2nd doi: 10.1186 / 1475-2867-10-2 .; BHY, MG63, SaOS-2, SW-872, MCF7, PC3 (Cell Line Service, Eppelheim, Germany), HN (DSMZ, Braunschweig, Germany).
  • cDNA was amplified with a gene-specific primer pairs in RT-PCR analyzes in the following cell lines: A 172, SKMG5, U87, U251, U373, TC620, MG63, SaOS-2, SW-872, B-CPAP, A549, BHY , GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60.
  • RT-PCR analyzes of tumor antigens were carried out, the names of the tumor antigens being abbreviated to the left of the gel traces (see Fig. 1).
  • Example 1 Identification of Acrosine (ACR) as a Diagnostic and Therapeutic Target
  • ACR is the major protease in the acrosome of sperm. It causes lysis of the zona pellucida of the egg.
  • the sequence is published in the gene database under accession number NM_001097.2.
  • Acrosin has a molecular weight of 46 kD as preproprotein. In tumors so far no expression has been described.
  • ACR transcripts can be used according to the invention as target structures (targets) of antibodies. These antibodies, monoclonal or too
  • Tumor cells can be used for both diagnostic and therapeutic procedures.
  • the protein coding sequences can be used to induce tumor-specific immune responses (T cell and B cell mediated immune responses).
  • T cell and B cell mediated immune responses can be used to induce tumor-specific immune responses.
  • the invention according to the cellular function of the ACR molecule, it is possible to develop substances, in particular smaller molecules, which inhibit or modulate the function of ACR on tumor cells.
  • the gene product according to the invention is suitable as a target for diagnosis and therapy.
  • the sequence of the acrosin binding protein is in the Genbank under the
  • ACRBP is a protein with a molecular weight of approximately 59 kDa that is expressed in the acrosome of the testis. Expression in bladder, breast, lung, liver and colon tumors has been demonstrated (Ono T, Kurashige T, Harada N, Noguchi Y, Saika T, Nikamawa N, Aoe M, Nakamura S, Higashi T, Hiraki A, Wada H, Kumon H, Old LJ, Nakayama E. Identification of proacrosin binding protein sp32 precursor as a human cancer / testis antigen. Proc Natl Acad See USA 2001 Mar 13; 98 (6): 3282-7).
  • RT-PCR studies with an ACRBP-specific primer pair in Figure 1 show an expression of ACRBP in the following cell lines: A 172, U87-MG, U251, TC620, MG63, SW-872, B-CPAP, A549, GLC-2 , HN, HeLa, HT29, MCF7, PC3, HL60.
  • the expected PCR product is 270 bp long.
  • the gene product according to the invention is suitable as a target for diagnosis and therapy.
  • CATSPER1 is a membrane protein of molecular weight 90 kDa expressed in flagella of spermatozoa. Expression in tumors is not known (Ren D, Navarro B, Perez G, Jackson AC, Hsu S, Shi Q, Tilly JL, Clapham DE, Sperm ion Channel required for sperm motility and male fertility, Nature, 2001 Oct 11; 413 (6856): 603-9).
  • RT-PCR analysis in Fig. 1 with a CATSPER1-specific primer pair confirms expression in the following cell lines (245 bp expected fragment length): A 172, SKMG5, U87-MG, U251, U373, TC620, MG63, SW-872, B CPAP, A549, BHY, GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60.
  • Example 4 Identification of CATSPER2 as a Diagnostic and Therapeutic Target
  • CATSPER2 is published in GenBank under accession number NM_172095.2.
  • CATSPER2 is a membrane protein with a molecular weight of 62 kDa expressed in flagella of spermatozoa. Expression in tumors is not known (Quill TA, Ren D, Clapham DE, Garber's DL, A voltage-gated ionic channel, specifically in spermatozoa.) Proc Natt Acad See USA 2001 Oct 23; 98 (22): 12527-31 ,
  • RT-PCR assay in Fig. 1 with a specific primer pair confirms expression in the following cell lines (expected fragment length 270 base pairs): A172, SKMG5, U87-MG, U251, U373, TC620, MG63, SW-872, B-CPAP , BHY, GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60.
  • the gene product according to the invention is suitable as a target for diagnosis and therapy.
  • CATSPER4 is a membrane protein with a molecular weight of 54 kDa that is expressed exclusively in spermatozoa. Expression in tumors is not yet known (Lobley A, Pierron V, Reynolds L, Allen L, Michalovich D. Identification of human and mouse CatSper3 and CatSper4 genes: characterization of a common interaction domain and evidence for expression in testis Reprod Biol Endocrino 2003; 1: 53)
  • CATSPERB is published in the GenBank under the accession number v NM_024764.2.
  • CATSPERB is a membrane protein of molecular weight 125 kDa expressed in flagella of spermatozoa. Expression in tumors is not known (Liu J, Xia J, Cho KH, Clapham DE, Ren D. CatSperbeta, a novel transmembrane protein in the CatSper Channel Complex J Biol Chem. 2007 Jun 29; 282 (26): 18945- 52nd Epub 2007 May 3).
  • CATSPERB in the following cell lines examined (expected fragment length 371 bp): TC620, A549, BHY, HeLa, HT29, MCF7.
  • the gene product according to the invention is suitable as a target for diagnosis and therapy.
  • CATSPERD The sequence of CATSPERD is published in GenBank under accession number NM_152784.3.
  • CATSPERD is a membrane protein with a molecular weight of 91 kDa expressed in flagella of spermatozoa. Expression in tumors is not known (Chung JJ, Navarro B, Krapivinsky G, Krapivinsky L, Clapham DE, A novel gene required for male fertility and functional CATSPER channel formation in spermatozoa, Nat Commun., 2011 Jan 11; 2: 153).
  • Base pairs A172, U251, U373, TC620, A549, HN, HeLa, HT29, MCF7.
  • Example 8 Identification of CATSPERG as a Diagnostic and Therapeutic Target
  • CATSPERG The sequence of CATSPERG is published in GenBank under accession number NM_021185.4.
  • CATSPERG is a transmembrane protein with a MW of 129 kD that is expressed in flagella of spermatozoa. Expression in tumors is not known (Wang H, Liu J, Cho KH, Ren D.
  • a novel, single transmembrane protein CATSPERG is associated with CATSPER1 channel protein, Biol Reprod., 2009 Sep; 81 (3): 539-44. doi: 10.1095 / biolreprod.109.077107. Epub 2009 Jun 10. RT-PCR assay in Fig.
  • the gene product according to the invention is suitable as a target for diagnosis and therapy.
  • CRISP3 is published in GenBank under accession number NM_001190986.1.
  • CRISP3 is a 28 kD MW protein. Expression in salivary glands, pancreas, prostate, epididymis, ovaries, thymus and large intestine as well as in prostate tumors is known (Grupp K, Kohl S, Sirma H, Simon R, Steurer S, Becker A, Adam M, Izbicki J, Sauter G, Minner S, Schlomm T, Tsourlakis MC Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence. Mod Pathol.
  • CRISP cysteine-rich secretory protein family -1, CRISP-2 and CRISP-3, Eur J Biochem 1996 Mar 15; 236 (3): 827-36).
  • RT-PCR analysis in Fig. 1 with a specific primer pair confirms expression in the following cell lines examined (expected fragment size: 149 base pairs): SKMG5, TC620, MG63, A549, HT29, PC3.
  • the gene product according to the invention is suitable as target for diagnosis and therapy.
  • FER1 L5 The sequence of FER1 L5 is published in GenBank under accession number NM_001 113382.1.
  • FER1 L5 is a membrane protein with a MW of 242 kD and is expressed in myoblasts. Expression in tumors is not known (Posey AD Jr, Pytel P, Gardikiotes K, Demonstration AR, Rainey M, George M, Band H, McNally EM, Endocytic recycling proteins EHD1 and EHD2 interact with fer-1-like-5 (Fer1 L5) and mediate myoblastic fusion J Biol Chem., 2011 Mar 4; 286 (9): 7379-88, doi: 10.1074 / jbc.M110.157222. Epub 2010 Dec 22.
  • RT-PCR assay in Fig. 1 with a specific primer pair confirms expression in the following cell lines examined (expected fragment length of 278 base pairs): U87-MG, U251, TC620, B-CPAP, HT29, PC3.
  • the gene product according to the invention is suitable as target for diagnosis and therapy.
  • FER1 L6 The sequence of FER1 L6 is published in GenBank under accession number NM_001039112.2. FER1L6 is a membrane protein with an MW of around 209 kD. Expression in ovaries. Expression in tumors is not known (S, Röpke A, Wieacker, P. Copy number variants in premature ovarian failure and ovarian dysgenesis, Sex Dev., 2010, Sep; 4 (4-5): 225-32, doi: 10.1159 / 000314958 Epub 2010 Jul 3).
  • RT-PCR assay in Fig.1 with a specific primer pair confirms expression in the following cell lines examined (expected fragment length 260 base pairs): A172, SKMG5, U87-MG, U251, U373, SW-872, B-CPAP, A549 , BHY, GLC-2, HT29, MCF7, PC3.
  • the gene product according to the invention is suitable as a target for diagnosis and therapy.
  • FOLR4 is a GPI-anchored protein with a MW of around 28 kD. Expression is probably confined to oocytes (Bianchi E, Doe B, Goulding D, Wright GJ, Juno is the Egg Izumo receptor and essential for mammalian fertilization, Nature. 2014; 508: 483-7).
  • RT-PCR examination in Fig. 1 with a specific primer pair confirms expression in the following cell lines examined (expected fragment length 288 base pairs): U87-MG, TC620, A549, B-CPAP, BHY.
  • the gene product according to the invention is suitable as a target for diagnosis and therapy.
  • GGN1 gametogenetin 1
  • CRISP2 cysteine-rich secretory protein 2
  • GGN2 Germ cell specific protein gametogenetine protein 2
  • RT-PCR assay in Fig. 1 with a specific primer pair confirm expression in the following cell lines examined (expected fragment length 280 base pairs): A 172, SKMG5, U87-MG, U251, U373, TC620, MG63, SW-872, B-CPAP, A549, BHY, GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60.
  • the gene product according to the invention could also serve as target for diagnosis and therapy.
  • GGNBP2 The sequence of GGNBP2 is in the GenBank under the accession number
  • GGNBP2 is a 79 kDa protein expressed in germ cells (Zhang J, Wang Y, Zhou Y, Cao Z, Huang P, Lu B. Yeast two-hybrid screens imply that GGNBP1, GGNBP2 and OAZ3 are potential interaction partners of testicular germ cell-specific protein GGN1, FEBS Lett., 2005; 579 (2): 559-66). Expression in tumors is unknown.
  • RT-PCR assay in Fig. 1 with a specific primer pair confirms expression in the following cell lines examined (expected fragment length 344 base pairs): A172, SKMG5, U87-MG, U251, U373, TC620, MG63, SW-872, B CPAP, A549, BHY, GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60. Since all
  • Example 15 Identification of IZUM01 as a Diagnostic and Therapeutic Target
  • IZUM01 The sequence of IZUM01 is in the GenBank under the accession number
  • IZUM01 is a 56 kDa transmembrane protein expressed on sperm cells (Ellerman DA, Pei J, Gupta S, Snell WJ, Myles D, Primakoff P. Izumo is part of a multiprotein family members of large scale mammalian sperm. Mol Reprod Dev. 2009; 76: 1188-99).
  • RT-PCR examination in Fig.1 with a specific primer pair showed no expression in the following cell lines examined (expected fragment length 394 base pairs): A172, SKMG5, U87-MG, U251, U373, TC620, MG63, SW-872, B CPAP, A549, BHY, GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60. Since no expression is detectable in any of the investigated cell lines, the gene is
  • PSG1 The sequence of PSG1 is published in GenBank under accession number NM_182575.2. Is a secreted protein with a molecular weight of about 70 kDa expressed in the placenta (Camolotto SA, Racca AC, Ridano ME, Genti-Raimondi S, Panzetta-Dutari GM.) PSG gene expression is up-regulated by lysine acetylation involving histone and nonhistone proteins. PLoS One.
  • RT-PCR examination in Fig. 1 with a specific primer pair showed expression in the following investigated cell lines (expected fragment length 305 Base pairs): A172, SKMG5, U87-MG, U251, U373, TC620, MG63, SW-872, B-CPAP, A549, BHY, HN, HeLa, MCF7, PC3. Since the cell lines investigated have an expression, the gene product according to the invention could also serve as target for diagnosis and therapy.
  • PSG2 The sequence of PSG2 is published in GenBank under accession number NM_031246.3. Is a secreted protein with a molecular weight of about 60 kDa expressed in the placenta (Pan CJ, Chamberlin ME, Wu SM, Chan WY, Chou JY, Pregnancy-specific glycoprotein gene expression and the induction by 5-bromo-2 ' -deoxyuridine, Biochemistry, 1994 Jun 14; 33 (23): 7260-6).
  • RT-PCR analysis in Fig. 1 with a specific primer pair showed expression in the following cell lines examined (expected fragment length 305 base pairs): A 172, SKMG5, U87-MG, U251, U373, TC620, MG63, SW-872, B CPAP, BHY, HN, HeLa, MCF7, PC3. Since the examined cell lines a
  • the gene product according to the invention could also serve as a target for diagnosis and therapy.
  • PSG5 The sequence of PSG5 is published in GenBank under accession number NM_002781.3. Is a secreted protein with a molecular weight of about 60 kDa expressed in the placenta (Pan CJ, Chamberlin ME, Wu SM, Chan WY, Chou JY, Pregnancy-specific glycoprotein gene expression and the induction by 5-bromo-2 ' -deoxyuridine, Biochemistry, 1994 Jun 14; 33 (23): 7260-6).
  • RT-PCR examination in Fig. 1 with a specific primer pair showed no expression in the following investigated cell lines (expected fragment length 394 Base pairs): A172, SKMG5, U87-MG, U251, U373, TC620, MG63, SW-872, B-CPAP, A549, BHY, GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60. Since no expression is detectable in any of the investigated cell lines, the gene is
  • ROPN1 L is published in GenBank under accession number NM_031916.4.
  • ROPN1L is a 26 kDa protein.
  • Normal expression in spermatozoa (Carr DW 1 , Fujita A, Stentz CL, Liberty GA, Olson GE, Narumiya S. Identification of sperm-specific proteins that interact with A-kinase anchoring proteins in a manner similar to the type II regulatory subunit of PKA. J Biol Chem. 2001; 276 (20): 17332-8, Epub 2001 Feb. 7) is also associated with breast cancer (Sehrawat B, Sridharan M, Ghosh S, Robson P, Cass CE, Mackey JR, Greiner R, Damaraju S.
  • RT-PCR assay in Fig. 1 with a specific primer pair confirms expression in the following cell lines examined (expected fragment length 185 base pairs): A172, SKMG5, U87-MG, U251, U373, TC620, MG63, SW-872, B CPAP, A549, BHY, GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60. Since all
  • SPAG6 is published in GenBank under accession number CR533552.1.
  • SPAG6 is a 55 kDa protein. Normal expression is restricted to spermatozoa (Neilson LI, Schneider PA, Van Deerlin PG, Kiriakidou M, Driscoll DA, Pellegrini MC, Millinder S, Yamamoto KK, French CK, Strauss JF 3rd.
  • spermatozoa Neilson LI, Schneider PA, Van Deerlin PG, Kiriakidou M, Driscoll DA, Pellegrini MC, Millinder S, Yamamoto KK, French CK, Strauss JF 3rd.
  • RT-PCR assay in Fig. 1 with a specific primer pair confirms expression in the following cell lines examined (Expected fragment length 362 base pairs): SKMG5, U87-MG, U251, U373, SW-872, B-CPAP, GLC-2, HeLa, MCF7, PC3.
  • the gene product according to the invention could also serve as target for diagnosis and therapy
  • SPAG8 is in the GenBank under the accession number
  • SPAG8 is a 55 kDa protein. Normal expression is restricted to spermatozoa (Zhang XD, Miao SY, Wang LF, Li Y, Zong SD, Yan YC, Koide SS. Human sperm membrane protein (hSMP-1): a developmental testis-specific component during germ cell differentiation. Arch Androl 2000 Nov-Dec; 45 (3): 239-46). Expression in lung and lung
  • RT-PCR examination in FIG. 1 with a specific primer pair confirms expression in the following investigated cell lines (expected fragment length 365 Base pairs): A172, SKMG5, U87-MG, U251, U373, MG63, SW-872, B-CPAP, A549, BHY, GLC-2, HeLa, HT29, MCF7, PC3, HL60.
  • the gene product according to the invention could also serve as target for diagnosis and therapy.
  • SPAG17 is in the GenBank under the accession number
  • SPAG17 is a 252 kDa protein. Normal expression is restricted to spermatozoa (Zhang Z, Jones BH, Tang W, Moss SB, Wei Z, Ho C, Pollack M, Horowitz E, Bennett J, Baker ME, Strauss JF 3rd Dissecting the axoneme interactome: the mammalian orthologue of Chlamydomonas PF6 interacts with sperm-associated antigen 6, the mammalian orthologue of Chlamydomonas PF16, Mol Cell Proteomics, 2005 Jul; 4 (7): 914-23, Epub 2005 Apr 12). Expression in lung and breast tumors is described (Silina K, Zayakin P, Kalnina Z, Ivanova L, Master I, Endlet E, Abol's A,
  • RT-PCR assay in Fig. 1 with a specific primer pair confirms expression in the following cell lines tested (expected fragment length 325 base pairs): A172, SKMG5, U87-MG, U251, U373, MG63, SW-872, B-CPAP , A549, BHY, HN, HeLa, MCF7, PC3, HL60.
  • the gene product according to the invention could also serve as target for diagnosis and therapy.
  • Dysferlin is a transmembrane protein with a molecular weight of 230 kD. The expression of dysferlin occurs in monocytes and tracheal epithelium. In tumors so far no expression has been described. (Leung C, Shaheen F, Bernatchez P, hackett TL) Expression of myoferlin in human airway epithelium and its role in cell adhesion and zonula occludens-1 expression, PLoS One. 2012; 7 (7): e40478. Doi: 10.1371 / journal .pone.0040478). RT-PCR analysis revealed specific expression of DYSF in the following cell lines ( Figure 2, expected 250 bp PCR product): A 1207, SK-MG-5, SKN-MC, HL 60, BCPAP.
  • the gene product according to the invention is suitable as a target for diagnosis and therapy.
  • ZP1 glycosylated membrane protein with a molecular weight of approximately 97 kDa that is expressed in oocytes. Expression in tumors is unknown.
  • Schabanowitz RB, O'Rand MG Molecular Changes in the Human Zone of Pellucida Associated with Fertilization and Human Sperm-zona Interactions, Ann NY Acad Sci. 1988; 541: 621- RT-PCR studies with a ZP 1 -specific primer pair show in Fig.
  • Example 25 Identification of ZP2 as a Diagnostic and Therapeutic Target
  • ZP2 is published in GenBank under accession number NM_003460.1.
  • ZP2 is a glycosylated membrane protein with a molecular weight of 64 to 78 kDa that is expressed in oocytes. Expression in tumors is not known (Gupta SK, Bhandari B, Shrestha A, Biswal BK, Palaniappan C, Malhotra SS, Gupta N.Mammalian zona pellucida glycoproteins: structure and function during fertilization., Cell Tissue Res. 2012; 349: 665- 78).
  • the RT-PCR assay in Figure 2 with a specific primer pair confirms expression in the following cell lines (358 bp expected fragment length): GLC-8A. Since an examined cell line has an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy.
  • Example 26 Identification of ZP3 as a Diagnostic and Therapeutic Target
  • ZP3 is published in GenBank under accession number NM_007155.5.
  • the sequence of ZP 3 is published in GenBank under accession number NM_007155.5.
  • ZP3 is a glycosylated membrane protein with a molecular weight of 57 to 73 kDa that is expressed in oocytes. Expression in ovarian tumors has been described (Rahman NA, et al., A novel treatment strategy for ovarian cancer based on immunization against zona pellucida protein (ZP) 3. FASEB J. 2012; 26: 324-33).
  • the gene product according to the invention is suitable as a target for diagnosis and therapy.
  • Example 27/28 Identification of CRISP 1 and CRISP 2 as a Diagnostic and Therapeutic Target
  • the sequence of CRISP 1 is published in GenBank under accession number NM_001131.2.
  • the sequence of CRISP 2 is published in GenBank under accession number NM_003296.3.
  • CRISP1 and CRISP2 are secreted or membrane-associated proteins with molecular weights between 25 and 32 kDa. Expression of CRISP1 or CRISP2 is not previously described in tumors. In the mouse, CRISP proteins show not only testis-restricted expression.
  • a RT-PCR assay with a specific primer pair confirms expression of CRISP1 in the following cell lines (expected fragment length 183 bp, TV2 only): A 172, A 1207, U251, U373, SK-MG-5, U 87-MG, TC620, U178, SKN-MC, GLC 8A, SCLC-24H, H 146, HL 60, HELA, HT-29, BCPAP, FTC-133, CAL-62, GLC-2, 1184, A549. Since three investigated cell lines have no expression, the gene product according to the invention is suitable as a target for diagnosis and therapy.
  • RT-PCR assay confirms expression of CRISP2 in the following cell lines (expected fragment lengths 257, 263, 294, 300 bp): A172, U373, U87-MG, U178, SH-SY5Y, HL-60, BCPAP, H1184. Since at least one examined cell line has an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy.
  • Example 29 Identification of MYOF as a Diagnostic and Therapeutic Target
  • MYOF The sequence of MYOF is published in GenBank under accession number AF182316.1.
  • Myoferlin is a transmembrane protein with a MW of 234 kD and is expressed in muscle and endothelial cells. Expression in mammary carcinomas has been demonstrated (Leung C, Yu C, Lin MI, Tognon C, Bernatchez P. Expression of myoferlin in human and murine carcinoma tumors: role in membrane repair, cell proliferation, and tumorigenesis.) On J Pathol., 2013; 182: 1900-9).
  • the RT-PCR assay in Fig. 2 with a specific primer pair confirms expression in the following cell lines (expected fragment length 259 base pairs): A 172, A 1207, U 251, U 373, SK-MG-5, U87-MG, TC 620, U 178, SKN-MC, HL 60, HELA, HT 29, BCP AP, GLC-2, GLC-36, H1184. Since several investigated cell lines have an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy.
  • Example 30 Identification of OTOF as Diagnostic and Therapeutic
  • Otoferlin is a transmembrane protein of 227 kD. In the mouse, otoferlin is expressed in the inner ear, cerebellum, hippocampus, testes, perhaps also in kidney or heart. For humans, there are no exact dates. Expression in tumors is not described (Schug N, Braig C, Zimmermann U, Engel J, Winter H, Ruth P, Blin N, Pfister M, Kaibacher H, Knipper M. Differential expression of otoferlin in brain, vestibular system, immature and mature cochlea of the rat, Eur J Neurosci., 2006; 24: 3372-80).
  • the RT-PCR assay in Fig. 2 with a specific primer pair confirms expression in the following cell lines (expected fragment length: 229 base pairs): A 172, A 1207, U 251, U 373, TC 620, U 178, SKN-MC, SH-SY5Y, GLC-8A, SCLC-24H, H146, HL60, HELA, HT29, BCP AP, FTC-133, GLC-2, GLC- 36, H1184. Since several investigated cell lines have an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy.
  • SED1 is published in GenBank under accession number NM_001114614.1.
  • SED-1 is a membrane-associated protein with a MW of 45 kD and is expressed in MIkroglia and macrophages.
  • Expression in bladder and breast cancers, in melanomas, in tumors of hematopoietic systems, as well as in HeLa and C6 glioma cells (rat) has been described (Liu Y, Yang X, Guo C, None P, Liu Y, Ma J. Essential role of MFG -E8 for phagocytic properties of microglial cells, PLoS One.
  • the RT-PCR assay in Fig. 2 with a specific primer pair confirms expression in the following cell lines (expected fragment length of 267 base pairs): A 172, A 1207, U 251, U 373, SK-MG-5, U87-MG , TC620, U178, SKN-MC, SH-SY5Y, GLC-8A, SCLC-24H, H146, HL60, HELA, HT29, BCP AP, FTC-133, GLC-36, H1184, A549. Since several investigated cell lines have an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy.
  • Example 32 Identification of ZAN as a Diagnostic and Therapeutic Target
  • ZAN The sequence of ZAN is published in GenBank under accession number NM_003386.1.
  • Zonadhesin is a membrane protein with a MW of around 240 kD. Expression in sperm cells. Expression in tumors is not known (Herlyn H, Zischler H. The molecular evolution of sperm zonadhesin, Int J Dev Biol. 2008; 52: 781-90).
  • the RT-PCR assay in Fig. 2 with a specific primer pair confirms expression in the following cell lines (expected fragment length 252 base pairs): A 172, A 1207, U 251, U 373, SK-MG-5, U87-MG, TC620, U178, SKN-MC, GLC-8A, SCLC-24H, H146, HL60, HT29, BCP AP, FTC-133, GLC2, H1184, A549. Since several investigated cell lines have an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy.
  • MMP15 is published in GenBank under accession number NM_002428.2.
  • MMP15 is a membrane protein of 76 kDa expressed in esophageal carcinomas (Chen et al., Anticancer Res. 2010, 30: 4363).
  • the RT-PCR assay in Fig. 2 with a specific primer pair confirms expression in the following cell lines (expected fragment length 193 basepairs): A 172, A 1207, U251, U373, SK-MG-5, U 87-MG, TC620 , U178, SKN-MC, GLC 8A, SCLC-24H, H 146, HL 60, HELA, HT-29, BCPAP, GLC-2, GLC-36, H 1184. Since several cell lines studied have expression, the gene product is According to the invention suitable as a target for diagnosis and therapy.
  • Example 34 Identification of MMP 16 as a Diagnostic and Therapeutic Target
  • MMP16 is a membrane protein of 52 kDa expressed in cartilage cells. Expression in lung tumors (NSCLC) and astrocytomas has been described (Darrah C, Donell ST, Shepstone L, Porter S, Brockbank SM, Edwards DR, Parker AE, Clark IM Arthritis Rheum. 2004; 50: 131-141; Grant GM, Giambernardi TA, Grant AM, Adhesive RJ. Overview of expression of matrix metalloproteinases (MMP-17, MMP-18, and MMP). 20) in cultured human cells, Matrix Biol. 1999; 18: 145-8).
  • the RT-PCR assay in Fig. 2 with a specific primer pair confirms expression in the following cell lines investigated (expected fragment length 192 base pairs): A 172, A 1207, U251, U373, SK-MG-5, U 87-MG, TC620, U178, SKN-MC, GLC 8A, H 146, BCPAP, GLC-2, GLC-36, H 1184. Since several examined cell lines have an expression, the gene product according to the invention is suitable as target for diagnosis and therapy.
  • MMP-17 is a membrane protein of 76 kDa. Normal expression in eosinophils (Gauthier MC, Racine C, Ferland C, Flamand N, Chakir J, Tremblay GM, Laviolette M. Expression of membrane type-4 matrix metalloproteinase (metalloproteinase-17) by human eosinophils Int J Biochem Cell Biol.
  • Example 36 Identification of MMP 20 as Diagnostic and Therapeutic
  • MMP20 is a membrane protein of 76 kDa. Normal expression is limited to enamel-forming ameloblasts (Bartlett JD, Simmer JP, Proteinases in developing dental enamel, Crit Rev Oral Biol Med. 1999; 10: 425-4). Expression in lingual carcinomas has been demonstrated (Väänänen A, Srinivas R, Parikka M, Palosaari H, Bartlett JD, Iwata K, Grenman R, Stenman UH, Sorsa T, Salo T expression of regulation of MMP-20 in human tongue carcinoma cells Dent Res. 2001; 80: 1884-9).
  • FIG. 3 The following cell lines were investigated for example 36 (FIG. 3): A 172, A 1207, U251, U373, SK-MG-5, U 87-MG, TC 620, U 178, SKN-MC, SH-SY5Y, GLC 8A, SCLC-24H, H146, HL 60, HELA, HT-29, BCPAP, FTC-133, CAL-62, GLC-2, GLC-36, H 1184, A549.
  • the upper gel half shows: B-CPAP (lane 1), FTC-133 (lane 2), CAL-62 (lane 3), GLC-2 (lane 4), GLC-8A (lane 5), GLC-36 (lane 6), SCLC-24H (lane 7), H146 (lane 8), H-1184 (lane 9), A549 (lane 10), A172 (lane 11), A1207 (lane 12), blank (lane 13), negative control (Lane 14).
  • the lower half of the gel shows: U251 (lane 1), U373 (lane 2), SK-MG-5 (lane 3), U87-MG (lane 4), TC620 (lane 5), U178 (lane 6), SKN-MC (Lane 7), SH-SY5Y (lane 8), HL-60 (lane 9), HeLa (lane 10), HT-29 (lane 11), empty (lane 12, 13), negative control (lane 14).
  • the RT-PCR assay in Figure 3 with a specific primer pair confirms expression in the following cell line cell lines (expected fragment length 223 base pairs): H-1184, A172, A1207, U251, U87-MG, HT-29. Since several investigated cell lines have an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy.
  • ZP1 Zona pellucida protein 1
  • ZP2 Zona pellucida protein 2
  • ZP3 Zona pellucida protein 3
  • Otoferlin Otoferlin

Abstract

The invention relates to a pharmaceutical composition comprising an agent which detects or inhibits the expression or activity of a tumour-associated antigen, and to a method for the treatment and diagnosis of a tumour disease. These agents and methods make it possible to offer target structures for the diagnosis and treatment of diseases, in particular cancers.

Description

Tumor-assoziierte Antigene und Genprodukte in der Diagnose und Therapie  Tumor-associated antigens and gene products in diagnosis and therapy
Die Erfindung betrifft eine pharmazeutische Zusammensetzung, umfassend ein Mittel, das die Expression oder Aktivität eines Tumor-assoziierten Antigens nachweist oder inhibiert, sowie ein Verfahren zur Behandlung und Diagnose einer Tumorerkrankung. The invention relates to a pharmaceutical composition comprising an agent which detects or inhibits the expression or activity of a tumor-associated antigen, and a method for the treatment and diagnosis of a tumor disease.
Trotz interdisziplinärer Ansätze und erschöpfender Nutzung der klassischen therapeutischen Verfahren, gehören Krebserkrankungen auch heute noch zu den weltweit führenden Todesursachen. Neuere therapeutische Konzepte zielen darauf ab, das Immunsystem des Patienten in das therapeutische Gesamtkonzept mit Hilfe von rekombinanten Tumorvakzinen und anderen spezifischen Maßnahmen wie Antikörper Therapie einzubinden. Eine Voraussetzung für den Erfolg einer solchen Strategie ist die Erkennung von Tumor-spezifischen oder Tumor -assoziierten Antigenen oder Epitopen. Tumorzellen unterscheiden sich biologisch wesentlich von ihren nichtmalignen Ursprungszellen. Die Tumorentwicklung ist im Ergebnis unter anderem auch auf die Bildung qualitativ oder quantitativ veränderter molekularer Strukturen in den Krebszellen zurückzuführen. Despite interdisciplinary approaches and exhaustive use of classical therapeutic procedures, cancer is still one of the leading causes of death worldwide. More recent therapeutic concepts aim to integrate the patient's immune system into the overall therapeutic concept with the help of recombinant tumor vaccines and other specific measures such as antibody therapy. A prerequisite for the success of such a strategy is the recognition of tumor-specific or tumor-associated antigens or epitopes. Tumor cells differ biologically significantly from their non-malignant cells of origin. Among other things, tumor development can be attributed to the formation of qualitatively or quantitatively altered molecular structures in the cancer cells.
Die potentielle klinisch-therapeutische Bedeutung von Tumor-assoziierten Antigenen resultiert aus der Tatsache, dass durch die Erkennung von Antigenen auf Zellen, die eine Neubildung von Tumoren begünstigen, eine Elimination der Krebszellen durch das Immunsystem erfolgen kann. Dementsprechend ist ein zentrales Ziel der Tumorimmunologie, diese Strukturen molekular zu definieren. Die molekulare Struktur vieler Antigene wurde lange nicht erkannt. Erst nach der Entwicklung von geeigneten Klon-Techniken, wie beispielsweise cDNA -Expressionsbanken von Tumoren, war es möglich, systematisch Tumor-assoziierte Antigene durch Analyse der Zielstrukturen zu ermitteln. Hierzu wurden cDNA-Expressionsbanken aus frischem Tumorgewebe hergestellt und als Proteine rekombinant exprimiert. The potential clinical-therapeutic importance of tumor-associated antigens stems from the fact that the recognition of antigens on cells that promote neoplasm of tumors can cause the elimination of cancer cells by the immune system. Accordingly, a central goal of tumor immunology is to define these structures molecularly. The molecular structure of many antigens has long been unrecognized. Only after the development of suitable cloning techniques, such as cDNA expression libraries of tumors, was it possible to systematically identify tumor-associated antigens by analysis of the target structures. For this purpose, cDNA expression libraries were prepared from fresh tumor tissue and expressed recombinantly as proteins.
In den letzten Jahren sind eine Vielzahl von Antigenen in verschiedenen Tumoren durch diese Ansätze definiert worden. Die für die Antigenidentifikation mit Hilfe klassischer Methoden eingesetzten Proteine betreffen jedoch Tumore, die bereits ein Tumorwachstum im fortgeschrittenen Stadium aufweisen. Aus einer Reihe von In recent years, a variety of antigens in various tumors have been defined by these approaches. However, the proteins used for antigen identification by classical methods involve tumors that already have advanced tumor growth. From a series of
Bestätigungskop e| Experimenten geht hervor, dass im Verlauf der Erkrankung, vor allem jene Confirmation header | Experiments show that in the course of the disease, especially those
Informationen, die eine effektive Immunerkennung bewirken könnten, bei Information that could lead to effective immune recognition at
Fortschreiten des Tumorwachstums verlorengehen. Progression of tumor growth is lost.
Aufgabe der vorliegenden Erfindung ist es daher Antigene für die Diagnose und/oder Therapie bereitzustellen, die auf normalem Gewebe überhaupt nicht oder zumindest nicht überwiegend exprimiert werden. Hierdurch wird eine weitgehend eindeutige Identifikation (im Rahmen diagnostischer Verfahren) oder eine zielgerichtete It is therefore an object of the present invention to provide antigens for diagnosis and / or therapy which are not expressed at all on normal tissue or at least not predominantly expressed. As a result, a largely unique identification (in the context of diagnostic procedures) or a targeted
Ausschaltung (im Rahmen therapeutischer Verfahren) von Tumorzellen ermöglicht. Diese Aufgabe wird in therapeutischer Hinsicht durch eine pharmazeutische Elimination (as part of therapeutic procedures) of tumor cells allows. This task is therapeutically by a pharmaceutical
Zusammensetzung zur Hemmung oder Inhibierung der Expression eines Tumor - assoziierten Antigens gelöst, wobei das Tumor-assoziierte Antigen eine Sequenz aufweist, die von einer Nukleinsäure, die ausgewählt ist aus der Gruppe bestehend aus:  A composition for inhibiting or inhibiting expression of a tumor-associated antigen, wherein the tumor-associated antigen has a sequence selected from a nucleic acid selected from the group consisting of:
(a) einer Nukleinsäure, die eine Nukleinsäuresequenz umfasst, die aus der (a) a nucleic acid comprising a nucleic acid sequence derived from the
Gruppe SEQ ID NO: 1 bis 36, einem Teil oder einem Derivat davon  Group SEQ ID NO: 1 to 36, part or derivative thereof
(b) einer Nukleinsäure, die unter stringenten Bedingungen mit der Nukleinsäure unter (a) hybridisiert,  (b) a nucleic acid which hybridizes under stringent conditions with the nucleic acid under (a),
(c) einer Nukleinsäure, die in Bezug auf die Nukleinsäure unter (a) oder (b)  (c) a nucleic acid which in relation to the nucleic acid under (a) or (b)
degeneriert ist und  is degenerate and
(d) einer Nukleinsäure, die zu der Nukleinsäure unter (a), (b) oder (c)  (d) a nucleic acid which can be added to the nucleic acid under (a), (b) or (c)
komplementär ist. Gemäß der Erfindung ist es möglich die Erkennung von Tumor-assoziierten  is complementary. According to the invention, it is possible the recognition of tumor-associated
Antigenen oder die Bestimmung der Menge eines Tumor-assoziierte Antigens durch Verwendung beispielsweise eines Antikörpers, der spezifisch an das Tumorassoziierte Antigen bindet, vorzunehmen. So kann eine pharmazeutische Zusammensetzung für eine Identifizierung von Tumor-assoziierten Antigenen und der dafür kodierenden Nukleinsäuren  Antigens or the determination of the amount of a tumor-associated antigen by using, for example, an antibody that binds specifically to the tumor-associated antigen to make. Thus, a pharmaceutical composition for identification of tumor-associated antigens and the nucleic acids coding for it
herangezogen werden. Bestimmte Gene exprimieren Organ-spezifisch be used. Certain genes express organ-specific
ausschließlich in bestimmten Gewebebereichen, wie beispielsweise im Darm-, Lungen-, Nieren-, Blasen-, Gastrointestinal-, Haut-, Hirn-, Knochen-, Brust-, exclusively in certain tissue areas, such as in the intestinal, Lung, kidney, bladder, gastrointestinal, skin, brain, bone, breast,
Schilddrüsen-, Ovarien-, Pankreas-, Prostata-, Leber-, Lymphdrüsen-Gewebe. In den entsprechenden Organen können diese Gene Tumorzellen und darüber hinaus in anderen Geweben ein Tumorwachstum aktivieren. Die Erfindung betrifft insofern die Möglichkeit zur Identifizierung von  Thyroid, ovarian, pancreatic, prostate, liver, lymphatic tissue. In the corresponding organs, these genes can activate tumor cells and, in addition, tumor growth in other tissues. In this respect, the invention relates to the possibility of identifying
gewebespezifischen und differentiell in Tumoren exprimierten Proteinen. Die erfindungsgemäß identifizierten Tumor-assoziierten Antigene betreffen insbesondere Acrosin, ACRBP, CATSPER1 , CATSPER2, CATSPER4, CATSPERB, CATSPERD, CATSPERG, CRISP3, FER1 L5, FER1 L6, FOLR4, GGN, GGNBP2, IZUMO1 , PSG1 , PSG2, PSG5, ROPN1L, SPAG6, SPAG8, SPAG17, CRISP 1 , CRISP 2, DYSF, MMP 15, MMP 16, MMP 17, MMP 20, MYOF, OTOF, SED-1 , ZAN, ZP 1 , ZP 2, ZP 3. tissue-specific and differentially expressed in tumors proteins. The tumor-associated antigens identified according to the invention relate in particular to acrosin, ACRBP, CATSPER1, CATSPER2, CATSPER4, CATSPERB, CATSPERD, CATSPERG, CRISP3, FER1 L5, FER1 L6, FOLR4, GGN, GGNBP2, IZUMO1, PSG1, PSG2, PSG5, ROPN1L, SPAG6 , SPAG8, SPAG17, CRISP1, CRISP2, DYSF, MMP15, MMP16, MMP17, MMP20, MYOF, OTOF, SED-1, ZAN, ZP1, ZP2, ZP3.
Erfindungsgemäß werden Gene beschrieben, die in Tumorzellen selektiv exprimiert werden und Tumor-assoziierte Antigene darstellen. Diese Gene oder ihre Derivate insbesondere Nukleinsäuren sind bevorzugte Zielstrukturen für therapeutischeAccording to the invention, genes are described which are selectively expressed in tumor cells and represent tumor-associated antigens. These genes or their derivatives, in particular nucleic acids, are preferred targets for therapeutic
Ansätze. Konzeptionell können die therapeutischen Ansätze auf eine Hemmung der Aktivität des selektiv exprimierten Tumor-assoziierten Genproduktes zielen. Approaches. Conceptually, the therapeutic approaches may target an inhibition of the activity of the selectively expressed tumor-associated gene product.
Eine Nukleinsäure ist erfindungsgemäß vorzugsweise Desoxyribonukleinsäure (DNA) oder Ribonukleinsäure (RNA). Nukleinsäuren umfassen erfindungsgemäß genomische DNA, cDNA, mRNA, rekombinant hergestellte und chemisch According to the invention, a nucleic acid is preferably deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). Nucleic acids according to the invention comprise genomic DNA, cDNA, mRNA, recombinantly produced and chemically
synthetisierte Moleküle. Eine Nukleinsäure kann erfindungsgemäß als synthesized molecules. A nucleic acid can be used according to the invention as
einzelsträngiges oder doppelsträngiges und lineares oder kovalent kreisförmig geschlossenes Molekül vorliegen. Mit "Derivat" einer Nukleinsäure ist single-stranded or double-stranded and linear or covalently closed circular molecule. With "derivative" of a nucleic acid
erfindungsgemäß gemeint, dass einzelne oder multiple Nukleotidsubstitution, - deletion und/oder -addition in der Nukleinsäure vorliegen. Weiterhin umfasst der Begriff eine chemische Derivatisierung einer Nukleinsäure an einer Nukleotidbase, am Zucker oder am Phosphat. Der Begriff„Derivat" umfasst auch Nukleinsäuren, die nicht in der Natur vorkommende Nukleotide und Nukleotidanaloga enthalten. According to the invention, it is meant that single or multiple nucleotide substitution, deletion and / or addition are present in the nucleic acid. Furthermore, the term comprises a chemical derivatization of a nucleic acid on a nucleotide base, on the sugar or on the phosphate. The term "derivative" also includes nucleic acids containing non-naturally occurring nucleotides and nucleotide analogs.
Die erfindungsgemäß beschriebenen Nukleinsäuren sind vorzugsweise isoliert. Der Begriff "isolierte Nukleinsäure" bedeutet erfindungsgemäß, dass die Nukleinsäure (i) in vitro amplifiziert wurde, zum Beispiel durch Polymerase-Kettenreaktion (PCR), (ii) rekombinant durch Klonierung produziert wurde, (iii) gereinigt wurde, zum Beispiel durch Spaltung und gelelektrophoretische Auftrennung oder (iv) synthetisiert wurde, zum Beispiel durch chemische Synthese. Eine isolierte Nukleinsäure ist eine The nucleic acids described according to the invention are preferably isolated. The term "isolated nucleic acid" means according to the invention that the nucleic acid (i) has been amplified in vitro, for example by polymerase chain reaction (PCR), (ii) (iii) was purified, for example by cleavage and gel electrophoretic separation, or (iv) was synthesized, for example by chemical synthesis. An isolated nucleic acid is one
Nukleinsäure, die für eine Manipulierung durch rekombinante DNA-Techniken zur Verfügung steht. Nucleic acid available for manipulation by recombinant DNA techniques.
In einer bevorzugten Ausführungsform ist ein rekombinantes DNA-Molekül erfindungsgemäß ein Vektor, gegebenenfalls mit einem Promotor, der die Expression einer Nukleinsäure, z.B. einer Nukleinsäure, die für ein erfindungsgemäßes Tumor assoziiertes Antigen kodiert, steuert. Der Begriff "Vektor" wird dabei in seiner allgemeinsten Bedeutung verwendet. Vektoren werden vorzugsweise in der Zelle repliziert und/oder exprimiert. Vektoren umfassen Plasmide, Phagemide oder Virusgenome. In a preferred embodiment, a recombinant DNA molecule according to the invention is a vector, optionally with a promoter, which promotes the expression of a nucleic acid, e.g. a nucleic acid encoding an antigen associated with a tumor of the invention. The term "vector" is used in its most general meaning. Vectors are preferably replicated and / or expressed in the cell. Vectors include plasmids, phagemids or viral genomes.
Der Begriff "Expression" wird erfindungsgemäß in seiner allgemeinsten Bedeutung verwendet und umfasst die Produktion von RNA oder von RNA und Protein. The term "expression" is used according to the invention in its most general meaning and includes the production of RNA or of RNA and protein.
Der Begriff im Rahmen der Erfindung benutzte Begriff "Antisense-Molekül" oder "Antisense-Nukleinsäure" betrifft erfindungsgemäß ein Oligonukleotid, das ein Oligoribonukleotid, Oligodesoxyribonukleotid, modifiziertes Oligoribonukleotid oder modifiziertes Oligodesoxyribonukleotid ist und das unter physiologischen The term "antisense molecule" or "antisense nucleic acid" as used in the invention refers to an oligonucleotide which is an oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide or modified oligodeoxyribonucleotide according to the invention
Bedingungen an DNA, die ein bestimmtes Gen umfasst, oder mRNA dieses Gens hybridisiert, wodurch die Transkription dieses Gens und/oder die Translation dieser mRNA gehemmt werden kann. Die erfindungsgemäß beschriebenen Proteine und Polypeptide können in einem im Wesentlichen aufgereinigten Zustand vorliegen. Der Begriff "im wesentlichen aufgereinigt" bedeutet, dass das Protein oder Polypeptid im Wesentlichen frei von anderen Substanzen vorliegt, mit denen es in der Natur oder in vivo vorliegt. Solche Proteine und Polypeptide dienen beispielsweise der Herstellung von  Conditions on DNA comprising a particular gene or hybridizes mRNA of this gene, whereby the transcription of this gene and / or the translation of this mRNA can be inhibited. The proteins and polypeptides described in this invention may be in a substantially purified state. The term "substantially purified" means that the protein or polypeptide is substantially free of other substances present in nature or in vivo. Such proteins and polypeptides are used, for example, for the production of
Antikörpern und sind in einem immunologischen oder diagnostischen Assay oder als Therapeutika einsetzbar. Erfindungsgemäß beschriebene Proteine und Polypeptide können aus biologischen Proben isoliert werden und können auch rekombinant in einer Vielzahl pro- oder eukaryontischer Expressionssysteme exprimiert werden. Antibodies and are useful in an immunological or diagnostic assay or as therapeutics. Proteins and polypeptides described in accordance with the invention can be isolated from biological samples and can also be expressed recombinantly in a variety of pro- or eukaryotic expression systems.
Die vorliegende Erfindung betrifft allgemein die Verwendung von erfindungsgemäß identifizierten Tumor-assoziierten Antigenen oder von Teilen davon, von dafür kodierenden Nukleinsäuren oder von Nukleinsäuren, die gegen die kodierenden Nukleinsäuren gerichtet sind oder von Antikörpern, die gegen die erfindungsgemäß identifizierten Tumor-assoziierten Antigene oder Teile davon gerichtet sind, für die Therapie und Diagnose. Die Nutzung kann einzelne, aber auch Kombinationen von mehreren dieser The present invention relates in general to the use of tumor-associated antigens identified in accordance with the invention or of parts thereof, nucleic acids coding therefor or nucleic acids directed against the coding nucleic acids or of antibodies directed against the tumor-associated antigens identified in accordance with the invention or parts thereof are directed for therapy and diagnosis. The usage can be single, but also combinations of several of these
Antigene, funktionale Fragmente, Nukleinsäuren, Antikörper etc. betreffen, in einer Ausführungsform, aber auch in Kombination mit anderen Tumor-assoziierten Genen und Antigenen für eine Diagnose, Therapie und Verlaufskontrolle. Bevorzugte Erkrankungen für eine Therapie und/oder Diagnose sind solche, bei denen eine selektive Expression oder auch abnormale Expression von einem oder mehreren der erfindungsgemäß identifizierten Tumor-assoziierten Antigene vorliegt. Die Erfindung betrifft auch Nukleinsäuren und Genprodukte, die Tumorzellen assoziiert exprimiert werden und die durch veränderte Prozessierung beispielsweise bei der Transkription oder Translation bekannter Gene entstehen.  Antigens, functional fragments, nucleic acids, antibodies, etc., in one embodiment, but also in combination with other tumor-associated genes and antigens for diagnosis, therapy and follow-up. Preferred diseases for therapy and / or diagnosis are those in which there is a selective expression or also abnormal expression of one or more of the tumor-associated antigens identified according to the invention. The invention also relates to nucleic acids and gene products which are expressed associated tumor cells and caused by altered processing, for example, in the transcription or translation of known genes.
Diese Nukleinsäuren umfassen die Sequenzen gemäß Identifikationsnummern entsprechend Seite "http://www.ncbi.nlm.nih.gov/nuccore/":  These nucleic acids comprise the sequences according to identification numbers corresponding to page "http://www.ncbi.nlm.nih.gov/nuccore/":
ACR: Homo sapiens acrosin; NM_001097.2. ACR: Homo sapiens acrosin; NM_001097.2.
ACRBP: Homo sapiens acrosin binding protein; NM_032489.2. CATSPER1 : Homo sapiens cation Channel, sperm associated 1 1 ; NM_053054. ACRBP: Homo sapiens acrosin binding protein; NM_032489.2. CATSPER1: Homo sapiens cation channel, sperm associated 1 1; NM_053054.
CATSPER2: Homo sapiens cation Channel, sperm associated 2; NM_172095.2. CATSPER2: Homo sapiens cation channel, sperm associated 2; NM_172095.2.
CATSPER4: Homo sapiens cation Channel, sperm associated 4; NM_198137.1. CATSPER4: Homo sapiens cation channel, sperm associated 4; NM_198137.1.
CATSPERB: Homo sapiens catsper Channel auxiliary subunit beta; NM_024764.2. CATSPERB: Homo sapiens catsper Channel auxiliary subunit beta; NM_024764.2.
CATSPERD: Homo sapiens catsper Channel auxiliary subunit delta; NM_152784.3. CATSPERG: Homo sapiens catsper Channel auxiliary subunit gamma; NM_021185.4.CATSPERD: Homo sapiens catsper Channel auxiliary subunit delta; NM_152784.3. CATSPERG: Homo sapiens catsper Channel auxiliary subunit gamma; NM_021185.4.
CRISP3: Homo sapiens cysteine-rich secretory protein 3; NM_001190986.1. CRISP3: Homo sapiens cysteine-rich secretory protein 3; NM_001190986.1.
FER1 L5: Homo sapiens fer-1-like 5; NM_001113382.1.  FER1 L5: Homo sapiens fer-1-like 5; NM_001113382.1.
FER1 L6: Homo sapiens fer-1 -like 6; NM_001039112.2.  FER1 L6: Homo sapiens fer-1 -like 6; NM_001039112.2.
FOLR4: Homo sapiens folate receptor 4, delta; NM_001199206.1  FOLR4: Homo sapiens folate receptor 4, delta; NM_001199206.1
GGN: Homo sapiens gametogenin; NM_152657.3. GGN: Homo sapiens gametogenin; NM_152657.3.
GGNBP2: Homo sapiens gametgenin binding protein 2; BC137491.1.  GGNBP2: Homo sapiens gametgenin binding protein 2; BC137491.1.
IZUM01 : Homo sapiens izumo sperm-egg fusion 1 ; NM_182575.2  IZUM01: Homo sapiens izumo sperm-egg fusion 1; NM_182575.2
PSG1 : Homo sapiens pregnancy specific beta-1-glycoprotein; NM_001184825.1 PSG1: Homo sapiens pregnancy specific beta-1-glycoprotein; NM_001184825.1
PSG2: Homo sapiens pregnancy specific beta-1-glycoprotein 2; NM_031246.3 PSG5: Homo sapiens pregnancy specific beta-1-glycoprotein 5; NM_002781.3PSG2: Homo sapiens pregnancy specific beta-1-glycoprotein 2; NM_031246.3 PSG5: Homo sapiens pregnancy specific beta-1-glycoprotein 5; NM_002781.3
ROPN1 L: Homo sapiens rhophilin associated tail protein 1 -like; NM_031916.4.ROPN1 L: Homo sapiens rhophilin associated tail protein 1 -like; NM_031916.4.
SPAG6: Homo sapiens sperm associated antigen 6; CR533552.1. SPAG6: Homo sapiens sperm associated antigen 6; CR533552.1.
SPAG8: Homo sapiens sperm associated antigen 8; NM_172312.1.  SPAG8: Homo sapiens sperm associated antigen 8; NM_172312.1.
SPAG17: Homo sapiens sperm associated antigen 17; NM_206996.2.  SPAG17: Homo sapiens sperm associated antigen 17; NM_206996.2.
DYSF: Homo sapiens dysferlin; GenBank: AF075575.1. DYSF: Homo sapiens dysferlin; GenBank: AF075575.1.
ZP1 : Homo sapiens zona pellucida glycoprotein 1 ; NM_207341.2  ZP1: Homo sapiens zona pellucida glycoprotein 1; NM_207341.2
ZP2: Homo sapiens zona pellucida glycoprotein 2; NM_003460.1.  ZP2: Homo sapiens zona pellucida glycoprotein 2; NM_003460.1.
ZP3: Homo sapiens zona pellucida glycoprotein 3; NM_007155.5..  ZP3: Homo sapiens zona pellucida glycoprotein 3; NM_007155.5 ..
Crispl : Homo sapiens cysteine-rich secretory protein 1 ; NM_001131.2.  Crispl: Homo sapiens cysteine-rich secretory protein 1; NM_001131.2.
Crisp2: Homo sapiens cysteine-rich secretory protein 1 ; NM_001142417.2. Crisp2: Homo sapiens cysteine-rich secretory protein 1; NM_001142417.2.
MYOF: Homo sapiens myoferlin (MYOF); GenBank: AF182316.1.  MYOF: Homo sapiens myoferlin (MYOF); GenBank: AF182316.1.
OTOF: Homo sapiens otoferlin (OTOF); NM_004802.3. MMP15: Homo sapiens matrix metallopeptidase 15; NM_002428.2. OTOF: Homo sapiens otoferlin (OTOF); NM_004802.3. MMP15: Homo sapiens matrix metallopeptidase 15; NM_002428.2.
MMP16: Homo sapiens matrix metalloproteinase 16; NM_005941.4 1. MMP16: Homo sapiens matrix metalloproteinase 16; NM_005941.4 1.
MMP17: Homo sapiens matrix metalloproteinase 17; NM_016155.4. MMP17: Homo sapiens matrix metalloproteinase 17; NM_016155.4.
MMP20: Homo sapiens matrix metalloproteinase 20; NM_004771.3. MMP20: Homo sapiens matrix metalloproteinase 20; NM_004771.3.
SED1 : (secreted protein containing EGF repeats and Discoidin/F5/8. SED1: (secreted protein containing EGF repeats and discoidin / F5 / 8.
complement domains); NM_001114614.1.  complement domains); NM_001114614.1.
ZAN: Homo sapiens zonadhesin variant 1 (ZAN); GenBank: AF332975.1 ZAN: Homo sapiens zonadhesin variant 1 (ZAN); GenBank: AF332975.1
Ferner umfassen die Genprodukte Sequenzen gemäß (SEQ ID NO: 1 bis 36) des Sequenzprotokolls. Die Antigene sind erfindungsgemäß als Targets für die Furthermore, the gene products comprise sequences according to (SEQ ID NO: 1 to 36) of the sequence listing. The antigens are according to the invention as targets for the
Diagnostik und Therapie von Tumorerkrankungen verwendbar. Diagnosis and therapy of tumor diseases usable.
Für die Entstehung von Genprodukten durch veränderte Prozessierung For the production of gene products through altered processing
beispielsweise bei der Transkription können verschiedenste Mechanismen ursächlich sein, wie beispielsweise die Nutzung variabler Transkriptionsstellen, die Nutzung zusätzlicher Exons, die Mutation veränderte Regulatorsequenzen oder die For example, in transcription, a variety of mechanisms may be causative, such as the use of variable transcription sites, the use of additional exons, the mutation altered regulatory sequences or the
unvollständige Elimination von Intronsequenzen. Die veränderte Prozessierung eines Gens führt zu einer veränderten Transkriptsequenz. Wird nun ein Gen im Bereich einer veränderten Sequenz translatiert, so resultiert ein verändertes Protein, welches sich von dem ursprünglichen in Struktur und Funktion deutlich unterscheiden kann. Bei tumorassoziierten Proteinvarianten können tumorassoziierte Transkripte und tumorassoziierte Proteine/Antigene entstehen. incomplete elimination of intron sequences. The altered processing of a gene leads to an altered transcript sequence. If a gene is now translated in the region of an altered sequence, the result is an altered protein, which may differ significantly from the original structure and function. In tumor-associated protein variants, tumor-associated transcripts and tumor-associated proteins / antigens can arise.
Protei ne/Antigene können als molekulare Marker sowohl zum Nachweis von Proteins / antigens can act as molecular markers for both the detection of
Tumorzellen als auch zum therapeutischen Targeting von Tumoren genutzt werden. Zum Nachweis können beispielsweise radioaktive oder nicht-radioaktive Isotope, Photosensitizer, Nanopartikel, Radionuklide, Enzyme oder Antikörper verwendet werden. Die Diagnose und/oder Behandlung von Tumorzellen z.B. in Blut, Serum, Knochenmark, Sputum, Bronchial-Lavage, Körpersekreten und Gewebsbiopsien kann erfindungsgemäß z.B. nach Extraktion von Nukleinsäuren durch PCR- Amplifikation erfolgen. Zum Nachweis eignen sich erfindungsgemäß alle Sequenz-abhängigenTumor cells are used as well as for the therapeutic targeting of tumors. For example, radioactive or non-radioactive isotopes, photosensitizers, nanoparticles, radionuclides, enzymes or antibodies can be used for the detection. The diagnosis and / or treatment of tumor cells, for example in blood, serum, bone marrow, sputum, bronchial lavage, Körpersekreten and tissue biopsies can be carried out according to the invention, for example, after extraction of nucleic acids by PCR amplification. For the detection according to the invention all sequence-dependent are suitable
Detektionssysteme. Neben der PCR sind diese z.B. Microarraysysteme, Northern- Blot, RNAse protection assays (RDA) und andere. Allen Detektionssystemen ist gemeinsam, dass die Detektion auf einer spezifischen Hybridisierung mit Detection systems. In addition to the PCR, these are e.g. Microarray systems, Northern blot, RNAse protection assays (RDA) and others. All detection systems have in common that the detection on a specific hybridization with
mindestens einer spezifischen Nukleinsäuresequenz basiert. Die Detektion von Tumorzellen kann jedoch auch erfindungsgemäß durch Antikörper erfolgen, die ein kodiertes spezifisches Epitop erkennen. based on at least one specific nucleic acid sequence. However, the detection of tumor cells can also be carried out according to the invention by antibodies which recognize a coded specific epitope.
Die erfindungsgemäße pharmazeutische Zusammensetzung zur Hemmung oder Inhibierung der Expression eines Tumor -assoziierten Antigens kann ferner ein Agens oder Mittel umfassen, das das erfindungsgemäß identifizierte Tumorassoziierte Antigen erkennt und vorzugsweise selektiv für Zellen ist, die eine The pharmaceutical composition of the invention for inhibiting or inhibiting the expression of a tumor-associated antigen may further comprise an agent or agent which recognizes the tumor-associated antigen identified according to the invention and is preferably selective for cells having a
Expression eines erfindungsgemäß identifizierten Tumor-assoziierten Antigens aufweisen. Das Mittel kann in bestimmten Ausführungsformen als diagnostisches oder therapeutisches Mittel die Induktion des Zelltods, die Reduktion des Expression of a tumor-associated antigen identified according to the invention. The agent may, in certain embodiments as a diagnostic or therapeutic agent, be the induction of cell death, the reduction of the
Zellwachstums, die Schädigung der Zellmembran oder die Sekretion von Zytokinen bewirken und weist vorzugsweise eine tumorhemmende Aktivität auf. Cell growth, causing damage to the cell membrane or the secretion of cytokines and preferably has a tumor-inhibiting activity.
In einer Ausführungsform ist das Mittel eine Antisense-Nukleinsäure, die selektiv mit der Nukleinsäure hybridisiert, die für das Tumor-assoziierte Antigen kodiert. In einer weiteren Ausführungsform ist das Mittel ein Antikörper, der selektiv an das Tumorassoziierte Antigen bindet, insbesondere ein komplementaktivierender oder Toxin- konjugierter Antikörper, der selektiv an das Tumor-assoziierte Antigen bindet. Ein komplementaktivierender Antikörper ist, ein ADCC aktivierender Antikörper oder ein Antikörper der weitere humorale oder zelluläre Immunantworten auslöst, In one embodiment, the agent is an antisense nucleic acid that selectively hybridizes to the nucleic acid encoding the tumor-associated antigen. In another embodiment, the agent is an antibody that selectively binds to the tumor-associated antigen, in particular a complement-activating or toxin-conjugated antibody that selectively binds to the tumor-associated antigen. A complement-activating antibody, an ADCC-activating antibody or an antibody that triggers further humoral or cellular immune responses,
insbesondere ein(e) Anti-Zytokin Antikörper. Es ist erfindungsgemäß auch in particular an anti-cytokine antibody. It is also according to the invention
vorgesehen, dass Antikörper-ähnliche Moleküle, wie Small-Molecules, humanisierte Antikörperfragmente oder vergleichbare Moleküle aus Schmetterlingen verwendet werden können. In einer weiteren Ausführungsform umfasst das Mittel mehrere Mittel, die jeweils selektiv verschiedene Tumor-assoziierte Antigene erkennen, wobei mindestens eines der Tumor-assoziierten Antigene ein erfindungsgemäß provided that antibody-like molecules, such as small molecules, humanized antibody fragments or similar molecules from butterflies can be used. In another embodiment, the agent comprises a plurality of agents, each of which selectively recognizes different tumor-associated antigens, wherein at least one of the tumor-associated antigens according to the invention
identifiziertes Tumor-assoziiertes Antigen ist. Die Erkennung muss nicht direkt mit einer Hemmung von Aktivität oder Expression des Antigens einhergehen. In einer bevorzugten Ausführungsform ist das Mittel eine Antisense-Nukleinsäure, die selektiv mit der Nukleinsäure hybridisiert, die für das Tumor-assoziierte Antigen kodiert. is identified tumor-associated antigen. The recognition need not be directly associated with an inhibition of the activity or expression of the antigen. In a preferred embodiment, the agent is an antisense nucleic acid that selectively hybridizes to the nucleic acid encoding the tumor-associated antigen.
In einer weiteren Ausführungsform ist das Mittel ein Antikörper, der selektiv an das Tumor-assoziierte Antigen bindet. In einer weiteren Ausführungsform umfasst das Mittel mehrere Mittel, die jeweils selektiv die Expression oder Aktivität verschiedener Tumor-assoziierter Antigene hemmen, wobei mindestens eines der Tumorassoziierten Antigene ein erfindungsgemäß identifiziertes Tumor-assoziiertes In another embodiment, the agent is an antibody that selectively binds to the tumor-associated antigen. In another embodiment, the agent comprises a plurality of agents each selectively inhibiting the expression or activity of various tumor-associated antigens, wherein at least one of the tumor-associated antigens comprises a tumor-associated antigen identified in accordance with the invention
Antigen ist. Antigen is.
In der erfindungsgemäßen pharmazeutischen Zusammensetzung können ein monoklonaler, ein chimärer oder humanisierter Antikörper, ein Fragment eines natürlichen Antikörpers, oder ein synthetischer Antikörper verwendet werden. Die Antikörper können mit einem therapeutisch oder diagnostisch nützlichen Mittel gekoppelt sein. In the pharmaceutical composition of the present invention, a monoclonal, a chimeric or humanized antibody, a fragment of a natural antibody, or a synthetic antibody can be used. The antibodies may be coupled to a therapeutically or diagnostically useful agent.
Therapeutische Mittel können erfindungsgemäß Taxine, Alkylantien, Colchicine, Vincaalkaloide wie beispielsweise Vinblastin und Vincristin, Bleomycin, Therapeutic agents may according to the invention taxines, alkylating agents, colchicines, vinca alkaloids such as vinblastine and vincristine, bleomycin,
Combretastatin, Podophyllotoxin, Angiostatin, Endostatin, Vasculostatin, Interleukine einschließlich Antikrebsmittel, mit radioaktivem lod versehene Verbindungen, Toxine, cytostatische oder cytolytische Arzneistoffe, usw. Antikrebsmittel umfassen Combretastatin, podophyllotoxin, angiostatin, endostatin, vasculostatin, interleukins including anticancer agents, radioactive iodine-containing compounds, toxins, cytostatic or cytolytic drugs, etc. Anticancer agents
beispielsweise Aminoglutethimid, Azathioprin, Bleomycinsulfat, Busulfan, Carmustin, Chlorambucil, Cisplatin, Cyclophosphamid, Cyclosporin, Cytarabidin, Dacarbazin, Dactinomycin, Daunorubin, Doxorubicin, Taxol, Etoposid, Fluoruracil, Interferon- &agr;, Lomustin, Mercaptopurin, Methotrexat, Mitotan, Procarbazin-HCI, Thioguanin sowie Hochenergie-emittierende Radionuklide wie Kobalt-60 sein, sowie Mischungen dieser Mittel. for example, aminoglutethimide, azathioprine, bleomycin sulfate, busulfan, carmustine, chlorambucil, cisplatin, cyclophosphamide, cyclosporin, cytarabidine, dacarbazine, dactinomycin, daunorubin, doxorubicin, taxol, etoposide, fluorouracil, interferon-α, lomustine, mercaptopurine, methotrexate, mitotane, procarbazine HCI, thioguanine and high energy emitting radionuclides such as cobalt-60, as well as mixtures of these agents.
Diagnostische Mittel können umfassen in nicht begrenzender Weise Bariumsulfat, locetaminsäure, lopansäure, Calcium-Ipodat, Natrium-Diatrizoat, Meglumin- Diatrizoat, Metrizamid, Natrium-Tyropanoat und Radiodiagnostika für die Diagnostic agents may include, but are not limited to, barium sulfate, locetamic acid, lopanoic acid, calcium ipodate, sodium diatrizoate, meglumine diatrizoate, metrizamide, sodium tylopanoate and radiodiagnostics for the
Computertomographie, einschließlich Positronen-Emitter wie Fluorin-18 und Carbon- 11 , gamma-Emitter wie lodin-123, Technitium-99m, lod-131 und lndium-111 , Nuklide, insbesondere Nanoteilchen für magnetische Kernresonanz wie Fluorin, Gadolinium, Eisenoxid etc. umfassen. Computed tomography, including positron emitters such as fluorine-18 and carbon-11, gamma emitters such as iodine-123, technitium-99m, iodine-131 and indium-111, Nuclides, in particular nanoparticles for nuclear magnetic resonance such as fluorine, gadolinium, iron oxide, etc. include.
Eine in einer erfindungsgemäßen pharmazeutischen Zusammensetzung enthaltene Antisense-Nukleinsäure kann eine Sequenz von 8 - 20 Basen, bevorzugt aus der translatierten Region des Transkripts mit zusammenhängenden Nukleotiden aus der Nukleinsäure, die für das erfindungsgemäß identifizierte Tumor assoziierte Antigenen kodiert, umfassen. An antisense nucleic acid contained in a pharmaceutical composition of the invention may comprise a sequence of 8-20 bases, preferably from the translated region of the transcript, with contiguous nucleotides from the nucleic acid encoding antigens associated with the invention identified according to the invention.
In weiteren Ausführungsformen bindet ein ADCC aktivierender Antikörper oder ein Antikörper der weitere humorale oder zelluläre Immunantworten auslöst, In further embodiments, an ADCC-activating antibody or antibody will elicit further humoral or cellular immune responses,
insbesondere eine Anti-Zytokin Antikörper entweder direkt oder durch die In particular, an anti-cytokine antibody either directly or through the
Expression einer Nukleinsäure bereitgestelltes Tumor-assoziiertes Antigen auf der Oberfläche von Zellen, wobei die Bindung vorzugsweise eine Zytokinausschüttung induziert oder verhindert. Expression of a nucleic acid provided tumor-associated antigen on the surface of cells, wherein the binding preferably induces or prevents a cytokine secretion.
Eine erfindungsgemäße pharmazeutische Zusammensetzung kann einen A pharmaceutical composition according to the invention can be a
pharmazeutisch verträglichen Träger und/oder einen Hilfsstoff umfassen. Der pharmaceutically acceptable carrier and / or excipient. Of the
Hilfsstoff kann aus der Gruppe Saponin, GM-CSF, CpG-Nukleotiden, RNA oder einem Zytokin ausgewählt sein. Excipient may be selected from the group of saponin, GM-CSF, CpG nucleotides, RNA or a cytokine.
Eine erfindungsgemäße pharmazeutische Zusammensetzung wird vorzugsweise zur Behandlung einer Erkrankung wie beispielsweise Krebs eingesetzt, die sich durch die selektive Expression oder abnormale Expression eines Tumor-assoziierten Antigens auszeichnet. Der Begriff "Erkrankung" betrifft erfindungsgemäß jeden pathologischen Zustand, bei dem Tumor-assoziierte Antigene exprimiert oder abnormal exprimiert werden. Ein Beispiel einer solchen Erkrankung ist Krebs, insbesondere Seminome, Melanome, Teratome, Gliome, Gastrointestinal, Kolorektal- , Pankreas-, Hals, Nasen, Ohren (HNO)-, Brust-, Prostata-, Gebärmutter-, Ovarial-, und Lungenkrebs, Seminome, Melanome, Teratome, Tumore des Nervensystems (wie Gliome, Meningiome, Neuroblastome, Medulloblastome, Schwannome, neuroendokrine Tumore), Gastrointestinal-, Pankreas-, Hals-, Nasen-, Ohren- (HNO)- , Blasen-, Brust, Knochen-, Leber-, Nieren-, Prostata-, Gebärmutter-, Ovarial-, Lungen- und Schilddrüsentumore, Lymphome, sowie Tumorarten des blutbildenden Systems (Leukämien etc.). A pharmaceutical composition according to the invention is preferably used for the treatment of a disease, such as cancer, which is characterized by the selective expression or abnormal expression of a tumor-associated antigen. The term "disease" according to the invention relates to any pathological condition in which tumor-associated antigens are expressed or abnormally expressed. An example of such a disease is cancer, especially seminomas, melanomas, teratomas, gliomas, gastrointestinal, colorectal, pancreatic, cervical, nasal, ear (ENT), breast, prostate, uterine, ovarian and lung cancers, Seminomas, melanomas, teratomas, tumors of the nervous system (such as gliomas, meningiomas, neuroblastomas, medulloblastomas, schwannomas, neuroendocrine tumors), gastrointestinal, pancreatic, cervical, nasal, ear (ENT), bladder, breast, bone , Liver, kidney, prostate, uterus, ovarian, Pulmonary and thyroid tumors, lymphomas, as well as tumor types of the blood-forming system (leukemia, etc.).
Auch betrifft die Erfindung ein Verfahren zur Behandlung oder Diagnose einer Erkrankung, die sich durch die Expression eines oder mehrerer Tumor-assoziierter Antigene auszeichnet umfassend die Behandlung die Verabreichung einer The invention also relates to a method for the treatment or diagnosis of a disease characterized by the expression of one or more tumor-associated antigens, comprising the treatment of the administration of a disease
erfindungsgemäßen pharmazeutischen Zusammensetzung. inventive pharmaceutical composition.
Des Weiteren betrifft die Erfindung ein Verfahren zur Behandlung und/oder Diagnose eine Tumorerkrankung umfassend Furthermore, the invention relates to a method for the treatment and / or diagnosis comprising a tumor disease
a. in Kontaktbringen einer Gewebe- oder Flüssigkeitsprobe eines zu a. in contacting a tissue or fluid sample one to
untersuchenden Individuums mit einem Mittel, das mit einem Tumor-assoziierten Antigen interagiert, wobei das Antigen eine Sequenz aufweist, die aus der Gruppe ausgewählt ist, bestehend aus: einer Nukleinsäure, die eine Nukleinsäuresequenz umfasst, die aus der examining individual with an agent that interacts with a tumor-associated antigen, wherein the antigen has a sequence selected from the group consisting of: a nucleic acid comprising a nucleic acid sequence derived from the
Gruppe SEQ ID NO: 1 bis 36, Group SEQ ID NO: 1 to 36,
einem Teil oder einem Derivat davon  a part or a derivative thereof
einer Nukleinsäure, die unter stringenten Bedingungen mit der  a nucleic acid which under stringent conditions with the
Nukleinsäure unter (a) hybridisiert,  Nucleic acid hybridized under (a),
einer Nukleinsäure, die in Bezug auf die Nukleinsäure unter (a) oder (b) degeneriert ist und  a nucleic acid which is degenerate with respect to the nucleic acid under (a) or (b), and
einer Nukleinsäure, die zu der Nukleinsäure unter (a), (b) oder (c) komplementär ist,  a nucleic acid complementary to the nucleic acid of (a), (b) or (c),
Nachweis der Interaktion des besagten Mittels an Bestandteile der Probe, umfassend PCR, ELISA, Northern-, Southern-, Western-Blot, Immuncyto- und Immunhistologie, MRT, CT, PET, LC/MS. Detecting the interaction of said agent with components of the sample comprising PCR, ELISA, Northern, Southern, Western blot, immunocytochemistry and immunohistology, MRI, CT, PET, LC / MS.
Zur Anwendung des Verfahrens wird eine biologische Probe vorzugsweise von Patienten, die eine Krebserkrankung aufweisen oder bei denen Krebserkrankung vermutet wird oder ein bei denen ein Potential für die Krebserkrankung besteht, isoliert, wobei die Gegenwart der Nukleinsäure und/oder des Tumor-assoziierte Antigens und/oder einer bestimmten Menge einer Nukleinsäure und/oder des Tumor- assoziierten Antigens, als Hinweis für eine Krebserkrankung oder als potentieller Ausganspunkt für die Entwicklung einer Krebserkrankung gesehen. For the application of the method, a biological sample is preferably isolated from patients who have or are suspected of having or are suspected to have cancer, the presence of the nucleic acid and / or the tumor-associated antigen and / or or a certain amount of a nucleic acid and / or of the tumor associated antigen, as an indication of a cancer or as a potential starting point for the development of cancer.
Das Verfahren zur Diagnose und/oder Behandlung umfasst auch die Detektion oder die Bestimmung der Menge der Nukleinsäure und/oder des Tumor-assoziierten Antigens. So ist es möglich, zu prognostizieren ob eine Metastasierung einer The method of diagnosis and / or treatment also includes the detection or determination of the amount of nucleic acid and / or the tumor-associated antigen. So it is possible to predict whether a metastasis of a
Krebserkrankung erfolgen kann. Dies erfolgt durch Anwendung von PCR, ELISA, Northern-, Southern-, Western-Blot, Immuncyto- und Immunhistologie, MRT, CT, PET, LC/MS Methoden. Erfindungsgemäß wird die Detektion einer Nukleinsäure unter Verwendung eines Oligo- oder Polynukleotids, das spezifisch an die Nukleinsäure hybridisiert, durchgeführt, wobei eine selektive Amplifikation der Nukleinsäure, z. B. mittels PCR- Amplifikation erfolgt. Gemäß der Erfindung ist es auch möglich die Erkennung von Tumor-assoziierten Antigenen oder die Bestimmung der Menge eines Tumor-assoziierte Antigens durch Verwendung beispielsweise eines Antikörpers, der spezifisch an das Tumorassoziierte Antigen bindet, vorzunehmen. In einem weiteren Aspekt betrifft das erfindungsgemäße Verfahren zur Behandlung, Diagnose einer Erkrankung, die sich durch die Expression eines erfindungsgemäß identifizierten Tumor-assoziierten Antigens auszeichnet, umfassend die Cancer can be done. This is done by using PCR, ELISA, Northern, Southern, Western blotting, immunocytochemistry and immunohistology, MRI, CT, PET, LC / MS methods. According to the invention, the detection of a nucleic acid using an oligo- or polynucleotide which hybridizes specifically to the nucleic acid, carried out, wherein a selective amplification of the nucleic acid, for. B. by PCR amplification. According to the invention, it is also possible to make the detection of tumor-associated antigens or the determination of the amount of a tumor-associated antigen by using, for example, an antibody which binds specifically to the tumor-associated antigen. In a further aspect, the method according to the invention relates to the treatment, diagnosis of a disease which is characterized by the expression of a tumor-associated antigen identified according to the invention, comprising the
Verabreichung eines Antikörpers, der an das Tumor-assoziierte Antigen oder einen Teil davon bindet und mit einem therapeutischen oder diagnostischen Mittel gekoppelt ist. Administering an antibody which binds to the tumor-associated antigen or portion thereof and is coupled to a therapeutic or diagnostic agent.
Die vorliegende Erfindung wird durch die nachstehenden Beispiele und Abbildungen beschrieben, die ausschließlich der Erläuterung dienen und nicht begrenzend zu verstehen sind. Dem Fachmann sind aufgrund der Beschreibung und Beispiele weitere Ausführungsformen zugänglich, die ebenfalls erfindungsgemäß umfasst sind. The present invention is described by the following examples and figures, which are given by way of illustration only and are not intended to be limiting. The person skilled in the art will be able to access further embodiments based on the description and examples which are likewise included according to the invention.
RNA-Extraktion: Aus 500 ng Gesamt-RNA wurde in einem Reaktionsansatz entsprechend denRNA extraction: From 500 ng total RNA was in a reaction mixture according to the
Angaben des Herstellers eine Erststrang-cDNA-Synthese durchgeführt. Integrität und Qualität der cDNA wurden durch Amplifikation in einer 40 Zyklen-PCR überprüft. According to the manufacturer, a first-strand cDNA synthesis was performed. Integrity and quality of the cDNA were checked by amplification in a 40-cycle PCR.
Es wurde ein Archiv aus Erststrang-cDNAs aus einer Reihe von Normalgeweben und Tumorentitäten hergestellt. Für Expressionsstudien wurden 1 μΙ dieser cDNAs in einem 25 μΙ Reaktionsansatz mit spezifischen Primern (siehe unten) amplifiziert. Die finalen Primerkonzentrationen waren 250 nM für jeden Primer. An archive of first-strand cDNAs from a variety of normal tissues and tumor entities was prepared. For expression studies, 1 μΙ of these cDNAs were amplified in a 25 μΙ reaction using specific primers (see below). The final primer concentrations were 250 nM for each primer.
Die Hybridisierungstemperaturen wurden mit Hilfe des Online-Tools„TM Calculator" (NEB) ermittelt. Nach 5 Minuten bei 95°C zur Aktivierung der Polymerase wurden 40 Zyklen PCR (Denaturierung bei 95°C für 15 s, Hybridisierungstemperatur 65°C für 30 s und abschließende Elongation bei 72°C für 30 s) durchgeführt. 20 μΙ dieser Reaktion wurden auf einem mit Ethidiumbromid gefärbten 2% Agarosegel aufgetrennt und analysiert. Hybridization temperatures were determined using the online tool "TM Calculator" (NEB) After 5 minutes at 95 ° C to activate the polymerase, 40 cycles of PCR (denaturation at 95 ° C for 15 s, hybridization temperature 65 ° C for 30 s and final elongation at 72 ° C for 30 sec.) 20 μΙ of this reaction was separated on an ethidium bromide stained 2% agarose gel and analyzed.
Folgende Primer wurden für die Expressionsanalyse der entsprechenden Antigene verwendet: The following primers were used for the expression analysis of the corresponding antigens:
Acrosin (ACR):  Acrosine (ACR):
Sense: 5 -GTCGGCAAAAATAATGTGCATGACTGGAG-3' Sense: 5 -GTCGGCAAAATAATGTGCATGACTGGAG-3 '
Antisense: 5 '-ATGGCCTGGGGGCTTTCTCTTC-3 ' Antisense: 5 '-ATGGCCTGGGGGCTTTCTCTTC-3'
Acrosin binding protein (ACRBP): Acrosine binding protein (ACRBP):
Sense: 5 '-GCAACCAGGTAGGGTCCCCAG AATCA-3 ' Sense: 5 '-GCAACCAGGTAGGGTCCCCAG AATCA-3'
Antisense: 5 -TGCGGGACACCTTCCGATTGCG-3' Antisense: 5 -TGCGGGACACCTTCCGATTGCG-3 '
Cation Channel, sperm associated 1 (CATSPER1 ): Cation Channel, sperm associated with 1 (CATSPER1):
Sense: 5 -CCAGTACTTCATCTTCCTCAACCTGGTG-3 ' Sense: 5 -CCAGTACTTCATCTTCCTCAACCTGGTG-3 '
Antisense: 5 '-GGAGCTCCTGCTGCTTCTCAGTC-3 ' Cation Channel, sperm associated 2 (CATSPER2): Antisense: 5 ' -GGAGCTCCTGCTGCTTCTCAGTC-3 ' cation channel, sperm associated 2 (CATSPER2):
Sense: 5'-AGTACCATGTGTTCTTCTCGGACCTC-3' Sense: 5 '-AGTACCATGTGTTCTTCTCGGACCTC-3'
Antisense: 5 -GTTG ACTAGCTCCTCTTGAACTGTCCTC-3 ' Cation Channel, sperm associated 4 (CATSPER4): Antisense: 5-GTTG ACTAGCTCCTCTTGAACTGTCCTC-3 ' Cation Channel, sperm associated with 4 (CATSPER4):
Sense: 5 '-TCAACTACACTCTCAGGGCGCTTC-3 ' Sense: 5 ' -TCAACTACACTCTCAGGGCGCTTC-3 '
Antisense: 5 '-TCCCTCTTCTCTGTCTG G AAGTCACTG-3 ' Antisense: 5 'G -TCCCTCTTCTCTGTCTG AAGTCACTG-3'
Catsper Channel auxiliary subunit beta (CATSPERB): Catsper Channel auxiliary subunit beta (CATSPERB):
Sense: 5'-TCTTTTTGGACAGCCTCCAGATATGGG-3' Antisense: 5'-ACAAGGCCTGAACAACTTGTGAATCA-3' Sense: 5 '-TCTTTTTGGACAGCCTCCAGATATGGG-3' antisense: 5 '-ACAAGGCCTGAACAACTTGTGAATCA-3'
Catsper Channel auxiliary subunit delta (CATSPERD): Catsper Channel auxiliary subunit delta (CATSPERD):
Sense: 5 '-GGTGGAGCTGTGGCGAAAAGAC-3 ' Scythe: 5 ' -GGTGGAGCTGTGGCGAAAAGAC-3 '
Antisense: 5 '-CTCCAGTTGACAGTAGCTGTAGTACGG-3 ' Antisense: 5 '-CTCCAGTTGACAGTAGCTGTAGTACGG-3'
Catsper Channel auxiliary subunit gamma (CATSPERG): Catsper Channel auxiliary subunit gamma (CATSPERG):
Sense: 5 '-TCCAGGGCAGCTATGTTCTGCT-3 ' Sense: 5 '-TCCAGGGCAGCTATGTTCTGCT-3'
Antisense: 5'-ACGCTAGCTGACACCATGATGATGA-3' Antisense: 5 '-ACGCTAGCTGACACCATGATGATGA-3'
Cysteine-rich secretory protein 3 (CRISP3): Cysteine-rich secretory protein 3 (CRISP3):
Sense: 5'-GCAAATGAAGATAAGGATCCCGCTTTTACTG-3' Antisense: 5 '-GCCTCTTTGTTCCATTCCATCTTCAGC-3 ' Fer-1 -like 5 (FER1 L5): Sense: 5 '-GCAAATGAAGATAAGGATCCCGCTTTTACTG-3' antisense: 5 '-GCCTCTTTGTTCCATTCCATCTTCAGC-3' Fer-1 -like 5 (FER1 L5):
Sense: 5'-CGCTTGTCGGGCAAGGTGAAG-3' Sense: 5 '-CGCTTGTCGGGCAAGGTGAAG-3'
Antisense: 5'-GCCAAATAGTGCGGAGCTGAATAGATG-3' Antisense: 5 '-GCCAAATAGTGCGGAGCTGAATAGATG-3'
Fer-1 -like 6 (Fer1 L6): Fer-1-like 6 (Fer1 L6):
Sense: 5 '-GAAG AGG ACACTGATGAGACAGTGGAG-3 ' Antisense: 5'-ACTCTCAATTCGTATCCTTTGGGTCGC-3' Sense: 5 'AGG -GAAG ACACTGATGAGACAGTGGAG-3' antisense: 5 '-ACTCTCAATTCGTATCCTTTGGGTCGC-3'
Folate receptor 4 (FOLR4) Folate receptor 4 (FOLR4)
Sense: 5 '- ATCCCCTGG AAGGACAATGC -3 ' Scythe: 5 ' - ATCCCCTGG AAGGACAATGC -3 '
Antisense: 5'- ACAGTCTTCCCACCACTCCT -3' lzumo-1 (IZUM01 ) Antisense: 5 ' - ACAGTCTTCCCACCACTCCT -3 ' lzumo-1 (IZUM01)
Sense: 5 '- AACCTTACCCTCGTCCCCAA -3 ' Scythe: 5 ' - AACCTTACCCTCGTCCCCAA -3 '
Antisense: 5'- GACCGTTAGGAAGGGTGCTC -3' Antisense: 5 ' - GACCGTTAGGAAGGGTGCTC -3 '
Pregnanacy specific beta-1 glycoprotein 1 (PSG1 ): Pregnanacy specific beta-1 glycoprotein 1 (PSG1):
Sense: 5'-CCTGAATCTCCTCCCF AAGCTG-3' Sense: 5 '-CCTGAATCTCCTCCCF AAGCTG-3'
Antisense: 5 -GGTCTGGACCATAGAGGACATTYAGG-3' Antisense: 5 -GGTCTGGACCATAGAGGACATTYAGG-3 '
Pregnancy specific beta-1 glycoprotein 2 (PSG2): Pregnancy specific beta-1 glycoprotein 2 (PSG2):
Sense: 5 -CACCTTATACCTGGAGACTCCCAAGC-3' Antisense: 5'-GAGGTCTGGACCATGGAGGAGA-3' Sense: 5 -CACCTTATACCTGGAGACTCCCAAGC-3 'antisense: 5' -GAGGTCTGGACCATGGAGGAGA-3 '
Pregnancy specific beta-1 glycoprotein 5 (PSG5): Pregnancy specific beta-1 glycoprotein 5 (PSG5):
Sense: 5'-CCTTCAACTTATACCTGAAGCTGCCC-3' Sense: 5 '-CCTTCAACTTATACCTGAAGCTGCCC-3'
Antisense: 5 -GTCTGGACCATAGAGGACATTCAGG-3' Antisense: 5 -GTCTGGACCATAGAGGACATTCAGG-3 '
Gametogenetin (GGN): Gametogenetin (GGN):
Sense: 5 -ACGCGCAGGAACAAGGGTT-3' Scythe: 5 -ACGCGCAGGAACAAGGGTT-3 '
Antisense: 5'-ATGTGCTCAGCCAGGCAGAGAC-3' Gametogenetin binding protein 2 (GGNBP2): Antisense: 5 '-ATGTGCTCAGCCAGGCAGAGAC-3' Gametogenetin binding protein 2 (GGNBP2):
Sense: 5'-CCAAAACCTTTGGGAGGTTGTTGGAT-3' Antisense: 5'-CTTTCTCTTCGCCCTCCTGCG-3' Sense: 5 '-CCAAAACCTTTGGGAGGTTGTTGGAT-3' antisense: 5 '-CTTTCTCTTCGCCCTCCTGCG-3'
Rhophilin associated tail protein 1-like (ROPN1 L): Rhophilin associated tail protein 1-like (ROPN1 L):
Sense: 5'-GCACAAGCAGTGTCACCACAAGC-3' Antisense: 5 -CAGTGTTCAAGGACCCACCAAGCA-3' Sense: 5 '-GCACAAGCAGTGTCACCACAAGC-3' antisense: 5 -CAGTGTTCAAGGACCCACCAAGCA-3 '
Sperm associated antigen 6 (SPAG6): Sperm associated antigen 6 (SPAG6):
Sense: 5 '-GCTAAATTG AAGCATCAGATCCTTTCAGC-3 ' Antisense: 5'-CAGACTGACAACTGGGGTACACC-3' Sense: 5 '-GCTAAATTG AAGCATCAGATCCTTTCAGC-3' antisense: 5 '-CAGACTGACAACTGGGGTACACC-3'
Sperm associated antigen 8 (SPAG8): Sperm associated antigen 8 (SPAG8):
Sense: 5 '-AACTGGGAGGAAGAGAGAGCCAC-3 ' Antisense: 5 '-CGGTAGTCGTGAGGCTTTGTTGG-3 ' Scythe: 5 ' -AACTGGGAGGAAGAGAGAGCCAC-3 ' Antisense: 5 '-CGGTAGTCGTGAGGCTTTGTTGG-3'
Sperm associated antigen 17 (SPAG17): Sperm associated antigen 17 (SPAG17):
Sense: 5 '-TGTCAATGGAACGGTTATGACAACTCGA-3 ' Scythe: 5 ' -TGTCAATGGAACGGTTATGACAACTCGA-3 '
Antisense: 5 -TGG AGGTAACACCTGGTATGTTCCC-3 ' Antisense: 5 -TGG AGGTAACACCGGTATGTTCCC-3 '
DYSF (Dysferlin, limb gridle muscular dystrophy 2B) DYSF (Dysferlin, limb gridle muscular dystrophy 2B)
Sense: 5'-TGGTGGTCAAAGACCATGAG-3' Scythe: 5 ' -TGGTGGTCAAAGACCATGAG-3 '
Antisense: 5'-ACATCCAGGTCAGGCAGAGT-3' ZP 1 (Zona pellucida glycoprotein 1 ) Antisense: 5 '-ACATCCAGGTCAGGCAGAGT-3' ZP 1 (zona pellucida glycoprotein 1)
Sense: 5'-GTGTCTGGCATCCACATCCA-3' Sense: 5 ' -GTGTCTGGCATCCACATCCA-3 '
Antisense: 5 -G AAAGGGCATCCGTCTG ACA-3 ' Antisense: 5 -G AAAGGGCATCCGTCTG ACA-3 '
ZP 2 (Zona pellucida glycoprotein 2) ZP 2 (zona pellucida glycoprotein 2)
Sense: 5 '-GCCTGTCTTTGAGGCTCAGT-3 ' Sense: 5 '-GCCTGTCTTTGAGGCTCAGT-3'
Antisense: 5'-TTGGTTGGCGGAGGAATCTC-3' Antisense: 5 ' -TTGGTTGGCGGAGGAATCTC-3 '
ZP 3 (Zona pellucida glycoprotein 3) ZP 3 (Zona pellucida glycoprotein 3)
Sense: 5'-GGATGTGTCCGGTGCCATAG-3' Scythe: 5 ' -GGATGTGTCCGGTGCCATAG-3 '
Antisense: 5 -CACTCGTGGAGTCCAACCTC-3 ' Antisense: 5 -CACTCGTGGAGTCCAACCTC-3 '
CRISP 1 (Cysteine-rich secretory protein 1 ) CRISP 1 (Cysteine-rich secretory protein 1)
Sense: 5 '-TGTCATG ACTAACCCCTGCATCT-3 ' Scythe: 5 ' -TGTCATG ACTAACCCCTGCATCT-3 '
Antisense: 5'-TCTCCTCCTCATCGTCACAGCA-3' Antisense: 5 ' -TCTCCTCCTCATCGTCACAGCA-3 '
CRISP 2 (Cysteine-rich secretory protein 2) CRISP 2 (Cysteine-rich secretory protein 2)
Sense: 5 '-TGCAGGAAGGTCTGTGCTCTGGA-3 ' Sense: 5 '-TGCAGGAAGGTCTGTGCTCTGGA-3'
Antisense: 5 -CCCTTTGCACTTGCAACTGGGTGGT-3' Antisense: 5 -CCCTTTGCACTTGCAACTGGGTGGT-3 '
MYOF (Myoferlin) MYOF (myoferlin)
Sense: 5 -TGTGGAATCTGCCAGCAATA-3 ' Sense: 5 -TGTGGAATCTGCCAGCAATA-3 '
Antisense: 5 -CAGGTCCTTCAGGGCTACAG-3' OTOF (Otoferlin) Antisense: 5 -CAGGTCCTTCAGGGCTACAG-3 ' OTOF (Otoferlin)
Sense: 5 -ATGGCCACCGGGGAGGTGGA-3' Sense: 5 -ATGGCCACCGGGGAGGTGGA-3 '
Antisense: 5 -AGCTCGTGTCGGGCCGGTTG-3' Antisense: 5-AGCTCGTGTCGGGCCGGTTG-3 '
SED-1 (secreted protein containing EGF repeats and SED-1 (secreted protein containing EGF repeats and
Discoidin/F5/8 complement domains)  Discoidin / F5 / 8 complement domains)
Sense: 5 -CCTCCAGCAGCTACAAGACC-3' Scythe: 5 -CCTCCAGCAGCTACAAGACC-3 '
Antisenses: 5'-TGGGGTCCTGGTACTCAGTC-3' Anti Senses: 5 '-TGGGGTCCTGGTACTCAGTC-3'
ZAN (Zonadhesin) ZAN (zonadhesin)
Sense: 5 '-TCTGGACTCTGCTGCTTCTG-3' Scythe: 5 ' -TCTGGACTCTGCTGCTTCTG-3 '
Antisense: 5 -GATAGCTGCCCTCTCCGTTA-3' Antisense: 5-GATAGCTGCCCTCTCCGTTA-3 '
MMP 15 (Matrix metallopeptidase 15) MMP 15 (matrix metallopeptidase 15)
Sense: 5 -CCCGCTGTGGGGTGCCAGAC-3' Sense: 5-CCCGCTGTGGGGTGCCAGAC-3 '
Antisense: 5'-TGCTCCCACACGCGGAAGGC-3' Antisense: 5 ' -TGCTCCCACACGCGGAAGGC-3 '
MMP 16 (Matrix metallopeptidase 16) MMP 16 (matrix metallopeptidase 16)
Sense: 5'-CGGCCTCCAACCGGCAGACC-3' Sense: 5 '-CGGCCTCCAACCGGCAGACC-3'
Antisense: 5 -AGGAGGCAAGCCCCGCCAGA-3' Antisense: 5-AGGAGGCAAGCCCCGCCAGA-3 '
MMP 17 (Matrix metallopeptidase 17) MMP 17 (matrix metallopeptidase 17)
Sense: 5 -ACGCCGTGTACGAGCGCACC-3' Scythe: 5 -ACGCCGTGTACGAGCGCACC-3 '
Antisense: 5 -ACCAGCGCATGGCGTCGTCC-3' MMP 20 (Matrix metallopeptidase 20) Antisense: 5 -ACCAGCGCATGGCGTCGTCC-3 ' MMP 20 (matrix metallopeptidase 20)
Sense: 5 '-GGG AG ATGGATACAGCTACG-3 ' Scythe: 5 ' -GGG AG ATGGATACAGCTACG-3 '
Antisense: 5 -TTAGCAACCAATCCAGGAACTAGAT-3' Antisense: 5 -TTAGCAACCAATCCAGGAACTAGAT-3 '
Klonierung und Sequenzanalyse Cloning and sequence analysis
Klonierung von Genen bzw. Genfragmenten erfolgte nach gängigen Methoden. Im Folgenden sind die Referenzen für die mit den untersuchten Tumorzellinien aufgeführt: Cloning of genes or gene fragments was carried out according to common methods. The following are the references for the tumor cell lines studied:
A 172, U251 , U373, U 87-MG, TC620, SKMG5, U178: Kuklinski S, Pesheva P, Heimann C, Urschel S, Gloor S, Graeber S, Herzog V, Pietsch T, Wiestier OD, Probstmeier R. Expression pattern of galectin-3 in neural tumor cell lines. J Neurosci Res. 2000;60:45-57; GLC-2: Murmann T, Carrillo-Garcia C, Veit N, Courts C, A 172, U251, U373, U87-MG, TC620, SKMG5, U178: Kuklinski S, Pesheva P, Heimann C, Urschel S, Gloor S, Graeber S, Herzog V, Pietsch T, Wiestier OD, Probstmeier R. Expression pattern of galectin-3 in neural tumor cell lines. J Neurosci Res. 2000; 60: 45-57; GLC-2: Murmann T, Carrillo-Garcia C, Veit N, Courts C,
Glassmann A, Janzen V, Madea B, Reinartz M, Harzen A, Nowak M, Perner S, Winter J, Probstmeier R. Staurosporine and extracellular matrix proteins mediate the differentiation of small cell lung Carcinoma cells into a neuron-like phenotype 2014, PLOSONE ; in press; HeLa: Landry JJ, Pyl PT, Rausch T, Zichner T, Tekkedil MM, Stütz AM, Jauch A, Aiyar RS, Pau G, Delhomme N, Gagneur J, Korbel JO, Huber W, Steinmetz LM. The genomic and transcriptomic landscape of a HeLa cell line. G3 (Bethesda). 2013;3:1213-24; B-CPAP: Schweppe RE, Klopper JP, Korch C, Glassmann A, Janzen V, Madea B, Reinartz M, Resins A, Nowak M, Perner S, Winter J, Probstmeier R. Staurosporine and extracellular matrix proteins. Carcinoma cells into a neuron-like phenotype 2014, PLOSONE ; in press; HeLa: Landry JJ, Pyl PT, Noise T, Zichner T, Tekkedil MM, Supports AM, Jauch A, Aiyar RS, Pau G, Delhomme N, Gagneur J, Korbel JO, Huber W, Steinmetz LM. The genomic and transcriptomic landscape of a HeLa cell line. G3 (Bethesda). 2013; 3: 1213-24; B-CPAP: Schweppe RE, Klopper JP, Korch C,
Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR. Deoxyribonucleic acid profiling analysis of human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and
misidentification. J Clin Endocrinol Metab. 2008;93:4331-41 ; HL60: Birnie GD. The HL60 cell line: a model System for studying human myeloid cell differentiation. Br J Cancer Suppl. 1988;9:41-5; HT-29: Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknaes M, Hektoen M, Lind GE, Lothe RA. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis. 2013;2:e71. doi: 10.1038/oncsis.2013.35; misidentification. J Clin Endocrinol Metab. 2008; 93: 4331-41; HL60: Birnia GD. The HL60 cell line: a model for human myeloid cell differentiation. Br J Cancer Suppl. 1988; 9: 41-5; HT-29: Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknaes M, Hektoen M, Lind GE, Lothe RA. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis. 2013; 2: e71. doi: 10.1038 / oncsis.2013.35;
A549: Watanabe T, Miura T, Degawa Y, Fujita Y, Inoue M, Kawaguchi M, Furihata C. Comparison of lung cancer cell lines representing four histopathological Subtypes with gene expression profiling using quantitative real-time PCR. Cancer Cell Int. 2010;10:2. doi: 10.1186/1475-2867-10-2.; BHY, MG63, SaOS-2, SW-872, MCF7, PC3 (Cell Line Service, Eppelheim, Deutschland), HN (DSMZ, Braunschweig, Deutschland).  A549: Watanabe T, Miura T, Degawa Y, Fujita Y, Inoue M, Kawaguchi M, Furihata C. Comparison of lung cancer cell lines versus four histopathological subtypes with gene expression profiling using quantitative real-time PCR. Cancer Cell Int. 2010; 10: 2nd doi: 10.1186 / 1475-2867-10-2 .; BHY, MG63, SaOS-2, SW-872, MCF7, PC3 (Cell Line Service, Eppelheim, Germany), HN (DSMZ, Braunschweig, Germany).
Erfindungsgemäß wurde mit einem Gen-spezifischen Primerpaaren in RT-PCR- Analysen cDNA in folgenden Zelllinien amplifiziert: A 172, SKMG5, U87, U251 , U373, TC620, MG63, SaOS-2, SW-872, B-CPAP, A549, BHY, GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60. Dabei wurden RT-PCR-Analysen von Tumorantigenen durchgeführt, wobei die Namen der Tumorantigene in abgekürzter Form links neben den Gelspuren genannt sind (vgl. Abb.1 ). Beispiel 1 : Identifizierung von Acrosin (ACR) als diagnostisches und therapeutisches Target According to the invention, cDNA was amplified with a gene-specific primer pairs in RT-PCR analyzes in the following cell lines: A 172, SKMG5, U87, U251, U373, TC620, MG63, SaOS-2, SW-872, B-CPAP, A549, BHY , GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60. RT-PCR analyzes of tumor antigens were carried out, the names of the tumor antigens being abbreviated to the left of the gel traces (see Fig. 1). Example 1: Identification of Acrosine (ACR) as a Diagnostic and Therapeutic Target
ACR ist die Hauptprotease im Akrosom von Spermien. Es bewirkt die Lyse der Zona pellucida der Eizelle. Die Sequenz ist in der Gendatenbank unter der Zugangsnummer NM_001097.2 veröffentlicht. Acrosin besitzt als Präproprotein ein Molekulargewicht von 46 kD. In Tumoren ist bislang keine Expression beschrieben worden. ACR is the major protease in the acrosome of sperm. It causes lysis of the zona pellucida of the egg. The sequence is published in the gene database under accession number NM_001097.2. Acrosin has a molecular weight of 46 kD as preproprotein. In tumors so far no expression has been described.
Es wurde nach Abb. 1 herausgefunden, dass ACR in folgenden Zelllinien It was found after Fig. 1 that ACR in the following cell lines
nachweisbar ist: A 172, SKMG5, U87-MG, U251 , U373, TC620, MG63, B-CPAP, A549, HN, HeLa, HT29, MCF7, PC3. Die selektive und teilweise hohe Expression von ACR-Transkripten können erfindungsgemäß als Zielstrukturen (Targets) von Antikörpern genutzt werden. Diese Antikörper, die monoklonal oder auch detectable: A 172, SKMG5, U87-MG, U251, U373, TC620, MG63, B-CPAP, A549, HN, HeLa, HT29, MCF7, PC3. The selective and partially high expression of ACR transcripts can be used according to the invention as target structures (targets) of antibodies. These antibodies, monoclonal or too
rekombinanter Art sein können, binden spezifisch an die Zelloberfläche der can specifically bind to the cell surface of the
Tumorzellen und können sowohl für diagnostische als auch therapeutische Verfahren genutzt werden. Des Weiteren können die für Proteine kodierenden Sequenzen zur Induktion von Tumor-spezifischen Immun-Antworten (T-Zell und B-Zell-vermittelte Immun-Reaktionen) genutzt werden. Ferner können entsprechend der zellulären Funktion des ACR-Moleküls erfindungsgemäß Substanzen, insbesondere kleinere Moleküle entwickelt werden, welche die Funktion von ACR auf Tumorzellen inhibieren oder modulieren. Tumor cells and can be used for both diagnostic and therapeutic procedures. Furthermore, the protein coding sequences can be used to induce tumor-specific immune responses (T cell and B cell mediated immune responses). Furthermore, according to the invention, according to the cellular function of the ACR molecule, it is possible to develop substances, in particular smaller molecules, which inhibit or modulate the function of ACR on tumor cells.
Da mehrere untersuchte Zelllinien eine Expression aufweisen, ist das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet.  Since several investigated cell lines have an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy.
Beispiel 2: Identifizierung von ACRBP als diagnostisches und therapeutisches Example 2: Identification of ACRBP as Diagnostic and Therapeutic
Target  target
Die Sequenz des Acrosin binding protein ist in der Genbank unter der The sequence of the acrosin binding protein is in the Genbank under the
Zugangsnummer NM_032489.2 veröffentlicht. Bei ACRBP handelt es sich um ein Protein mit einem Molekulargewicht von rund 59 kDa, das im Akrosom des Testis exprimiert wird. Eine Expression in Blasen-, Brust-, Lungen-, Leber- und Colon- Tumoren ist nachgewiesen (Ono T, Kurashige T, Harada N, Noguchi Y, Saika T, Niikawa N, Aoe M, Nakamura S, Higashi T, Hiraki A, Wada H, Kumon H, Old LJ, Nakayama E. Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen. Proc Natl Acad Sei U S A. 2001 Mar 13;98(6):3282-7). Accession number NM_032489.2 published. ACRBP is a protein with a molecular weight of approximately 59 kDa that is expressed in the acrosome of the testis. Expression in bladder, breast, lung, liver and colon tumors has been demonstrated (Ono T, Kurashige T, Harada N, Noguchi Y, Saika T, Nikamawa N, Aoe M, Nakamura S, Higashi T, Hiraki A, Wada H, Kumon H, Old LJ, Nakayama E. Identification of proacrosin binding protein sp32 precursor as a human cancer / testis antigen. Proc Natl Acad See USA 2001 Mar 13; 98 (6): 3282-7).
RT-PCR-Untersuchungen mit einem ACRBP-spezifischem Primerpaar zeigen in Abb.1 eine Expression von ACRBP in folgenden Zelllinien: A 172, U87-MG, U251 , TC620, MG63, SW-872, B-CPAP, A549, GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60. Das erwartete PCR-Produkt ist 270 bp lang. RT-PCR studies with an ACRBP-specific primer pair in Figure 1 show an expression of ACRBP in the following cell lines: A 172, U87-MG, U251, TC620, MG63, SW-872, B-CPAP, A549, GLC-2 , HN, HeLa, HT29, MCF7, PC3, HL60. The expected PCR product is 270 bp long.
Da mehrere untersuchte Zelllinien eine Expression aufweisen, ist das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet.  Since several investigated cell lines have an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy.
Beispiel 3: Identifizierung von CATSPER1 als diagnostisches und therapeutisches Example 3: Identification of CATSPER1 as Diagnostic and Therapeutic
Target  target
Die Sequenz von CATSPER1 ist in der GenBank unter der ZugangsnummerThe sequence of CATSPER1 is in the GenBank under the accession number
NM_053054 veröffentlicht. Bei CATSPER1 handelt es sich um ein Membranprotein mit einem Molekulargewicht von 90 kDa, das in Flagellen von Spermatozoen exprimiert wird. Eine Expression in Tumoren ist nicht bekannt (Ren D, Navarro B, Perez G, Jackson AC, Hsu S, Shi Q, Tilly JL, Clapham DE. A sperm ion Channel required for sperm motility and male fertility. Nature. 2001 Oct 11 ;413(6856):603-9). NM_053054 published. CATSPER1 is a membrane protein of molecular weight 90 kDa expressed in flagella of spermatozoa. Expression in tumors is not known (Ren D, Navarro B, Perez G, Jackson AC, Hsu S, Shi Q, Tilly JL, Clapham DE, Sperm ion Channel required for sperm motility and male fertility, Nature, 2001 Oct 11; 413 (6856): 603-9).
RT-PCR-Untersuchung in Abb.1 mit einem CATSPER1 -spezifischen Primerpaar bestätigt eine Expression in folgenden Zelllinien (245 bp erwartete Fragmentlänge): A 172, SKMG5, U87-MG, U251 , U373, TC620, MG63, SW-872, B-CPAP, A549, BHY, GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60. RT-PCR analysis in Fig. 1 with a CATSPER1-specific primer pair confirms expression in the following cell lines (245 bp expected fragment length): A 172, SKMG5, U87-MG, U251, U373, TC620, MG63, SW-872, B CPAP, A549, BHY, GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60.
Da mehrere untersuchte Zelllinien eine Expression aufweisen, ist das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet. Beispiel 4: Identifizierung von CATSPER2 als diagnostisches und therapeutisches Target Since several investigated cell lines have an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy. Example 4: Identification of CATSPER2 as a Diagnostic and Therapeutic Target
Die Sequenz von CATSPER2 ist in der GenBank unter der Zugangsnummer NM_172095.2 veröffentlicht. Bei CATSPER2 handelt es sich um ein Membranprotein mit einem Molekulargewicht von 62 kDa, das in Flagellen von Spermatozoen exprimiert wird. Eine Expression in Tumoren ist nicht bekannt (Quill TA, Ren D, Clapham DE, Garbers DL. A voltage-gated ion Channel expressed specifically in spermatozoa. Proc Natt Acad Sei U S A. 2001 Oct 23;98(22):12527-31. The sequence of CATSPER2 is published in GenBank under accession number NM_172095.2. CATSPER2 is a membrane protein with a molecular weight of 62 kDa expressed in flagella of spermatozoa. Expression in tumors is not known (Quill TA, Ren D, Clapham DE, Garber's DL, A voltage-gated ionic channel, specifically in spermatozoa.) Proc Natt Acad See USA 2001 Oct 23; 98 (22): 12527-31 ,
RT-PCR-Untersuchung in Abb.1 mit einem spezifischen Primerpaar bestätigt eine Expression in folgenden Zelllinien (erwartete Fragmentlänge 270 Basenpaare): A 172, SKMG5, U87-MG, U251 , U373, TC620, MG63, SW-872, B-CPAP, BHY, GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60. RT-PCR assay in Fig. 1 with a specific primer pair confirms expression in the following cell lines (expected fragment length 270 base pairs): A172, SKMG5, U87-MG, U251, U373, TC620, MG63, SW-872, B-CPAP , BHY, GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60.
Da mehrere untersuchte Zelllinien eine Expression aufweisen, ist das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet.  Since several investigated cell lines have an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy.
Beispiel 5: Identifizierung von CATSPER4 als diagnostisches und therapeutisches Example 5: Identification of CATSPER4 as Diagnostic and Therapeutic
Target  target
Die Sequenz von CATSPER4 ist in der GenBank unter der Zugangsnummer The sequence of CATSPER4 is in the GenBank under the accession number
NM_ 98137.1 veröffentlicht. Bei CATSPER4 handelt es sich um ein Membranprotein mit einem Molekulargewicht von 54 kDa, das exklusiv in Spermatozoen exprimiert wird. Eine Expression in Tumoren ist bisher nicht bekannt (Lobley A, Pierron V, Reynolds L, Allen L, Michalovich D. Identification of human and mouse CatSper3 and CatSper4 genes: characterisation of a common interaction domain and evidence for expression in testis. Reprod Biol Endocrino 2003;1 :53) NM_ 98137.1 published. CATSPER4 is a membrane protein with a molecular weight of 54 kDa that is expressed exclusively in spermatozoa. Expression in tumors is not yet known (Lobley A, Pierron V, Reynolds L, Allen L, Michalovich D. Identification of human and mouse CatSper3 and CatSper4 genes: characterization of a common interaction domain and evidence for expression in testis Reprod Biol Endocrino 2003; 1: 53)
RT-PCR-Untersuchung in Abb.1 mit einem spezifischen Primerpaar bestätigt eine Expression in folgender Zelllinie (erwartete Fragmentlänge 259 Basenpaare): MCF7. Beispiel 6: Identifizierung von CATSPERB als diagnostisches und therapeutisches Target RT-PCR examination in Fig. 1 with a specific primer pair confirms expression in the following cell line (expected fragment length 259 base pairs): MCF7. Example 6: Identification of CATSPERB as a Diagnostic and Therapeutic Target
Die Sequenz von CATSPERB ist in der GenBank unter der Zugangsnummer v NM_024764.2 veröffentlicht. CATSPERB ist ein Membranprotein mit einem Molekulargewicht von 125 kDa, das in Flagellen von Spermatozoen exprimiert wird. Eine Expression in Tumoren ist nicht bekannt (Liu J, Xia J, Cho KH, Clapham DE, Ren D. CatSperbeta, a novel transmembrane protein in the CatSper Channel complex. J Biol Chem. 2007 Jun 29;282(26):18945-52. Epub 2007 May 3). The sequence of CATSPERB is published in the GenBank under the accession number v NM_024764.2. CATSPERB is a membrane protein of molecular weight 125 kDa expressed in flagella of spermatozoa. Expression in tumors is not known (Liu J, Xia J, Cho KH, Clapham DE, Ren D. CatSperbeta, a novel transmembrane protein in the CatSper Channel Complex J Biol Chem. 2007 Jun 29; 282 (26): 18945- 52nd Epub 2007 May 3).
RT-PCR-Untersuchung mit einem spezifischen Primerpaar bestätigte eine RT-PCR assay with a specific primer pair confirmed one
Expression von CATSPERB in den folgenden untersuchten Zelllinien (erwartete Fragmentlänge 371 bp): TC620, A549, BHY, HeLa, HT29, MCF7.  Expression of CATSPERB in the following cell lines examined (expected fragment length 371 bp): TC620, A549, BHY, HeLa, HT29, MCF7.
Da mehrere untersuchte Zelllinien eine Expression aufweisen, ist das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet. Since several investigated cell lines have an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy.
Beispiel 7: Identifizierung von CATSPERD als diagnostisches und therapeutisches Example 7: Identification of CATSPERD as Diagnostic and Therapeutic
Target Die Sequenz von CATSPERD ist in der GenBank unter der Zugangsnummer NM_152784.3 veröffentlicht. CATSPERD ist ein Membranprotein mit einem Molekulargewicht von 91 kDa, das in Flagellen von Spermatozoen exprimiert wird. Eine Expression in Tumoren ist nicht bekannt (Chung JJ, Navarro B, Krapivinsky G, Krapivinsky L, Clapham DE. A novel gene required for male fertility and functional CATSPER Channel formation in spermatozoa. Nat Commun. 2011 Jan 11 ;2:153).  Target The sequence of CATSPERD is published in GenBank under accession number NM_152784.3. CATSPERD is a membrane protein with a molecular weight of 91 kDa expressed in flagella of spermatozoa. Expression in tumors is not known (Chung JJ, Navarro B, Krapivinsky G, Krapivinsky L, Clapham DE, A novel gene required for male fertility and functional CATSPER channel formation in spermatozoa, Nat Commun., 2011 Jan 11; 2: 153).
RT-PCR-Untersuchung mit einem spezifischen Primerpaar bestätigte eine RT-PCR assay with a specific primer pair confirmed one
Expression in den untersuchten Zelllinien (erwartete Fragmentlänge 358 Expression in the investigated cell lines (expected fragment length 358
Basenpaare): A 172, U251 , U373, TC620, A549, HN, HeLa, HT29, MCF7. Base pairs): A172, U251, U373, TC620, A549, HN, HeLa, HT29, MCF7.
Da mehrere untersuchte Zelllinien eine Expression aufweisen, ist das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet. Beispiel 8: Identifizierung von CATSPERG als diagnostisches und therapeutisches Target Since several investigated cell lines have an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy. Example 8: Identification of CATSPERG as a Diagnostic and Therapeutic Target
Die Sequenz von CATSPERG ist in der GenBank unter der Zugangsnummer NM_021185.4 veröffentlicht. CATSPERG ist ein Transmembranprotein mit einem MW von 129 kD, das in Flagellen von Spermatozoen exprimiert wird. Eine Expression in Tumoren ist nicht bekannt (Wang H, Liu J, Cho KH, Ren D. A novel, Single, transmembrane protein CATSPERG is associated with CATSPER1 Channel protein. Biol Reprod. 2009 Sep;81(3):539-44. doi: 10.1095/biolreprod.109.077107. Epub 2009 Jun 10. RT-PCR-Untersuchung in Abb.1 mit einem spezifischen Primerpaar bestätigt eine Expression in den folgenden untersuchten Zelllinien (erwartete Fragmentlänge 403 Basenpaare): SKMG5, U87-MG, U373, B-CPAP, A549, BHY, GLC-2, HN, HT29, MCF7, PC3. The sequence of CATSPERG is published in GenBank under accession number NM_021185.4. CATSPERG is a transmembrane protein with a MW of 129 kD that is expressed in flagella of spermatozoa. Expression in tumors is not known (Wang H, Liu J, Cho KH, Ren D. A novel, single transmembrane protein CATSPERG is associated with CATSPER1 channel protein, Biol Reprod., 2009 Sep; 81 (3): 539-44. doi: 10.1095 / biolreprod.109.077107. Epub 2009 Jun 10. RT-PCR assay in Fig. 1 with a specific primer pair confirms expression in the following cell lines examined (expected fragment length 403 base pairs): SKMG5, U87-MG, U373, B CPAP, A549, BHY, GLC-2, HN, HT29, MCF7, PC3.
Da mehrere untersuchte Zelllinien eine Expression aufweisen ist, das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet.  Since several examined cell lines have an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy.
Beispiel 9: Identifizierung von CRISP3 als diagnostisches und therapeutisches Example 9: Identification of CRISP3 as Diagnostic and Therapeutic
Target  target
Die Sequenz von CRISP3 ist in der GenBank unter der Zugangsnummer NM_001190986.1 veröffentlicht. CRISP3 ist ein Protein mit einem MW von 28 kD. Eine Expression in Speicheldrüsen, Pankreas, Prostata, Epididymis, Ovarien, Thymus und Dickdarm sowie in Prostatatumoren ist bekannt (Grupp K, Kohl S, Sirma H, Simon R, Steurer S, Becker A, Adam M, Izbicki J, Sauter G, Minner S, Schlomm T, Tsourlakis MC. Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate Cancers with early biochemical recurrence. Mod Pathol. 2013 May;26(5):733-42. doi: 10.1038/modpathol.2012.206. Epub 2012 Nov 30; Krätzschmar J, Haendler B, Eberspaecher U, Roosterman D, Donner P, Schleuning WD. The human cysteine-rich secretory protein (CRISP) family. Primary structure and tissue distribution of CRISP-1 , CRISP-2 and CRISP-3. Eur J Biochem. 1996 Mar 15;236(3):827-36). RT-PCR-Untersuchung in Abb.1 mit einem spezifischen Primerpaar bestätigt eine Expression in den folgenden untersuchten Zelllinien (erwartete Fragmentgrösse: 149 Basenpaare): SKMG5, TC620, MG63, A549, HT29, PC3. The sequence of CRISP3 is published in GenBank under accession number NM_001190986.1. CRISP3 is a 28 kD MW protein. Expression in salivary glands, pancreas, prostate, epididymis, ovaries, thymus and large intestine as well as in prostate tumors is known (Grupp K, Kohl S, Sirma H, Simon R, Steurer S, Becker A, Adam M, Izbicki J, Sauter G, Minner S, Schlomm T, Tsourlakis MC Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence. Mod Pathol. 2013 May; 26 (5): 733-42. doi: 10.1038 / modpathol.2012.206, Epub 2012 Nov 30, Krätzschmar J, Haendler B, Eberspaecher U, Roosterman D, Thunder P, Schleuning WD The human cysteine-rich secretory protein (CRISP) family -1, CRISP-2 and CRISP-3, Eur J Biochem 1996 Mar 15; 236 (3): 827-36). RT-PCR analysis in Fig. 1 with a specific primer pair confirms expression in the following cell lines examined (expected fragment size: 149 base pairs): SKMG5, TC620, MG63, A549, HT29, PC3.
Da mehrere untersuchte Zelllinien eine Expression aufweisen ist das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet. Since several examined cell lines have an expression, the gene product according to the invention is suitable as target for diagnosis and therapy.
Beispiel 10: Identifizierung von FER1 L5 als diagnostisches und therapeutisches Example 10: Identification of FER1 L5 as Diagnostic and Therapeutic
Target Die Sequenz von FER1 L5 ist in der GenBank unter der Zugangsnummer NM_001 113382.1 veröffentlicht. FER1 L5 ist ein Membranprotein mit einem MW von 242 kD und wird in Myoblasten exprimiert. Eine Expression in Tumoren ist nicht bekannt (Posey AD Jr, Pytel P, Gardikiotes K, Demonbreun AR, Rainey M, George M, Band H, McNally EM. Endocytic recycling proteins EHD1 and EHD2 interact with fer-1-like-5 (Fer1 L5) and mediate myoblast fusion. J Biol Chem. 2011 Mar 4;286(9):7379-88. doi: 10.1074/jbc.M110.157222. Epub 2010 Dec 22.  Target The sequence of FER1 L5 is published in GenBank under accession number NM_001 113382.1. FER1 L5 is a membrane protein with a MW of 242 kD and is expressed in myoblasts. Expression in tumors is not known (Posey AD Jr, Pytel P, Gardikiotes K, Demonstration AR, Rainey M, George M, Band H, McNally EM, Endocytic recycling proteins EHD1 and EHD2 interact with fer-1-like-5 (Fer1 L5) and mediate myoblastic fusion J Biol Chem., 2011 Mar 4; 286 (9): 7379-88, doi: 10.1074 / jbc.M110.157222. Epub 2010 Dec 22.
RT-PCR-Untersuchung in Abb.1 mit einem spezifischen Primerpaar bestätigt eine Expression in den folgenden untersuchten Zelllinien (erwartete Fragmentlänge von 278 Basenpaaren): U87-MG, U251 , TC620, B-CPAP, HT29, PC3. RT-PCR assay in Fig. 1 with a specific primer pair confirms expression in the following cell lines examined (expected fragment length of 278 base pairs): U87-MG, U251, TC620, B-CPAP, HT29, PC3.
Da mehrere untersuchte Zelllinien eine Expression aufweisen ist das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet. Since several examined cell lines have an expression, the gene product according to the invention is suitable as target for diagnosis and therapy.
Beispiel 11 : Identifizierung von FER1 L6 als diagnostisches und therapeutisches Target Example 11: Identification of FER1 L6 as a Diagnostic and Therapeutic Target
Die Sequenz von FER1 L6 ist in der GenBank unter der Zugangsnummer NM_001039112.2 veröffentlicht. Bei FER1L6 handelt es sich um ein Membranprotein mit einem MW von rund 209 kD. Expression in Ovarien. Eine Expression in Tumoren ist nicht bekannt (Ledig S, Röpke A, Wieacker P. Copy number variants in premature ovarian failure and ovarian dysgenesis. Sex Dev. 2010 Sep;4(4-5):225-32. doi: 10.1159/000314958. Epub 2010 Jul 3). RT-PCR-Untersuchung in Abb.1 mit einem spezifischen Primerpaar bestätigt eine Expression in den folgenden untersuchten Zelllinien (erwartete Fragmentlänge 260 Basenpaare): A 172, SKMG5, U87-MG, U251 , U373, SW-872, B-CPAP, A549, BHY, GLC-2, HT29, MCF7, PC3. The sequence of FER1 L6 is published in GenBank under accession number NM_001039112.2. FER1L6 is a membrane protein with an MW of around 209 kD. Expression in ovaries. Expression in tumors is not known (S, Röpke A, Wieacker, P. Copy number variants in premature ovarian failure and ovarian dysgenesis, Sex Dev., 2010, Sep; 4 (4-5): 225-32, doi: 10.1159 / 000314958 Epub 2010 Jul 3). RT-PCR assay in Fig.1 with a specific primer pair confirms expression in the following cell lines examined (expected fragment length 260 base pairs): A172, SKMG5, U87-MG, U251, U373, SW-872, B-CPAP, A549 , BHY, GLC-2, HT29, MCF7, PC3.
Da mehrere untersuchte Zelllininien eine Expression aufweisen ist das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet.  Since several investigated cell lines have an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy.
Beispiel 12: Identifizierung von FOLR4 als diagnostisches und therapeutisches Example 12: Identification of FOLR4 as Diagnostic and Therapeutic
Target  target
Die Sequenz von FOLR4 ist in der GenBank unter der Zugangsnummer The sequence of FOLR4 is in the GenBank under the accession number
NM_001199206.1 veröffentlicht. Bei FOLR4 handelt es sich um ein GPI-verankertes Protein mit einem MW von rund 28 kD. Die Expression ist wohl auf Eizellen beschränkt (Bianchi E, Doe B, Goulding D, Wright GJ. Juno is the egg Izumo receptor and is essential for mammalian fertilization. Nature. 2014;508:483-7). NM_001199206.1 released. FOLR4 is a GPI-anchored protein with a MW of around 28 kD. Expression is probably confined to oocytes (Bianchi E, Doe B, Goulding D, Wright GJ, Juno is the Egg Izumo receptor and essential for mammalian fertilization, Nature. 2014; 508: 483-7).
Eine Expression in Tumoren ist nicht bekannt (Spiegelstein O, Eudy JD, Finnell RH. Identification of two putative novel folate receptor genes in humans and mouse. Gene. 2000;258:117-25.).  Expression in tumors is not known (Spiegelstein O, Eudy JD, Finnell RH, Identification of two putative novel folate receptor genes in human and mouse genes, 2000; 258: 117-25).
RT-PCR-Untersuchung in Abb.1 mit einem spezifischen Primerpaar bestätigt eine Expression in den folgenden untersuchten Zelllinien (erwartete Fragmentlänge 288 Basenpaare): U87-MG, TC620, A549, B-CPAP, BHY.  RT-PCR examination in Fig. 1 with a specific primer pair confirms expression in the following cell lines examined (expected fragment length 288 base pairs): U87-MG, TC620, A549, B-CPAP, BHY.
Da mehrere untersuchte Zelllininien eine Expression aufweisen ist das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet.  Since several investigated cell lines have an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy.
Beispiel 13: Identifizierung von GGN als diagnostisches und therapeutisches Example 13: Identification of GGN as Diagnostic and Therapeutic
Target  target
Die Sequenz von GGN ist in der GenBank unter der Zugangsnummer NM_152657.3 veröffentlicht. GGN wird in Keimzellen exprimiert, ist ein membran-assoziiertes Protein und besitzt ein MW von 67 kDa (Jamsai D, Bianco DM, Smith SJ, Merriner DJ, Ly-Huynh JD, Herlihy A, Niranjan B, Gibbs GM, O'Bryan MK. Characterization of gametogenetin 1 (GGN1 ) and its potential role in male fertility through the interaction with the ion Channel regulator, cysteine-rich secretory protein 2 (CRISP2) in the sperm tail. Reproduction. 2008 Jun;135(6):751-9. doi: 10.1530/REP-07-0485; Zhao Q, Zhou Y, Cao Z, Zhu H, Huang P, Lu B. Germ-cell specific protein gametogenetin protein 2 (GGN2), expression in the testis, and association with intracellular membrane. Mol Reprod Dev. 2005 Sep;72(1 ):31-9.). Eine Expression in Tumoren ist nicht bekannt. The sequence of GGN is published in GenBank under accession number NM_152657.3. GGN is expressed in germ cells, is a membrane-associated protein and has a MW of 67 kDa (Jamsai D, Bianco DM, Smith SJ, Merriner DJ, Ly-Huynh JD, Herlihy A, Niranjan B, Gibbs GM, O'Bryan MK Characterization of gametogenetin 1 (GGN1) and its potential role in male fertility through the interaction with the ion channel regulator, cysteine-rich secretory protein 2 (CRISP2) in the sperm tail. Reproduction. 2008 Jun; 135 (6): 751-9. doi: 10.1530 / REP-07-0485; Zhao Q, Zhou Y, Cao Z, Zhu H, Huang P, Lu B. Germ cell specific protein gametogenetine protein 2 (GGN2), expression in the testis, and association with intracellular membrane. Mol Reprod Dev. 2005 Sep; 72 (1): 31-9.). Expression in tumors is unknown.
RT-PCR-Untersuchung in Abb. 1 mit einem spezifischen Primerpaar bestätig« eine Expression in den folgenden untersuchten Zelllinien (Erwartete Fragmentlänge 280 Basenpaare): A 172, SKMG5, U87-MG, U251 , U373, TC620, MG63, SW-872, B- CPAP, A549, BHY, GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60. RT-PCR assay in Fig. 1 with a specific primer pair confirm expression in the following cell lines examined (expected fragment length 280 base pairs): A 172, SKMG5, U87-MG, U251, U373, TC620, MG63, SW-872, B-CPAP, A549, BHY, GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60.
Da die untersuchten Zelllininien eine Expression aufweisen, könnte das Genprodukt erfindungsgemäß auch als Target für Diagnostik und Therapie dienen.  Since the cell lines investigated have an expression, the gene product according to the invention could also serve as target for diagnosis and therapy.
Beispiel 14: Identifizierung von GGNBP2 als diagnostisches und therapeutisches Example 14: Identification of GGNBP2 as Diagnostic and Therapeutic
Target  target
Die Sequenz von GGNBP2 ist in der GenBank unter der Zugangsnummer The sequence of GGNBP2 is in the GenBank under the accession number
BC137491.1 veröffentlicht. GGNBP2 ist ein Protein von 79 kDa, das in Keimzellen exprimiert wird (Zhang J, Wang Y, Zhou Y, Cao Z, Huang P, Lu B. Yeast two-hybrid screens imply that GGNBP1 , GGNBP2 and OAZ3 are potential interaction partners of testicular germ cell-specific protein GGN1. FEBS Lett. 2005;579(2):559-66). Eine Expression in Tumoren ist nicht bekannt. BC137491.1 released. GGNBP2 is a 79 kDa protein expressed in germ cells (Zhang J, Wang Y, Zhou Y, Cao Z, Huang P, Lu B. Yeast two-hybrid screens imply that GGNBP1, GGNBP2 and OAZ3 are potential interaction partners of testicular germ cell-specific protein GGN1, FEBS Lett., 2005; 579 (2): 559-66). Expression in tumors is unknown.
RT-PCR-Untersuchung in Abb.1 mit einem spezifischen Primerpaar bestätigt eine Expression in den folgenden untersuchten Zelllinien (erwartete Fragmentlänge 344 Basenpaare): A 172, SKMG5, U87-MG, U251 , U373, TC620, MG63, SW-872, B- CPAP, A549, BHY, GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60. Da alle RT-PCR assay in Fig. 1 with a specific primer pair confirms expression in the following cell lines examined (expected fragment length 344 base pairs): A172, SKMG5, U87-MG, U251, U373, TC620, MG63, SW-872, B CPAP, A549, BHY, GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60. Since all
untersuchten Zelllinien eine Expression aufweisen, ist das Genprodukt examined cell lines have an expression is the gene product
erfindungsgemäß als Target für Diagnostik und Therapie geeignet. Beispiel 15: Identifizierung von IZUM01 als diagnostisches und therapeutisches Target According to the invention suitable as a target for diagnosis and therapy. Example 15: Identification of IZUM01 as a Diagnostic and Therapeutic Target
Die Sequenz von IZUM01 ist in der GenBank unter der Zugangsnummer  The sequence of IZUM01 is in the GenBank under the accession number
NM_182575.2 veröffentlicht. IZUM01 ist ein Transmembranprotein von 56 kDa, das auf Spermienzellen exprimiert wird (Ellerman DA, Pei J, Gupta S, Snell WJ, Myles D, Primakoff P. Izumo is part of a multiprotein family whose members form large complexes on mammalian sperm. Mol Reprod Dev. 2009;76:1188-99). Eine NM_182575.2 published. IZUM01 is a 56 kDa transmembrane protein expressed on sperm cells (Ellerman DA, Pei J, Gupta S, Snell WJ, Myles D, Primakoff P. Izumo is part of a multiprotein family members of large scale mammalian sperm. Mol Reprod Dev. 2009; 76: 1188-99). A
Expression in Tumoren ist nicht bekannt. Expression in tumors is unknown.
RT-PCR-Untersuchung in Abb.1 mit einem spezifischen Primerpaar zeigten keine Expression in den folgenden untersuchten Zelllinien (erwartete Fragmentlänge 394 Basenpaare): A 172, SKMG5, U87-MG, U251 , U373, TC620, MG63, SW-872, B- CPAP, A549, BHY, GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60. Da in keinen der untersuchten Zelllinien eine Expression nachweisbar ist, ist das Gen RT-PCR examination in Fig.1 with a specific primer pair showed no expression in the following cell lines examined (expected fragment length 394 base pairs): A172, SKMG5, U87-MG, U251, U373, TC620, MG63, SW-872, B CPAP, A549, BHY, GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60. Since no expression is detectable in any of the investigated cell lines, the gene is
erfindungsgemäß als Target für Diagnostik und Therapie primär nicht geeignet. according to the invention as a target for diagnosis and therapy is not primarily suitable.
Beispiel 16: Identifizierung von PSG1 als diagnostisches und therapeutisches Example 16: Identification of PSG1 as Diagnostic and Therapeutic
Target  target
Die Sequenz von PSG1 ist in der GenBank unter der Zugangsnummer NM_182575.2 veröffentlicht. Ist ein sekretiertes Protein mit einem Molekulargewicht von rund 70 kDa, das in der Plazenta exprimiert wird (Camolotto SA, Racca AC, Ridano ME, Genti-Raimondi S, Panzetta-Dutari GM. PSG gene expression is up-regulated by lysine acetylation involving histone and nonhistone proteins. PLoS One. The sequence of PSG1 is published in GenBank under accession number NM_182575.2. Is a secreted protein with a molecular weight of about 70 kDa expressed in the placenta (Camolotto SA, Racca AC, Ridano ME, Genti-Raimondi S, Panzetta-Dutari GM.) PSG gene expression is up-regulated by lysine acetylation involving histone and nonhistone proteins. PLoS One.
2013;8(2):e55992. doi: 10.1371/journal.pone.0055992). Eine Expression ist nur in Brust-, Darm-, Hoden-, Lungen- Magen- und Ovartumoren beschrieben (Inaba N, Renk T, Wurster K, Rapp W, Bohn H. Ectopic synthesis of pregnancy specific beta 1- glycoprotein (SP1 ) and placental specific tissue proteins (PP5, PP10, PP11 , PP12) in nontrophoblastic malignant tumours. Possible markers in oncology. Klin Wochenschr. 1980 ;58:789-91.) 2013; 8 (2): e55992. doi: 10.1371 / journal.pone.0055992). Expression is only described in breast, intestinal, testicular, lung, gastric and ovarian tumors (Inaba N, Renk T, Wurster K, Rapp W, Bohn H. Ectopic synthesis of pregnancy specific beta-1-glycoprotein (SP1) and placental specific tissue proteins (PP5, PP10, PP11, PP12) in nontrophoblastic malignant tumors, Possible markers in oncology, Klin Wochenschr., 1980; 58: 789-91.)
RT-PCR-Untersuchung in Abb.1 mit einem spezifischen Primerpaar zeigten eine Expression in den folgenden untersuchten Zelllinien (erwartete Fragmentlänge 305 Basenpaare): A 172, SKMG5, U87-MG, U251 , U373, TC620, MG63, SW-872, B- CPAP, A549, BHY, HN, HeLa, MCF7, PC3. Da die untersuchten Zelllininien eine Expression aufweisen, könnte das Genprodukt erfindungsgemäß auch als Target für Diagnostik und Therapie dienen. RT-PCR examination in Fig. 1 with a specific primer pair showed expression in the following investigated cell lines (expected fragment length 305 Base pairs): A172, SKMG5, U87-MG, U251, U373, TC620, MG63, SW-872, B-CPAP, A549, BHY, HN, HeLa, MCF7, PC3. Since the cell lines investigated have an expression, the gene product according to the invention could also serve as target for diagnosis and therapy.
Beispiel 17: Identifizierung von PSG2 als diagnostisches und therapeutisches Example 17: Identification of PSG2 as Diagnostic and Therapeutic
Target  target
Die Sequenz von PSG2 ist in der GenBank unter der Zugangsnummer NM_031246.3 veröffentlicht. Ist ein sekretiertes Protein mit einem Molekulargewicht von rund 60 kDa, das in der Plazenta exprimiert wird (Pan CJ, Chamberlin ME, Wu SM, Chan WY, Chou JY. Pregnancy-specific glycoprotein gene expression and the induction by 5-bromo-2'-deoxyuridine. Biochemistry. 1994 Jun 14;33(23):7260-6). Eine  The sequence of PSG2 is published in GenBank under accession number NM_031246.3. Is a secreted protein with a molecular weight of about 60 kDa expressed in the placenta (Pan CJ, Chamberlin ME, Wu SM, Chan WY, Chou JY, Pregnancy-specific glycoprotein gene expression and the induction by 5-bromo-2 ' -deoxyuridine, Biochemistry, 1994 Jun 14; 33 (23): 7260-6). A
Expression in Tumoren ist nicht bekannt. RT-PCR-Untersuchung in Abb.1 mit einem spezifischen Primerpaar zeigten eine Expression in den folgenden untersuchten Zelllinien (erwartete Fragmentlänge 305 Basenpaare): A 172, SKMG5, U87-MG, U251 , U373, TC620, MG63, SW-872, B- CPAP, BHY, HN, HeLa, MCF7, PC3. Da die untersuchten Zelllininien eine Expression in tumors is unknown. RT-PCR analysis in Fig. 1 with a specific primer pair showed expression in the following cell lines examined (expected fragment length 305 base pairs): A 172, SKMG5, U87-MG, U251, U373, TC620, MG63, SW-872, B CPAP, BHY, HN, HeLa, MCF7, PC3. Since the examined cell lines a
Expression aufweisen, könnte das Genprodukt erfindungsgemäß auch als Target für Diagnostik und Therapie dienen. Having expression, the gene product according to the invention could also serve as a target for diagnosis and therapy.
Beispiel 18: Identifizierung von PSG5 als diagnostisches und therapeutisches Example 18: Identification of PSG5 as Diagnostic and Therapeutic
Target  target
Die Sequenz von PSG5 ist in der GenBank unter der Zugangsnummer NM_002781.3 veröffentlicht. Ist ein sekretiertes Protein mit einem Molekulargewicht von rund 60 kDa, das in der Plazenta exprimiert wird (Pan CJ, Chamberlin ME, Wu SM, Chan WY, Chou JY. Pregnancy-specific glycoprotein gene expression and the induction by 5-bromo-2'-deoxyuridine. Biochemistry. 1994 Jun 14;33(23):7260-6). Eine The sequence of PSG5 is published in GenBank under accession number NM_002781.3. Is a secreted protein with a molecular weight of about 60 kDa expressed in the placenta (Pan CJ, Chamberlin ME, Wu SM, Chan WY, Chou JY, Pregnancy-specific glycoprotein gene expression and the induction by 5-bromo-2 ' -deoxyuridine, Biochemistry, 1994 Jun 14; 33 (23): 7260-6). A
Expression in Tumoren ist nicht bekannt. Expression in tumors is unknown.
RT-PCR-Untersuchung in Abb.1 mit einem spezifischen Primerpaar zeigten keine Expression in den folgenden untersuchten Zelllinien (erwartete Fragmentlänge 394 Basenpaare): A 172, SKMG5, U87-MG, U251 , U373, TC620, MG63, SW-872, B- CPAP, A549, BHY, GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60. Da in keinen der untersuchten Zelllinien eine Expression nachweisbar ist, ist das Gen RT-PCR examination in Fig. 1 with a specific primer pair showed no expression in the following investigated cell lines (expected fragment length 394 Base pairs): A172, SKMG5, U87-MG, U251, U373, TC620, MG63, SW-872, B-CPAP, A549, BHY, GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60. Since no expression is detectable in any of the investigated cell lines, the gene is
erfindungsgemäß als Target für Diagnostik und Therapie primär nicht geeignet. according to the invention as a target for diagnosis and therapy is not primarily suitable.
Beispiel 19: Identifizierung von ROPN1 L als diagnostisches und therapeutisches Target Example 19: Identification of ROPN1 L as a Diagnostic and Therapeutic Target
Die Sequenz von ROPN1 L ist in der GenBank unter der Zugangsnummer NM_031916.4 veröffentlicht. ROPN1L ist ein Protein von 26 kDa. Normalexpression in Spermatozoen (Carr DW1, Fujita A, Stentz CL, Liberty GA, Olson GE, Narumiya S. Identification of sperm-specific proteins that interact with A-kinase anchoring proteins in a manner similar to the type II regulatory subunit of PKA. J Biol Chem. 2001 ;276(20): 17332-8. Epub 2001 Feb 7), wird ausserdem mit Brustkrebs in Verbindung gebracht (Sehrawat B, Sridharan M, Ghosh S, Robson P, Cass CE, Mackey JR, Greiner R, Damaraju S. Potential novel candidate polymorphisms identified in genome-wide association study for breast Cancer susceptibility. Hum Genet. 2011 Oct;130(4):529-37. doi: 10.1007/s00439-011-0973-1. Epub 2011 Mar 19). RT-PCR-Untersuchung in Abb.1 mit einem spezifischen Primerpaar bestätigt eine Expression in den folgenden untersuchten Zelllinien (erwartete Fragmentlänge 185 Basenpaare): A 172, SKMG5, U87-MG, U251 , U373, TC620, MG63, SW-872, B- CPAP, A549, BHY, GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60. Da alle The sequence of ROPN1 L is published in GenBank under accession number NM_031916.4. ROPN1L is a 26 kDa protein. Normal expression in spermatozoa (Carr DW 1 , Fujita A, Stentz CL, Liberty GA, Olson GE, Narumiya S. Identification of sperm-specific proteins that interact with A-kinase anchoring proteins in a manner similar to the type II regulatory subunit of PKA. J Biol Chem. 2001; 276 (20): 17332-8, Epub 2001 Feb. 7) is also associated with breast cancer (Sehrawat B, Sridharan M, Ghosh S, Robson P, Cass CE, Mackey JR, Greiner R, Damaraju S. Potential novel candidate polymorphisms identified in genome-wide association study for breast cancer susceptibility.Hum Genet., 2011 Oct; 130 (4): 529-37, doi: 10.1007 / s00439-011-0973-1. Epub 2011 Mar 19 ). RT-PCR assay in Fig. 1 with a specific primer pair confirms expression in the following cell lines examined (expected fragment length 185 base pairs): A172, SKMG5, U87-MG, U251, U373, TC620, MG63, SW-872, B CPAP, A549, BHY, GLC-2, HN, HeLa, HT29, MCF7, PC3, HL60. Since all
untersuchten Zelllinien eine Expression aufweisen, ist das Genprodukt examined cell lines have an expression is the gene product
erfindungsgemäß als Target für Diagnostik und Therapie geeignet. According to the invention suitable as a target for diagnosis and therapy.
Beispiel 20: Identifizierung von SPAG6 als diagnostisches und therapeutisches Example 20: Identification of SPAG6 as Diagnostic and Therapeutic
Target  target
Die Sequenz von SPAG6 ist in der GenBank unter der Zugangsnummer CR533552.1 veröffentlicht. Bei SPAG6 handelt es sich um ein Protein von 55 kDa. Die normale Expression ist auf Spermatozoen beschränkt (Neilson LI, Schneider PA, Van Deerlin PG, Kiriakidou M, Driscoll DA, Pellegrini MC, Millinder S, Yamamoto KK, French CK, Strauss JF 3rd. cDNA cloning and characterization of a human sperm antigen The sequence of SPAG6 is published in GenBank under accession number CR533552.1. SPAG6 is a 55 kDa protein. Normal expression is restricted to spermatozoa (Neilson LI, Schneider PA, Van Deerlin PG, Kiriakidou M, Driscoll DA, Pellegrini MC, Millinder S, Yamamoto KK, French CK, Strauss JF 3rd. cDNA cloning and characterization of a human sperm antigen
(SPAG6) with homology to the product of the Chlamydomonas PF16 locus. (SPAG6) with homology to the product of the Chlamydomonas PF16 locus.
Genomics. 1999 Sep 15;60(3):272-80). Eine Expression in Lungen- und Genomics. 1999 Sep 15; 60 (3): 272-80). Expression in lung and lung
Brusttumoren ist beschrieben (Silina K, Zayakin P, Kalnina Z, Ivanova L, Meistere I, Endzelins E, Aböls A, Stengrevics A, Leja M, Ducena K, Kozirovskis V, Line A. Breast tumors are described (Silina K, Zayakin P, Kalnina Z, Ivanova L, Master I, Endzelin E, Abol A, Stengrevics A, Leja M, Ducena K, Kozirovsky V, Line A.
Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients. J Immunother. 2011 Jan;34(1 ):28- 44. doi: 10.1097/CJI.0b013e3181fb64fa). RT-PCR-Untersuchung in Abb. 1 mit einem spezifischen Primerpaar bestätigt eine Expression in den folgenden untersuchten Zelllinien (Erwartete Fragmentlänge 362 Basenpaare): SKMG5, U87-MG, U251 , U373, SW-872, B-CPAP, GLC-2, HeLa, MCF7, PC3.  Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients. J Immunother. 2011 Jan; 34 (1): 28- 44. doi: 10.1097 / CJI.0b013e3181fb64fa). RT-PCR assay in Fig. 1 with a specific primer pair confirms expression in the following cell lines examined (Expected fragment length 362 base pairs): SKMG5, U87-MG, U251, U373, SW-872, B-CPAP, GLC-2, HeLa, MCF7, PC3.
Da die untersuchten Zelllininien eine Expression aufweisen, könnte das Genprodukt erfindungsgemäß auch als Target für Diagnostik und Therapie dienen  Since the cell lines investigated have an expression, the gene product according to the invention could also serve as target for diagnosis and therapy
Beispiel 21 : Identifizierung von SPAG8 als diagnostisches und therapeutisches Example 21: Identification of SPAG8 as Diagnostic and Therapeutic
Target  target
Die Sequenz von SPAG8 ist in der GenBank unter der Zugangsnummer The sequence of SPAG8 is in the GenBank under the accession number
NM_172312.1 veröffentlicht. Bei SPAG8 handelt es sich um ein Protein von 55 kDa. Die normale Expression ist auf Spermatozoen beschränkt (Zhang XD, Miao SY, Wang LF, Li Y, Zong SD, Yan YC, Koide SS. Human sperm membrane protein (hSMP-1 ): a developmental testis-specific component during germ cell differentiation. Arch Androl. 2000 Nov-Dec;45(3):239-46). Eine Expression in Lungen- und  NM_172312.1 released. SPAG8 is a 55 kDa protein. Normal expression is restricted to spermatozoa (Zhang XD, Miao SY, Wang LF, Li Y, Zong SD, Yan YC, Koide SS. Human sperm membrane protein (hSMP-1): a developmental testis-specific component during germ cell differentiation. Arch Androl 2000 Nov-Dec; 45 (3): 239-46). Expression in lung and lung
Brusttumoren ist beschrieben (Silina K, Zayakin P, Kalnina Z, Ivanova L, Meistere I, EndzeliQS E, Aböls A, Stengrevics A, Leja M, Ducena K, Kozirovskis V, Line A.  Breast tumors are described (Silina K, Zayakin P, Kalnina Z, Ivanova L, Master I, EndzeliQS E, Abol's A, Stengrevics A, Leja M, Ducena K, Kozirovski's V, Line A.
Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients. J Immunother. 2011 Jan;34(1 ):28- 44. doi: 10.1097/CJI.0b013e3181fb64fa). Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients. J Immunother. 2011 Jan; 34 (1): 28- 44. doi: 10.1097 / CJI.0b013e3181fb64fa).
RT-PCR-Untersuchung in Abb. 1 mit einem spezifischen Primerpaar bestätigt eine Expression in den folgenden untersuchten Zelllinien (Erwartete Fragmentlänge 365 Basenpaare): A 172, SKMG5, U87-MG, U251 , U373, MG63, SW-872, B-CPAP, A549, BHY, GLC-2, HeLa, HT29, MCF7, PC3, HL60. RT-PCR examination in FIG. 1 with a specific primer pair confirms expression in the following investigated cell lines (expected fragment length 365 Base pairs): A172, SKMG5, U87-MG, U251, U373, MG63, SW-872, B-CPAP, A549, BHY, GLC-2, HeLa, HT29, MCF7, PC3, HL60.
Da die untersuchten Zelllininien eine Expression aufweisen, könnte das Genprodukt erfindungsgemäß auch als Target für Diagnostik und Therapie dienen.  Since the cell lines investigated have an expression, the gene product according to the invention could also serve as target for diagnosis and therapy.
Beispiel 22: Identifizierung von SPAG17 als diagnostisches und therapeutisches Example 22: Identification of SPAG17 as Diagnostic and Therapeutic
Target  target
Die Sequenz von SPAG17 ist in der GenBank unter der Zugangsnummer  The sequence of SPAG17 is in the GenBank under the accession number
NM_206996.2 veröffentlicht. Bei SPAG17 handelt es sich um ein Protein von 252 kDa. Die normale Expression ist auf Spermatozoen beschränkt (Zhang Z, Jones BH, Tang W, Moss SB, Wei Z, Ho C, Pollack M, Horowitz E, Bennett J, Baker ME, Strauss JF 3rd. Dissecting the axoneme interactome: the mammalian orthologue of Chlamydomonas PF6 interacts with sperm-associated antigen 6, the mammalian orthologue of Chlamydomonas PF16. Mol Cell Proteomics. 2005 Jul;4(7):914-23. Epub 2005 Apr 12). Eine Expression in Lungen- und Brusttumoren ist beschrieben (Silina K, Zayakin P, Kalnina Z, Ivanova L, Meistere I, Endzelins E, Aböls A, NM_206996.2 released. SPAG17 is a 252 kDa protein. Normal expression is restricted to spermatozoa (Zhang Z, Jones BH, Tang W, Moss SB, Wei Z, Ho C, Pollack M, Horowitz E, Bennett J, Baker ME, Strauss JF 3rd Dissecting the axoneme interactome: the mammalian orthologue of Chlamydomonas PF6 interacts with sperm-associated antigen 6, the mammalian orthologue of Chlamydomonas PF16, Mol Cell Proteomics, 2005 Jul; 4 (7): 914-23, Epub 2005 Apr 12). Expression in lung and breast tumors is described (Silina K, Zayakin P, Kalnina Z, Ivanova L, Master I, Endlet E, Abol's A,
Stengrevics A, Leja M, Ducena K, Kozirovskis V, Line A. Sperm-associated antigens as targets for Cancer immunotherapy: expression pattern and humoral immune response in cancer patients. J Immunother. 2011 Jan;34(1 ):28-44. doi: Stengrevics A, Leja M, Ducena K, Kozirovski V, Line A. Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and immune response in cancer patients. J Immunother. 2011 Jan; 34 (1): 28-44. doi:
10.1097/CJI.0b013e3181fb64fa). 10.1097 / CJI.0b013e3181fb64fa).
RT-PCR-Untersuchung in Abb. 1 mit einem spezifischen Primerpaar bestätigt eine Expression in den folgenden untersuchten Zelllinien (Erwartete Fragmentlänge 325 Basenpaare): A 172, SKMG5, U87-MG, U251 , U373, MG63, SW-872, B-CPAP, A549, BHY, HN, HeLa, MCF7, PC3, HL60. RT-PCR assay in Fig. 1 with a specific primer pair confirms expression in the following cell lines tested (expected fragment length 325 base pairs): A172, SKMG5, U87-MG, U251, U373, MG63, SW-872, B-CPAP , A549, BHY, HN, HeLa, MCF7, PC3, HL60.
Da die untersuchten Zelllininien eine Expression aufweisen, könnte das Genprodukt erfindungsgemäß auch als Target für Diagnostik und Therapie dienen.  Since the cell lines investigated have an expression, the gene product according to the invention could also serve as target for diagnosis and therapy.
Für die Beispiele 23 bis 35 (siehe Abb.2) wurden RT-PCR-Analysen bestimmter Tumorantigene durchgeführt, wobei die Namen der Tumorantigene sind in For examples 23 to 35 (see FIG. 2), RT-PCR analyzes of specific tumor antigens were carried out, the names of the tumor antigens being in
abgekürzter Form neben den Gelspuren genannt sind. Es wurden folgende Zelllinien untersucht: A 172, A 1207, U251 , U373, SK-MG-5, U 87-MG, TC620, U178, SKN- MC, SH-SY5Y, GLC 8A, SCLC-24H, H 146, HL 60, HELA, HT-29, BCPAP, FTC-133, CAL-62, GLC-2, GLC-36, H 1184, A549. abbreviated form next to the gel traces are called. The following cell lines were investigated: A 172, A 1207, U251, U373, SK-MG-5, U 87-MG, TC620, U178, SKN- MC, SH-SY5Y, GLC 8A, SCLC-24H, H 146, HL 60, HELA, HT-29, BCPAP, FTC-133, CAL-62, GLC-2, GLC-36, H 1184, A549.
Beispiel 23: Identifizierung von DYSF (Dysferlin) als diagnostisches und therapeutisches Target Example 23: Identification of DYSF (Dysferlin) as a Diagnostic and Therapeutic Target
DYSF reguliert die Zelladhäsion in menschlichen Monocyten. Die Sequenz ist in der Gendatenbank unter der Zugangsnummer AF075575 veröffentlicht. Dysferlin ist ein Transmembranprotein mit einem molekularen Gewicht von 230 kD. Die Expression von Dysferlin erfolgt in Monocyten und Luftröhrenepithel. In Tumoren ist bislang keine Expression beschrieben worden. (Leung C, Shaheen F, Bernatchez P, Hackett TL. Expression of myoferlin in human airway epithelium and its role in cell adhesion and zonula occludens-1 expression. PLoS One. 2012;7(7):e40478. doi: 10.1371/journal.pone.0040478). RT-PCR-Analysen ergaben eine spezifische Expression von DYSF in folgenden Zelllinien (Abbildung 2; erwartetes PCR-Produkt 250 bp): A 1207, SK-MG-5, SKN- MC, HL 60, BCPAP. DYSF regulates cell adhesion in human monocytes. The sequence is published in the gene database under accession number AF075575. Dysferlin is a transmembrane protein with a molecular weight of 230 kD. The expression of dysferlin occurs in monocytes and tracheal epithelium. In tumors so far no expression has been described. (Leung C, Shaheen F, Bernatchez P, Hackett TL) Expression of myoferlin in human airway epithelium and its role in cell adhesion and zonula occludens-1 expression, PLoS One. 2012; 7 (7): e40478. Doi: 10.1371 / journal .pone.0040478). RT-PCR analysis revealed specific expression of DYSF in the following cell lines (Figure 2, expected 250 bp PCR product): A 1207, SK-MG-5, SKN-MC, HL 60, BCPAP.
Da mehrere der untersuchten Zelllinien eine Expression aufweisen, ist das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet.  Since several of the cell lines investigated have an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy.
Beispiel 24: Identifizierung von ZP1 als diagnostisches und therapeutisches Target Example 24: Identification of ZP1 as a Diagnostic and Therapeutic Target
Die Sequenz des ZP1 Glykoproteins ist in der Genbank unter der Zugangsnummer NM_207341.2 veröffentlicht. Bei ZP1 handelt es sich um ein glykosyliertes Membranprotein mit einem Molekulargewicht von rund 97 kDa, das in Oocyten exprimiert wird. Eine Expression in Tumoren ist nicht bekannt. (Shabanowitz RB, O'Rand MG. Molecular changes in the human zona pellucida associated with fertilization and human sperm-zona interactions. Ann N Y Acad Sei. 1988;541 :621- RT-PCR-Untersuchungen mit einem ZP 1 -spezifischem Primerpaar zeigen in Abb.2 eine Expression von ZP 1 in folgenden Zelllinien: A 1207 (schwach), SKN-MC, GLC- 8A, SCLC-24H, H 146, H1184. Das erwartete PCR-Produkt ist 390 bp lang. Da mehrere der untersuchten Zelllinien eine Expression aufweisen, ist das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet. The sequence of the ZP1 glycoprotein is published in the Genbank under accession number NM_207341.2. ZP1 is a glycosylated membrane protein with a molecular weight of approximately 97 kDa that is expressed in oocytes. Expression in tumors is unknown. (Shabanowitz RB, O'Rand MG, Molecular Changes in the Human Zone of Pellucida Associated with Fertilization and Human Sperm-zona Interactions, Ann NY Acad Sci. 1988; 541: 621- RT-PCR studies with a ZP 1 -specific primer pair show in Fig. 2 an expression of ZP 1 in the following cell lines: A 1207 (weak), SKN-MC, GLC-8A, SCLC-24H, H 146, H1184. The expected PCR product is 390 bp long. Since several of the cell lines investigated have an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy.
Beispiel 25: Identifizierung von ZP2 als diagnostisches und therapeutisches Target Example 25: Identification of ZP2 as a Diagnostic and Therapeutic Target
Die Sequenz von ZP2 ist in der GenBank unter der Zugangsnummer NM_003460.1 veröffentlicht. Bei ZP2 handelt es sich um ein glykosyliertes Membranprotein mit einem Molekulargewicht von 64 bis 78 kDa, das in Oocyten exprimiert wird. Eine Expression in Tumoren ist nicht bekannt (Gupta SK, Bhandari B, Shrestha A, Biswal BK, Palaniappan C, Malhotra SS, Gupta N. Mammalian zona pellucida glycoproteins: structure and function during fertilization. Cell Tissue Res. 2012;349:665-78). The sequence of ZP2 is published in GenBank under accession number NM_003460.1. ZP2 is a glycosylated membrane protein with a molecular weight of 64 to 78 kDa that is expressed in oocytes. Expression in tumors is not known (Gupta SK, Bhandari B, Shrestha A, Biswal BK, Palaniappan C, Malhotra SS, Gupta N.Mammalian zona pellucida glycoproteins: structure and function during fertilization., Cell Tissue Res. 2012; 349: 665- 78).
Die RT-PCR-Untersuchung in Abb. 2 mit einem spezifischen Primerpaar bestätigt eine Expression in folgenden Zelllinien (358 bp erwartete Fragmentlänge): GLC-8A. Da eine untersuchte Zelllinie eine Expression aufweist, ist das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet. The RT-PCR assay in Figure 2 with a specific primer pair confirms expression in the following cell lines (358 bp expected fragment length): GLC-8A. Since an examined cell line has an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy.
Beispiel 26: Identifizierung von ZP3 als diagnostisches und therapeutisches Target Example 26: Identification of ZP3 as a Diagnostic and Therapeutic Target
Die Sequenz von ZP3 ist in der GenBank unter der Zugangsnummer NM_007155.5 veröffentlicht. Die Sequenz von ZP 3 ist in der GenBank unter der Zugangsnummer NM_007155.5 veröffentlicht. Bei ZP3 handelt es sich um ein glykosyliertes Membranprotein mit einem Molekulargewicht von 57 bis 73 kDa, das in Oocyten exprimiert wird. Eine Expression in Ovarialtumoren ist beschrieben (Rahman NA, et al. A novel treatment strategy for ovarian Cancer based on immunization against zona pellucida protein (ZP) 3. FASEB J. 2012;26:324-33). Die RT-PCR-Untersuchung in Abb.2 mit einem spezifischen Primerpaar bestätigt eine Expression in folgenden Zelllinien (erwartete Fragmentlänge 375 Basenpaare): A 1207, TC 620, GLC-8A, SCLC-24H, H 146, HI-60, HELA, HT-29, BCP AP, GLC 36, H1148. Da die übrigen untersuchten Zelllininien keine Expression aufweisen, ist das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet. The sequence of ZP3 is published in GenBank under accession number NM_007155.5. The sequence of ZP 3 is published in GenBank under accession number NM_007155.5. ZP3 is a glycosylated membrane protein with a molecular weight of 57 to 73 kDa that is expressed in oocytes. Expression in ovarian tumors has been described (Rahman NA, et al., A novel treatment strategy for ovarian cancer based on immunization against zona pellucida protein (ZP) 3. FASEB J. 2012; 26: 324-33). The RT-PCR assay in Fig. 2 with a specific primer pair confirms expression in the following cell lines (expected fragment length 375 base pairs): A 1207, TC 620, GLC-8A, SCLC-24H, H 146, HI-60, HELA, HT-29, BCP AP, GLC 36, H1148. Since the other cell lines studied have no expression, the gene product according to the invention is suitable as a target for diagnosis and therapy.
Beispiel 27/28: Identifizierung von CRISP 1 und CRISP 2 als diagnostisches und therapeutisches Target Die Sequenz von CRISP 1 ist in der GenBank unter der Zugangsnummer NM_001131.2 veröffentlicht. Die Sequenz von CRISP 2 ist in der GenBank unter der Zugangsnummer NM_003296.3 veröffentlicht. CRISP1 und CRISP2 sind sekretierte oder membranassoziierende Proteine mit Molekulargewichten zwischen 25 und 32 kDa. Eine Expression von CRISP1 oder CRISP2 ist in Tumoren bislang nicht beschrieben. In der Maus, zeigen CRISP-Proteine eine nicht nur auf die Hoden beschränkte Expression. Für den Menschen liegen keine ausreichenden Daten vor (Gibbs GM, Roelants K, O'Bryan MK. The CAP superfamily: cysteine-rich secretory proteins, antigen 5, and pathogenesis-related 1 proteins-roles in reproduction, Cancer, and immune defense. Endoer Rev. 2008;29:865-97). Example 27/28: Identification of CRISP 1 and CRISP 2 as a Diagnostic and Therapeutic Target The sequence of CRISP 1 is published in GenBank under accession number NM_001131.2. The sequence of CRISP 2 is published in GenBank under accession number NM_003296.3. CRISP1 and CRISP2 are secreted or membrane-associated proteins with molecular weights between 25 and 32 kDa. Expression of CRISP1 or CRISP2 is not previously described in tumors. In the mouse, CRISP proteins show not only testis-restricted expression. There are no adequate data available for humans (Gibbs GM, Roelants K, O'Bryan MK, The CAP superfamily: cysteine-rich secretory proteins, antigen 5, and pathogenesis-related 1 protein roles in reproduction, cancer, and immune defense. Endoer Rev. 2008; 29: 865-97).
Eine RT-PCR-Untersuchung mit einem spezifischen Primerpaar bestätigt eine Expression von CRISP1 in den folgenden Zelllinien (erwartete Fragmentlänge 183 bp, nur TV2): A 172, A 1207, U251 , U373, SK-MG-5, U 87-MG, TC620, U178, SKN- MC, GLC 8A, SCLC-24H, H 146, HL 60, HELA, HT-29, BCPAP, FTC-133, CAL-62, GLC-2, 1184, A549. Da drei untersuchte Zelllinien keine Expression aufweisen, ist das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet. A RT-PCR assay with a specific primer pair confirms expression of CRISP1 in the following cell lines (expected fragment length 183 bp, TV2 only): A 172, A 1207, U251, U373, SK-MG-5, U 87-MG, TC620, U178, SKN-MC, GLC 8A, SCLC-24H, H 146, HL 60, HELA, HT-29, BCPAP, FTC-133, CAL-62, GLC-2, 1184, A549. Since three investigated cell lines have no expression, the gene product according to the invention is suitable as a target for diagnosis and therapy.
Eine RT-PCR-Untersuchung mit einem spezifischen Primerpaar bestätigt eine Expression von CRISP2 in den folgenden Zelllinien (erwartete Fragmentlängen 257, 263, 294, 300 bp): A172, U373, U87-MG, U178, SH-SY5Y, HL-60, BCPAP, H1184. Da zumindest eine untersuchte Zelllinie eine Expression aufweist, ist das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet. Beispiel 29: Identifizierung von MYOF als diagnostisches und therapeutisches Target An RT-PCR assay with a specific primer pair confirms expression of CRISP2 in the following cell lines (expected fragment lengths 257, 263, 294, 300 bp): A172, U373, U87-MG, U178, SH-SY5Y, HL-60, BCPAP, H1184. Since at least one examined cell line has an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy. Example 29: Identification of MYOF as a Diagnostic and Therapeutic Target
Die Sequenz von MYOF ist in der GenBank unter der Zugangsnummer AF182316.1 veröffentlicht. Myoferlin ist ein Transmembranprotein mit einem MW von 234 kD und wird in Muskel- und Endothelzellen exprimiert. Die Expression in Mammakarzinomen, ist nachgewiesen (Leung C, Yu C, Lin MI, Tognon C, Bernatchez P. Expression of myoferlin in human and murine Carcinoma tumors: role in membrane repair, cell proliferation, and tumorigenesis. Am J Pathol. 2013;182:1900-9). The sequence of MYOF is published in GenBank under accession number AF182316.1. Myoferlin is a transmembrane protein with a MW of 234 kD and is expressed in muscle and endothelial cells. Expression in mammary carcinomas has been demonstrated (Leung C, Yu C, Lin MI, Tognon C, Bernatchez P. Expression of myoferlin in human and murine carcinoma tumors: role in membrane repair, cell proliferation, and tumorigenesis.) On J Pathol., 2013; 182: 1900-9).
Die RT-PCR-Untersuchung in Abb.2 mit einem spezifischen Primerpaar bestätigt eine Expression in den folgenden Zelllinien (erwartete Fragmentlänge 259 Basenpaare): A 172, A 1207, U 251 , U 373, SK-MG-5, U87-MG, TC 620, U 178, SKN-MC, HL 60, HELA, HT 29, BCP AP, GLC-2, GLC-36, H1184. Da mehrere untersuchte Zelllinien eine Expression aufweisen, ist das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet. The RT-PCR assay in Fig. 2 with a specific primer pair confirms expression in the following cell lines (expected fragment length 259 base pairs): A 172, A 1207, U 251, U 373, SK-MG-5, U87-MG, TC 620, U 178, SKN-MC, HL 60, HELA, HT 29, BCP AP, GLC-2, GLC-36, H1184. Since several investigated cell lines have an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy.
Beispiel 30: Identifizierung von OTOF als diagnostisches und therapeutisches Example 30: Identification of OTOF as Diagnostic and Therapeutic
Target  target
Die Sequenz von OTOF ist in der GenBank unter der Zugangsnummer NM_004802.3 veröffentlicht. Otoferlin ist ein Transmembranprotein von 227 kD. In der Maus wird Otoferlin im Innenohr, Cerebellum, Hippocampus, Hoden, vielleicht auch in Niere oder Herz exprimiert. Für den Menschen liegen keine genauen Daten vor. Eine Expression in Tumoren ist nicht beschrieben (Schug N, Braig C, Zimmermann U, Engel J, Winter H, Ruth P, Blin N, Pfister M, Kaibacher H, Knipper M. Differential expression of otoferlin in brain, vestibulär System, immature and mature Cochlea of the rat. Eur J Neurosci. 2006;24:3372-80).  The sequence of OTOF is published in GenBank under accession number NM_004802.3. Otoferlin is a transmembrane protein of 227 kD. In the mouse, otoferlin is expressed in the inner ear, cerebellum, hippocampus, testes, perhaps also in kidney or heart. For humans, there are no exact dates. Expression in tumors is not described (Schug N, Braig C, Zimmermann U, Engel J, Winter H, Ruth P, Blin N, Pfister M, Kaibacher H, Knipper M. Differential expression of otoferlin in brain, vestibular system, immature and mature cochlea of the rat, Eur J Neurosci., 2006; 24: 3372-80).
Die RT-PCR-Untersuchung in Abb.2 mit einem spezifischen Primerpaar bestätigt eine Expression in den folgenden Zelllinien (erwartete Fragmentlänge: 229 Basenpaare): A 172, A 1207, U 251 , U 373, TC620, U 178, SKN-MC, SH-SY5Y, GLC-8A, SCLC-24H, H 146, HL 60, HELA, HT 29, BCP AP, FTC-133, GLC-2, GLC- 36, H1184. Da mehrere untersuchte Zelllinien eine Expression aufweisen, ist das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet. The RT-PCR assay in Fig. 2 with a specific primer pair confirms expression in the following cell lines (expected fragment length: 229 base pairs): A 172, A 1207, U 251, U 373, TC 620, U 178, SKN-MC, SH-SY5Y, GLC-8A, SCLC-24H, H146, HL60, HELA, HT29, BCP AP, FTC-133, GLC-2, GLC- 36, H1184. Since several investigated cell lines have an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy.
Beispiel 31 : Identifizierung von SED 1 als diagnostisches und therapeutisches Example 31: Identification of SED 1 as Diagnostic and Therapeutic
Target  target
Die Sequenz von SED1 ist in der GenBank unter der Zugangsnummer NM_001114614.1 veröffentlicht. SED-1 ist ein Membran-assoziiertes Protein mit einem MW von 45 kD und wird in MIkroglia und Makrophagen exprimiert. Eine Expression in Blasen- und Mammakarzinomen, in Melanomen, Tumoren blutbildender Systeme, sowie in HeLa und C6-Gliomzellen (Ratte) ist beschrieben (Liu Y, Yang X, Guo C, Nie P, Liu Y, Ma J. Essential role of MFG-E8 for phagocytic properties of microglial cells. PLoS One. 2013; 8(2):e55754. doi: 10.1371/journal.pone.0055754; Bu HF, Zuo XL, Wang X, Ensslin MA, Koti V, Hsueh W, Raymond AS, Shur BD, Tan XD. Milk fat globule-EGF factor 8/lactadherin plays a crucial role in maintenance and repair of murine intestinal epithelium. J Clin Invest. 2007;117:3673-83; Goldberg GS, Bechberger JF, Tajima Y, Merritt M, Omori Y, Gawinowicz MA, Narayanan R, Tan Y, Sanai Y, Yamasaki H, Naus CC, Tsuda H, Nicholson BJ. Connexin43 suppresses MFG-E8 while inducing contact growth Inhibition of glioma cells. Cancer Res. 2000 Nov 1 ;60(21 ):6018-26). The sequence of SED1 is published in GenBank under accession number NM_001114614.1. SED-1 is a membrane-associated protein with a MW of 45 kD and is expressed in MIkroglia and macrophages. Expression in bladder and breast cancers, in melanomas, in tumors of hematopoietic systems, as well as in HeLa and C6 glioma cells (rat) has been described (Liu Y, Yang X, Guo C, Never P, Liu Y, Ma J. Essential role of MFG -E8 for phagocytic properties of microglial cells, PLoS One. 2013; 8 (2): e55754, doi: 10.1371 / journal.pone.0055754; Bu HF, Zuo XL, Wang X, Ensslin MA, Koti V, Hsueh W, Raymond AS, Shur BD, Tan XD Milk fat globule EGF factor 8 / lactadherin plays a crucial role in the maintenance and repair of murine intestinal epithelium J Clin Invest 2007; 117: 3673-83; Goldberg GS, Bechberger JF, Tajima Y , Morritt M, Omori Y, Gawinowicz MA, Narayanan R, Tan Y, Sanai Y, Yamasaki H, Naus CC, Tsuda H, Nicholson BJ Connexin43 suppresses MFG-E8 while inducing contact growth inhibition of glioma cells 1; 60 (21): 6018-26).
Die RT-PCR-Untersuchung in Abb.2 mit einem spezifischen Primerpaar bestätigt eine Expression in den folgenden Zelllinien (erwartete Fragmentlänge von 267 Basenpaaren): A 172, A 1207, U 251 , U 373, SK-MG-5, U87-MG, TC620, U 178, SKN-MC, SH-SY5Y, GLC-8A, SCLC-24H, H 146, HL 60, HELA, HT 29, BCP AP, FTC-133, GLC-36, H1184, A549. Da mehrere untersuchte Zelllinien eine Expression aufweisen, ist das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet. Beispiel 32: Identifizierung von ZAN als diagnostisches und therapeutisches Target The RT-PCR assay in Fig. 2 with a specific primer pair confirms expression in the following cell lines (expected fragment length of 267 base pairs): A 172, A 1207, U 251, U 373, SK-MG-5, U87-MG , TC620, U178, SKN-MC, SH-SY5Y, GLC-8A, SCLC-24H, H146, HL60, HELA, HT29, BCP AP, FTC-133, GLC-36, H1184, A549. Since several investigated cell lines have an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy. Example 32: Identification of ZAN as a Diagnostic and Therapeutic Target
Die Sequenz von ZAN ist in der GenBank unter der Zugangsnummer NM_003386.1 veröffentlicht. Bei Zonadhesin handelt es sich um ein Membranprotein mit einem MW von rund 240 kD. Expression in Spermienzellen. Eine Expression in Tumoren ist nicht bekannt (Herlyn H, Zischler H. The molecular evolution of sperm zonadhesin. Int J Dev Biol. 2008;52:781-90). The sequence of ZAN is published in GenBank under accession number NM_003386.1. Zonadhesin is a membrane protein with a MW of around 240 kD. Expression in sperm cells. Expression in tumors is not known (Herlyn H, Zischler H. The molecular evolution of sperm zonadhesin, Int J Dev Biol. 2008; 52: 781-90).
Die RT-PCR-Untersuchung in Abb.2 mit einem spezifischen Primerpaar bestätigt eine Expression in den folgenden Zelllinien (erwartete Fragmentlänge 252 Basenpaare): A 172, A 1207, U 251 , U 373, SK-MG-5, U87-MG, TC620, U 178, SKN-MC, GLC-8A, SCLC-24H, H 146, HL 60, HT 29, BCP AP, FTC-133, GLC2, H1184, A549. Da mehrere untersuchte Zelllinien eine Expression aufweisen, ist das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet. The RT-PCR assay in Fig. 2 with a specific primer pair confirms expression in the following cell lines (expected fragment length 252 base pairs): A 172, A 1207, U 251, U 373, SK-MG-5, U87-MG, TC620, U178, SKN-MC, GLC-8A, SCLC-24H, H146, HL60, HT29, BCP AP, FTC-133, GLC2, H1184, A549. Since several investigated cell lines have an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy.
Beispiel 33: Identifizierung von MMP 15 als diagnostisches und therapeutisches Example 33: Identification of MMP 15 as Diagnostic and Therapeutic
Target  target
Die Sequenz von MMP 15 ist in der GenBank unter der Zugangsnummer NM_002428.2 veröffentlicht. MMP15 ist ein Membranprotein von 76 kDa, das in Ösophaguskarzinomen exprimiert wird (Chen et al., Anticancer Res. 2010, 30:4363). The sequence of MMP 15 is published in GenBank under accession number NM_002428.2. MMP15 is a membrane protein of 76 kDa expressed in esophageal carcinomas (Chen et al., Anticancer Res. 2010, 30: 4363).
Die RT-PCR-Untersuchung in Abb.2 mit einem spezifischen Primerpaar bestätigt eine Expression in den folgenden Zelllinien (erwartete Fragmentlänge 193 basenpaare): A 172, A 1207, U251 , U373, SK-MG-5, U 87-MG, TC620, U178, SKN- MC, GLC 8A, SCLC-24H, H 146, HL 60, HELA, HT-29, BCPAP, GLC-2, GLC-36, H 1184. Da mehrere untersuchte Zelllinien eine Expression aufweisen, ist das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet. Beispiel 34: Identifizierung von MMP 16 als diagnostisches und therapeutisches Target The RT-PCR assay in Fig. 2 with a specific primer pair confirms expression in the following cell lines (expected fragment length 193 basepairs): A 172, A 1207, U251, U373, SK-MG-5, U 87-MG, TC620 , U178, SKN-MC, GLC 8A, SCLC-24H, H 146, HL 60, HELA, HT-29, BCPAP, GLC-2, GLC-36, H 1184. Since several cell lines studied have expression, the gene product is According to the invention suitable as a target for diagnosis and therapy. Example 34: Identification of MMP 16 as a Diagnostic and Therapeutic Target
Die Sequenz von MMP16 ist in der GenBank unter der Zugangsnummer NM_005941.4 veröffentlicht. MMP16 ist ein Membranprotein von 52 kDa, das in Knorpelzellen exprimiert wird Eine Expression in Lungentumoren (NSCLC) und Astrocytomen ist beschrieben (Darrah C, Donell ST, Shepstone L, Porter S, Brockbank SM, Edwards DR, Parker AE, Clark IM. Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum. 2004; 50: 131- 141 ; Grant GM, Giambernardi TA, Grant AM, Klebe RJ. Overview of expression of matrix metalloproteinases (MMP-17, MMP-18, and MMP-20) in cultured human cells. Matrix Biol. 1999; 18: 145-8). The sequence of MMP16 is published in GenBank under accession number NM_005941.4. MMP16 is a membrane protein of 52 kDa expressed in cartilage cells. Expression in lung tumors (NSCLC) and astrocytomas has been described (Darrah C, Donell ST, Shepstone L, Porter S, Brockbank SM, Edwards DR, Parker AE, Clark IM Arthritis Rheum. 2004; 50: 131-141; Grant GM, Giambernardi TA, Grant AM, Adhesive RJ. Overview of expression of matrix metalloproteinases (MMP-17, MMP-18, and MMP). 20) in cultured human cells, Matrix Biol. 1999; 18: 145-8).
Die RT-PCR-Untersuchung in Abb.2 mit einem spezifischen Primerpaar bestätigt eine Expression in den folgenden untersuchten Zelllinien (erwartete Fragmentlänge 192 Basenpaare): A 172, A 1207, U251 , U373, SK-MG-5, U 87-MG, TC620, U178, SKN-MC, GLC 8A, H 146, BCPAP, GLC-2, GLC-36, H 1184. Da mehrere untersuchte Zelllinien eine Expression aufweisen, ist das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet. The RT-PCR assay in Fig. 2 with a specific primer pair confirms expression in the following cell lines investigated (expected fragment length 192 base pairs): A 172, A 1207, U251, U373, SK-MG-5, U 87-MG, TC620, U178, SKN-MC, GLC 8A, H 146, BCPAP, GLC-2, GLC-36, H 1184. Since several examined cell lines have an expression, the gene product according to the invention is suitable as target for diagnosis and therapy.
Beispiel 35: Identifizierung von MMP 17 als diagnostisches und therapeutisches Example 35: Identification of MMP 17 as Diagnostic and Therapeutic
Target  target
Die Sequenz von MMP 17 ist in der GenBank unter der Zugangsnummer NM_016155.4 veröffentlicht. MMP-17 ist ein Membranprotein von 76 kDa. Normalexpression in Eosinophilen (Gauthier MC, Racine C, Ferland C, Flamand N, Chakir J, Tremblay GM, Laviolette M. Expression of membrane type-4 matrix metalloproteinase (metalloproteinase-17) by human eosinophils. Int J Biochem Cell Biol. 2003; 35: 1667-73; eine Expression in Hirn-, Kolon-, Lungen- (NSCLC) und Mammakarzinomen ist bekannt (Grant GM, Giambernardi TA, Grant AM, Klebe RJ. Overview of expression of matrix metalloproteinases (MMP-17, MMP-18, and MMP- 20) in cultured human cells. Matrix Biol. 1999; 18: 145-8). Die RT-PCR-Untersuchung in Abb.2 mit einem spezifischen Primerpaar bestätigt eine Expression in den folgenden Zelllinien (erwartete Fragmentlänge 300 Basenpaare): A 172, A 1207, U251 , U373, SK-MG-5, U 87-MG, TC620, U178, SKN- MC, GLC 8A, SCLC-24H, H 146, HL 60, HELA, BCPAP, GLC-2, GLC-36, H 1184. Da mehrere untersuchte Zelllinien eine Expression aufweisen, ist das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet. The sequence of MMP 17 is published in GenBank under accession number NM_016155.4. MMP-17 is a membrane protein of 76 kDa. Normal expression in eosinophils (Gauthier MC, Racine C, Ferland C, Flamand N, Chakir J, Tremblay GM, Laviolette M. Expression of membrane type-4 matrix metalloproteinase (metalloproteinase-17) by human eosinophils Int J Biochem Cell Biol. 35: 1667-73, expression in brain, colon, lung (NSCLC) and mammary carcinomas is well known (Grant GM, Giambernardi TA, Grant AM, Klebe RJ, Overview of expression of matrix metalloproteinases (MMP-17, MMP). 18, and MMP-20) in cultured human cells, Matrix Biol. 1999; 18: 145-8). The RT-PCR assay in Fig. 2 with a specific primer pair confirms expression in the following cell lines (expected fragment length 300 base pairs): A 172, A 1207, U251, U373, SK-MG-5, U 87-MG, TC620 , U178, SKN-MC, GLC 8A, SCLC-24H, H 146, HL 60, HELA, BCPAP, GLC-2, GLC-36, H 1184. Since several examined cell lines have an expression, the gene product is according to the invention as a target for Diagnostics and therapy suitable.
Beispiel 36: Identifizierung von MMP 20 als diagnostisches und therapeutisches Example 36: Identification of MMP 20 as Diagnostic and Therapeutic
Target  target
Die Sequenz von MMP 20 ist in der GenBank unter der Zugangsnummer NM_004771.3 veröffentlicht. Bei MMP20 handelt es sich um ein Membranprotein von 76 kDa. Die normale Expression ist auf zahnschmelzbildende Ameloblasten beschränkt (Bartlett JD, Simmer JP. Proteinases in developing dental enamel. Crit Rev Oral Biol Med. 1999; 10: 425-4). Eine Expression in Zungenkarzinomen ist nachgewiesen (Väänänen A, Srinivas R, Parikka M, Palosaari H, Bartlett JD, Iwata K, Grenman R, Stenman UH, Sorsa T, salo T Expression an regulation of MMP-20 in human tongue Carcinoma cells. J Dent Res. 2001 ; 80: 1884-9). The sequence of MMP 20 is published in GenBank under accession number NM_004771.3. MMP20 is a membrane protein of 76 kDa. Normal expression is limited to enamel-forming ameloblasts (Bartlett JD, Simmer JP, Proteinases in developing dental enamel, Crit Rev Oral Biol Med. 1999; 10: 425-4). Expression in lingual carcinomas has been demonstrated (Väänänen A, Srinivas R, Parikka M, Palosaari H, Bartlett JD, Iwata K, Grenman R, Stenman UH, Sorsa T, Salo T expression of regulation of MMP-20 in human tongue carcinoma cells Dent Res. 2001; 80: 1884-9).
Für das Beispiel 36 (Abb. 3) wurden folgende Zelllinien untersucht: A 172, A 1207, U251 , U373, SK-MG-5, U 87-MG, TC620, U178, SKN-MC, SH-SY5Y, GLC 8A, SCLC-24H, H146, HL 60, HELA, HT-29, BCPAP, FTC-133, CAL-62, GLC-2, GLC-36, H 1184, A549. The following cell lines were investigated for example 36 (FIG. 3): A 172, A 1207, U251, U373, SK-MG-5, U 87-MG, TC 620, U 178, SKN-MC, SH-SY5Y, GLC 8A, SCLC-24H, H146, HL 60, HELA, HT-29, BCPAP, FTC-133, CAL-62, GLC-2, GLC-36, H 1184, A549.
Die obere Gelhälfte zeigt: B-CPAP (Spur 1 ), FTC-133 (Spur 2), CAL-62 (Spur 3), GLC-2 (Spur 4), GLC-8A (Spur 5), GLC-36 (Spur 6), SCLC-24H (Spur 7), H146 (Spur 8), H-1184 (Spur 9), A549 (Spur 10), A172 (Spur 11 ), A1207 (Spur 12), leer (Spur 13), Negativkontrolle (Spur 14). The upper gel half shows: B-CPAP (lane 1), FTC-133 (lane 2), CAL-62 (lane 3), GLC-2 (lane 4), GLC-8A (lane 5), GLC-36 (lane 6), SCLC-24H (lane 7), H146 (lane 8), H-1184 (lane 9), A549 (lane 10), A172 (lane 11), A1207 (lane 12), blank (lane 13), negative control (Lane 14).
Die untere Gelhälfte zeigt: U251 (Spur 1), U373 (Spur 2), SK-MG-5 (Spur 3), U87- MG (Spur 4), TC620 (Spur 5), U178 (Spur 6), SKN-MC (Spur 7), SH-SY5Y (Spur 8), HL-60 (Spur 9), HeLa (Spur 10), HT-29 (Spur 11 ), leer (Spur 12, 13), Negativkontrolle (Spur 14). Die RT-PCR-Untersuchung in Abb. 3 mit einem spezifischen Primerpaar bestätigt eine Expression in den folgenden untersuchten Zelllinien Zelllinien (erwartete Fragmentlänge 223 Basenpaare): H-1184, A172, A1207, U251 , U87-MG, HT-29. Da mehrere untersuchte Zelllinien eine Expression aufweisen, ist das Genprodukt erfindungsgemäß als Target für Diagnostik und Therapie geeignet. The lower half of the gel shows: U251 (lane 1), U373 (lane 2), SK-MG-5 (lane 3), U87-MG (lane 4), TC620 (lane 5), U178 (lane 6), SKN-MC (Lane 7), SH-SY5Y (lane 8), HL-60 (lane 9), HeLa (lane 10), HT-29 (lane 11), empty (lane 12, 13), negative control (lane 14). The RT-PCR assay in Figure 3 with a specific primer pair confirms expression in the following cell line cell lines (expected fragment length 223 base pairs): H-1184, A172, A1207, U251, U87-MG, HT-29. Since several investigated cell lines have an expression, the gene product according to the invention is suitable as a target for diagnosis and therapy.
Sequenzprotokolle: Sequence listings:
<110> Universität Bonn  <110> University of Bonn
Probstmeier Dr., Rainer  Probstmeier Dr., Rainer
Winter Dr., Jochen  Winter Dr., Jochen
Kraus Dr., Dominik  Kraus Dr., Dominik
<120> Tumor-assoziierte Antigene und Genprodukte in der Diagnose und <120> Tumor-associated antigens and gene products in the diagnosis and
Therapie  therapy
<130> 3883-13  <130> 3883-13
<160> 36  <160> 36
<170> Microsoft Word <170> Microsoft Word
<210> 1 (Acrosin NM_001097.2) <210> 1 (Acrosine NM_001097.2)
<211 > 1384 <211> 1384
<212> DNA <212> DNA
<213> Homo sapiens <213> Homo sapiens
<400> 1 <400> 1
1 agtgccagga gtatggttga gatgctacca actgccattc tgctggtctt ggcagtgtcc 61 gtggttgcta aagataacgc cacgtgtgat ggcccctgtg ggttacggtt caggcaaaac 121 ccacagggtg gtgtccgcat cgtcggcggg aaggctgcac agcatggggc ctggccctgg 181 atggtcagcc tccagatctt cacgtacaac agccacaggt accacacatg tggaggcagc 241 ttgctgaatt cacgatgggt gctcactgct gctcactgct tcgtcggcaa aaataatgtg 301 catgactgga gactggtttt cggagcaaag gaaattacat atgggaacaa taaaccagta 361 aaggcgcctc tgcaagagag atatgtggag aaaatcatca ttcatgaaaa atacaactct 421 gcgacagagg gaaatgacat tgccctcgtg gagatcaccc ctcccatttc gtgtgggcgc 481 ttcattgggc cgggctgcct gccccacttt aaggcaggcc tccccagagg ctcccagagc 541 tgctgggtgg ccggctgggg atatatagaa gagaaagccc ccaggccatc atctatactg 601 atggaggcac gtgtggatct catcgacctg gacttgtgta actcgaccca gtggtacaat 661 gggcgcgttc agccaaccaa tgtgtgcgcg gggtatcctg taggcaagat cgacacctgc 721 cagggagaca gcggcgggcc tctcatgtgc aaagacagca aggaaagcgc ctatgtggtc 781 gtgggaatca caagctgggg ggtaggctgt gcccgtgcca agcgccccgg aatctacacg 841 gccacctggc cctatctgaa ctggatcgcc tccaagattg gttctaacgc tttgcgtatg 901 attcaatcgg ccacccctcc acctcccacc actcgaccgc ccccgattcg accccccttc 961 tcccacccta tctctgctca ccttccttgg tatttccaac cgccccctcg accacttcca 1021 ccccgaccac cggcagccca gccccgaccc ccaccttcac ccccgccccc acccccacct 1081 ccagcctcac ctttaccccc acccccaccc ccacccccac ctacaccctc atctaccaca 1141 aaacttcccc aaggactttc ttttgccaag cgcctacagc agctcataga ggtcttgaag 1201 gggaagacct attccgacgg aaagaaccat tatgacatgg agaccacaga gctcccagaa 1261 ctgacctcga cctcctgatc tgacctggtt ctcaacagac ccagtgagcc cttcactcct 1321 gagaaaaagg aaagatgaaa taaataaata aacatatata tatagatata aaaaaaaaaa 1381 aaaa <210> 2 (Acrosin binding protein NM_032489.2) 1 agtgccagga gtatggttga gatgctacca actgccattc tgctggtctt ggcagtgtcc 61 gtggttgcta aagataacgc cacgtgtgat ggcccctgtg ggttacggtt caggcaaaac 121 ccacagggtg gtgtccgcat cgtcggcggg aaggctgcac agcatggggc ctggccctgg 181 atggtcagcc tccagatctt cacgtacaac agccacaggt accacacatg tggaggcagc 241 ttgctgaatt cacgatgggt gctcactgct gctcactgct tcgtcggcaa aaataatgtg 301 catgactgga gactggtttt cggagcaaag gaaattacat atgggaacaa taaaccagta 361 aaggcgcctc tgcaagagag atatgtggag aaaatcatca ttcatgaaaa atacaactct 421 gcgacagagg gaaatgacat tgccctcgtg gagatcaccc ctcccatttc gtgtgggcgc 481 ttcattgggc cgggctgcct gccccacttt aaggcaggcc tccccagagg ctcccagagc 541 tgctgggtgg ccggctgggg atatatagaa gagaaagccc ccaggccatc atctatactg 601 atggaggcac gtgtggatct catcgacctg gacttgtgta actcgaccca gtggtacaat 661 gggcgcgttc agccaaccaa tgtgtgcgcg gggtatcctg taggcaagat cgacacctgc 721 cagggagaca gcggcgggcc tctcatgtgc aaagacagca aggaaagcgc ctatgtggtc 781 gtgggaatca caagctgggg ggtaggctgt gcccgtgcca agcgccccgg aatctacacg 841 gccacctggc cctatctg aa ctggatcgcc tccaagattg gttctaacgc tttgcgtatg 901 attcaatcgg ccacccctcc acctcccacc actcgaccgc ccccgattcg accccccttc 961 tcccacccta tctctgctca ccttccttgg tatttccaac cgccccctcg accacttcca 1021 ccccgaccac cggcagccca gccccgaccc ccaccttcac ccccgccccc acccccacct 1081 ccagcctcac ctttaccccc acccccaccc ccacccccac ctacaccctc atctaccaca 1141 aaacttcccc aaggactttc ttttgccaag cgcctacagc agctcataga ggtcttgaag 1201 gggaagacct attccgacgg aaagaaccat tatgacatgg agaccacaga gctcccagaa 1261 ctgacctcga cctcctgatc tgacctggtt ctcaacagac ccagtgagcc cttcactcct 1321 gagaaaaagg aaagatgaaa taaataaata aacatatata tatagatata aaaaaaaaaa 1381 aaaa <210> 2 (Acrosine binding protein NM_032489.2)
<211 > 1886  <211> 1886
<212> DNA  <212> DNA
<213> Homo Sapiens  <213> Homo Sapiens
<400> 2  <400> 2
1 gttagaggcg gcttgtgtcc acgggacgcg ggcggatctt ctccggccat gaggaagcca 61 gccgctggct tccttccctc actcctgaag gtgctgctcc tgcctctggc acctgccgca 121 gcccaggatt cgactcaggc ctccactcca ggcagccctc tctctcctac cgaatacgaa 181 cgcttcttcg cactgctgac tccaacctgg aaggcagaga ctacctgccg tctccgtgca 241 acccacggct gccggaatcc cacactcgtc cagctggacc aatatgaaaa ccacggctta 301 gtgcccgatg gtgctgtctg ctccaacctc ccttatgcct cctggtttga gtctttctgc 361 cagttcactc actaccgttg ctccaaccac gtctactatg ccaagagagt cctgtgttcc 421 cagccagtct ctattctctc acctaacact ctcaaggaga tagaagcttc agctgaagtc 481 tcacccacca cgatgacctc ccccatctca ccccacttca cagtgacaga acgccagacc 541 ttccagccct ggcctgagag gctcagcaac aacgtggaag agctcctaca atcctccttg 601 tccctgggag gccaggagca agcgccagag cacaagcagg agcaaggagt ggagcacagg 661 caggagccga cacaagaaca caagcaggaa gaggggcaga aacaggaaga gcaagaagag 721 gaacaggaag aggagggaaa gcaggaagaa ggacagggga ctaaggaggg acgggaggct 781 gtgtctcagc tgcagacaga ctcagagccc aagtttcact ctgaatctct atcttctaac 841 ccttcctctt ttgctccccg ggtacgagaa gtagagtcta ctcctatgat aatggagaac 901 atccaggagc tcattcgatc agcccaggaa atagatgaaa tgaatgaaat atatgatgag 961 aactcctact ggagaaacca aaaccctggc agcctcctgc agctgcccca cacagaggcc 1021 ttgctggtgc tgtgctattc gatcgtggag aatacctgca tcataacccc cacagccaag 1081 gcctggaagt acatggagga ggagatcctt ggtttcggga agtcggtctg tgacagcctt 1141 gggcggcgac acatgtctac ctgtgccctc tgtgacttct gctccttgaa gctggagcag 1201 tgccactcag aggccagcct gcagcggcaa caatgcgaca cctcccacaa gactcccttt 1261 gtcagcccct tgcttgcctc ccagagcctg tccatcggca accaggtagg gtccccagaa 1321 tcaggccgct tttacgggct ggatttgtac ggtgggctcc acatggactt ctggtgtgcc 1381 cggcttgcca cgaaaggctg tgaagatgtc cgagtctctg ggtggctcca gactgagttc 1441 cttagcttcc aggatgggga tttccctacc aagatttgtg acacagacta tatccagtac 1501 ccaaactact gttccttcaa aagccagcag tgtctgatga gaaaccgcaa tcggaaggtg 1561 tcccgcatga gatgtctgca gaatgagact tacagtgcgc tgagccctgg caaaagtgag 1621 gacgttgtgc ttcgatggag ccaggagttc agcaccttga ctctaggcca gttcggatga 1681 gctggcgtct attctgccca caccccagcc caacctgccc acgttctcta ttgttttgag 1741 accccattgc tttcaggctg ccccttctgg gtctgttact cggcccctac tcacatttcc 1801 ttgggttgga gcaacagtcc cagagagggc cacggtggga gctgcgccct ccttaaaaga 1861 tgactttaca taaaatgttg atcttc 1 gttagaggcg gcttgtgtcc acgggacgcg ggcggatctt ctccggccat gaggaagcca 61 gccgctggct tccttccctc actcctgaag gtgctgctcc tgcctctggc acctgccgca 121 gcccaggatt cgactcaggc ctccactcca ggcagccctc tctctcctac cgaatacgaa 181 cgcttcttcg cactgctgac tccaacctgg aaggcagaga ctacctgccg tctccgtgca 241 acccacggct gccggaatcc cacactcgtc cagctggacc aatatgaaaa ccacggctta 301 gtgcccgatg gtgctgtctg ctccaacctc ccttatgcct cctggtttga gtctttctgc 361 cagttcactc actaccgttg ctccaaccac gtctactatg ccaagagagt cctgtgttcc 421 cagccagtct ctattctctc acctaacact ctcaaggaga tagaagcttc agctgaagtc 481 tcacccacca cgatgacctc ccccatctca ccccacttca cagtgacaga acgccagacc 541 ttccagccct ggcctgagag gctcagcaac aacgtggaag agctcctaca atcctccttg 601 tccctgggag gccaggagca agcgccagag cacaagcagg agcaaggagt ggagcacagg 661 caggagccga cacaagaaca caagcaggaa gaggggcaga aacaggaaga gcaagaagag 721 gaacaggaag aggagggaaa gcaggaagaa ggacagggga ctaaggaggg acgggaggct 781 gtgtctcagc tgcagacaga ctcagagccc aagtttcact ctgaatctct atcttctaac 841 ccttcctctt ttgctccc cg ggtacgagaa gtagagtcta ctcctatgat aatggagaac 901 atccaggagc tcattcgatc agcccaggaa atagatgaaa tgaatgaaat atatgatgag 961 aactcctact ggagaaacca aaaccctggc agcctcctgc agctgcccca cacagaggcc 1021 ttgctggtgc tgtgctattc gatcgtggag aatacctgca tcataacccc cacagccaag 1081 gcctggaagt acatggagga ggagatcctt ggtttcggga agtcggtctg tgacagcctt 1141 gggcggcgac acatgtctac ctgtgccctc tgtgacttct gctccttgaa gctggagcag 1201 tgccactcag aggccagcct gcagcggcaa caatgcgaca cctcccacaa gactcccttt 1261 gtcagcccct tgcttgcctc ccagagcctg tccatcggca accaggtagg gtccccagaa 1321 tcaggccgct tttacgggct ggatttgtac ggtgggctcc acatggactt ctggtgtgcc 1381 cggcttgcca cgaaaggctg tgaagatgtc cgagtctctg ggtggctcca gactgagttc 1441 cttagcttcc aggatgggga tttccctacc aagatttgtg acacagacta tatccagtac 1501 ccaaactact gttccttcaa aagccagcag tgtctgatga gaaaccgcaa tcggaaggtg 1561 tcccgcatga gatgtctgca gaatgagact tacagtgcgc tgagccctgg caaaagtgag 1621 gacgttgtgc ttcgatggag ccaggagttc agcaccttga ctctaggcca gttcggatga 1681 gctggcgtct attctgccca CACCC cagcc caacctgccc acgttctcta ttgttttgag 1741 accccattgc tttcaggctg ccccttctgg gtctgttact cggcccctac tcacatttcc 1801 ttgggttgga gcaacagtcc cagagagggc cacggtggga gctgcgccct ccttaaaaga 1861 tgactttaca taaaatgttg atcttc
<210> 3 (CATSPER1 NM_053054) <210> 3 (CATSPER1 NM_053054)
<211 > 2625  <211> 2625
<212> DNA  <212> DNA
<213> Homo Sapiens  <213> Homo Sapiens
<400> 3 1 acgagaatag tcaggccttt ctggaagccc agtgccacag tctgcattga gcttggctca<400> 3 1 acgagaatag tcaggccttt ctggaagccc agtgccacag tctgcattga gcttggctca
61 ggaaagaagg gaaatccagg cggggcctgt tgggcccagg tcttgagctc ttttggctcc 121 agagttccca gcacagtcat ggatcaaaac tcagtgcctg aaaaggctca gaatgaggca 181 gacaccaata acgcagatag gttctttcgc tctcactcat cacccccaca ccacaggcca 241 ggccacagca gagctctcca ccattacgag ttgcaccatc acggcgtgcc ccaccaacgt 301 ggtgaatctc accaccctcc ggagttccaa gacttccacg accaagcctt gtcctcccat 361 gtccaccaat ctcaccacca cagcgaggca cggaatcacg gcagagccca tggccccaca 421 ggctttggtc tggctccctc tcaaggcgcc gtcccctccc accgttccta cggtgaggac 481 taccatgatg agctccaacg tgatggcagg aggcatcatg atgggtccca atacggtggg 541 ttccatcagc agagtgactc ccattaccat agggggtctc accatggcag accccaatat 601 ctcggtgaga atttatccca ctattcctct ggcgtgcccc accacggtga ggcttcccac 661 catggtgggt cctacctccc ccatggaccc aatccctaca gtgagtcctt ccaccacagc 721 gaggcttccc accttagcgg gctccaacac gatgagtccc agcatcacca agtcccccac 781 cgtggctggc cccaccatca ccaagtccac caccatggca ggtcccgtca tcatgaagcc 841 caccagcatg gaaagtctcc tcatcacgga gagaccattt cccctcattc ctctgtgggg 901 tcctaccagc gtgggatatc tgactatcac agcgagtacc accaaggtga tcaccacccc 961 agtgagtacc accatggcga ccatccccac cacacacagc accactacca ccagacccac 1021 cggcaccgag actaccatca gcaccaagac caccacggcg cgtatcattc cagttacctc 1081 catggcgact acgtccagag cacttcccaa ctctctatcc cacacacatc ccggagcctg 1141 attcacgatg cccccggccc tgctgcttct cgtacaggag tcttccccta tcacgtagca 1201 cacccacggg gctcggctca cagcatgact cggtcctcca gcacaatccg ctcacgtgtc 1261 acccagatgt ccaaaaaagt ccatacccag gatatctcca ccaaacattc agaagactgg 1321 ggcaaagaag aagggcaatt tcagaaacgc aaaaccggcc ggctccagcg gacccgcaag 1381 aagggacact ctaccaatct cttccagtgg ctgtgggaaa agctaacctt cctcattcag 1441 ggcttccggg aaatgatccg gaacctgacc caatccttgg cctttgaaac tttcatcttc 1501 ttcgttgtct gcctcaacac cgtcatgctg gtggcccaga ccttcgctga agtcgagatc 1561 cggggcgagt ggtacttcat ggccttggac tccatattct tctgcatcta cgtggtggaa 1621 gccctgctca agatcatcgc cctgggcctc tcgtacttct ttgacttctg gaacaatttg 1681 gacttcttca ttatggccat ggccgtgctg gacttcttgc tgatgcagac ccactccttc 1741 gccatctacc accaaagcct cttccggatc ctcaaggtct tcaagagcct gcgggccctg 1801 agggcaatcc gggtcctgcg gaggctcagc ttcctgacca gcgtccagga agtgacaggg 1861 accctgggcc agtccttgcc gtccatcgca gccatcctca tcctcatgtt tacctgcctc 1921 ttcctcttct ccgcggtcct ccgggcactg ttccgcaaat ctgaccccaa gcgcttccag 1981 aacatcttca ccaccatctt caccctcttc accttgctca cgctggatga ctggtccctc 2041 atctacatgg acagccgtgc ccagggcgcc tggtacatca ttcccatcct cgtaatttac 2101 atcatcatcc agtacttcat cttcctcaac ctggtgatta ctgtcctggt ggatagcttc 2161 cagacggcgc tgttcaaagg ccttgagaaa gcgaagcagg agagggccgc ccggatccaa 2221 gagaagctgc tggaagactc actgacggag ctcagagctg cagagcccaa agaggtggcg 2281 agtgaaggca ccatgctgaa gcggctcatc gagaaaaagt ttgggaccat gactgagaag 2341 cagcaggagc tcctgttcca ttacctgcag ctggtggcaa gcgtggagca ggagcagcag 2401 aagttccgct cccaggcagc cgtcatcgat gagattgtgg acaccacatt tgaggctgga 2461 gaagaggact tcaggaattg accccaggag gacaccagat acagacttca gcccctggca 2521 gtctgcccac ctgggtgcac tgggacgggt ccccagatct gctggaatga ttgtccgggc 2581 cctgcagagc aggggcccca acagagtttt taaaccccaa aaaaaaaaaa aaaa 61 ggaaagaagg gaaatccagg cggggcctgt tgggcccagg tcttgagctc ttttggctcc 121 agagttccca gcacagtcat ggatcaaaac tcagtgcctg aaaaggctca gaatgaggca 181 gacaccaata acgcagatag gttctttcgc tctcactcat cacccccaca ccacaggcca 241 ggccacagca gagctctcca ccattacgag ttgcaccatc acggcgtgcc ccaccaacgt 301 ggtgaatctc accaccctcc ggagttccaa gacttccacg accaagcctt gtcctcccat 361 gtccaccaat ctcaccacca cagcgaggca cggaatcacg gcagagccca tggccccaca 421 ggctttggtc tggctccctc tcaaggcgcc gtcccctccc accgttccta cggtgaggac 481 taccatgatg agctccaacg tgatggcagg aggcatcatg atgggtccca atacggtggg 541 ttccatcagc agagtgactc ccattaccat agggggtctc accatggcag accccaatat 601 ctcggtgaga atttatccca ctattcctct ggcgtgcccc accacggtga ggcttcccac 661 catggtgggt cctacctccc ccatggaccc aatccctaca gtgagtcctt ccaccacagc 721 gaggcttccc accttagcgg gctccaacac gatgagtccc agcatcacca agtcccccac 781 cgtggctggc cccaccatca ccaagtccac caccatggca ggtcccgtca tcatgaagcc 841 caccagcatg gaaagtctcc tcatcacgga gagaccattt cccctcattc ctctgtgggg 901 tcctaccagc gtggga tatC tgactatcac agcgagtacc accaaggtga tcaccacccc 961 agtgagtacc accatggcga ccatccccac cacacacagc accactacca ccagacccac 1021 cggcaccgag actaccatca gcaccaagac caccacggcg cgtatcattc cagttacctc 1081 catggcgact acgtccagag cacttcccaa ctctctatcc cacacacatc ccggagcctg 1141 attcacgatg cccccggccc tgctgcttct cgtacaggag tcttccccta tcacgtagca 1201 cacccacggg gctcggctca cagcatgact cggtcctcca gcacaatccg ctcacgtgtc 1261 acccagatgt ccaaaaaagt ccatacccag gatatctcca ccaaacattc agaagactgg 1321 ggcaaagaag aagggcaatt tcagaaacgc aaaaccggcc ggctccagcg gacccgcaag 1381 aagggacact ctaccaatct cttccagtgg ctgtgggaaa agctaacctt cctcattcag 1441 ggcttccggg aaatgatccg gaacctgacc caatccttgg cctttgaaac tttcatcttc 1501 ttcgttgtct gcctcaacac cgtcatgctg gtggcccaga ccttcgctga agtcgagatc 1561 cggggcgagt ggtacttcat ggccttggac tccatattct tctgcatcta cgtggtggaa 1621 gccctgctca agatcatcgc cctgggcctc tcgtacttct ttgacttctg gaacaatttg 1681 gacttcttca ttatggccat ggccgtgctg gacttcttgc tgatgcagac ccactccttc 1741 gccatctacc accaaagcct ct tccggatc ctcaaggtct tcaagagcct gcgggccctg 1801 agggcaatcc gggtcctgcg gaggctcagc ttcctgacca gcgtccagga agtgacaggg 1861 accctgggcc agtccttgcc gtccatcgca gccatcctca tcctcatgtt tacctgcctc 1921 ttcctcttct ccgcggtcct ccgggcactg ttccgcaaat ctgaccccaa gcgcttccag 1981 aacatcttca ccaccatctt caccctcttc accttgctca cgctggatga ctggtccctc 2041 atctacatgg acagccgtgc ccagggcgcc tggtacatca ttcccatcct cgtaatttac 2101 atcatcatcc agtacttcat cttcctcaac ctggtgatta ctgtcctggt ggatagcttc 2161 cagacggcgc tgttcaaagg ccttgagaaa gcgaagcagg agagggccgc ccggatccaa 2221 gagaagctgc tggaagactc actgacggag ctcagagctg cagagcccaa agaggtggcg 2281 agtgaaggca ccatgctgaa gcggctcatc gagaaaaagt ttgggaccat gactgagaag 2341 cagcaggagc tcctgttcca ttacctgcag ctggtggcaa gcgtggagca ggagcagcag 2401 aagttccgct cccaggcagc cgtcatcgat gagattgtgg acaccacatt tgaggctgga 2461 gaagaggact tcaggaattg accccaggag gacaccagat acagacttca gcccctggca 2521 gtctgcccac ctgggtgcac tgggacgggt ccccagatct gctggaatga ttgtccgggc 2581 cctgcagagc aggggcccca acagagtt tta taaccaa aaaaaaaaaa aaaa
<210> 4 (CATSPER2 NM_172095.2) <210> 4 (CATSPER2 NM_172095.2)
<211 > 1947  <211> 1947
<212> DNA  <212> DNA
<213> Homo Sapiens  <213> Homo Sapiens
<400> 4  <400> 4
1 gctccgcatg gtcctgggct gtgggtaggg gctagggccg ggtcccgggg tgagccgaaa 61 cctgggggtc gagcggggcg gggaatgggg cgcagtgagg ctgggagccg gccctgagct 121 cgtcttgcat aggggtagcc aggctcgggg cacctgagct ggaggcggaa gcgtgaaata 181 aggactgagt gggcaaagag aacctgggct gagacatggc cgcttaccaa caagaagagc 241 agatgcagct tccccgagct gatgccattc gttcacgtct catcgatact ttctctctca 301 ttgagcattt gcaaggcttg agccaagctg tgccgcggca cactatcagg gagttacttg 361 atccttcccg ccagaagaaa cttgtattgg gagatcaaca ccagctagtg cgtttctcta 421 taaagcctca gcgtatagaa cagatttcac atgcccagag gctgttgagc aggcttcatg 481 tgcgctgcag tcagaggcca cctctttctt tgtgggccgg atgggtcctt gagtgtcctc 541 tcttcaaaaa cttcatcatc ttcctggtct ttttgaatac gatcatattg atggttgaaa 601 tagaattgct ggaatccaca aataccaaac tatggccatt gaagctgacc ttggaggtgg 661 cagcttggtt tatcttgctt attttcatcc tggagatcct tcttaagtgg ctatccaact 721 tttctgtttt ctggaagagt gcctggaatg tctttgactt tgttgttacc atgttgtccc 781 tgcttcccga ggttgtggta ttggtagggg taacaggcca atcggtgtgg cttcagcttc 841 tgaggatctg ccgggtgctg aggtctctca aactccttgc acaattccgt caaattcaaa 901 ttattatttt ggtcctggtc agggccctca agagcatgac cttcctcttg atgttgctgc 961 tcatcttctt ctacattttt gctgtgactg gtgtctacgt cttctcagag tacacccgtt 1021 cacctcgtca ggacctggag taccatgtgt tcttctcgga cctcccgaat tccctggtaa 1081 cagtgttcat tctcttcacc ttggatcatt ggtatgcact gcttcaggac gtctggaagg 1141 tgcctgaagt cagtcgcatc ttcagcagca tctatttcat cctttggttg ttgcttggct 1201 ccattatctt tcgaagtatc atagtagcca tgatggttac taactttcag aatatcagga 1261 aagagctgaa tgaggagatg gcgcgtcggg aggttcagct caaagctgac atgttcaagc 1321 ggcagatcat ccagaggaga aaaaacatgt cacatgaagc actgacgtca agccatagca 1381 aaatagagga cagttcaaga ggagctagtc aacaaaggga aagtttggac ttatcagaag 1441 tgtctgaagt agagtctaat tatggtgcca ctgaagagga tttaataaca tctgcatcaa 1501 aaacagaaga gaccttgtca aaaaagagag agtaccagtc ttcctcctgt gtctcctcca 1561 catcctcttc ctattcttcc tcttctgaat ccagattttc tgaatctatt ggtcgtttgg 1621 actgggagac tcttgtgcac gaaaatctgc ccgggctaat ggaaatggat caggatgacc 1681 gtgtttggcc cagagactca ctcttccgat attttgagtt gctagaaaag cttcagtata 1741 acctagagga acgtaagaag ttacaagagt ttgcagtgca ggcactgatg aacttggaag 1801 acaagtaaag caatggatgg cttcaatatc cttgggccca gcaaaagata atgaagggaa 1861 ttgttggaaa tagagaattg aaaatataaa cattcagata gaacaatgtc tgttcattaa 1921 aattaaaaag tataagtgtc taggcca 1 gctccgcatg gtcctgggct gtgggtaggg gctagggccg ggtcccgggg tgagccgaaa 61 cctgggggtc gagcggggcg gggaatgggg cgcagtgagg ctgggagccg gccctgagct 121 cgtcttgcat aggggtagcc aggctcgggg cacctgagct ggaggcggaa gcgtgaaata 181 aggactgagt gggcaaagag aacctgggct gagacatggc cgcttaccaa caagaagagc 241 agatgcagct tccccgagct gatgccattc gttcacgtct catcgatact ttctctctca 301 ttgagcattt gcaaggcttg agccaagctg tgccgcggca cactatcagg gagttacttg 361 atccttcccg ccagaagaaa cttgtattgg gagatcaaca ccagctagtg cgtttctcta 421 taaagcctca gcgtatagaa cagatttcac atgcccagag gctgttgagc aggcttcatg 481 tgcgctgcag tcagaggcca cctctttctt tgtgggccgg atgggtcctt gagtgtcctc 541 tcttcaaaaa cttcatcatc ttcctggtct ttttgaatac gatcatattg atggttgaaa 601 tagaattgct ggaatccaca aataccaaac tatggccatt gaagctgacc ttggaggtgg 661 cagcttggtt tatcttgctt attttcatcc tggagatcct tcttaagtgg ctatccaact 721 tttctgtttt ctggaagagt gcctggaatg tctttgactt tgttgttacc atgttgtccc 781 tgcttcccga ggttgtggta ttggtagggg taacaggcca atcggtgtgg cttcagcttc 841 tgaggatctg ccgggtgctg aggtctctca aactccttgc acaattccgt caaattcaaa 901 ttattatttt ggtcctggtc agggccctca agagcatgac cttcctcttg atgttgctgc 961 tcatcttctt ctacattttt gctgtgactg gtgtctacgt cttctcagag tacacccgtt 1021 cacctcgtca ggacctggag taccatgtgt tcttctcgga cctcccgaat tccctggtaa 1081 cagtgttcat tct cttcacc ttggatcatt ggtatgcact gcttcaggac gtctggaagg 1141 tgcctgaagt cagtcgcatc ttcagcagca tctatttcat cctttggttg ttgcttggct 1201 ccattatctt tcgaagtatc atagtagcca tgatggttac taactttcag aatatcagga 1261 aagagctgaa tgaggagatg gcgcgtcggg aggttcagct caaagctgac atgttcaagc 1321 ggcagatcat ccagaggaga aaaaacatgt cacatgaagc actgacgtca agccatagca 1381 aaatagagga cagttcaaga ggagctagtc aacaaaggga aagtttggac ttatcagaag 1441 tgtctgaagt agagtctaat tatggtgcca ctgaagagga tttaataaca tctgcatcaa 1501 aaacagaaga gaccttgtca aaaaagagag agtaccagtc ttcctcctgt gtctcctcca 1561 catcctcttc ctattcttcc tcttctgaat ccagattttc tgaatctatt ggtcgtttgg 1621 actgggagac tcttgtgcac gaaaatctgc ccgggctaat ggaaatggat caggatgacc 1681 gtgtttggcc cagagactca ctcttccgat attttgagtt gctagaaaag cttcagtata 1741 acctagagga acgtaagaag ttacaagagt ttgcagtgca ggcactgatg aacttggaag 1801 acaagtaaag caatggatgg cttcaatatc cttgggccca gcaaaagata atgaagggaa 1861 ttgttggaaa tagagaattg aaaatataaa cattcagata gaacaatgtc tgttcattaa 1921 aattaaaaag tataagtgt c taggcca
<210> 5 (CATSPER4 NMJ98137.1 ] <210> 5 (CATSPER4 NMJ98137.1]
<211 > 1419  <211> 1419
<212> DNA  <212> DNA
<213> Homo Sapiens  <213> Homo Sapiens
<400> 5 <400> 5
1 atgagggata atgaaaaggc ctggtggcag caatggacct cccatacagg cctcgagggg 61 tggggcggga ctcaggagga ccgtatgggg tttggagggg cagtagctgc actgaggggc1 atgagggata atgaaaaggc ctggtggcag caatggacct cccatacagg cctcgagggg 61 tggggcggga ctcaggagga ccgtatgggg tttggagggg cagtagctgc actgaggggc
121 cgcccctctc ccctgcagag taccattcac gagtcctacg gtcggccaga ggagcaagtg 181 ctcatcaacc gccaggaaat cacgaacaaa gcggacgcct gggacatgca ggagttcatc121 cgcccctctc ccctgcagag taccattcac gagtcctacg gtcggccaga ggagcaagtg 181 ctcatcaacc gccaggaaat cacgaacaaa gcggacgcct gggacatgca ggagttcatc
241 actcacatgt acatcaagca gctgctccga caccccgcct tccaactgct gctggccctg241 actcacatgt acatcaagca gctgctccga caccccgcct tccaactgct gctggccctg
301 ctgctggtga tcaatgccat caccatcgct ctccgtacca actcctacct ggaccagaaa301 ctgctggtga tcaatgccat caccatcgct ctccgtacca actcctacct ggaccagaaa
361 cactatgagt tgttctctac catagatgac attgtgctga ccatccttct ttgtgaggtt361 cactatgagt tgtctctac catagatgac attgtgctga ccatccttct ttgtgaggtt
421 ctccttggct ggctcaatgg cttctggatt ttctggaagg acggctggaa catcctcaac 481 ttcattatcg tctttatctt gctcttgcgg ttcttcatta atgaaatcaa tattccctcc421 ctccttggct ggctcaatgg cttctggatt ttctggaagg acggctggaa catcctcaac 481 ttcattatcg tctttatctt gctcttgcgg ttcttcatta atgaaatcaa tattccctcc
541 atcaactaca ctctcagggc gcttcgtctg gtgcatgtgt gcatggcggt ggagcccctc541 atcaactaca ctctcagggc gcttgtgtg gtgcatgtgt gcatggcggt ggagcccctc
601 gcccggatca tccgcgtcat cctgcagtcg gtgcctgaca tggccaatat catggtcctc601 gcccggatca tccgcgtcat cctgcagtcg gtgcctgaca tggccaatat catggtcctc
661 atcctcttct tcatgctggt tttttccgtg tttggagtaa cactctttgg tgcattcgtg661 atcctcttct tcatgctggt tttttccgtg tttggagtaa cactctttgg tgcattcgtg
721 cccaagcatt tccagaacat acaggttgcg ctgtacaccc tcttcatctg catcacccag 781 gacggctggg tggacatcta cagtgacttc cagacagaga agagggaata tgcaatggag721 cccaagcatt tccagaacat acaggttgcg ctgtacaccc tcttcatctg catcacccag 781 gacggctggg tggacatcta cagtgacttc cagacagaga agagggaata tgcaatggag
841 attgggggtg ccatctactt taccatcttc atcaccatcg gtgccttcat tggcatcaac841 attgggggtg ccatctacttaccatcttc atcaccatcg gtgccttcat tggcatcaac
901 ctgttcgtca tcgtggtgac caccaacctg gagcaaatga tgaaggcagg agagcaggga 961 caacagcaac gaataacctt tagtgagaca ggcgcagagg aagaggagga gaatgaccag901 ctgttcgtca tcgtggtgac caccaacctg gagcaaatga tgaaggcagg agagcaggga 961 caacagcaac gaataacctt tagtgagaca ggcgcagagg aagaggagga gaatgaccag
1021 ctgccactgg tgcattgtgt ggtcgcccgc tcggagaaat ctggtctcct ccaggaaccc1021 ctgccactgg tgcattgtgt ggtcgcccgc tcggagaaat ctggtctcct ccaggaaccc
1081 cttgcgggag gccccctgtc gaacctctca gaaaacacgt gtgacaactt ttgcttggtg1081 cttgcgggag gccccctgtc gaacctctca gaaaacacgt gtgacaactt ttgcttggtg
1141 cttgaggcaa tacaggagaa cctgaggcag tacaaggaga tccgagatga actcaacatg1141 cttgaggcaa tacaggagaa cctgaggcag tacaaggaga tccgagatga actcaacatg
1201 attgtggagg aggtgcgcgc aatccgcttc aaccaggagc aggagtcaga ggtgttgaac 1261 aggcgctcgt cgacgagcgg gtcgttggag actacgtcat ccaaggacat ccgccagatg1201 attgtggagg aggtgcgcgc aatccgcttc aaccaggagc aggagtcaga ggtgttgaac 1261 aggcgctcgt cgacgagcgg gtcgttggag actacgtcat ccaaggacat ccgccagatg
1321 tctcaacagc aagacttgct cagtgcgctc gttagcatgg aaaaggttca tgactctagc1321 tctcaacagc aagacttgct cagtgcgctc gttagcatgg aaaaggttca tgactctagc
1381 tcacaaatac tccttaaaaa acacaagagc agccactga 1381 tcacaaatac tccttaaaaa acacaagagc agccactga
<210> 6 (CATSPERB NM_024764.2) <210> 6 (CATSPERB NM_024764.2)
<211 > 3606  <211> 3606
<212> DNA  <212> DNA
<213> Homo Sapiens  <213> Homo Sapiens
<400> 6 <400> 6
1 aaaggtgact agagtgctaa gccagtcaac agggaaaact tggctcctga ctttgggtct 61 ttcttctcag tctatatgga agaaaactga gaaaaaatat aaaaaagaag aacacaacta 121 gttgcgcatc tcctaaagag atggaatcgc cacttatata tgtttcagtt ttgcttttga 181 acatatttga attttcatca ggaatagtat ataataaaga tgatacagag aaacgctttg 241 catgttctaa caaagggttc cctcaagaga atgaaataat caagttgtat cttttcttag 301 aaaacttgaa aatccagtgt ttcttccaaa ctgaaaatga aattgcatca aaagcaatgc 361 taagtgtgtt cacatcagga ggacttgctc ccagcttggg aatcatgaat agtacatata 421 atggcatctt ccactttaat ttaacgttgt tcagtgatcg gattttgtgg ttggttgata 481 ttcctagaga aaacatcaca caaagcacag atattgcagc tgtagaagaa tggttagtaa 541 gaatcacttt acatcatgga ctaaatattt atgctactga aggaactcta ttggatgtta 601 ttcgagaacc gattcttcag tggactcctg gggatgtgat tccagaaagt gaaatcagta 661 aattatatcc acatgtggta gatctcaaag tgacaaaatg cccctgtgcc aatgatgtgg 721 cattactagg cttcattgtg gatacaatag ttgatggtgt ttacataggc ataacctttg 781 gtggattctg gcatgattat gataccacat ggtttaacat gacacagact atctattccc 841 aacttcaaga agaatatgaa gacctttcat tggtggatat ggttttaacg aatcattttt 901 tagttatcct cacctctttg ggcctttttg taagtgaaga tcttcgttat ccatcacgcc 961 acagcttatc gttttccagg gcagactttt gtggttttga aagggttgac tatgtgaaag 1021 gaaaactgtg gtataatgaa agatgttttg ctaacagaga gcactttgaa gttgattatg 1081 ttacagttac ctttgagaga aacagaaccc taagtgagtc aagctcttgt ttttatagtc 1141 aggaaccatt tcttgaatgg gtaccctgct tacctcacat ttttaaagga ataaaaattt 1201 ttccaactgt gctaacattt cttgttgacc aagagcgtgg tactggagtt tacctcttct 1261 ataacaaggt caggaaaact gccattgcct ctgtgagcac cctgagaaat aatgaaccaa 1321 attcacaatc aaaatttcca atttttcggt ttccttcatc attctcttct cccgttggaa 1381 tggtatttca tccccgaagc cactttttgt atgcttatgg caatcagata tggctttcag 1441 ttgatggcgg caacaccttt caattaatag ctaactttca tgatgatatc ataaagaaga 1501 cttttcatag tttttataca tcagctatta cttttgtttc tcaacgtgga aaggtttact 1561 cgacaaaggc aggaatggga agatacagtg cagtcggaag tgttactgag agaattttca 1621 cattatacta tgatcacttg ggattcctac ataagctgac tctgggtcgc tttgaagcta 1681 gtggaccacc cacagccttt ggaaattcta gaaatctttt tggacagcct ccagatatgg 1741 gctttgagac tgcgcttgcc ccacagcaca cctccttaga tgaaattatc ttttttgcat 1801 atgtacctga gaacgaaccc caggaaacga tctacagcaa gaagttcggc aatatacact 1861 atggaaaagt gatacactct gggaaaactg gaagagctta cataagaaag gtattgcaac 1921 atacgactcc taaaggattt ttgtcctcag ttattgcaga aatgaaagag ccctttggat 1981 tagaagaagt gaatgagagc tcttgtttgt ctagttccct tttgattaat aaagctggaa 2041 atgtctataa actcactctt gattcacaag ttgttcaggc cttgtttgaa gatacagata 2101 tagagaagac tgtagtgctt cccgggtaca gcagcttcct catcacaagc attttagata 2161 ataagaatgc attagccatt gctaccatgc ctgaaagtgc acccaacaat atgacctttc1 aaaggtgact agagtgctaa gccagtcaac agggaaaact tggctcctga ctttgggtct 61 ttcttctcag tctatatgga agaaaactga gaaaaaatat aaaaaagaag aacacaacta 121 gttgcgcatc tcctaaagag atggaatcgc cacttatata tgtttcagtt ttgcttttga 181 acatatttga attttcatca ggaatagtat ataataaaga tgatacagag aaacgctttg 241 catgttctaa caaagggttc cctcaagaga atgaaataat caagttgtat cttttcttag 301 aaaacttgaa aatccagtgt ttcttccaaa ctgaaaatga aattgcatca aaagcaatgc 361 taagtgtgtt cacatcagga ggacttgctc ccagcttggg aatcatgaat agtacatata 421 atggcatctt ccactttaat ttaacgttgt tcagtgatcg gattttgtgg ttggttgata 481 ttcctagaga aaacatcaca caaagcacag atattgcagc tgtagaagaa tggttagtaa 541 gaatcacttt acatcatgga ctaaatattt atgctactga aggaactcta ttggatgtta 601 ttcgagaacc gattcttcag tggactcctg gggatgtgat tccagaaagt gaaatcagta 661 aattatatcc acatgtggta gatctcaaag tgacaaaatg cccctgtgcc aatgatgtgg 721 cattactagg cttcattgtg gatacaatag ttgatggtgt ttacataggc ataacctttg 781 gtggattctg gcatgattat gataccacat ggtttaacat gacacagact atctattccc 841 aacttcaaga agaatatg aa gacctttcat tggtggatat ggttttaacg aatcattttt 901 tagttatcct cacctctttg ggcctttttg taagtgaaga tcttcgttat ccatcacgcc 961 acagcttatc gttttccagg gcagactttt gtggttttga aagggttgac tatgtgaaag 1021 gaaaactgtg gtataatgaa agatgttttg ctaacagaga gcactttgaa gttgattatg 1081 ttacagttac ctttgagaga aacagaaccc taagtgagtc aagctcttgt ttttatagtc 1141 aggaaccatt tcttgaatgg gtaccctgct tacctcacat ttttaaagga ataaaaattt 1201 ttccaactgt gctaacattt cttgttgacc aagagcgtgg tactggagtt tacctcttct 1261 ataacaaggt caggaaaact gccattgcct ctgtgagcac cctgagaaat aatgaaccaa 1321 attcacaatc aaaatttcca atttttcggt ttccttcatc attctcttct cccgttggaa 1381 tggtatttca tccccgaagc cactttttgt atgcttatgg caatcagata tggctttcag 1441 ttgatggcgg caacaccttt caattaatag ctaactttca tgatgatatc ataaagaaga 1501 cttttcatag tttttataca tcagctatta cttttgtttc tcaacgtgga aaggtttact 1561 cgacaaaggc aggaatggga agatacagtg cagtcggaag tgttactgag agaattttca 1621 cattatacta tgatcacttg ggattcctac ataagctgac tctgggtcgc tttgaagcta 1681 gtggaccacc cacagccttt ggaaa ttcta gaaatctttt tggacagcct ccagatatgg 1741 gctttgagac tgcgcttgcc ccacagcaca cctccttaga tgaaattatc ttttttgcat 1801 atgtacctga gaacgaaccc caggaaacga tctacagcaa gaagttcggc aatatacact 1861 atggaaaagt gatacactct gggaaaactg gaagagctta cataagaaag gtattgcaac 1921 atacgactcc taaaggattt ttgtcctcag ttattgcaga aatgaaagag ccctttggat 1981 tagaagaagt gaatgagagc tcttgtttgt ctagttccct tttgattaat aaagctggaa 2041 atgtctataa actcactctt gattcacaag ttgttcaggc cttgtttgaa gatacagata 2101 tagagaagac tgtagtgctt cccgggtaca gcagcttcct catcacaagc attttagata 2161 ataagaatgc attagccatt gctaccatgc ctgaaagtgc acccaacaat atgacctttc
2221 taaagagcac atggttctta tacaactttg ggcaaaggaa tggacgaaca tggaaaatat2221 taaagagcac atggttctta tacaactttg ggcaaaggaa tggacgaaca tggaaaatat
2281 attcaaaacc atgtaattat tggtttcaac atgatgattc accatccctc aacattgtga2281 attcaaaacc atgtaattat tggtttcaac atgatgattc accatccctc aacattgtga
2341 aatacattga tctgggaaac tcttatgttt taaaagctaa ggtcatacgg aatgcaaaag2341 aatacattga tctgggaaac tcttatgttt taaaagctaa ggtcatacgg aatgcaaaag
2401 gttttcgaat gcttgaaata ccactactga ctgtgtttgt tggaaaccct aatttgttgg 2461 aagttacagc tgaagtcact tttgatgata ctgacagtta tgtaataaca atttctgcag2401 gttttcgaat gcttgaaata ccactactga ctgtgtttgt tggaaaccct aatttgttgg 2461 aagttacagc tgaagtcact tttgatgata ctgacagtta tgtaataaca atttctgcag
2521 ctagcaaagt tttacatcag ggttcaactt cactggcatt tattatgtgg tcagcctcta2521 ctagcaaagt tttacatcag ggttcaactt cactggcatt tattatgtgg tcagcctcta
2581 ctgagtgctt tgttacgaca atggtgccaa cactgaaaag cagctgtagt tatctcagat2581 ctgagtgctt tgttacgaca atggtgccaa cactgaaaag cagctgtagt tatctcagat
2641 ctatgcatca cattcctagc aaatttatcc catttgaaga ctggattagt ggagttcata2641 ctatgcatca cattcctagc aaatttatcc catttgaaga ctggattagt ggagttcata
2701 aagacagtca gggttttaac ctcatcaaaa ctttgccgat aaactacagg cctccatcta 2761 atatgggaat tgctattcca ctcacagata atttttatca tgcagatcct agcaaaccca2701 aagacagtca gggttttaac ctcatcaaaa ctttgccgat aaactacagg cctccatcta 2761 atatgggaat tgctattcca ctcacagata atttttatca tgcagatcct agcaaaccca
2821 taccaagaaa catgtttcac atgtcaaaga aaaccggtaa attcaaacag tgtgctaatg2821 taccaagaaa catgtttcac atgtcaaaga aaaccggtaa attcaaacag tgtgctaatg
2881 tttccactcg ggaggagtgt aactgcacaa aggatcagaa gttttcacat gctgttgctt2881 tttccactcg ggaggagtgt aactgcacaa aggatcagaa gttttcacat gctgttgctt
2941 tctcggattg cagggaaaaa gttcctcgct ttaagtttcc aattacacaa tatccagttt2941 tctcggattg cagggaaaaa gttcctcgct ttaagtttcc aattacacaa tatccagttt
3001 ctttggaaat tatcaacgag gatggacgtg tcccattgca atctccatat ctggttactg 3061 tgactgaagt gaacatgagg cacaactgga aactgaaaca cactgtgcca gaaaatatta3001 ctttggaaat tatcaacgag gatggacgtg tcccattgca atctccatat ctggttactg 3061 tgactgaagt gaacatgagg cacaactgga aactgaaaca cactgtgcca gaaaatatta
3121 aaagaatgaa acaattagta gaaccaattc ttggtgctgc agtgtataat ccttcaggtc3121 aaagaatgaa acaattagta gaaccaattc ttggtgctgc agtgtataat ccttcaggtc
3181 tcaacttaag cataaagggc tctgaacttt tccactttag agtgaccgtc atttcaggag3181 tcaacttaag cataaagggc tctgaacttt tccactttag agtgaccgtc atttcaggag
3241 taactttttg taacttaatt gaagaatttc agatttatgt tgatgaggca ccattgccat3241 taactttttg taacttaatt gaagaatttc agatttatgt tgatgaggca ccattgccat
3301 tcccaggaca cacgcttatt gccgtggcaa cagcggtagt gctaggggga ttaattttta 3361 tagcatttat gtttcaactg caaggcatcc atccgtggag gacattccaa agatggatta3301 tcccaggaca cacgcttatt gccgtggcaa cagcggtagt gctaggggga ttaattttta 3361 tagcatttat gtttcaactg caaggcatcc atccgtggag gacattccaa agatggatta
3421 gaagaaacca agagaagttt tcaagtatct ctctcagtga gctgattcat agatcaaagt3421 gaagaaacca agagaagttt tcaagtatct ctctcagtga gctgattcat agatcaaagt
3481 ctgaagagtg aacacatggt gatcataatt tctctttatt ttctagtttt atcagccaat3481 ctgaagagtg aacacatggt gatcataatt tctctttatt ttctagtttt atcagccaat
3541 tcctagaaca atatatttaa atgttaaata tgcaagctac ataaaatcct aaagaattgt3541 tcctagaaca atatatttaa atgttaaata tgcaagctac ataaaatcct aaagaattgt
3601 cattat 3601 cattat
<210> 7 (CATSPERD NM_152784.3) <210> 7 (CATSPERD NM_152784.3)
<211 > 2528  <211> 2528
<212> DNA  <212> DNA
<213> Homo Sapiens  <213> Homo Sapiens
<400> 7  <400> 7
1 gattgtgcag cgactccccg tggcggttga ggggcagtgg tggcggcgga agcccaagtc 61 gatgctgatg ttgatgctgg tggcggctgt gaccatgtgg ctccgaccgc tggtcacagc1 gattgtgcag cgactccccg tggcggttga ggggcagtgg tggcggcgga agcccaagtc 61 gatgctgatg ttgatgctgg tggcggctgt gaccatgtgg ctccgaccgc tggtcacagc
121 tcagctctgt cgttctcgca cagtgaggac aggaaaagtg tttaatctga tacaggacgt121 tcagctctgt cgttctcgca cagtgaggac aggaaaagtg tttaatctga tacaggacgt
181 tcaaggggac cgcctgtatt ttcatcctac aacaacacgc ttgattaaac atccttgcga181 tcaaggggac cgctctatt ttcatcctac aacaacacgc ttgattaaac atccttgcga
241 gaaaaatata gcactatatc tagggaaaca agtttttttc acaatggata actttgagac241 gaaaaatata gcactatatc tagggaaaca agtttttttc acaatggata actttgagac
301 tagtctcctt ccatttacca tccctacatc aatgcaggtc ggcgtaccag aagtgacatc 361 agcacatttt gctggttcgt tattgctgtt agtagtggat caaaaagtct atatttatga301 tctctctt ccatttacca tccctacatc aatgcaggtc ggcgtaccag aagtgacatc 361 agcacatttt gctggttcgt tattgctgtt agtagtggat caaaaagtct atatttatga
421 ttatgaaaat aattcttgga gcatgtcttt aggtataaaa caccctgtta cacatgtctc421 ttatgaaaat aattcttgga gcatgtcttt aggtataaaa caccctgtta cacatgtctc
481 tggtgataat tgttgttata ctggaagttt gttttgtgtg catgtcagta atttggtttt481 tggtgataat tgttgttata ctggaagttt gttttgtgtg catgtcagta atttggtttt
541 tgcatatttc cgtggagatc agatatccca gacttatata tattattcaa atactggggg541 tgcatatttc cgtggagatc agatatccca gacttatata tattattcaa atactggggg
601 attcagtttt tggaagtatc actatgacag acaggcagaa atcattgggt ctttaggcgg 661 aatcttccac tttttttctt tgtcacaggt tgcgatgctt gtagtgaatc aagggaaggg601 attcagtttt ggaagtatc actatgacag acaggcagaa atcattgggt ctttaggcgg 661 aatcttccac tttttttctt tgtcacaggt tgcgatgctt gtagtgaatc aagggaaggg
721 catgttcaag tactcagatc accccctcaa ccggagtttc gggctgtctt ttgactataa721 catgttcaag tactcagatc accccctcaa ccggagtttc gggctgtctt ttgactataa
781 tgggactcta gacatcctca tcgcccccgg ccagagaggc atcctgctcc tatggtttga 841 gaacagcctg ttgttttccc ataatgcagg tcagctcgtc gacaccgtcc gggtgaaaaa781 tgggactcta gacatcctca tcgcccccgg ccagagaggc atcctgctcc tatggtttga 841 gaacagcctg ttgttttccc ataatgcagg tcagctcgtc gacaccgtcc gggtgaaaaa
901 aggagaccag accttgtttt cttccatttt tgaagccaag atcaccatcc acaacattgc901 aggagaccag accttgtttt cttccatttt tgaagccaag atcaccatcc acaacattgc
961 tgtcactgaa aatgaactgg cagttataac tcgggaggat aatttgtatt atggcaatct961 tgtcactgaa aatgaactgg cagttataac tcgggaggat aatttgtatt atggcaatct
1021 gggcatcgtg ccaagttcca taatcaaatt tgcagaccaa tacatctggt cagaagacgt1021 gggcatcgtg ccaagttcca taatcaaatt tgcagaccaa tacatctggt cagaagacgt
1081 ggccctgatg ttcaggagcc cagggactct ggaaatactg accccactgc gtgacacagc 1141 ctttccagct tttgatttcc agaagtgcct cgtgaatatc caggcgcttc tcatggaccc1081 ggccctgatg ttcaggagcc cagggactct ggaaatactg accccactgc gtgacacagc 1141 ctttccagct tttgatttcc agaagtgcct cgtgaatatc caggcgcttc tcatggaccc
1201 tgaactccac gttggaaagt gcaagataga gtttctgaca ggagaattta tatacaggat1201 tgaactccac gttggaaagt gcaagataga gtttctgaca ggagaattta tatacaggat
1261 gtataccatt gacatgcaca gccagctgga attgactgct tcgttgatac cccagccagg1261 gtataccatt gacatgcaca gccagctgga attgactgct tcgttgatac cccagccagg
1321 cacatccctg attcctctgg tgatggtgag caacccccac tccctggggt tccaggccac1321 cacatccctg attcctctgg tgatggtgag caacccccac tccctggggttccaggccac
1381 cttctacgag aacggttaca catcagatgg gaacaccaag tacaaactgg atattttcct 1441 aaaacagcag cagcactggg gcaggaccga ctccaacttc acttccagtt taaagaaagc1381 cttctacgag aacggttaca catcagatgg gaacaccaag tacaaactgg atattttcct 1441 aaaacagcag cagcactggg gcaggaccga ctccaacttc acttccagtt taaagaaagc
1501 caccatgtct accttaactg tggacatagc aaacaaggaa atttcatgtg tggatatcaa1501 caccatgtct accttaactg tggacatagc aaacaaggaa atttcatgtg tggatatcaa
1561 gccactgtcg acactgattt cagttggctg cgacctggat aaaaagatcg tcatccagaa1561 gccactgtcg acactgattt cagttggctg cgacctggat aaaaagatcg tcatccagaa
1621 caaagtttcc gcctgttcca tgggcatcct ggaccccttg accctgcaag acaattacag1621 caaagtttcc gcctgttcca tgggcatcct ggaccccttg accctgcaag acaattacag
1681 cttcatcatc gagaaggaat tctacgaccc cggcttccag gggcagcagt cctccgagga 1741 cctgcacgtg ttttactcct accagcagct gggctgtcct ctcctcgtct actatgacac1681 cttcatcatc gagaaggaat tctacgaccc cggcttccag gggcagcagt cctccgagga 1741 cctgcacgtg ttttactcct accagcagct gggctgtcct ctcctcgtct actatgacac
1801 cctatggaag cccgtggtgg agctgtggcg aaaagacagt ttccaggagg tcatcgacgc1801 cctatggaag cccgtggtgg agctgtggcg aaaagacagt ttccaggagg tcatcgacgc
1861 cgagtatgtg ttactggagg tgaacgggca gttctcatac tcctattccc tgacggccca1861 cgagtatgtg ttactggagg tgaacgggca gttctcatac tcctattccc tgacggccca
1921 gtcggccatg tgtacctccc agccgcagaa ctggaccacc atgataaagg aattcggggg1921 gtcggccatg tgtacctccc agccgcagaa ctggaccacc atgataaagg aattcgggggg
1981 gcccttcttc tggaacagag agaactatgt gagctgccac gaccccaaca acaatgcccc 2041 tttgaggtgg ccagacgtcc agtatcagat cttgggcggc cggacagcaa accagatcat1981 gcccttcttc tggaacagag agaactatgt gagctgccac gaccccaaca acaatgcccc 2041 tttgaggtgg ccagacgtcc agtatcagat cttgggcggc cggacagcaa accagatcat
2101 tttcggccac aatggctttt atgtcttcta catttcgatc gtggatccgt actacagcta2101 tttcggccac aatggctttt atgtcttcta catttcgatc gtggatccgt actacagcta
2161 ctgtcaactg gagaccatct ttagcatcta cgtgtatgga gcattccccg tgcagctggt2161 ctgtcaactg gagaccatct ttagcatcta cgtgtatgga gcattccccg tgcagctggt
2221 ctctgctgga gtcgtcatcc tactgatcat ctccagcatc ctggggtccg tttggctggc2221 ctctgctgga gtcgtcatcc tactgatcat ctccagcatc ctggggtccg tttggctggc
2281 ctacaagacc cccaagctgc tacgcacagc acgcggccgc aggatcaaga agtgtgcgac 2341 acagctgtgt aggagatgca agacggtctg ccagttcagg gcctcagcca cagccagggc2281 ctacaagacc cccaagctgc tacgcacagc acgcggccgc aggatcaaga agtgtgcgac 2341 acagctgtgt aggagatgca agacggtctg ccagttcagg gcctcagcca cagccagggc
2401 aggcacagag cccccgggac gccaccgcac tcctcacgga ggcaggtctg accactgagg2401 aggcacagag cccccgggac gccaccgcac tcctcacgga ggcaggtctg accactgagg
2461 ccggtccaca gggtcccaac cccttgtctt caaataaagt ataatgtaac ataaaaaaaa2461 ccggtccaca gggtcccaac cccttgtctt caaataaagt ataatgtaac ataaaaaaaa
2521 aaaaaaaa 2521 aaaaaaaa
<210> 8 (CATSPERG NM_021185.4) <210> 8 (CATSPERG NM_021185.4)
<211 > 3727  <211> 3727
<212> DNA  <212> DNA
<213> Homo Sapiens  <213> Homo Sapiens
<400> 8 <400> 8
1 attttgagac cgggcaagag gggcgggact ggtgcggccg agtgacagtt gaccggtttt 61 aaccaagtga ctggttctag ccacgttatg tgcggcccag ccatgttccc tgccggtcct 121 ccgtggccca gagtccgagt cgtgcaggtg ctgtgggccc tgctggcagt gctcctggcg 181 tcgtggaggc tgtgggcgat caaggatttc caggaatgca cctggcaggt tgtcctgaac 241 gagtttaaga gggtaggcga gagtggtgtg agcgacagct tctttgagca agagcccgtg 301 gacacagtga gcagcttgtt tcacatgctg gtggactcac ccatcgaccc gagcgagaaa 361 tacctgggct tcccttacta cctgaagatc aactactcct gcgaggaaaa gccctctgag 421 gacctggtgc gcatgggcca cctgacgggg ctaaagcccc tggtgctggt caccttccag 481 tccccagtca acttctaccg ctggaagata gagcagctgc agatccagat ggaggctgcc 541 cccttccgca gcaaagagcc atgcatggca gaagaagtgt gtagcatgag ctggtacacg 601 cccatgccca tcaagaaagg cagtgtggtc atgcgtgtgg acatcagcag caatggcctg 661 gggaccttca ttccagataa aaggttccag atgaatatca acggcttcct gaagagagac 721 cgggacaata acatccaatt cactgtggga gaggagctct tcaacctgat gccccagtac 781 tttgtgggtg tctcatcgag gcccttgtgg cacactgtgg accagtcacc tgtgcttatc 841 ctgggaggca ttcccaatga gaagtacgtc ctgatgactg acaccagctt caaggacttc 901 tctctcgtgg agctgagcat tgacagttgc tgggtgggct ccttctactg cccccattct 961 ggcttcacag ccaccatcta tgacactatt gccaccgaga gcaccctctt cattcggcag 1021 aaccagctgg tctactattt tacaggcacc tataccacac tctatgagag aaaccgcggc 1081 agtggcagtt ggattcgtgt cctggccagc gagtgcatca agaagctgtg ccctgtgtat 1141 ttccatagca atggctctga gtacataatg gccctcacca cgggcaagca tgagggttat 1201 gtacacttcg ggaccatcag agatggccag gtgtcctttg agatgctgcc caggcagtgg 1261 tctgtgtgcg agcagatagg agttaccacc tgctccataa tttggtctga atacatcgcg 1321 ggtgagtata ctctactgct gctggtggag agtggatatg gtaatgcaag taaacgtttc 1381 caggtggtca gctacaacac agctagtgat gacctggaac ttctctacca catcccagaa 1441 ttcatccctg aagctcgagg attggagttc ctgatgatcc tagggacaga gtcctacacc 1501 agcactgcaa tggcccccaa gggcatcttc tgtaacccgt acaacaatct gatcttcatc 1561 tggggcaact tcctcctgca gagctctaac aaggaaaact tcatctacct ggcagacttc 1621 cccaaggaac tgtccatcaa atacatggcc agatcgttcc gtggggctgt ggctattgtc 1681 acagagacgg aggagatctg gtacctcctg gagggcagct accgggtcta ccagctgttc 1741 ccttccaagg gctggcaggt gcacatcagc ttaaagctga tgcaacagtc ctctctctac 1801 gcatccaatg agaccatgct gaccctcttc tacgaagaca gcaaactgta ccagctggtg 1861 taccttatga acaaccagaa gggccagctg gtcaagaggc tcgtgcccgt ggagcagctt 1921 ctgatgtatc aacagcacac cagccactat gacttggagc ggaaaggggg ctacttgatg 1981 ctctccttca tcgacttctg ccccttctcg gtgatgcgcc tgcggagcct gcccagtccg 2041 cagagataca cgcgccagga gcgctaccgg gcgcggccgc cgcgcgtcct ggagcgctcg 2101 ggcttccaca acgagaactc gctcgccatc taccagggcc tggtctacta cctgctgtgg 2161 ctgcactccg tgtacgacaa gccgtacgcg gacccggtgc acgaccccac ctggcgctgg 2221 tgggcgaaca acaaacaaga ccaggattac tacttcttct tggcgagcaa ttggcgaagc 2281 gcgggcggcg tgtccataga aatggacagc tacgaaaaga tctacaacct cgagtccgcg 2341 tacgagctgc cggagcgcat tttcctggac aagggcactg agtacagctt cgccatcttc 2401 ctgtcggcgc agggccactc gttccggacg cagtcagaac tcggcaccgc cttccagctg 2461 catagccagg tggacgtggg cgtggtgctg gccgaccccg gctgcatcga ggcctcggtg 2521 aagcaggagg tcctgattaa tcgcaactcg gtgctatttt cgattacgct caaggataaa 2581 aagctttgct atgaccaagg cattagtgga catcacctta tggagacttc catgacggtc 2641 aatgtggtgg gttcatccgg gctctgcttc caggaaacac acctggggcc ccatatgcaa 2701 ggcaacctga tggtgccagt gttcattggc tgccccccag gcaagcgcct ggccttcgac 2761 atcacctaca cgctggaata cagccgcctg aagaacaaac actactttga ctgcgttaac 2821 gtgaacccgg agatgccctg ctttctcttc cgggacattt tctacccctt cttcttgatt 2881 caagatttgg tgacaggaga ctccggcagt ttccagggca gctatgttct gctggtggtg 2941 ggtggcgggc ccacactgga cagcctcaag gactacagtg aggacgaaat ctaccgcttc 3001 aacagccccc tggacaagac caacagcctt atctggacca cgaggaccac aaggaccacc 3061 aaagactcag cctttcacat catgtcccac gagagcccag gcatcgagtg gctctgtctg 3121 gagaatgccc catgctatga caatgttccc caaggcatct ttgcccctga attcttcttc 3181 aaggtgttgg tgagcaatag aggagtggac acgagcacct actgcaacta ccagctcacc 3241 ttcctgctgc acatccacgg gctgccactc agtcccaagc gggccctttt catcatcatg 3301 gtgtcagcta gcgtgtttgt gggcctggtg atcttctaca tcgccttctg cctcctgtgg 3361 cccctcgtgg tgaagggctg cacgatgatc cggtggaaga taaacaacct cattgcctca 3421 gaatcctact acacctacgc ctccatttcc ggaatctcga gcatgccgtc tctgagacat 3481 tccaggatgg gctccatgtt cagctccagg atgacagagg acagggctga acccaaggaa 3541 gccgtggaga gacagttgat gacctgagtg tcccacctgc cccagccccc agttactgtc 3601 acgcctctct tatgaggccc atcttgaaga tgcaacctgt cacccagccc aggcctctct 3661 ttctgttttg cttgatgttt acttctcgtt cagactcaaa taaagccttt tttcaggacc 3721 agcaaaa <210> 9 (CRISP3 NM_001190986.1 ) 1 attttgagac cgggcaagag gggcgggact ggtgcggccg agtgacagtt gaccggtttt 61 aaccaagtga ctggttctag ccacgttatg tgcggcccag ccatgttccc tgccggtcct 121 ccgtggccca gagtccgagt cgtgcaggtg ctgtgggccc tgctggcagt gctcctggcg 181 tcgtggaggc tgtgggcgat caaggatttc caggaatgca cctggcaggt tgtcctgaac 241 gagtttaaga gggtaggcga gagtggtgtg agcgacagct tctttgagca agagcccgtg 301 gacacagtga gcagcttgtt tcacatgctg gtggactcac ccatcgaccc gagcgagaaa 361 tacctgggct tcccttacta cctgaagatc aactactcct gcgaggaaaa gccctctgag 421 gacctggtgc gcatgggcca cctgacgggg ctaaagcccc tggtgctggt caccttccag 481 tccccagtca acttctaccg ctggaagata gagcagctgc agatccagat ggaggctgcc 541 cccttccgca gcaaagagcc atgcatggca gaagaagtgt gtagcatgag ctggtacacg 601 cccatgccca tcaagaaagg cagtgtggtc atgcgtgtgg acatcagcag caatggcctg 661 gggaccttca ttccagataa aaggttccag atgaatatca acggcttcct gaagagagac 721 cgggacaata acatccaatt cactgtggga gaggagctct tcaacctgat gccccagtac 781 tttgtgggtg tctcatcgag gcccttgtgg cacactgtgg accagtcacc tgtgcttatc 841 ctgggaggca ttcccaatga gaagtacgtc ctgatgactg acaccagctt caaggacttc 901 tctctcgtgg agctgagcat tgacagttgc tgggtgggct ccttctactg cccccattct 961 ggcttcacag ccaccatcta tgacactatt gccaccgaga gcaccctctt cattcggcag 1021 aaccagctgg tctactattt tacaggcacc tataccacac tctatgagag aaaccgcggc 1081 agtggcagtt ggattcgtgt cctggccagc gagtgcatca agaagctgtg ccctgtgtat 1141 ttccatagca atggctctga gtacataatg gccctcacca cgggcaagca tgagggttat 1201 gtacacttcg G gaccatcag agatggccag gtgtcctttg agatgctgcc caggcagtgg 1261 tctgtgtgcg agcagatagg agttaccacc tgctccataa tttggtctga atacatcgcg 1321 ggtgagtata ctctactgct gctggtggag agtggatatg gtaatgcaag taaacgtttc 1381 caggtggtca gctacaacac agctagtgat gacctggaac ttctctacca catcccagaa 1441 ttcatccctg aagctcgagg attggagttc ctgatgatcc tagggacaga gtcctacacc 1501 agcactgcaa tggcccccaa gggcatcttc tgtaacccgt acaacaatct gatcttcatc 1561 tggggcaact tcctcctgca gagctctaac aaggaaaact tcatctacct ggcagacttc 1621 cccaaggaac tgtccatcaa atacatggcc agatcgttcc gtggggctgt ggctattgtc 1681 acagagacgg aggagatctg gtacctcctg gagggcagct accgggtcta ccagctgttc 1741 ccttccaagg gctggcaggt gcacatcagc ttaaagctga tgcaacagtc ctctctctac 1801 gcatccaatg agaccatgct gaccctcttc tacgaagaca gcaaactgta ccagctggtg 1861 taccttatga acaaccagaa gggccagctg gtcaagaggc tcgtgcccgt ggagcagctt 1921 ctgatgtatc aacagcacac cagccactat gacttggagc ggaaaggggg ctacttgatg 1981 ctctccttca tcgacttctg ccccttctcg gtgatgcgcc tgcggagcct gcccagtccg 2041 cagagataca cgcgcca gga gcgctaccgg gcgcggccgc cgcgcgtcct ggagcgctcg 2101 ggcttccaca acgagaactc gctcgccatc taccagggcc tggtctacta cctgctgtgg 2161 ctgcactccg tgtacgacaa gccgtacgcg gacccggtgc acgaccccac ctggcgctgg 2221 tgggcgaaca acaaacaaga ccaggattac tacttcttct tggcgagcaa ttggcgaagc 2281 gcgggcggcg tgtccataga aatggacagc tacgaaaaga tctacaacct cgagtccgcg 2341 tacgagctgc cggagcgcat tttcctggac aagggcactg agtacagctt cgccatcttc 2401 ctgtcggcgc agggccactc gttccggacg cagtcagaac tcggcaccgc cttccagctg 2461 catagccagg tggacgtggg cgtggtgctg gccgaccccg gctgcatcga ggcctcggtg 2521 aagcaggagg tcctgattaa tcgcaactcg gtgctatttt cgattacgct caaggataaa 2581 aagctttgct atgaccaagg cattagtgga catcacctta tggagacttc catgacggtc 2641 aatgtggtgg gttcatccgg gctctgcttc caggaaacac acctggggcc ccatatgcaa 2701 ggcaacctga tggtgccagt gttcattggc tgccccccag gcaagcgcct ggccttcgac 2761 atcacctaca cgctggaata cagccgcctg aagaacaaac actactttga ctgcgttaac 2821 gtgaacccgg agatgccctg ctttctcttc cgggacattt tctacccctt cttcttgatt 2881 caagatttgg tgacaggaga ct ccggcagt ttccagggca gctatgttct gctggtggtg 2941 ggtggcgggc ccacactgga cagcctcaag gactacagtg aggacgaaat ctaccgcttc 3001 aacagccccc tggacaagac caacagcctt atctggacca cgaggaccac aaggaccacc 3061 aaagactcag cctttcacat catgtcccac gagagcccag gcatcgagtg gctctgtctg 3121 gagaatgccc catgctatga caatgttccc caaggcatct ttgcccctga attcttcttc 3181 aaggtgttgg tgagcaatag aggagtggac acgagcacct actgcaacta ccagctcacc 3241 ttcctgctgc acatccacgg gctgccactc agtcccaagc gggccctttt catcatcatg 3301 gtgtcagcta gcgtgtttgt gggcctggtg atcttctaca tcgccttctg cctcctgtgg 3361 cccctcgtgg tgaagggctg cacgatgatc cggtggaaga taaacaacct cattgcctca 3421 gaatcctact acacctacgc ctccatttcc ggaatctcga gcatgccgtc tctgagacat 3481 tccaggatgg gctccatgtt cagctccagg atgacagagg acagggctga acccaaggaa 3541 gccgtggaga gacagttgat gacctgagtg tcccacctgc cccagccccc agttactgtc 3601 acgcctctct tatgaggccc atcttgaaga tgcaacctgt cacccagccc aggcctctct 3661 ttctgttttg cttgatgttt acttctcgtt cagactcaaa taaagccttt tttcaggacc 3721 agcaaaa <210> 9 (CRISP3 NM_001190986.1)
<211 > 2231  <211> 2231
<212> DNA  <212> DNA
<213> Homo Sapiens  <213> Homo Sapiens
<400> 9  <400> 9
1 aaaacaggaa ataggtgttt catatatacg gctctaacct tctctctctg caccttcctt 61 ctgtcaatag atgaaacaaa tacttcatcc tgctctggaa accactgatc cctgttccac 121 cggttttgtt ttcccagcaa tgacattatt cccagtgctg ttgttcctgg ttgctgggct 181 gcttccatct tttccagcaa atgaagataa ggatcccgct tttactgctt tgttaaccac 241 ccaaacacaa gtgcaaaggg agattgtgaa taagcacaat gaactgagga gagcagtatc 301 tccccctgcc agaaacatgc tgaagatgga atggaacaaa gaggctgcag caaatgccca 361 aaagtgggca aaccagtgca attacagaca cagtaaccca aaggatcgaa tgacaagtct 421 aaaatgtggt gagaatctct acatgtcaag tgcctccagc tcatggtcac aagcaatcca 481 aagctggttt gatgagtaca atgattttga ctttggtgta gggccaaaga ctcccaacgc 541 agtggttgga cattatacac aggttgtttg gtactcttca tacctcgttg gatgtggaaa 601 tgcctactgt cccaatcaaa aagttctaaa atactactat gtttgccaat attgtcctgc 661 tggtaattgg gctaatagac tatatgtccc ttatgaacaa ggagcacctt gtgccagttg 721 cccagataac tgtgacgatg gactatgcac caatggttgc aagtacgaag atctctatag 781 taactgtaaa agtttgaagc tcacattaac ctgtaaacat cagttggtca gggacagttg 841 caaggcctcc tgcaattgtt caaacagcat ttattaaata cgcattacac accgagtagg 901 gctatgtaga gaggagtcag attatctact tagatttggc atctacttag atttaacata 961 tactagctga gaaattgtag gcatgtttga tacacatttg atttcaaatg tttttcttct 1021 ggatctgctt tttattttac aaaaatattt ttcatacaaa tggttaaaaa gaaacaaaat 1081 ctataacaac aactttggat ttttatatat aaactttgtg atttaaattt actgaattta 1141 attagggtga aaattttgaa agttgtattc tcatatgact aagttcacta aaaccctgga 1201 ttgaaagtga aaattatgtt cctagaacaa aatgtacaaa aagaacaata taattttcac 1261 atgaaccctt ggctgtagtt gcctttccta gctccactct aaggctaagc atcttcaaag 1321 acgttttccc atatgctgtc ttaattcttt tcactcattc acccttcttc ccaatcatct 1381 ggctggcatc ctcacaattg agttgaagct gttcctccta aaacaatcct gacttttatt 1441 ttgccaaaat caatacaatc ctttgaattt tttatctgca taaattttac agtagaatat 1501 gatcaaacct tcatttttaa acctctcttc tctttgacaa aacttcctta aaaaagaata 1561 caagataata taggtaaata ccctccactc aaggaggtag aactcagtcc tctcccttgt 1621 gagtcttcac taaaatcagt gactcacttc caaagagtgg agtatggaaa gggaaacata 1681 gtaactttac aggggagaaa aatgacaaat gacgtcttca ccaagtgatc aaaattaacg 1741 tcaccagtga taagtcattc agatttgttc tagataatct ttctaaaaat tcataatccc 1801 aatctaatta tgagctaaaa catccagcaa actcaagttg aaggacattc tacaaaatat 1861 ccctggggta ttttagagta ttcctcaaaa ctgtaaaaat catggaaaat aagggaatcc 1921 tgagaaacaa tcacagacca catgagacta aggagacatg tgagccaaat gcaatgtgct 1981 tcttggatca gatcctggaa cagaaaaaga tcagtaatga aaaaactgat gaagtctgaa 2041 tagaatctgg agtattttta acagtagtgt tgatttctta atcttgataa atatagcagg 2101 gtaatgtaag atgataacgt tagagaaact gaaactgggt gagggctatc taggaattct 2161 ctgtactatc ttaccaaatt ttcggtaagt ctaagaaagc aatgcaaaat aaaaagtgtc 2221 ttgaaaaaaa a 1 aaaacaggaa ataggtgttt catatatacg gctctaacct tctctctctg caccttcctt 61 ctgtcaatag atgaaacaaa tacttcatcc tgctctggaa accactgatc cctgttccac 121 cggttttgtt ttcccagcaa tgacattatt cccagtgctg ttgttcctgg ttgctgggct 181 gcttccatct tttccagcaa atgaagataa ggatcccgct tttactgctt tgttaaccac 241 ccaaacacaa gtgcaaaggg agattgtgaa taagcacaat gaactgagga gagcagtatc 301 tccccctgcc agaaacatgc tgaagatgga atggaacaaa gaggctgcag caaatgccca 361 aaagtgggca aaccagtgca attacagaca cagtaaccca aaggatcgaa tgacaagtct 421 aaaatgtggt gagaatctct acatgtcaag tgcctccagc tcatggtcac aagcaatcca 481 aagctggttt gatgagtaca atgattttga ctttggtgta gggccaaaga ctcccaacgc 541 agtggttgga cattatacac aggttgtttg gtactcttca tacctcgttg gatgtggaaa 601 tgcctactgt cccaatcaaa aagttctaaa atactactat gtttgccaat attgtcctgc 661 tggtaattgg gctaatagac tatatgtccc ttatgaacaa ggagcacctt gtgccagttg 721 cccagataac tgtgacgatg gactatgcac caatggttgc aagtacgaag atctctatag 781 taactgtaaa agtttgaagc tcacattaac ctgtaaacat cagttggtca gggacagttg 841 caaggcctcc tgcaattg tt caaacagcat ttattaaata cgcattacac accgagtagg 901 gctatgtaga gaggagtcag attatctact tagatttggc atctacttag atttaacata 961 tactagctga gaaattgtag gcatgtttga tacacatttg atttcaaatg tttttcttct 1021 ggatctgctt tttattttac aaaaatattt ttcatacaaa tggttaaaaa gaaacaaaat 1081 ctataacaac aactttggat ttttatatat aaactttgtg atttaaattt actgaattta 1141 attagggtga aaattttgaa agttgtattc tcatatgact aagttcacta aaaccctgga 1201 ttgaaagtga aaattatgtt cctagaacaa aatgtacaaa aagaacaata taattttcac 1261 atgaaccctt ggctgtagtt gcctttccta gctccactct aaggctaagc atcttcaaag 1321 acgttttccc atatgctgtc ttaattcttt tcactcattc acccttcttc ccaatcatct 1381 ggctggcatc ctcacaattg agttgaagct gttcctccta aaacaatcct gacttttatt 1441 ttgccaaaat caatacaatc ctttgaattt tttatctgca taaattttac agtagaatat 1501 gatcaaacct tcatttttaa acctctcttc tctttgacaa aacttcctta aaaaagaata 1561 caagataata taggtaaata ccctccactc aaggaggtag aactcagtcc tctcccttgt 1621 gagtcttcac taaaatcagt gactcacttc caaagagtgg agtatggaaa gggaaacata 1681 gtaactttac aggggagaaa aatga caaat gacgtcttca ccaagtgatc aaaattaacg 1741 tcaccagtga taagtcattc agatttgttc tagataatct ttctaaaaat tcataatccc 1801 aatctaatta tgagctaaaa catccagcaa actcaagttg aaggacattc tacaaaatat 1861 ccctggggta ttttagagta ttcctcaaaa ctgtaaaaat catggaaaat aagggaatcc 1921 tgagaaacaa tcacagacca catgagacta aggagacatg tgagccaaat gcaatgtgct 1981 tcttggatca gatcctggaa cagaaaaaga tcagtaatga aaaaactgat gaagtctgaa 2041 tagaatctgg agtattttta acagtagtgt tgatttctta atcttgataa atatagcagg 2101 gtaatgtaag atgataacgt tagagaaact gaaactgggt gagggctatc taggaattct 2161 ctgtactatc ttaccaaatt ttcggtaagt ctaagaaagc aatgcaaaat aaaaagtgtc 2221 ttgaaaaaaa a
<210> 10 (FER1 L5 NM_001113382.1 ) <210> 10 (FER1 L5 NM_001113382.1)
<211 > 6477  <211> 6477
<212> DNA  <212> DNA
<213> Homo Sapiens <400> 10 <213> Homo Sapiens <400> 10
1 atgctgcggc ttgtggtgca gtcggccaag attgacccac cactagcccc actacccagg 61 ccctgcatgt ccatcgactt cagagatatc aagaaaagaa ctcgtgtggt ggaagggaat 121 gatcccgtgt ggaatgagac cctaatctgg cacctctgga accgccccct ggaaaatgac 181 tccttcctgc aagtcaccct tcaggacatg ggctcacaaa agaaagaaag attcattggc 241 ctggccacag tactgctcaa gccattgttg aaacaaccaa gtgaggtcct ttttgtgaag 301 gacttgaccc tgctcaacca ttccatgaag cccacagatt gtactgtcac cctacaggtg 361 gcccacatga gcaaccagga tattgagaag acaggagctg aagaccacct gggcataacg 421 gcaagagagg cagccagtca gaaactgatg gtccctggct ccactgcgca cagggctctg 481 tcctcaaagc ctcagcactt tcaggttcga gtgaaggtgt ttgaagcccg acagctcatg 541 ggcaacaaca tcaaaccagt ggtgaaggtg tccatcgcag gccagcagca ccagacacgc 601 atcaagatgg gaaacaaccc tttctttaat gagatcttct tccagaattt tcatgaggtt 661 cctgcaaagt tctttgatga gaccatctta atccagacag atattgggtt tatctaccat 721 tctccaggtc acacactcct aaggaaatgg ctaggcctct gccagccaaa taaccctggc 781 agtggtgtga caggctacct gaaagtcacc atctatgccc tcggtgtggg agaccaggcc 841 ctgatagatc aaaagctgct ctatggcacc gatgacaccg atattcagat cttcaagtca 901 gcggtagtcc cgatcaacat ggcttactta cagctcttca tctactgcgc agaggacctt 961 cacctcaaga aacaccagtc agtgaatcct cagttggagg tggaactaat tggggaaaag 1021 ctcaggacac acatgcagac ccaaaccgac aacccgatat ggaaccagat cctgaccttc 1081 cggattcagc taccctgcct ctccagctac atcaagttca gagtcttgga ctgccgcaag 1141 aaggactgcc cggatgagat tgggactgcc agcctgtccc tcaaccagat ctcgtccacc 1201 ggagaagaga tagaaggcaa gcaaagcctc gagcccactt cctacacccc tcgagtgtac 1261 tccggcttcc tgccctgctt tggccccagc ttcctgactc tgcatggggg taaaaaggcc 1321 cctttcagga tccaggaaga aggcgcttgt attcccgact ctgttaggga tggtttagct 1381 tatcgaggcc gagtcttcct ggagttaatc acccaaatca agtcctatca agactccacg 1441 ataaaggatc tctcccatga agtgaccagg atagagaagc accagaaccg ccaaaagtat 1501 gggctgtgcg tcatcttcct ttcctgtacc atgatgccca actttaaaga gctgatccat 1561 ttcgaggtca gcatcggtca ctatgggaac aagatggacc tgaattacaa gcctctagtc 1621 tcaagcacac cgtacagccc agtgatatat gatgggaaca tctaccatta tgtgccctgg 1681 tacaacacca agcctgtcgt ggccgtgacc tccaactggg aggacgtcag cttccgcatg 1741 aactgcctca acctcctcca cttcactcgg gaccgcctga aagccaacct ggacaccctg 1801 aaatccacgc ggaatccgaa ggatccagct ctcctctacc agtgggagaa actgctgagg 1861 gagctggcag aggactgcaa gcgccctctg ccctgcatga cctatcagcc caaagccacc 1921 agcctggaca ggaagaggtg gcagctccgc agcctcctcc tgcaggaact ggcccaaaag 1981 gccaagcaag ccaagcccaa ggacatggtg gccacagcgg aggactggct gtaccgcctc 2041 aacaccgtgc tccctgagcc ccagatgggc ctccctgacg tgatgatttg gctggtggcc 2101 aaggagcagc gagtggccta tgcacaggtg cctgcccact ccgtcctctt ctccccggca 2161 ggggctctgc actccggcag gctctgtggg aagatacaga cactcttcct acagtaccca 2221 gagggtgaag gacagaagga tgtgctccca gctcacctcc gggtctgcat gtggcttggc 2281 aatgtcacag acagcaagga cctgcagctg ctccgccagg gtgacacagc ggtgtacgcc 2341 gagatgtatg agaatcaggc caagtataaa gaccagtggg ggcagcaggg gctgtatcac 2401 tgccccaact tctcggatgt catggggaac aagaccctcc ccatgacgga tttccaacca 2461 cccctgggat ggcactggca ggacagctgg acagtggaac ctcagagaag gctcctcctg 2521 gacatagaca tcaacaagag ccaggtgctg gaggaggtat atgagaacca gggccgtgac 2581 accagagggg cctgggggcc tgccgccatc ccaaacacag acgtgaatgg acagcccatg 2641 gaggcccggg agaacgtgaa gtgcccccaa ggctggcact ttaagaagga ctgggtggtg 2701 gagctgaacc acgcagtgga cagctgggag tatggagtgg ggatcccacc gtcgggcctg 2761 ccccaggtct ggagcccggt ggagaagacc taccactcgt gccgccgccg gcgctgggcg 2821 cgtgtgcgct tcaggaacca tggggagctg agccacgagc aggagaccct ctccttcctg 2881 cagctgggcc tggccaaggg cgaggaggag ggctgggagt atgacacctt cggctccaag 2941 ttccacctca accctcagcc ccagagccgg ttccgccgcc gctgctggcg ccgcaggctg 3001 gcccccaaca aggacaaggg catcgcgccc atattcctcc tggaggggtc cttggcttgc 3061 gagggtggca gtgtgaggga ggagggtgac tgggcctggg ctagaggaaa caggagcagc 3121 acccaagagc ctcaggggag actgtcctgg gtacaggcta tggatctgaa ataccacgct 3181 gggaaggaag aggacagcaa gacatggcca tggggtctgg acagacagtt cagggacccc 3241 cagaggcagg acacccggcc ccccaacttg cccttcatct actgcacctt caataagccc 3301 cactactacc agctcttctg ctacatctac caggcccgga acctggtgtc caatcagatc 3361 ctgacattcc aagggccctt cattcgggtg gtcttcctga accacagcca gtgcacccaa 3421 accctgagga gctctgcagg ccccacatgg gcccagacac tcatcttcca gcacctcctt 3481 ctgtacgaga acccacagga caccaaagag agcccaccgc ttgtggtgct ggagctgtgg 3541 cagcgtgact tctggggcaa ggagagcttg tggggacgga gcgtgtggcc cccaatggtc1 atgctgcggc ttgtggtgca gtcggccaag attgacccac cactagcccc actacccagg 61 ccctgcatgt ccatcgactt cagagatatc aagaaaagaa ctcgtgtggt ggaagggaat 121 gatcccgtgt ggaatgagac cctaatctgg cacctctgga accgccccct ggaaaatgac 181 tccttcctgc aagtcaccct tcaggacatg ggctcacaaa agaaagaaag attcattggc 241 ctggccacag tactgctcaa gccattgttg aaacaaccaa gtgaggtcct ttttgtgaag 301 gacttgaccc tgctcaacca ttccatgaag cccacagatt gtactgtcac cctacaggtg 361 gcccacatga gcaaccagga tattgagaag acaggagctg aagaccacct gggcataacg 421 gcaagagagg cagccagtca gaaactgatg gtccctggct ccactgcgca cagggctctg 481 tcctcaaagc ctcagcactt tcaggttcga gtgaaggtgt ttgaagcccg acagctcatg 541 ggcaacaaca tcaaaccagt ggtgaaggtg tccatcgcag gccagcagca ccagacacgc 601 atcaagatgg gaaacaaccc tttctttaat gagatcttct tccagaattt tcatgaggtt 661 cctgcaaagt tctttgatga gaccatctta atccagacag atattgggtt tatctaccat 721 tctccaggtc acacactcct aaggaaatgg ctaggcctct gccagccaaa taaccctggc 781 agtggtgtga caggctacct gaaagtcacc atctatgccc tcggtgtggg agaccaggcc 841 ctgatagatc aaaagctg ct ctatggcacc gatgacaccg atattcagat cttcaagtca 901 gcggtagtcc cgatcaacat ggcttactta cagctcttca tctactgcgc agaggacctt 961 cacctcaaga aacaccagtc agtgaatcct cagttggagg tggaactaat tggggaaaag 1021 ctcaggacac acatgcagac ccaaaccgac aacccgatat ggaaccagat cctgaccttc 1081 cggattcagc taccctgcct ctccagctac atcaagttca gagtcttgga ctgccgcaag 1141 aaggactgcc cggatgagat tgggactgcc agcctgtccc tcaaccagat ctcgtccacc 1201 ggagaagaga tagaaggcaa gcaaagcctc gagcccactt cctacacccc tcgagtgtac 1261 tccggcttcc tgccctgctt tggccccagc ttcctgactc tgcatggggg taaaaaggcc 1321 cctttcagga tccaggaaga aggcgcttgt attcccgact ctgttaggga tggtttagct 1381 tatcgaggcc gagtcttcct ggagttaatc acccaaatca agtcctatca agactccacg 1441 ataaaggatc tctcccatga agtgaccagg atagagaagc accagaaccg ccaaaagtat 1501 gggctgtgcg tcatcttcct ttcctgtacc atgatgccca actttaaaga gctgatccat 1561 ttcgaggtca gcatcggtca ctatgggaac aagatggacc tgaattacaa gcctctagtc 1621 tcaagcacac cgtacagccc agtgatatat gatgggaaca tctaccatta tgtgccctgg 1681 tacaacacca agcctgtcgt GGCCG tgacc tccaactggg aggacgtcag cttccgcatg 1741 aactgcctca acctcctcca cttcactcgg gaccgcctga aagccaacct ggacaccctg 1801 aaatccacgc ggaatccgaa ggatccagct ctcctctacc agtgggagaa actgctgagg 1861 gagctggcag aggactgcaa gcgccctctg ccctgcatga cctatcagcc caaagccacc 1921 agcctggaca ggaagaggtg gcagctccgc agcctcctcc tgcaggaact ggcccaaaag 1981 gccaagcaag ccaagcccaa ggacatggtg gccacagcgg aggactggct gtaccgcctc 2041 aacaccgtgc tccctgagcc ccagatgggc ctccctgacg tgatgatttg gctggtggcc 2101 aaggagcagc gagtggccta tgcacaggtg cctgcccact ccgtcctctt ctccccggca 2161 ggggctctgc actccggcag gctctgtggg aagatacaga cactcttcct acagtaccca 2221 gagggtgaag gacagaagga tgtgctccca gctcacctcc gggtctgcat gtggcttggc 2281 aatgtcacag acagcaagga cctgcagctg ctccgccagg gtgacacagc ggtgtacgcc 2341 gagatgtatg agaatcaggc caagtataaa gaccagtggg ggcagcaggg gctgtatcac 2401 tgccccaact tctcggatgt catggggaac aagaccctcc ccatgacgga tttccaacca 2461 cccctgggat ggcactggca ggacagctgg acagtggaac ctcagagaag gctcctcctg 2521 gacatagaca tcaacaagag ccaggtgctg gaggaggtat atgagaacca gggccgtgac 2581 accagagggg cctgggggcc tgccgccatc ccaaacacag acgtgaatgg acagcccatg 2641 gaggcccggg agaacgtgaa gtgcccccaa ggctggcact ttaagaagga ctgggtggtg 2701 gagctgaacc acgcagtgga cagctgggag tatggagtgg ggatcccacc gtcgggcctg 2761 ccccaggtct ggagcccggt ggagaagacc taccactcgt gccgccgccg gcgctgggcg 2821 cgtgtgcgct tcaggaacca tggggagctg agccacgagc aggagaccct ctccttcctg 2881 cagctgggcc tggccaaggg cgaggaggag ggctgggagt atgacacctt cggctccaag 2941 ttccacctca accctcagcc ccagagccgg ttccgccgcc gctgctggcg ccgcaggctg 3001 gcccccaaca aggacaaggg catcgcgccc atattcctcc tggaggggtc cttggcttgc 3061 gagggtggca gtgtgaggga ggagggtgac tgggcctggg ctagaggaaa caggagcagc 3121 acccaagagc ctcaggggag actgtcctgg gtacaggcta tggatctgaa ataccacgct 3181 gggaaggaag aggacagcaa gacatggcca tggggtctgg acagacagtt cagggacccc 3241 cagaggcagg acacccggcc ccccaacttg cccttcatct actgcacctt caataagccc 3301 cactactacc agctcttctg ctacatctac caggcccgga acctggtgtc caatcagatc 3361 ctgacattcc aagggccctt cattcgggtg gtcttc ctga accacagcca gtgcacccaa 3421 accctgagga gctctgcagg ccccacatgg gcccagacac tcatcttcca gcacctcctt 3481 ctgtacgaga acccacagga caccaaagag agcccaccgc ttgtggtgct ggagctgtgg 3541 cagcgtgact tctggggcaa ggagagcttg tggggacgga gcgtgtggcc cccaatggtc
3601 tggctggatc tccaggaccg gatcctgccc cccatgaggt ggcatcccct tgtaaaggag3601 tggctggatc tccaggaccg gatcctgccc cccatgaggt ggcatcccct tgtaaaggag
3661 ttggggaagg aagagggcga gatcttggca tcctgtgagc tgatcctcca gactgagaag3661 ttggggaagg aagagggcga gatcttggca tcctgtgagc tgatcctcca gactgagaag
3721 cttggagaga agcagctgcc tatcttaagc gttccctgga agaatggggc atacacactc3721 cttggagaga agcagctgcc tatcttaagc gttccctgga agaatggggc atacacactc
3781 cccaagagca tccagcccac gataaagagg atggccattg agatcctggc ctggggcctt 3841 cggaacatga agaaggcgag ctccccccag ctcctggtgg aattcgggga agagtccctg3781 cccaagagca tccagcccac gataaagagg atggccattg agatcctggc ctggggcctt 3841 cggaacatga agaaggcgag ctccccccag ctcctggtgg aattcgggga agagtccctg
3901 aggacagaac ccatcaggga ctttcagacc aaccccaact tccccgagtc tgagtctgtc3901 aggacagaac ccatcaggga ctttcagacc aaccccaact tccccgagtc tgagtctgtc
3961 ctagtcctca cagtgctcat gccgacggag gaggcctatg cactgcccct cgtggtgaag3961 ctagtcctca cagtgctcat gccgacggag gaggcctatg cactgcccct cgtggtgaag
4021 gtggtagaca actgggcctt cggccagcag accgtgacgg gccaggccaa catcgacttc4021 gtggtagaca actgggctt cggccagcag accgtgacgg gccaggccaa catcgacttc
4081 ctccagccct acttctgtga cccctgggct caagactata tgcacccaaa gcttccaacg 4141 ctgtctgaga agaagcacca agacttccta ggctacctct acagaaagtt ctggttcaag4081 ctccagccct acttctgtga cccctgggct caagactata tgcacccaaa gcttccaacg 4141 ctgtctgaga agaagcacca agacttccta ggctacctct acagaaagtt ctggttcaag
4201 tccagtaaag cagaggatga gtatgagcat gaggtggact ggtggagcaa gctgttctgg4201 tccagtaaag cagaggatga gtatgagcat gaggtggact ggtggagcaa gctgttctgg
4261 gccacagatg agcacaagtc cctgaagtac aagtacaaag actaccacac cctcaaggtg4261 gccacagatg agcacaagtc cctgaagtac aagtacaaag actaccacac cctcaaggtg
4321 tatgagtgtg agctggaggc cgtgccagcc ttccagggcc tgcaggactt ctgccagacc4321 tatgagtgtg agctggaggc cgtgccagcc ttccagggcc tgcaggactt ctgccagacc
4381 ttcaaactct accaggagca gcccaagttg gacagccccg tggtagggga gttcaagggc 4441 cttttccgca tctacccctt tcctgagaat ccagaagccc caaagccccc gctgcagttc4381 ttcaaactct accaggagca gcccaagttg gacagccccg tggtagggga gttcaagggc 4441 cttttccgca tctacccctt tcctgagaat ccagaagccc caaagccccc gctgcagttc
4501 ttggtttggc cagagagaga ggacttcccc cagccgtgct tggtgcgggt gtacatggta4501 ttggtttggc cagagagaga ggacttcccc cagccgtgct tggtgcgggt gtacatggta
4561 cgagccatca acctgcagcc ccaggactac aatggcctgt gtgaccctta tgtgatcctg4561 cgagccatca acctgcagcc ccaggactac aatggcctgt gtgaccctta tgtgatcctg
4621 aaactgggca agacagagct tggcaaccgg gacatgtacc agcccaacac tctggatccc4621 aaactgggca agacagagct tggcaaccgg gacatgtacc agcccaacac tctggatccc
4681 atctttggca tgatgtttga actcacctgc aacatacccc tggagaagga cctagagatc 4741 cagctctatg acttcgacct attttcacct gatgataaga taggaaccac agtcatcgac4681 atctttggca tgatgtttga actcacctgc aacatacccc tggagaagga cctagagatc 4741 cagctctatg acttcgacct attttcacct gatgataaga taggaaccac agtcatcgac
4801 cttgaaaacc gactcctatc tggctttgga gctcattgtg ggctctccaa atcctactgc4801 cttgaaaacc gactcctatc tggctttgga gctcattgtg ggctctccaa atcctactgc
4861 cagtcagggc cctttagatg gcgggatcag atgcccccaa gctacctcct agaacgctat4861 cagtcagggc cctttagatg gcgggatcag atgcccccaa gctacctcct agaacgctat
4921 gccaagcgga aagggctacc tccgcctctg ttcagtcctg aggaagatgc tgttttctat4921 gccaagcgga aagggctacc tccgcctctg ttcagtcctg aggaagatgc tgttttctat
4981 aatgggaaaa agttcaagct gcaaagcttt gagcccaaaa cccctactgt tcatggtttg 5041 ggacccaaga aggaacgcct tgcactgtac ctcctgcaca cccaggggct ggtacctgag4981 aatgggaaaa agttcaagct gcaaagcttt gagcccaaaa cccctactgt tcatggtttg 5041 ggacccaaga aggaacgcct tgcactgtac ctcctgcaca cccaggggct ggtacctgag
5101 cacgtggaga cccgcacact gtacagccac agccagccag gcatcgacca gggaaaggtg5101 cacgtggaga cccgcacact gtacagccac agccagccag gcatcgacca gggaaaggtg
5161 caaatgtggg tggacatctt ccccaagaag ctggggcctc ctggccccca agtcaacatc5161 caaatgtggg tggacatctt ccccaagaag ctggggcctc ctggccccca agtcaacatc
5221 aaccccagaa agcctaaacg caaagcctca gagcacagtg gccacaggta tgagctgcga5221 aaccccagaa agcctaaacg caaagcctca gagcacagtg gccacaggta tgagctgcga
5281 tgcatcatct ggaagactgc caatgtggac ctggtggatg acaatttaag tagagagaag 5341 acgagcgaca tctacatcaa agggtggtta tacgggctgg agaaggacat gcagaagaca5281 tgcatcatct ggaagactgc caatgtggac ctggtggatg acaatttaag tagagagaag 5341 acgagcgaca tctacatcaa agggtggtta tacgggctgg agaaggacat gcagaagaca
5401 gacatccact accactcgct gactggggag gccgacttca actggcggtt catctttacc5401 gacatccact accactcgct gactggggag gccgacttca actggcggtt catctttacc
5461 atggactacc tggcggcgga gcgcacgtgt gtccagagcc agaaggatta catatggagc5461 atggactacc tggcggcgga gcgcacgtgt gtccagagcc agaaggatta catatggagc
5521 ctggatgcca cgtccatgaa gttcccagcc cgacttatca tccaggtctg ggacaatgac5521 ctggatgcca cgtccatgaa gttcccagcc cgacttatca tccaggtctg ggacaatgac
5581 atcttctccc ccgacgactt cctaggggtc ctggagctgg atttgtctga catgcccctc 5641 ccggctcggc acgccaagca gtgctccatc aggatgatgg acgccgaccc caagtggccc5581 atcttctccc ccgacgactt cctaggggtc ctggagctgg atttgtctga catgcccctc 5641 ccggctcggc acgccaagca gtgctccatc aggatgatgg acgccgaccc caagtggccc
5701 tatttcatcc aatacaagca cttctccctc tttaagaaga agactgtgac tggctggtgg5701 tatttcatcc aatacaagca cttctccctc tttaagaaga agactgtgac tggctggtgg
5761 ccttgccagg tcctcgatgg tggcaaatgg cgcttgtcgg gcaaggtgaa gatgagcctg5761 ccttgccagg tcctcgatgg tggcaaatgg cgcttgtcgg gcaaggtgaa gatgagcctg
5821 gagattctgt cagagaagga agccttaatc aagccagccg ggcgaggcca gtcggaaccc5821 gagattctgt cagagaagga agccttaatc aagccagccg ggcgaggcca gtcggaaccc
5881 aaccagtacc ccacacttca tcctccccta cgcaccaaca cctctttcac gtggctgcgg 5941 tcaccagttc aaaacttctg ctatattttc tggaaacgct atcgcttcaa actcatagcc5881 aaccagtacc ccacacttca tcctccccta cgcaccaaca cctctttcac gtggctgcgg 5941 tcaccagttc aaaacttctg ctatattttc tggaaacgct atcgcttcaa actcatagcc
6001 tttatggtca tatcgattat agcacttatg ctgtttaact tcatctattc agctccgcac6001 tttatggtca tatcgattat agcacttatg ctgtttaact tcatctattc agctccgcac
6061 tatttggcca tgagctggat caaacctcaa cttcagctgt atcctcccat taaaatattc6061 tatttggcca tgagctggat caaacctcaa cttcagctgt atcctcccat taaaatattc
6121 aatatcatca attcactaaa caccagcaac gccagctctt ccatccttcc cacccaggat6121 aatatcatca attcactaaa caccagcaac gccagctctt ccatccttcc cacccaggat
6181 ccaaacctaa agcctacaat agaccatgag tggaaactcc acccaggacc cacaaatcac 6241 ctgagtgata ttttcccaga acttccagcc ccaggagact aattagtcca tgctgcctgg6181 ccaaacctaa agcctacaat agaccatgag tggaaactcc acccaggacc cacaaatcac 6241 ctgagtgata ttttcccaga acttccagcc ccaggagact aattagtcca tgctgcctgg
6301 ctttcctcct gctaccaaca gccctcccct tgggctggct accagttctt tgtttctatc6301 ctttcctcct gctaccaaca gccctcccct tgggctggct accagttctt tgtttctatc
6361 ttctagaata tatgcaagat gctaggaata ttctggctat tgtgttcaga aatcactttc6361 ttagaaga tatgcaagat gctaggaata ttctggctat tgtgttcaga aatcactttc
6421 aacaagacga gcagagctgt aattttccac tgaaataaac aagttctata acagaga 6421 aacaagacga gcagagctgt aattttccac tgaaataaac aagttctata acagaga
<210> 11 (FER1L6 NM_001039112.2) <210> 11 (FER1L6 NM_001039112.2)
<211 > 6061  <211> 6061
<212> DNA  <212> DNA
<213> Homo Sapiens <400> 1 1 <213> Homo Sapiens <400> 1 1
1 tggtgaggtt gcctgtaact gacttcaaaa ggccattcca ccattccgtc aagccagctg 61 ctttagaacg gttgggaaca ccgtgagacc agtgaattcc acgagcacga acccactgct 121 gcgcttcatt tgctgtgaag tgagtccctt gatcagagca atgctgtgtg gaccatcgtg 181 aaggtggaca aggcatttta aaggggatgt ttgggctgaa ggtgaagaag aagagaaata 241 aggcagagaa ggggttaatc ctagccaaca aggctgcgaa agatagtcaa ggtgacactg 301 aagcactgca ggaggagcct tctcaccagg aaggaccgag aggagatttg gtccatgatg 361 atgcttctat ctttcctgtc ccctcagctt ctccaaagag aagatcaaaa ctgttgacta 421 agatccatga tggggaggtc agatcccaaa attatcaaat tgccataacc atcaccgagg 481 ctcgccagct ggtgggtgag aacattgacc cagttgtgac cattgagatt ggggatgaga 541 agaagcaaag cacagtgaag gaaggaacca acagcccatt ttataatgaa tactttgtct 601 tcgacttcat tgggccccaa gtgcatcttt ttgacaagat catcaaaatc tccgtctttc 661 accacaagct gataggaagt gtactgattg gctctttcaa agtagacctg gggaccgtgt 721 acaaccaacc tggtcatcag ttctgcaaca agtgggccct gctcacagac cctggtgaca 781 tcaggactgg caccaagggg tacctgaaat gtgacatcag tgtcatggga aaaggtgatg 841 tcttgaagac cagccctaaa acttctgaca ccgaggagcc aatagaaaag aaccttttga 901 tccccaatgg gtttccactg gagagaccgt gggccagatt ctatgtgaga ctctacaaag 961 cagaagggtt gcccaaaatg aattcaagca tcatggcgaa cgtcaccaag gcatttgtgg 1021 gtgacagtaa ggacctggtg gatccctttg tggaggtctc ctttgctggg cagatggggc 1081 gaaccacagt gcagaagaac tgtgctgatc ctgtgtggca tgaacaggtg atcttcaagg 1141 aaatgttccc tcccttgtgt cggagggtga aaatccaggt gtgggatgaa ggcagcatga 1201 atgacgtagc cctggcaacc catttcattg acctgaagaa aatctccaac gaacaggatg 1261 gagacaaagg ctttctgccc acctttgggc ctgcctggat taacctgtat ggctcgccca 1321 ggaaccacag tctgatggat gactaccagg aaatgaacga aggctttggg gaaggtgtgt 1381 cattcagggg cagaatcttg gtagaaattg ctgtggaaat cctctcagga cgggcacagg 1441 aatctaaatt ttccaaggcc ctgaaggagc tcaagttgcc ttccaaggac aaagactcca 1501 aatcttccaa aggtaaagac aaggctgaca aaactgaaga tggaaaatcc caacaggctt 1561 caaacaaaac taactcaacc gaggtggagg tggaatcgtt cgatgtcccc ccggagattg 1621 taccagaaaa aaatgaggaa tttttactct ttggagcatt ttttgaagct accatgattg 1681 accggaagat tggagataaa cccatcagct ttgaagtttc tattggtaat tttggaaacc 1741 tgattgatgg aggatcccat catgggagta agaagtcagc tgaatcagct gaagaagacc 1801 tccttccact gcttcacgaa gggcaagggg atgtggccca tgatgttccc attcctatgg 1861 cctccaccac tcacccggag aagccactgg tgacagaagg gaacaggaat tacaactatt 1921 tgccatttga ggctaagaag ccctgtgtct atttcatcag ctcttgggga gaccagacct 1981 tcaggctgca ctggtccaac atgctggaga aaatggcaga cttcctggaa gaaagtatag 2041 aagaagtgag agaattgatc aagatttcac aggaggcacc tgaagagaaa atgaaaacag 2101 tgctcagtga cttcatcagt cggagcagtg cctttatctc tgaagcagaa aaaaagccca 2161 agatgttgaa ccaaaccact ttagataaga agcgacttac gctctgctgg caggagctgg 2221 aagcaatgtg caaggaggcc aaggggatca ttcagcagca gaagaaaaag ttatctgttg 2281 atgaaatgat tcacgaagcc caaaactttg tggaaaaaat ccgctttctt gttgatgagc 2341 cccagcacac tatccctgac gttttcatct ggatgctcag caacaacagg agagtggcct 2401 atgcccgcat cgcctccaaa gacctcctct attcccctgt cgcggggcag atgggcaaac 2461 actgcggcaa gatcaaaact cacttcctca aacctcctgg gaaacgaccg gctggttggt 2521 ctgtgcaagc aaaagtcgac gtgtacctgt ggctgggctc catcaagcat gccagtgcca 2581 ttttggacaa cttgccagta ggctatgaag cagaaatgtc ctccaaaggg gctggcacca 2641 atcacccccc atctaacctg ctctaccaag aacagcatgt ttttcagctg agggctcaca 2701 tgtaccaagc ccggggcctc atcgcagctg acagcaatgg actttcagac ccttttgcca 2761 aagtcacgtt cctttctcac tgccagacaa caaagataat ctcccagacc ctctctccga 2821 cctggaacca gatgctgctg ttcaatgatt tggtgctgca tggagatgtg aaggagctgg 2881 cagagtcccc gcccttagtg gtggtggagc tgtatgacag cgacgctgtg gggaagccag1 tggtgaggtt gcctgtaact gacttcaaaa ggccattcca ccattccgtc aagccagctg 61 ctttagaacg gttgggaaca ccgtgagacc agtgaattcc acgagcacga acccactgct 121 gcgcttcatt tgctgtgaag tgagtccctt gatcagagca atgctgtgtg gaccatcgtg 181 aaggtggaca aggcatttta aaggggatgt ttgggctgaa ggtgaagaag aagagaaata 241 aggcagagaa ggggttaatc ctagccaaca aggctgcgaa agatagtcaa ggtgacactg 301 aagcactgca ggaggagcct tctcaccagg aaggaccgag aggagatttg gtccatgatg 361 atgcttctat ctttcctgtc ccctcagctt ctccaaagag aagatcaaaa ctgttgacta 421 agatccatga tggggaggtc agatcccaaa attatcaaat tgccataacc atcaccgagg 481 ctcgccagct ggtgggtgag aacattgacc cagttgtgac cattgagatt ggggatgaga 541 agaagcaaag cacagtgaag gaaggaacca acagcccatt ttataatgaa tactttgtct 601 tcgacttcat tgggccccaa gtgcatcttt ttgacaagat catcaaaatc tccgtctttc 661 accacaagct gataggaagt gtactgattg gctctttcaa agtagacctg gggaccgtgt 721 acaaccaacc tggtcatcag ttctgcaaca agtgggccct gctcacagac cctggtgaca 781 tcaggactgg caccaagggg tacctgaaat gtgacatcag tgtcatggga aaaggtgatg 841 tcttgaagac cagcccta aa acttctgaca ccgaggagcc aatagaaaag aaccttttga 901 tccccaatgg gtttccactg gagagaccgt gggccagatt ctatgtgaga ctctacaaag 961 cagaagggtt gcccaaaatg aattcaagca tcatggcgaa cgtcaccaag gcatttgtgg 1021 gtgacagtaa ggacctggtg gatccctttg tggaggtctc ctttgctggg cagatggggc 1081 gaaccacagt gcagaagaac tgtgctgatc ctgtgtggca tgaacaggtg atcttcaagg 1141 aaatgttccc tcccttgtgt cggagggtga aaatccaggt gtgggatgaa ggcagcatga 1201 atgacgtagc cctggcaacc catttcattg acctgaagaa aatctccaac gaacaggatg 1261 gagacaaagg ctttctgccc acctttgggc ctgcctggat taacctgtat ggctcgccca 1321 ggaaccacag tctgatggat gactaccagg aaatgaacga aggctttggg gaaggtgtgt 1381 cattcagggg cagaatcttg gtagaaattg ctgtggaaat cctctcagga cgggcacagg 1441 aatctaaatt ttccaaggcc ctgaaggagc tcaagttgcc ttccaaggac aaagactcca 1501 aatcttccaa aggtaaagac aaggctgaca aaactgaaga tggaaaatcc caacaggctt 1561 caaacaaaac taactcaacc gaggtggagg tggaatcgtt cgatgtcccc ccggagattg 1621 taccagaaaa aaatgaggaa tttttactct ttggagcatt ttttgaagct accatgattg 1681 accggaagat tggagataaa cccat cagct ttgaagtttc tattggtaat tttggaaacc 1741 tgattgatgg aggatcccat catgggagta agaagtcagc tgaatcagct gaagaagacc 1801 tccttccact gcttcacgaa gggcaagggg atgtggccca tgatgttccc attcctatgg 1861 cctccaccac tcacccggag aagccactgg tgacagaagg gaacaggaat tacaactatt 1921 tgccatttga ggctaagaag ccctgtgtct atttcatcag ctcttgggga gaccagacct 1981 tcaggctgca ctggtccaac atgctggaga aaatggcaga cttcctggaa gaaagtatag 2041 aagaagtgag agaattgatc aagatttcac aggaggcacc tgaagagaaa atgaaaacag 2101 tgctcagtga cttcatcagt cggagcagtg cctttatctc tgaagcagaa aaaaagccca 2161 agatgttgaa ccaaaccact ttagataaga agcgacttac gctctgctgg caggagctgg 2221 aagcaatgtg caaggaggcc aaggggatca ttcagcagca gaagaaaaag ttatctgttg 2281 atgaaatgat tcacgaagcc caaaactttg tggaaaaaat ccgctttctt gttgatgagc 2341 cccagcacac tatccctgac gttttcatct ggatgctcag caacaacagg agagtggcct 2401 atgcccgcat cgcctccaaa gacctcctct attcccctgt cgcggggcag atgggcaaac 2461 actgcggcaa gatcaaaact cacttcctca aacctcctgg gaaacgaccg gctggttggt 2521 ctgtgcaagc aaaagtcgac gtgtacctgt ggctgggctc catcaagcat gccagtgcca 2581 ttttggacaa cttgccagta ggctatgaag cagaaatgtc ctccaaaggg gctggcacca 2641 atcacccccc atctaacctg ctctaccaag aacagcatgt ttttcagctg agggctcaca 2701 tgtaccaagc ccggggcctc atcgcagctg acagcaatgg actttcagac ccttttgcca 2761 aagtcacgtt cctttctcac tgccagacaa caaagataat ctcccagacc ctctctccga 2821 cctggaacca gatgctgctg ttcaatgatt tggtgctgca tggagatgtg aaggagctgg 2881 cagagtcccc gcccttagtg gtggtggagc tgtatgacag cgacgctgtg gggaagccag
2941 aatatttggg tgccacagtg gctgctcctg ttgtgaagct ggctgaccag gactatgagc 3001 cccccaggtt atgctatcac cccatctttt gtgggaatct ctctggaggg gatctccttg 3061 ctgtatttga actgctgcag gttcctcctt ctgggctgca aggcctccca cccgttgagc 3121 caccagacat cacccagatc tacccggttc ctgccaacat tcggccggtg ctgagcaaat 3181 accgagtgga ggttctcttc tggggagttc gggaaatgaa gaaggtgcag ctcctctctg 3241 tggatcggcc tcaggctctc attgagtgcg gaggacaagg tgtgaagtcc tgcgtgatcc 3301 agagctacaa gaacaacccg aacttcagca tccaggcaga cgctttcgaa gtggaactgc 3361 ctgagaacga gcttctgcac ccgccactga gcatctgcgt ggtggactgg agagcttttg 3421 ggaggagtac ccttgtgggc acctacacca tcaactactt gaagcagttt ttgtgtaaac 3481 tcagagagcc ccttgccccc atcacacagg tggatggaac ccagcctggg cacgatattt2941 aatatttggg tgccacagtg gctgctcctg ttgtgaagct ggctgaccag gactatgagc 3001 cccccaggtt atgctatcac cccatctttt gtgggaatct ctctggaggg gatctccttg 3061 ctgtatttga actgctgcag gttcctcctt ctgggctgca aggcctccca cccgttgagc 3121 caccagacat cacccagatc tacccggttc ctgccaacat tcggccggtg ctgagcaaat 3181 accgagtgga ggttctcttc tggggagttc gggaaatgaa gaaggtgcag ctcctctctg 3241 tggatcggcc tcaggctctc attgagtgcg gaggacaagg tgtgaagtcc tgcgtgatcc 3301 agagctacaa gaacaacccg aacttcagca tccaggcaga cgctttcgaa gtggaactgc 3361 ctgagaacga gcttctgcac ccgccactga gcatctgcgt ggtggactgg agagcttttg 3421 ggaggagtac ccttgtgggc acctacacca tcaactactt gaagcagttt ttgtgtaaac 3481 tcagagagcc ccttgccccc atcacacagg tggatggaac ccagcctggg cacgatattt
3541 cagattcgct aacagccact gagtcctctg gagcccacag ctcctcccag gatcccccag3541 cagattcgct aacagccact gagtctctg gagcccacag ctcctcccag gatcccccag
3601 cagatcacat ttatgtggat gttgagccac ctcccacagt ggtgcccgac tctgcccagg3601 cagatcacat ttatgtggat gttgagccac ctcccacagt ggtgcccgac tctgcccagg
3661 cccagccggc catcctggtt gacgtccctg actcatcccc gatgctggag cctgaacaca3661 cccagccggc catcctggtt gacgtccctg actcatcccc gatgctggag cctgaacaca
3721 cacctgtagc ccaggagcca ccaaaagatg gaaaacctaa ggatcccagg aagccttccc 3781 ggaggtccac taagaggaga aagaggacca tagcagatga atctgctgaa aacgtgattg3721 cacctgtagc ccaggagcca ccaaaagatg gaaaacctaa ggatcccagg aagccttccc 3781 ggaggtccac taagaggaga aagaggacca tagcagatga atctgctgaa aacgtgattg
3841 actggtggtc taagtattat gcctccctga agaaagccca gaaggcaaag gagagaaatc3841 actggtggtc taagtattat gcctccctga agaaagccca gaaggcaaag gagagaaatc
3901 ccaagggaaa aaaaggcaat acagaggcaa agccagatga ggtagtggta gatatagaag3901 ccaagggaaa aaaaggcaat acagaggcaa agccagatga ggtagtggta gatatagaag
3961 atgggccaaa gaagaagaaa gacaaaatgc tcaagaagaa acccaaagat gatggaatcc3961 atgggccaaa gaagaagaaa gacaaaatgc tcaagaagaa acccaaagat gatggaatcc
4021 ccaacctggc catcttgcag atatatgacg gtgatctcga gagtgaattc aacaattttg 4081 aagactgggt gaaaactttt gagctcttca gaggcaagtc tacggaagat gaccatggtc4021 ccaacctggc catcttgcag atatatgacg gtgatctcga gagtgaattc aacaattttg 4081 aagactgggt gaaaactttt gagctcttca gaggcaagtc tacggaagat gaccatggtc
4141 ttgatggaga ccgagtcata ggaaaattta agggctcctt ctgcatctac aaaagccccc4141 ttgatggaga ccgagtcata ggaaaattta agggctcctt ctgcatctac aaaagccccc
4201 aggattctag ctctgaggac agcgggcagc tgagaatcca gcaagggatt ccgcccaatc4201 aggattctag ctctgaggac agcgggcagc tgagaatcca gcaagggatt ccgcccaatc
4261 accctgtcac agtgctgatc agagtataca ttgtcgcggc atttaatctt agtccagctg4261 accctgtcac agtgctgatc agagtataca ttgtcgcggc atttaatctt agtccagctg
4321 atccagatgg caaatcagat ccctacattg tgatcaagct tggcaagaca gaaatcaaag 4381 accgggataa atacatccct aaacaactga acccagtatt tggaaggtca tttgagatcc4321 atccagatgg caaatcagat ccctacattg tgatcaagct tggcaagaca gaaatcaaag 4381 accgggataa atacatccct aaacaactga acccagtatt tggaaggtca tttgagatcc
4441 aagccacatt cccaaaagag tccctgctct ccatcctgat ctatgaccat gacatgattg4441 aagccacatt cccaaaagag tccctgctct ccatcctgat ctatgaccat gacatgattg
4501 gcacagatga ccttattggt gagaccaaga tcgacctgga gaaccgcttc tacagcaaac4501 gcacagatga ccttattggt gagaccaaga tcgacctgga gaaccgcttc tacagcaaac
4561 accgagccat ctgtggcttg cagagccagt atgagataga aggatacaat gcctggagag4561 accgagccat ctgtggcttg cagagccagt atgagataga aggatacaat gcctggagag
4621 acacgtccaa acccaccgaa atcctcacta agctctgcaa agacaacaag ctggatggac 4681 cctactttca ccctgggaaa atacagatag gaaaccaagt cttttctgga aaaactatct4621 acacgtccaa acccaccgaa atcctcacta agctctgcaa agacaacaag ctggatggac 4681 cctactttca ccctgggaaa atacagatag gaaaccaagt cttttctgga aaaactatct
4741 tcactgaaga ggacactgat gagacagtgg agtcttatga acacctggcc ctcaaggttt4741 tcactgaaga ggacactgat gagacagtgg agtcttatga acacctggcc ctcaaggttt
4801 tacactcttg ggaggatatc ccggaagtcg ggtgtaggct ggttcctgaa cacatagaaa4801 tacactcttg ggaggatatc ccggaagtcg ggtgtaggct ggttcctgaa cacatagaaa
4861 ctcggccact gtaccacaag gataagccag gaatggagca gggccgcctg cagatgtggg4861 ctcggccact gtaccacaag gataagccag gaatggagca gggccgcctg cagatgtggg
4921 tggacatgtt tcccaaggat atgcctcaac ctggacctcc tgttgacatc tctccaaggc 4981 gacccaaagg atacgaattg agagtgacca tctggaacac tgaagatgtc attttagagg4921 tggacatgtt tcccaaggat atgcctcaac ctggacctcc tgttgacatc tctccaaggc 4981 gacccaaagg atacgaattg agagtgacca tctggaacac tgaagatgtc attttagagg
5041 atgagaatat cttcacaggc caaaaatcaa gtgatattta tgtgaaaggg tggttaaagg5041 atgagaatat cttcacaggc caaaaatcaa gtgatattta tgtgaaaggg tggttaaagg
5101 gcttggagga tgacaagcag gagacagatg tgcattacaa ctccctgact ggagagggca5101 gcttggagga tgacaagcag gagacagatg tgcattacaa ctccctgact ggagagggca
5161 acttcaactg gcgcttcctg tttccctttc agtatctccc agctgagaag caaatggtca5161 acttcaactg gcgcttcctg tttccctttc agtatctccc agctgagaag caaatggtca
5221 ttaccaagag ggagaacatc ttctctttag agaagatgga gtgtaagact cctgctgtgt 5281 tggtgctgca ggtttgggat tttgaaaggc tgtcctcaga tgacttcctg ggcaccctgg5221 ttaccaagag ggagaacatc tctctttag agaagatgga gtgtaagact cctgctgtgt 5281 tggtgctgca ggtttgggat tttgaaaggc tgtcctcaga tgacttcctg ggcaccctgg
5341 aaatgaacct caacagtttc cctcgagcag ctaagtctgc caaagcctgt gatcttgcca5341 aaatgaacct caacagtttc cctcgagcag ctaagtctgc caaagcctgt gatcttgcca
5401 agtttgaaaa tgcaagtgag gagaccaaga tctctatatt ccagcaaaaa cgtgtgcgtg5401 agtttgaaaa tgcaagtgag gagaccaaga tctctatatt ccagcaaaaa cgtgtgcgtg
5461 gctggtggcc tttttctaaa agcaaagaac tcacaggcaa ggttgaagct gagttccacc5461 gctggtggcc tttttctaaa agcaaagaac tcacaggcaa ggttgaagct gagttccacc
5521 tagttacagc agaagaagct gagaaaaatc ctgttggaaa agcccgaaag gagccagagc 5581 ccctggccaa gcccaaccgc ccagacacct ccttttcgtg gttcatgagc ccctttaagt5521 tagttacagc agaagaagct gagaaaaatc ctgttggaaa agcccgaaag gagccagagc 5581 ccctggccaa gcccaaccgc ccagacacct ccttttgtg gttcatgagc cctctaagt
5641 gcctgtacta cctcatctgg aagaattaca aaaagtacat catcattgct ttcattctca5641 gcctgtacta cctcatctgg aagaattaca aaaagtacat catcattgct ttcattctca
5701 tcatcctcat catcttcctc gtccttttca tctacacctt gccaggagcc atcagccgaa5701 tcatcctcat catcttcctc gtccttttca tctacacctt gccaggagcc atcagccgaa
5761 ggatcgttgt gggctcatag aggatcatgg aggacccaga tcctcgccat atactaatcc5761 ggatcgttgt gggctcatag aggatcatgg aggacccaga tcctcgccat atactaatcc
5821 tctcttcctt atctgggagc atctaagaac atgtcccatg catggcactg tgctgagtgc 5881 taaggggaca gatcaaccct tcttggaaga gatggaaaag aaacatttcc tccctgctcc5821 tctcttcctt atctgggagc atctaagaac atgtcccatg catggcactg tgctgagtgc 5881 taaggggaca gatcaaccct tcttggaaga gatggaaaag aaacatttcc tccctgctcc
5941 aacccctgcc tccaagtttc aaacttgtaa ggcatgtttt atcccttggg cagcatgaaa5941 aacccctgcc tccaagtttc aaacttgtaa ggcatgtttt atcccttggg cagcatgaaa
6001 taaggcactt tcacctcatg gtaatcaaca atgacctcaa attgacttag a 6001 taaggcactt tcacctcatg gtaatcaaca atgacctcaa attgacttag a
<210> 12 (FOLR4 NM_001 199206.1 ) <210> 12 (FOLR4 NM_001 199206.1)
<21 1 > 753  <21 1> 753
<212> DNA  <212> DNA
<213> Homo Sapiens  <213> Homo Sapiens
<400> 12  <400> 12
1 atggcatgct ggtggccgct cctgctagag ctgtggacag tcatgcccac ctgggctggg 61 gacgagctgc tcaacatctg catgaatgcc aaacaccaca agagagtgcc cagcccagaa 121 gacaagctct atgaggagtg catcccctgg aaggacaatg cctgctgcac cctcacgaca 181 agctgggaag cccatctgga tgtatcccca ctctacaact tcagcctgtt tcactgtgga 241 ctgctgatgc ctggctgtcg gaagcacttc atccaggcta tctgcttcta tgagtgctcc 301 ccaaacctgg ggccctggat ccagccagtg ggaagcctgg ggtgggaggt ggccccgagt 361 gggcagggag agcgagttgt gaatgtgccg ctgtgccagg aggactgtga ggagtggtgg 421 gaagactgtc gcatgtctta cacatgcaaa tccaactggc gtggtggctg ggactggagt 481 caggggaaga accgctgccc caaaggggcc cagtgcctcc ctttctccca ttacttcccc 541 accccagctg acctgtgtga gaagacttgg agcaattcct tcaaagccag ccctgagcga 601 cggaacagtg ggcggtgtct ccagaagtgg tttgagcctg ctcagggcaa ccccaatgtg 661 gccgtggccc gcctcttcgc cagctctgcc ccatcctggg aactgtccta caccatcatg 721 gtctgctccc tgttcctgcc gttcctttcc tga 1 atggcatgct ggtggccgct cctgctagag ctgtggacag tcatgcccac ctgggctggg 61 gacgagctgc tcaacatctg catgaatgcc aaacaccaca agagagtgcc cagcccagaa 121 gacaagctct atgaggagtg catcccggg aaggacaatg cctgctgcac cctcacgaca 181 agctgggaag cccatctgga tgtatcccca ctctacaact tcagcctgtt tcactgtgga 241 ctgctgatgc ctggctgtcg gaagcacttc atccaggcta tctgcttcta tgagtgctcc 301 ccaaacctgg ggccctggat ccagccagtg ggaagcctgg ggtgggaggt ggccccgagt 361 gggcagggag agcgagttgt gaatgtgccg ctgtgccagg aggactgtga ggagtggtgg 421 gaagactgtc gcatgtctta cacatgcaaa tccaactggc gtggtggctg ggactggagt 481 caggggaaga accgctgccc caaaggggcc cagtgcctcc ctttctccca ttacttcccc 541 accccagctg acctgtgtga gaagacttgg agcaattcct tcaaagccag ccctgagcga 601 cggaacagtg ggcggtgtct ccagaagtgg tttgagcctg ctcagggcaa ccccaatgtg 661 gccgtggccc cctcttcgc cagctctgcc ccatcctggg aactgtccta caccatcatg 721 gtctgctccc tgttcctgcc gttcctttcc tga
<210> 13 (GGN NM_152657.3) <210> 13 (GGN NM_152657.3)
<211 > 2168 <211> 2168
<212> DNA <212> DNA
<213> Homo Sapiens <213> Homo Sapiens
<400> 13 <400> 13
1 agaaggcctg ggggcgagga acaagacctc ggagtatttc aaggggagac ctagttccct 61 gccctgcccc gggcccaggg cgccgcggtc tgaactctgc tcggctggag gactcgtctc 121 cgagctccgt cagaaatggg gaacttgcag tcggagccat ccgcgggcgg gggctcccga 181 aaagtgcagc cctcggaccg cgcccccgac tcccgccgga cgtccctggt ggagcccgag 241 atgacctccc aggccatgcg cctgactcgt gggctgggtg tctggttccc tggcagcgcc 301 acacccccgg gactcatggt accccgggag ccccaggcct caccctcgac cctgcccctc 361 accttagaac ggccctctcc agtgatgccc cctcctgaag aggcggccgc ggtctctgca 421 ccacccccgg cccccgcggg gactctgctg cccggcccgt ctaaatggca aaagcccgcg 481 ggcactccag ttccccggat ccgccgcctg ctggaggcga gccatcgcgg ccagggcgac 541 cctccgagcc tccgcccgct gaagccgccg ccgccgcccc ggcaactatc cgtgaaggac 601 actgtcccga gggccccatc ccaatttccg ccgcccctgg agacttggaa gccgccacca 661 ccattacctt ctgaacggca gccggcggac cgcagaatca ctcctgctct ggccacaccc 721 gcctcacccc cgacagaaag ccaggctggg ccccgcaacc agggccagac ggccggcagg 781 gctcgcggag gggcgcctcc ccatgcgggc gaaggcgaaa tggcccagcc tgcggattcc 841 gagtccggtc tgagcctgct gtgtaaaatc accttcaagt cgaggccctc tttggcccct 901 ccggcagcct cgagttcctt agcagccaaa gcttcgctgg ggggcggcgg aggcggcggc 961 ctctttgctg cctcaggtgc catctcttac gccgaggtcc tgaagcaagg gcccctgcct 1021 cctggagccg ctcgcccctt gggagaggtt tctcgagggg cacaggaagc cgagggaggt 1081 gatggagacg gcgaagggtg ctctggtcct ccctcggcgc ctgcgtccca agcccgggcc 1141 ctaccgccgc caccctacac caccttccca ggctcgaagc ccaaattcga ctgggttagc 1201 gctcccgacg gccctgaacg ccacttccgc ttcaacgggg ctggcggagg catcggggcg 1261 ccgcgacggc gtgcggccgc actctctggg ccttggggct cccctccgcc accaccagag 1321 cagatacact cagctcccgg gccccggagg cccgcacctg ccctgctggc gccgcctacg 1381 ttcatcttcc cagcacccac caatggcgag cccatgcgcc cggggcctcc aggcctgcag 1441 gagttaccac cgctgccacc gcccacaccg ccgcccacac tgcagccacc agcgctccag 1501 ccaacgccgc tgccggtggc tcccccgctc accccgggtc tgggccacaa ggagtcagcc 1561 ctggctccca ccgcagcccc tgctctgccc ccagccttag ccgccgacca ggccccggcc 1621 ccatccccgg ctccagctcc caccgtggct gagccctcgc cgcctgtgtc cgcgcccgca 1681 cccgcggctg cgcccatcaa gacccgcacg cgcaggaaca agggttcccg tgcagcccgg 1741 ggcgcgaccc gtaaggatgg cttgcatgga gatggtcctc gcgaacgagc tacagctacc 1801 gtgcctgaca gcagtggtgg agggggtggt ggcagcgggg cctctcagac tggggcagct 1861 aacacccgcg ctgcgcgcca ctggctgccc ttccaggtgc ttaactcctg tccctgcaag 1921 tgttactgcc accaccagcc acgccatcgc cgcctgccac gcaacgtctc tgcctggctg 1981 agcacatcca ccaaccacct gggcgagcca ccctgggttg ccaccatcaa gctgtccggc 2041 tctctggtgg ccaagctgga gcactacgac ttgcaggcca cccattccaa ctgagtgtag 2101 tcggctcaac accctccacc ttcccctcca tgccaataaa ataaccaatc cagaaaaaaa 2161 aaaaaaaa 1 agaaggcctg ggggcgagga acaagacctc ggagtatttc aaggggagac ctagttccct 61 gccctgcccc gggcccaggg cgccgcggtc tgaactctgc tcggctggag gactcgtctc 121 cgagctccgt cagaaatggg gaacttgcag tcggagccat ccgcgggcgg gggctcccga 181 aaagtgcagc cctcggaccg cgcccccgac tcccgccgga cgtccctggt ggagcccgag 241 atgacctccc aggccatgcg cctgactcgt gggctgggtg tctggttccc tggcagcgcc 301 acacccccgg gactcatggt accccgggag ccccaggcct caccctcgac cctgcccctc 361 accttagaac ggccctctcc agtgatgccc cctcctgaag aggcggccgc ggtctctgca 421 ccacccccgg cccccgcggg gactctgctg cccggcccgt ctaaatggca aaagcccgcg 481 ggcactccag ttccccggat ccgccgcctg ctggaggcga gccatcgcgg ccagggcgac 541 cctccgagcc tccgcccgct gaagccgccg ccgccgcccc ggcaactatc cgtgaaggac 601 actgtcccga gggccccatc ccaatttccg ccgcccctgg agacttggaa gccgccacca 661 ccattacctt ctgaacggca gccggcggac cgcagaatca ctcctgctct ggccacaccc 721 gcctcacccc cgacagaaag ccaggctggg ccccgcaacc agggccagac ggccggcagg 781 gctcgcggag gggcgcctcc ccatgcgggc gaaggcgaaa tggcccagcc tgcggattcc 841 gagtccggtc tgagcctg ct gtgtaaaatc accttcaagt cgaggccctc tttggcccct 901 ccggcagcct cgagttcctt agcagccaaa gcttcgctgg ggggcggcgg aggcggcggc 961 ctctttgctg cctcaggtgc catctcttac gccgaggtcc tgaagcaagg gcccctgcct 1021 cctggagccg ctcgcccctt gggagaggtt tctcgagggg cacaggaagc cgagggaggt 1081 gatggagacg gcgaagggtg ctctggtcct ccctcggcgc ctgcgtccca agcccgggcc 1141 ctaccgccgc caccctacac caccttccca ggctcgaagc ccaaattcga ctgggttagc 1201 gctcccgacg gccctgaacg ccacttccgc ttcaacgggg ctggcggagg catcggggcg 1261 ccgcgacggc gtgcggccgc actctctggg ccttggggct cccctccgcc accaccagag 1321 cagatacact cagctcccgg gccccggagg cccgcacctg ccctgctggc gccgcctacg 1381 ttcatcttcc cagcacccac caatggcgag cccatgcgcc cggggcctcc aggcctgcag 1441 gagttaccac cgctgccacc gcccacaccg ccgcccacac tgcagccacc agcgctccag 1501 ccaacgccgc tgccggtggc tcccccgctc accccgggtc tgggccacaa ggagtcagcc 1561 ctggctccca ccgcagcccc tgctctgccc ccagccttag ccgccgacca ggccccggcc 1621 ccatccccgg ctccagctcc caccgtggct gagccctcgc cgcctgtgtc cgcgcccgca 1681 cccgcggctg cgcccatcaa gaccc gcacg cgcaggaaca agggttcccg tgcagcccgg 1741 ggcgcgaccc gtaaggatgg cttgcatgga gatggtcctc gcgaacgagc tacagctacc 1801 gtgcctgaca gcagtggtgg agggggtggt ggcagcgggg cctctcagac tggggcagct 1861 aacacccgcg ctgcgcgcca ctggctgccc ttccaggtgc ttaactcctg tccctgcaag 1921 tgttactgcc accaccagcc acgccatcgc cgcctgccac gcaacgtctc tgcctggctg 1981 agcacatcca ccaaccacct gggcgagcca ccctgggttg ccaccatcaa gctgtccggc 2041 tctctggtgg ccaagctgga gcactacgac ttgcaggcca cccattccaa ctgagtgtag 2101 tcggctcaac accctccacc ttcccctcca tgccaataaa ataaccaatc cagaaaaaaa 2161 aaaaaaaa
<210> 14 (GGNBP2 AY383626.1 ) <210> 14 (GGNBP2 AY383626.1)
<211 > 897  <211> 897
<212> DNA <212> DNA
<213> Homo Sapiens <213> Homo Sapiens
<400> 14 <400> 14
1 ggctgctcct ccatgttccg ccaccagggt gccatttccc tgatgatgag ccaagaggga 1 ggctgctcct ccatgttccg ccaccagggt gccatttccc tgatgatgag ccaagaggga
61 catgtgagga ggagggggcc gggaccatct gccttgccgc cccacccctt ctctgtggcc 121 atacccaggg gcttctcaaa acggtcacag cagcctccct taaagctggg catggggcgt 181 atggtgacct acacctgcaa gagcaagaag gcctggcgga gaggtgaagt cagttctgcc 241 catagcaagc caggaggtgt tgggcaacct gcctgagaag gaggggaagg agccagcagg 301 ggacgcctct gggaaaacag gggcctcaga cagcagccac tttatccaga tcctgcagtt 361 gaaggaagaa tacctgcaga gagccacagg gccccgtgag gtcagccctg agccctccac 421 cagggagaag gagtgtctgc ttgaaggcct ggaccacccc acttgctgcc agcctgtcag 481 tgaccaccac ccattcacag gagactgcgt gttggcctct tccagggtgg aggcaactcc 541 ttggaaccac ttccacagtt tggacaagga gcttcaaaac tcggccatgg ccaaggtttg 601 cccagcgagg agaaaagtga ggaagagaaa atgaaggaag aggacagctc attcaagctc 661 tgtgtcccag gcattgttgc cctccagtcg ccaccgaaca aggctttcag atccacagac 721 acagtgggtt tcctggagtc ggagttgaag aagcttctgg gaatgcagca agagtcccgc 781 ctctggaagc taggcagcca agagggccga gagctgctta cccggccaga gatcaccgtg 841 gtggagtgcc tgcttcttga ggagaaaggt gagatgggaa actggcctcc agagtga 61 catgtgagga ggagggggcc gggaccatct gccttgccgc cccacccctt ctctgtggcc 121 atacccaggg gcttctcaaa acggtcacag cagcctccct taaagctggg catggggcgt 181 atggtgacct acacctgcaa gagcaagaag gcctggcgga gaggtgaagt cagttctgcc 241 catagcaagc caggaggtgt tgggcaacct gcctgagaag gaggggaagg agccagcagg 301 ggacgcctct gggaaaacag gggcctcaga cagcagccac tttatccaga tcctgcagtt 361 gaaggaagaa tacctgcaga gagccacagg gccccgtgag gtcagccctg agccctccac 421 cagggagaag gagtgtctgc ttgaaggcct ggaccacccc acttgctgcc agcctgtcag 481 tgaccaccac ccattcacag gagactgcgt gttggcctct tccagggtgg aggcaactcc 541 ttggaaccac ttccacagtt tggacaagga gcttcaaaac tcggccatgg ccaaggtttg 601 cccagcgagg agaaaagtga ggaagagaaa atgaaggaag aggacagctc attcaagctc 661 tgtgtcccag gcattgttgc cctccagtcg ccaccgaaca aggctttcag atccacagac 721 acagtgggtt tcctggagtc ggagttgaag aagcttctgg gaatgcagca agagtcccgc 781 ctctggaagc taggcagcca agagggccga gagctgctta cccggccaga gatcaccgtg 841 gtggagtgcc tgcttcttga ggagaaaggt gagatgggaa actggcctcc agagtga
<210> 15 (IZUM01 NM_182575.2) <210> 15 (IZUM01 NM_182575.2)
<211 > 1621 <211> 1621
<212> DNA <212> DNA
<213> Homo Sapiens <213> Homo Sapiens
<400> 15 <400> 15
1 ggaatatcta taaaggaatt cgggccccta cgtgagaagc tcggaggggg tggtttcagg 61 agttccttgt ggagagggga tcgtccgtga ctcagacccc gtcgaaaagc tctcgatttc 1 ggaatatcta taaaggaatt cgggccccta cgtgagaagc tcggaggggg tggtttcagg 61 agttccttgt ggagagggga tcgtccgtga ctcagacccc gtcgaaaagc tctcgatttc
121 acgcaaccaa ccttaccctc gtccccaaca caatccttga ttttacccct gggaaaatta 181 gcgtaggtgg tcatgacccc ggcttcctct ttaaaagccc tcagaacctg gaccgggctc121 acgcaaccaa ccttaccctc gtccccaaca caatccttga ttttacccct gggaaaatta 181 gcgtaggtgg tcatgacccc ggcttcctct ttaaaagccc tcagaacctg gaccgggctc
241 ctcaatgaac cctagtgtta gaggccacaa atcgggaacc aaggtcgggg agcggctgtt241 ctcaatgaac cctagtgtta gaggccacaa atcgggaacc aaggtcgggg agcgggtgtt
301 tagggtgcat cactgttcag gatgcatcgg ggctcctttt tctaagcgga agggtgcgcc301 tagggtgcat cactgttcag gatgcatcgg ggctcctttt tctaagcgga agggtgcgcc
361 ctgcaaattg ggagcccgtt agttttgggg aagggtgaac aagggccccc taggtctaga361 ctgcaaattg ggagcccgtt agttttgggg aagggtgaac aagggccccc taggtctaga
421 ggaccgcatg gagtctcgct taagtgttag tggggtcctc agttctagga atctgcgttc 481 tcctgctctc ggtttggggt gagagcaccc ttcctaacgg tcttcgggaa ctgtgcgcgc421 ggaccgcatg gagtctcgct taagtgttag tggggtcctc agttctagga atctgcgttc 481 tcctgctctc ggtttggggt gagagcaccc ttcctaacgg tcttcgggaa ctgtgcgcgc
541 cggctgcaat ggggccgcat tttaccctcc tgtgtgcggc gctggccggt tgcttgcttc541 cggctgcaat ggggccgcat tttaccctcc tgtgtgcggc gctggccggt tgcttgcttc
601 ctgccgaggg gtgtgttata tgtgacccgt ctgtcgtgct ggcgctaaag tccctggaga601 ctgccgaggg gtgtgtata tgtgacccgt ctgtcgtgct ggcgctaaag tccctggaga
661 aagattacct gcctggccac ctggatgcga agcatcacaa agccatgatg gaaagggtag661 aagattacct gcctggccac ctggatgcga agcatcacaa agccatgatg gaaagggtag
721 agaatgccgt gaaggatttc caggaactgt cgcttaatga ggatgcctat atgggggtcg 781 ttgatgaggc cacactgcaa aaggggtcct ggagtttgct gaaggatctg aaacgcatca 841 cagacagtga tgtaaaaggc gatctcttcg tgaaggagct attttggatg ttgcacttgc 901 aaaaggaaac ctttgccacc tatgttgctc gattccaaaa agaggcttat tgtcccaaca 961 aatgtggtgt gatgttgcaa actctgatct ggtgcaagaa ctgcaaaaag gaggttcacg 1021 cttgtcgaaa gtcctacgat tgcggggagc ggaatgtgga agttcctcaa atggaagaca 1081 tgatcctgga ctgtgagtta aactggcatc aggcttcgga aggcctcact gattacagct 1141 tttacagggt ttgggggaac aatacggaga ccttggtgtc caaggggaaa gaggccaccc 1201 tgaccaagcc catggtgggt ccagaggatg caggcagcta ccgctgcgag ctgggctctg 1261 tgaattccag cccagccacg atcatcaatt ttcacgtcac agtgttgccc aaaatgatca 1321 aggaggaaaa accttctcca aatatcgtaa ccccggggga ggcgaccacg gagtcgtcca 1381 taagcctcca gcctctgcag cccgagaaaa tgctggcaag ccgccttctg gggctgctga 1441 tctgcggctc cctagcactg ataaccggcc ttacctttgc gatatttcgt cgaaggaagg 1501 tgatcgattt catcaaatcc tcactgtttg gccttggcag tggagcggcc gagcaaaccc 1561 aggtcccaaa agaaaaggcc acagattcga ggcaacaata aagatttatc ttgttgtcta 1621 a 721 agaatgccgt gaaggatttc caggaactgt cgcttaatga ggatgcctat atgggggtcg 781 ttgatgaggc cacactgcaa aaggggtcct ggagtttgct gaaggatctg aaacgcatca 841 cagacagtga tgtaaaaggc gatctcttcg tgaaggagct attttggatg ttgcacttgc 901 aaaaggaaac ctttgccacc tatgttgctc gattccaaaa agaggcttat tgtcccaaca 961 aatgtggtgt gatgttgcaa actctgatct ggtgcaagaa ctgcaaaaag gaggttcacg 1021 cttgtcgaaa gtcctacgat tgcggggagc ggaatgtgga agttcctcaa atggaagaca 1081 tgatcctgga ctgtgagtta aactggcatc aggcttcgga aggcctcact gattacagct 1141 tttacagggt ttgggggaac aatacggaga ccttggtgtc caaggggaaa gaggccaccc 1201 tgaccaagcc catggtgggt ccagaggatg caggcagcta ccgctgcgag ctgggctctg 1261 tgaattccag cccagccacg atcatcaatt ttcacgtcac agtgttgccc aaaatgatca 1321 aggaggaaaa accttctcca aatatcgtaa ccccggggga ggcgaccacg gagtcgtcca 1381 taagcctcca gcctctgcag cccgagaaaa tgctggcaag ccgccttctg gggctgctga 1441 tctgcggctc cctagcactg ataaccggcc ttacctttgc gatatttcgt cgaaggaagg 1501 tgatcgattt catcaaatcc tcactgtttg gccttggcag tggagcggcc gagcaaaccc 1561 aggtcccaaa agaaaaggcc acagattcga ggcaacaata aagatttatc ttgttgtcta 1621 a
<210> 16 (PSG1 NM_001184825.1 ) <210> 16 (PSG1 NM_001184825.1)
<211 > 2071  <211> 2071
<212> DNA  <212> DNA
<213> Homo Sapiens <213> Homo Sapiens
<400> 16  <400> 16
1 gagcttgaga attgctcctg ccctgggaag aggctcagca cagaaagagg aaggacagca 61 cagctgacag ccgtgctcag agagtttctg gatcctaggc ttatctccac agaggagaac 121 acacaagcag cagagaccat gggaaccctc tcagcccctc cctgcacaca gcgcatcaaa 181 tggaaggggc tcctgctcac agcatcactt ttaaacttct ggaacctgcc caccactgcc 241 caagtcacga ttgaagccga gccaaccaaa gtttccgagg ggaaggatgt tcttctactt 301 gtccacaatt tgccccagaa tcttaccggc tacatctggt acaaagggca aatgagggac 361 ctctaccatt acattacatc atatgtagta gacggtgaaa taattatata tgggcctgca 421 tatagtggac gagaaacagc atattccaat gcatccctgc tgatccagaa tgtcacccgg 481 gaggacgcag gatcctacac cttacacatc ataaagggag atgatgggac tagaggagta 541 actggacgtt tcaccttcac cttacacctg gagactccta agccctccat ctccagcagc 601 aacttaaatc ccagggagac catggaggct gtgagcttaa cctgtgaccc tgagactcca 661 gacgcaagct acctgtggtg gatgaatggt cagagcctcc ctatgactca cagcttgaag 721 ctgtccgaaa ccaacaggac cctctttcta ttgggtgtca caaagtatac tgcaggaccc 781 tatgaatgtg aaatacggaa cccagtgagt gccagccgca gtgacccagt caccctgaat 841 ctcctcccga agctgcccaa gccctacatc accatcaaca acttaaaccc cagggagaat 901 aaggatgtct taaacttcac ctgtgaacct aagagtgaga actacaccta catttggtgg 961 ctaaatggtc agagcctccc ggtcagtccc agggtaaagc gacccattga aaacaggatc 1021 ctcattctac ccagtgtcac gagaaatgaa acaggaccct atcaatgtga aatacgggac 1081 cgatatggtg gcatccgcag tgacccagtc accctgaatg tcctctatgg tccagacctc 1141 cccagaattt acccttcatt cacctattac cgttcaggag aagtcctcta cttgtcctgt 1201 tctgcggact ctaacccacc ggcacagtat tcttggacaa ttaatgaaaa gtttcagcta 1261 ccaggacaaa agctctttat ccgccatatt actacaaagc atagcgggct ctatgtttgc 1321 tctgttcgta actcagccac tggcaaggaa agctccaaat ccatgacagt cgaagtctct 1381 gactggacag ttccctgaat tctactagta cctccaattc cattttctcc catggaatca 1441 ctaagagcaa gacccactct gttccagaag ccctataagc tggaggtgga caactcaatg 1501 taaatttcat gggaaaaccc ttgtacgtga agcatgagcc actcagaact caccaaaata 1561 ttcgacacca taacaacaga tgctcaaact gtaaaccagg acaacaagtg gatgacttca 1621 cactgtggac agtttttccc aagatgtcag aacaagactc cccatcatga tgaggctctc 1681 ccccctctta actgtccttg ctcatgcctg cctctttcac ttggcaggat aatgcagtca 1741 ttagaatttc acatgtagta gcttctgaga gtaacaacag agtgtcagat atgtcatctc 1801 aacctcaaac ttttacataa catctcaggg ggaaatgtgg ctctctccac cttgcataca 1861 gggctcccaa tagaaatgaa cacagagata ttgcctgtgt gtttgcagag aagatggttt1 gagcttgaga attgctcctg ccctgggaag aggctcagca cagaaagagg aaggacagca 61 cagctgacag ccgtgctcag agagtttctg gatcctaggc ttatctccac agaggagaac 121 acacaagcag cagagaccat gggaaccctc tcagcccctc cctgcacaca gcgcatcaaa 181 tggaaggggc tcctgctcac agcatcactt ttaaacttct ggaacctgcc caccactgcc 241 caagtcacga ttgaagccga gccaaccaaa gtttccgagg ggaaggatgt tcttctactt 301 gtccacaatt tgccccagaa tcttaccggc tacatctggt acaaagggca aatgagggac 361 ctctaccatt acattacatc atatgtagta gacggtgaaa taattatata tgggcctgca 421 tatagtggac gagaaacagc atattccaat gcatccctgc tgatccagaa tgtcacccgg 481 gaggacgcag gatcctacac cttacacatc ataaagggag atgatgggac tagaggagta 541 actggacgtt tcaccttcac cttacacctg gagactccta agccctccat ctccagcagc 601 aacttaaatc ccagggagac catggaggct gtgagcttaa cctgtgaccc tgagactcca 661 gacgcaagct acctgtggtg gatgaatggt cagagcctcc ctatgactca cagcttgaag 721 ctgtccgaaa ccaacaggac cctctttcta ttgggtgtca caaagtatac tgcaggaccc 781 tatgaatgtg aaatacggaa cccagtgagt gccagccgca gtgacccagt caccctgaat 841 ctcctcccga agctgccc aa gccctacatc accatcaaca acttaaaccc cagggagaat 901 aaggatgtct taaacttcac ctgtgaacct aagagtgaga actacaccta catttggtgg 961 ctaaatggtc agagcctccc ggtcagtccc agggtaaagc gacccattga aaacaggatc 1021 ctcattctac ccagtgtcac gagaaatgaa acaggaccct atcaatgtga aatacgggac 1081 cgatatggtg gcatccgcag tgacccagtc accctgaatg tcctctatgg tccagacctc 1141 cccagaattt acccttcatt cacctattac cgttcaggag aagtcctcta cttgtcctgt 1201 tctgcggact ctaacccacc ggcacagtat tcttggacaa ttaatgaaaa gtttcagcta 1261 ccaggacaaa agctctttat ccgccatatt actacaaagc atagcgggct ctatgtttgc 1321 tctgttcgta actcagccac tggcaaggaa agctccaaat ccatgacagt cgaagtctct 1381 gactggacag ttccctgaat tctactagta cctccaattc cattttctcc catggaatca 1441 ctaagagcaa gacccactct gttccagaag ccctataagc tggaggtgga caactcaatg 1501 taaatttcat gggaaaaccc ttgtacgtga agcatgagcc actcagaact caccaaaata 1561 ttcgacacca taacaacaga tgctcaaact gtaaaccagg acaacaagtg gatgacttca 1621 cactgtggac agtttttccc aagatgtcag aacaagactc cccatcatga tgaggctctc 1681 ccccctctta actgtccttg ctcat gcctg cctctttcac ttggcaggat aatgcagtca 1741 ttagaatttc acatgtagta gcttctgaga gtaacaacag agtgtcagat atgtcatctc 1801 aacctcaaac ttttacataa catctcaggg ggaaatgtgg ctctctccac cttgcataca 1861 gggctcccaa tagaaatgaa cacagagata ttgcctgtgt gtttgcagag aagatggttt
1921 gtatgaagac gtaggaaagc tgaaattata atagagtccc ctttaaatcc acattgtgtg1921 gtatgaagac gtaggaaagc tgaaattata atagagtccc ctttaaatcc acattgtgtg
1981 gatggctctt gccgtttcct aagagataca ttgtaaaacg tgacagtaag acattctagc1981 gatggctctt gccgtttcct aagagataca ttgtaaaacg tgacagtaag acattctagc
2041 agaataaaac atgtaccacc tttgctaata c 2041 agaataaaac atgtaccacc tttgctaata c
<210> 17 (PSG2 NM_031246.3) <210> 17 (PSG2 NM_031246.3)
<21 1 > 1612  <21 1> 1612
<212> DNA  <212> DNA
<213> Homo Sapiens  <213> Homo Sapiens
<400> 17 <400> 17
1 gacagagagg tgtcctgggc ctgaccccac ccatgagcct gggaattgct gctgccccag 61 gaagaggctc agtgcagaag gaggaaggac agcacagctg acagccgtgc tcaggaagtt 121 tctggatcct aggctcatct ccacagagga gaacacacag gcagcagaga ccatggggcc 181 cctctcagcc cctccctgca cagagcacat caaatggaag gggctcctgg tcacagcatc 241 acttttaaac ttctggaacc tgcccaccac tgcccaagtc acgattgaag cccagccacc 301 aaaagtttcc gaggggaagg atgttcttct acttgtccac aatttgcccc agaatcttac 361 tggctacatc tggtacaaag ggcaaatcag ggacctctac cattacatta catcatatgt 421 agtagacggt caaataatta tatatgggcc tgcatatagt ggacgagaaa cagcatattc 481 caatgcatcc ctgctgatcc agaatgtcac ccgggaggac gcaggatcct acaccttaca 541 catcataaag cgaggtgatg ggactagagg agtaactgga tatttcacct tcaccttata 601 cctggagact cccaagccct ccatctccag cagcaactta aaccccaggg aggccatgga 661 aactgtgatc ttaacctgtg atcctgagac tccggacaca agctaccagt ggtggatgaa 721 tggtcagagc ctccctatga ctcataggtt tcagctgtcc gaaaccaaca ggaccctctt 781 tctatttggt gtcacaaagt atactgcagg accctatgaa tgtgaaatac ggaactcagg 841 gagtgccagc cgcagtgacc cagtcaccct gaatctcctc catggtccag acctccccag 901 aattcaccct tcatacacca attaccgttc aggagataac ctctacttgt cttgcttcgc 961 gaactctaac ccaccggcac agtattcttg gacaattaat gggaagtttc agcaatcagg 1021 acaaaatctg tttatccccc aaattactac aaagcatagc gggctctatg tttgctctgt 1081 tcgtaactca gccactggcg aggaaagctc cacatcgttg acagtcaaag tctctgcttc 1141 tacaagaata ggacttcttc ctctccttaa tccaacatag cagctgtgat gtcatttctg 1201 tatttcagga agactggcag gagatttatg gaaaggtctc ttacaaggac tcttgaatac 1261 aagctcctga taacttcaag atcataccac tggactaaga actttcaaaa ttttaatgaa 1321 caggctgata ccttcatgaa attcaagaca aagaagaaaa atactcaatg ttattggact 1381 aaataatcaa aaggataatg atttcataat tttctatttg aaaatgtgct gattcttgga 1441 atgtttcatt ctccagattt atgaacattt tttcttgagc aattggtaaa gtatactttt 1501 gtaaacaaaa attgaaacat ttccttttgc tctctatctg agtgccccag aattgggaat 1561 ctattcatga gtattcatat gtttatggta ataaagctat ttgcacaagt tc  1 gacagagagg tgtcctgggc ctgaccccac ccatgagcct gggaattgct gctgccccag 61 gaagaggctc agtgcagaag gaggaaggac agcacagctg acagccgtgc tcaggaagtt 121 tctggatcct aggctcatct ccacagagga gaacacacag gcagcagaga ccatggggcc 181 cctctcagcc cctccctgca cagagcacat caaatggaag gggctcctgg tcacagcatc 241 acttttaaac ttctggaacc tgcccaccac tgcccaagtc acgattgaag cccagccacc 301 aaaagtttcc gaggggaagg atgttcttct acttgtccac aatttgcccc agaatcttac 361 tggctacatc tggtacaaag ggcaaatcag ggacctctac cattacatta catcatatgt 421 agtagacggt caaataatta tatatgggcc tgcatatagt ggacgagaaa cagcatattc 481 caatgcatcc ctgctgatcc agaatgtcac ccgggaggac gcaggatcct acaccttaca 541 catcataaag cgaggtgatg ggactagagg agtaactgga tatttcacct tcaccttata 601 cctggagact cccaagccct ccatctccag cagcaactta aaccccaggg aggccatgga 661 aactgtgatc ttaacctgtg atcctgagac tccggacaca agctaccagt ggtggatgaa 721 tggtcagagc ctccctatga ctcataggtt tcagctgtcc gaaaccaaca ggaccctctt 781 tctatttggt gtcacaaagt atactgcagg accctatgaa tgtgaaatac ggaactcagg 841 gagtgccagc cgcagtga cc cagtcaccct gaatctcctc catggtccag acctccccag 901 aattcaccct tcatacacca attaccgttc aggagataac ctctacttgt cttgcttcgc 961 gaactctaac ccaccggcac agtattcttg gacaattaat gggaagtttc agcaatcagg 1021 acaaaatctg tttatccccc aaattactac aaagcatagc gggctctatg tttgctctgt 1081 tcgtaactca gccactggcg aggaaagctc cacatcgttg acagtcaaag tctctgcttc 1141 tacaagaata ggacttcttc ctctccttaa tccaacatag cagctgtgat gtcatttctg 1201 tatttcagga agactggcag gagatttatg gaaaggtctc ttacaaggac tcttgaatac 1261 aagctcctga taacttcaag atcataccac tggactaaga actttcaaaa ttttaatgaa 1321 caggctgata ccttcatgaa attcaagaca aagaagaaaa atactcaatg ttattggact 1381 aaataatcaa aaggataatg atttcataat tttctatttg aaaatgtgct gattcttgga 1441 atgtttcatt ctccagattt atgaacattt tttcttgagc aattggtaaa gtatactttt 1501 gtaaacaaaa attgaaacat ttccttttgc tctctatctg agtgccccag aattgggaat 1561 ctattcatga gtattcatat gtttatggta ataaagctat ttgcacaagt tc
<210> 18 (PSG5 NM_002781.3) <210> 18 (PSG5 NM_002781.3)
<21 1 > 1669  <21 1> 1669
<212> DNA  <212> DNA
<213> Homo Sapiens  <213> Homo Sapiens
<400> 18 1 gagaagtgct cctgccctgg agagaggctc agcacagaag gaggaaggac agcacagcct<400> 18 1 gagaagtgct cctgccctgg agagaggctc agcacagaag gaggaaggac agcacagcct
61 acagccgtgc tcaggaagtt tctggatcct aggctcagct ccacagagga gaacacgcag 121 gcgcagagac catggggccc ctctcagccc ctccctgcac acagcacatc acctggaagg 181 ggctcctgct cacagcatca cttttaaact tctggaacct gcctatcact gctcaagtca 241 cgattgaagc cctgccaccc aaagtttccg aggggaagga tgttcttcta cttgtccaca 301 atttgcctca gaatcttgct ggctacatct ggtacaaagg acaactgatg gacctctacc 361 attacattac atcatatgta gtagacggtc aaataaatat atatgggcct gcatacactg 421 gacgagaaac agtatattcc aatgcatccc tgctgatcca gaatgtcacc cgggaagacg 481 caggatccta caccttacac atcataaagc gaggtgatag gactagagga gtaactggat 541 atttcacctt caacttatac ctgaagctgc ccaagcccta catcaccatc aacaactcaa 601 aacccaggga gaataaggat gtcttagcct tcacctgtga acctaagagt gagaactaca 661 cctacatttg gtggctaaat ggtcagagcc tcccggtcag tcccagggta aagcgaccca 721 ttgaaaacag gatcctcatt ctacccagtg tcacgagaaa tgaaacagga ccctatgaat 781 gtgaaatacg ggaccgagat ggtggcatgc gcagtgaccc agtcaccctg aatgtcctct 841 atggtccaga cctccccagc atttaccctt cattcaccta ttaccgttca ggagaaaacc 901 tctacttgtc ctgcttcgcg gaatctaacc caccggcaga gtatttttgg acaattaatg 961 ggaagtttca gcaatcagga caaaagctct ctatccccca aattactaca aagcatagag 1021 ggctctatac ttgctctgtt cgtaactcag ctactggcaa ggaaagctcc aaatccatga 1081 cagtcgaagt ctctgctcct tcaggaatag gacgtcttcc tctccttaat ccaatatagc 1141 agccgtgaag tcatttctgt atttcaggaa gactggcaga cagttgcttt gattcttcct 1201 caaactactt acaatcacct acagtccaaa attgcttttt cttcaaggag atttatggaa 1261 aagactctga caaggactct tgaatacaag ttcctgataa cttcaagatc ataccactgg 1321 actaagaact ttcaaaattt taatgaacag gctgatacct tcatgaaatt ctagacaaag 1381 aagaaaaaaa ctccatgtta ttggactaaa taatcaaaag cataatgttt tcataatttt 1441 ctatttgaaa atgtgctgat tctttgaatg ttttattctc cagatttatg aacttttttt 1501 cttgagcaat tggtaaagta tacttttgta aacaaaaatt gaaacatttg cttttgctct 1561 ctatctgagt gccccagaat tgggaaacta ttcatgagta ttcatatgtt tatggtaata 1621 aagttatctg cacaagttca aaaaaaaaaa aaaaaaaaaa aaaaaaaaa 61 acagccgtgc tcaggaagtt tctggatcct aggctcagct ccacagagga gaacacgcag 121 gcgcagagac catggggccc ctctcagccc ctccctgcac acagcacatc acctggaagg 181 ggctcctgct cacagcatca cttttaaact tctggaacct gcctatcact gctcaagtca 241 cgattgaagc cctgccaccc aaagtttccg aggggaagga tgttcttcta cttgtccaca 301 atttgcctca gaatcttgct ggctacatct ggtacaaagg acaactgatg gacctctacc 361 attac attac atcatatgta gtagacggtc aaataaatat atatgggcct gcatacactg 421 gacgagaaac agtatattcc aatgcatccc tgctgatcca gaatgtcacc cgggaagacg 481 caggatccta caccttacac atcataaagc gaggtgatag gactagagga gtaactggat 541. atttcacctt caacttatac ctgaagctgc ccaagcccta catcaccatc aacaactcaa 601. aacccaggga gaataaggat gtcttagcct tcacctgtga acctaagagt gagaactaca 661 cctacatttg gtggctaaat ggtcagagcc tcccggtcag tcccagggta aagcgaccca 721. ttgaaaacag gatcctcatt ctacccagtg tcacgagaaa tgaaacagga ccctatgaat 781 gtgaaatacg ggaccgagat ggtggcatgc gcagtgaccc agtcaccctg aatgtcctct 841 atggtccaga cctccccagc atttaccctt cattcaccta ttaccgttca ggagaaaacc 901. tctacttgtc ctgctt CGCG gaatctaacc caccggcaga gtatttttgg acaattaatg 961 ggaagtttca gcaatcagga caaaagctct ctatccccca aattactaca aagcatagag 1021 ggctctatac ttgctctgtt cgtaactcag ctactggcaa ggaaagctcc aaatccatga 1081 cagtcgaagt ctctgctcct tcaggaatag gacgtcttcc tctccttaat ccaatatagc 1141 agccgtgaag tcatttctgt atttcaggaa gactggcaga cagttgcttt gattcttcct 1201 caaactactt acaatcacct acagtccaaa attgcttttt cttcaaggag atttatggaa 1261 aagactctga caaggactct tgaatacaag ttcctgataa cttcaagatc ataccactgg 1321 actaagaact ttcaaaattt taatgaacag gctgatacct tcatgaaatt ctagacaaag 1381 aagaaaaaaa ctccatgtta ttggactaaa taatcaaaag cataatgttt tcataatttt 1441 ctatttgaaa atgtgctgat tctttgaatg ttttattctc cagatttatg aacttttttt 1501 cttgagcaat tggtaaagta tacttttgta aacaaaaatt gaaacatttg cttttgctct 1561 ctatctgagt gccccagaat tgggaaacta ttcatgagta ttcatatgtt tatggtaata 1621 aagttatctg cacaagttca aaaaaaaaaa aaaaaaaaaa aaaaaaaaa
<210> 19 (ROPN1 L NM_031916.4) <210> 19 (ROPN1 L NM_031916.4)
<211 > 1093 <211> 1093
<212> DNA <212> DNA
<213> Homo Sapiens <213> Homo Sapiens
<400> 19 <400> 19
1 aggggcgggg cctgctcgcg tcccgggtgc ctggataccg agcgcgtccg tagtggcggc 61 tggcgctagg gaactgcagg gtctagggtg ttgtcggagt ggcagttggt ccgaatttct 1 aggggcgggg cctgctcgcg tcccgggtgc ctggataccg agcgcgtccg tagtggcggc 61 tggcgctagg gaactgcagg gtctagggtg ttgtcggagt ggcagttggt ccgaatttct
121 cccgaagccc gcggaggagc gggtaagagc cccgcgaatc cggccccaac ctcgggaacg121 cccgaagccc gcggaggagc gggtaagagc cccgcgaatc cggccccaac ctcgggaacg
181 ggatgggagg cggccctggc cgcaagcccc gcgctgctag cgggtccacc gcgtcgtagc181 ggatgggagg cggccctggc cgcaagcccc gcgctgctag cgggtccacc gcgtcgtagc
241 cgacagccgc ccttcttcct cgcagcgcgc cgcgattcac cagcctggtc ccttctgcgg241 cgacagccgc ccttcttcct cgcagcgcgc cgcgattcac cagcctggtc ccttctgcgg
301 agagcgatgc cgcttcccga caccatgttc tgcgctcagc agatccacat tcccccggag 361 ctgccggaca tcctgaagca attcaccaag gctgccatcc gcacccagcc ggccgacgtg301 agagcgatgc cgcttcccga caccatgttc tgcgctcagc agatccacat tcccccggag 361 ctgccggaca tcctgaagca attcaccaag gctgccatcc gcacccagcc ggccgacgtg
421 ctgcggtggt ccgcgggcta tttttcagct ctgtcgagag gagatccact tcctgtaaag421 ctgcggtggt ccgcgggcta tttttcagct ctgtcgagag gagatccact tcctgtaaag
481 gacagaatgg aaatgcccac ggcaacccag aaaacagaca caggcctgac tcaaggactc481 gacagaatgg aaatgcccac ggcaacccag aaaacagaca caggcctgac tcaaggactc
541 ctgaaagttt tgcacaagca gtgtcaccac aagcggtatg tggaattaac agatcttgag541 ctgaaagttt tgcacaagca gtgtcaccac aagcggtatg tggaattaac agatcttgag
601 cagaagtgga agaacttgtg cctgccgaag gaaaaattca aagcgctctt acaactggat 661 ccttgtgaaa acaaaatcaa gtggataaac tttttagcgc ttggatgcag catgcttggt601 cagaagtgga agaacttgtg cctgccgaag gaaaaattca aagcgctctt acaactggat 661 ccttgtgaaa acaaaatcaa gtggataaac tttttagcgc ttggatgcag catgcttggt
721 gggtccttga acactgcgct gaagcacctg tgcgagatcc tcacggacga tccggagggc721 gggtccttga acactgcgct gaagcacctg tgcgagatcc tcacggacga tccggagggc
781 gggcccgctc gcatcccctt caagacgttt tcctacgttt accgctactt ggccagatta781 gggcccgctc gcatcccctt caagacgttt tcctacgttt accgctactt ggccagatta
841 gactcagatg tgtctccctt ggagacggaa tcctaccttg cctctctaaa ggaaaatata841 gactcagatg tgtctccctt ggagacggaa tcctaccttg cctctctaaa ggaaaatata
901 gacgccagga agaacggcat gataggtctt tcagatttct tctttccaaa gaggaaactt 961 ttagaaagca ttgaaaactc tgaagatgta ggccattaat acagagaaga atacatttta 1021 atgtcaaaat agtgctcttt aaaattctgg caccaaatac aacttaccct gaatcacaaa 1081 aaaaaaaaaa aaa 901 gacgccagga agaacggcat gataggtctt tcagatttct tctttccaaa gaggaaactt 961 ttagaaagca ttgaaaactc tgaagatgta ggccattaat acagagaaga atacatttta 1021 atgtcaaaat agtgctcttt aaaattctgg caccaaatac aacttaccct gaatcacaaa 1081 aaaaaaaaaa aaa
<210> 20 (SPAG6 CR533552.1 ) <210> 20 (SPAG6 CR533552.1)
<211 > 1728  <211> 1728
<212> DNA <212> DNA
<213> Homo Sapiens  <213> Homo Sapiens
<400> 20 <400> 20
1 atgagtcaga ggcaggtgct gcaagtgttc gagcaatacc agaaggccag gacccagttc 61 gtgcagatgg tggcggagct ggcgactaga ccccaaaaca tcgagacgct gcagaacgcg 121 ggtgtaatgt ctttgctgag aactcttctt ctggacgtgg tcccaacaat tcaacagact 181 gctgctttgg ctcttgggag actggccaat tataatgatg acctagcaga agctgttgtg 241 aagtgcgaca ttcttccaca gcttgtttat tcattggcag aacagaatcg cttctacaag 301 aaagcagctg cctttgtgtt acgagcagtt ggtaaacatt ctccccagct agctcaggca 361 atagtcgatt gtggagcact ggatacgctg gtcatatgct tggaagattt tgaccctgga 421 gtcaaggagg ctgcagcctg ggcacttaga tatattgcaa gacataatgc agaactgtca 481 cgagctgtgg tggatgcagg agctgttcct cttttagtac tctgtatcca ggagccagaa 541 attgctttga aaaggattgc tgcttcggcc ctcagtgata ttgcaaagca ttctccagag 601 ttagcacaga cagtagtgga tgcaggagct gttgctcatt tagcccagat gatcctgaac 661 cctgatgcta aattgaagca tcagatcctt tcagctctca gtcaggtttc aaaacattcc 721 gtggatctgg cagaaatggt tgttgaagca gagatttttc cagttgtact tacctgtctg 781 aaggacaagg atgaatacgt gaagaaaaat gcttctactt taattagaga gattgcaaaa 841 catacacccg agctttcaca gctggtagtt aacgcaggag gggttgctgc cgtgattgac 901 tgcattgggt cctgcaaagg gaacacacgg ctgcctggca tcatgatgct tggttatgta 961 gcagctcatt ctgagaacct agcaatggca gtcatcattt ctaagggtgt accccagttg 1021 tcagtctgct tgtcagaaga accggaagat catattaagg ctgcagctgc ttgggcctta 1081 ggacagattg gaagacacac tcctgaacac gcacgggctg ttgcagtcac aaatactttg 1141 ccagttctgc tttctttgta catgtcaaca gaaagttctg aggatctcca agtaaaaagt 1 atgagtcaga ggcaggtgct gcaagtgttc gagcaatacc agaaggccag gacccagttc 61 gtgcagatgg tggcggagct ggcgactaga ccccaaaaca tcgagacgct gcagaacgcg 121 ggtgtaatgt ctttgctgag aactcttctt ctggacgtgg tcccaacaat tcaacagact 181 gctgctttgg ctcttgggag actggccaat tataatgatg acctagcaga agctgttgtg 241 aagtgcgaca ttcttccaca gcttgtttat tcattggcag aacagaatcg cttctacaag 301 aaagcagctg cctttgtgtt acgagcagtt ggtaaacatt ctccccagct agctcaggca 361 atagtcgatt gtggagcact ggatacgctg gtcatatgct tggaagattt tgaccctgga 421 gtcaaggagg ctgcagcctg ggcacttaga tatattgcaa gacataatgc agaactgtca 481 cgagctgtgg tggatgcagg agctgttcct cttttagtac tctgtatcca ggagccagaa 541 attgctttga aaaggattgc tgcttcggcc ctcagtgata ttgcaaagca ttctccagag 601 ttagcacaga cagtagtgga tgcaggagct gttgctcatt tagcccagat gatcctgaac 661 cctgatgcta aattgaagca tcagatcctt tcagctctca gtcaggtttc aaaacattcc 721 gtggatctgg cagaaatggt tgttgaagca gagatttttc cagttgtact tacctgtctg 781 aaggacaagg atgaatacgt gaagaaaaat gcttctactt taattagaga gattgcaaaa 841 catacacccg agctttca ca gctggtagtt aacgcaggag gggttgctgc cgtgattgac 901 tgcattgggt cctgcaaagg gaacacacgg ctgcctggca tcatgatgct tggttatgta 961 gcagctcatt ctgagaacct agcaatggca gtcatcattt ctaagggtgt accccagttg 1021 tcagtctgct tgtcagaaga accggaagat catattaagg ctgcagctgc ttgggcctta 1081 ggacagattg gaagacacac tcctgaacac gcacgggctg ttgcagtcac aaatactttg 1141 ccagttctgc tttctttgta catgtcaaca gaaagttctg aggatctcca agtaaaaagt
1201 aaaaaagcca taaagaatat cctgcaaaaa tgtacctact taccagccct tgaaccattt 1261 ctatatgatg ctcctcccaa tattctgaaa catgtggttg gacagttcag taaggtgctg 1321 ccgcatgata gcaaagctcg acgacttttt gtaacaagtg gtggccttaa aaaagttcaa1201 aaaaaagcca taaagaatat cctgcaaaa tgtacctact taccagccct tgaaccattt 1261 ctatatgatg ctcctcccaa tattctgaaa catgtggttg gacagttcag taaggtgctg 1321 ccgcatgata gcaaagctcg acgacttttt gtaacaagtg gtggccttaa aaaagttcaa
1381 gagataaaag cagaacctgg ttctctcctt caagaataca tcaacagtat taacagttgt 1441 taccccgagg aaatagtgag gtattattcc cctggatatt cagatacact tctgcagagg 1501 gtggacagct atcaaccact taataactga gcaaagttat attgtgatac tcaaattcac 1561 agcagagtag ttttgagtaa cagtaattaa atccttctaa atatttgaac taagtatatt 1621 ctagatttat ttaatgggaa atacctttag ataatatttt ctaaatttat gtaatacttt 1681 aaacattcgt agcttgaata tgtgaggaac tattcatggt cattcgca 1381 gagataaaag cagaacctgg ttctctcctt caagaataca tcaacagtat taacagttgt 1441 taccccgagg aaatagtgag gtattattcc cctggatatt cagatacact tctgcagagg 1501 gtggacagct atcaaccact taataactga gcaaagttat attgtgatac tcaaattcac 1561 agcagagtag ttttgagtaa cagtaattaa atccttctaa atatttgaac taagtatatt 1621 ctagatttat ttaatgggaa atacctttag ataatatttt ctaaatttat gtaatacttt 1681 aaacattcgt agcttgaata tgtgaggaac tattcatggt cattcgca
<210> 21 (SPAG8 NM_172312.1 ) <210> 21 (SPAG8 NM_172312.1)
<211 > 2010 <211> 2010
<212> DNA  <212> DNA
<213> Homo Sapiens  <213> Homo Sapiens
<400> 21 1 gccccgcaga ggacttgcct ccaccgccac ctgcaagtcc gcccagctgt acttctgcgc 61 aggctccagg agttgtttgc tgtctctatg gcaacccagt agctggagtc tgaagatgga 121 gaccaacgag tctacggagg gatcgcggtc gcggtcgcga tctttagaca tacagcccag 181 ctccgaagga ctggggccca cttcggaacc gtttccttct tcagatgaca gtcccaggtc 241 ggccctggca gctgcaaccg cagcagctgc agcggctgca tcagctgctg cagctactgc 301 agccttcacc actgccaaag cagctgcatt atctacaaag accccagcgc cctgttctga 361 gttcatggag ccgtcctctg accccagcct tcttggggag ccctgtgcgg gacccggctt 421 tacccacaat atagcccatg ggagtcttgg ctttgagccc gtctatgttt cctgtattgc 481 tcaggacact tgcactacaa ctgaccatag ttctaatcct ggccctgttc caggctctag 541 ctctgggcct gttcttggtt ccagctcagg tgctggccat ggctctggct ctggctctgg 601 tcctggctgt ggctctgtcc ctggctctgg ctctggtcct ggtcctggct ctggtcctgg 661 ctctggtcct ggtcatggct ctggctctca tcctggtcct gcctctgggc ctggtccaga 721 cactggccct gactctgagc tcagcccctg tattcctcca gggttcagaa acctggtggc 781 agatcgggtc cctaactata cctcctggag tcagcactgc ccctgggagc cccagaaaca 841 accaccttgg gaatttttgc aagtcttaga accgggtgcc cgaggactat ggaaaccccc 901 agacattaaa gggaagctta tggtttgcta tgaaactttg ccgcggggcc agtgcctcct 961 ctacaactgg gaggaagaga gagccaccaa ccacctggat caagtcccaa gcatgcagga 1021 tggctctgag agttttttct tccgacacgg acaccgggga ctgctgacta tgcaactaaa 1081 gtcacccatg ccctccagca ccacccagaa agactcgtac cagccaccag gaaacgtcta 1141 ttggccactt cgagggaagc gtgaagccat gctggagatg ctcctgcagc atcagatctg 1201 taaagaggtg caggcagaac aggaacccac aaggaagctc ttcgaggttg agtctgtgac 1261 acaccatgac taccgaatgg agctggcaca agcagggact cctgccccaa caaagcctca 1321 cgactaccgc caggagcaac ctgagacctt ctggatacag agggcaccac agctgccgac 1381 atggtggcca ttgcccaccc aggtaccagc agcagaagac tatctgactt ggaaagaatg 1441 ggggtttaca ggagtccagg aggtcctttc cgctctccta agagccacac ctggtgaata 1501 ctcagtaaac atttgcggaa tgaatgaaca ccctgtctgc agcaggacat ggacaaatag 1561 gctctgccat caggaaatgg gaagcaagaa aacggtaact caagaggaca gaggctggtg 1621 aggaggtaaa gcaggcccag tgaaatggac ctgacagccc aaactgtcag agaggaggaa 1681 agcaggcatt tgattttggt aattgtgcca aagctatgta agagaataaa tgccattgtt 1741 ttaaggaaat acacagtgaa gtttttagga aatacacact aagtatttag ggataaagta 1801 gttatcccta aatagtagtc tgccacatgc caaacaatgt taggtacttt ccatacaacg 1861 aatctattat tcccatctta cagataaaac aactgaggct cagggagatt ctgtgactta 1921 cctaaggcca cacagttagc aacaagccaa tattcaaatc cagatgattt ttactcccaa 1981 ggacaataaa tccaactcaa taacttcaaa <400> 21 1 gccccgcaga ggacttgcct ccaccgccac ctgcaagtcc gcccagctgt acttctgcgc 61 aggctccagg agttgtttgc tgtctctatg gcaacccagt agctggagtc tgaagatgga 121 gaccaacgag tctacggagg gatcgcggtc gcggtcgcga tctttagaca tacagcccag 181 ctccgaagga ctggggccca cttcggaacc gtttccttct tcagatgaca gtcccaggtc 241 ggccctggca gctgcaaccg cagcagctgc agcggctgca tcagctgctg cagctactgc 301 agccttcacc actgccaaag cagctgcatt atctacaaag accccagcgc cctgttctga 361 gttcatggag ccgtcctctg accccagcct tcttggggag ccctgtgcgg gacccggctt 421 tacccacaat atagcccatg ggagtcttgg ctttgagccc gtctatgttt cctgtattgc 481 tcaggacact tgcactacaa ctgaccatag ttctaatcct ggccctgttc caggctctag 541 ctctgggcct gttcttggtt ccagctcagg tgctggccat ggctctggct ctggctctgg 601 tcctggctgt ggctctgtcc ctggctctgg ctctggtcct ggtcctggct ctggtcctgg 661 ctctggtcct ggtcatggct ctggctctca tcctggtcct gcctctgggc ctggtccaga 721 cactggccct gactctgagc tcagcccctg tattcctcca gggttcagaa acctggtggc 781 agatcgggtc cctaactata cctcctggag tcagcactgc ccctgggagc cccagaaaca 841 accaccttgg gaattttt gc aagtcttaga accgggtgcc cgaggactat ggaaaccccc 901 agacattaaa gggaagctta tggtttgcta tgaaactttg ccgcggggcc agtgcctcct 961 ctacaactgg gaggaagaga gagccaccaa ccacctggat caagtcccaa gcatgcagga 1021 tggctctgag agttttttct tccgacacgg acaccgggga ctgctgacta tgcaactaaa 1081 gtcacccatg ccctccagca ccacccagaa agactcgtac cagccaccag gaaacgtcta 1141 ttggccactt cgagggaagc gtgaagccat gctggagatg ctcctgcagc atcagatctg 1201 taaagaggtg caggcagaac aggaacccac aaggaagctc ttcgaggttg agtctgtgac 1261 acaccatgac taccgaatgg agctggcaca agcagggact cctgccccaa caaagcctca 1321 cgactaccgc caggagcaac ctgagacctt ctggatacag agggcaccac agctgccgac 1381 atggtggcca ttgcccaccc aggtaccagc agcagaagac tatctgactt ggaaagaatg 1441 ggggtttaca ggagtccagg aggtcctttc cgctctccta agagccacac ctggtgaata 1501 ctcagtaaac atttgcggaa tgaatgaaca ccctgtctgc agcaggacat ggacaaatag 1561 gctctgccat caggaaatgg gaagcaagaa aacggtaact caagaggaca gaggctggtg 1621 aggaggtaaa gcaggcccag tgaaatggac ctgacagccc aaactgtcag agaggaggaa 1681 agcaggcatt tgattttggt aattg tgcca aagctatgta agagaataaa tgccattgtt 1741 ttaaggaaat acacagtgaa gtttttagga aatacacact aagtatttag ggataaagta 1801 gttatcccta aatagtagtc tgccacatgc caaacaatgt taggtacttt ccatacaacg 1861 aatctattat tcccatctta cagataaaac aactgaggct cagggagatt ctgtgactta 1921 cctaaggcca cacagttagc aacaagccaa tattcaaatc cagatgattt ttactcccaa 1981 ggacaataaa tccaactcaa taacttcaaa
<210> 22 (SPAG17 NM_206996.2) <210> 22 (SPAG17 NM_206996.2)
<211> 7125  <211> 7125
<212> DNA  <212> DNA
<213> Homo Sapiens  <213> Homo Sapiens
<400> 22 <400> 22
1 gtggtagcgg ggacgcttag gcagggcctg cgcccagttt agaggccaat gcttctcccg 61 tcctttgcat ggcacccaag aaggagaaag gaggaactgt gaacaccagt tctaagatat 121 gggaaccctc gctcatagct gcacagttca atcagaacga ttggcaggcc tccattgctt 181 ttgtggttgg gaaccagatt gaagatgatc ttctcatcca agcccttacc gtggctgtcc 241 aggtccctca gcgtaaactc ttcagtatgg tgtcgtggca agacattctc cagcagatta 301 atgaaataaa tacacttgtt ggatctgctt catctaaaaa ggcaaaaaaa cctgtaggtg 361 gtaatgctcc tttatattat gaggtgttaa cggcagcaaa agcaattatg gatagtggag 421 agaaattaac cttaccactg atagggaaac tcttgaaatt tcaacttctc cagattaaat 481 ttaaggacca acagcgacgg gaaaatgaaa agaaggtaat agaagacaaa cctaagttag 541 aaaaggataa agggaaagca aaatctccca aggagaaaaa ggctccaagt gccaagcctg 601 ccaaaggaaa gggaaaggat cagcctgagg caaatgcacc agtgaaaaag accacccagt 661 taaagcggag aggagaagac gaccacacca atcgttacat tgacgatgag ccagatgatg 721 gtgcccaaca ttacattata gttgtgggct ttaacaatcc tcagctatta gcaattatgg 781 ctgagcttgg cattcctata accagcgtga ttaaaatatc ttcagagaat tatgaacctc 841 tgcagacaca cctggcagca gttaaccagc agcaggaagt tcttcttcag tcagaagatc 901 tagaagcaga aaaattgaag aaagaaaatg ccataaaaga gcttaaaact ttctggaagt 961 acttggaacc agtcctgaat aatgagaaac ctgaaacaaa tctctttgat gttgctcgac 1021 ttgagtacat ggtcaaagca gctgattttc cttctgactg gtcagatggt gagatgatgc 1081 tgaaattggg cactgatatt tttgaaaata ttgcctgctt gatgtatgac atcctggatt 1141 ggaaaaggca gcaccagcac tatttggaaa gcatgcagct tattaatgtt ccacaagtgg 1201 ttaatgagaa acctgtatta gaagccatgc caacttcaga ggctccacaa cctgctgtac 1261 cagctcctgg aaagaagaaa gcacagtatg aagaaccgca agctccacca ccagtgactt 1321 cagtcatcac aactgaagta gacatgagat attacaatta tttgctgaat ccaattcgag 1381 aggaattcat ttctgtgccc ctgatactgc attgtatgct ggaacaggtt gttgcaactg 1441 aagaagatct cgtcccaccc agtctgcggg agccatcccc cagagcagac gggctagacc 1501 acagaatcgc agctcacatt gtgtcccttc tgccctcact ctgtctctca gagagggaga 1561 aaaagaatct tcatgacata tttttatctg aagaagaaaa tgaaagcaaa gcagtgccca 1621 aaggccccct cctactgaac tatcatgatg cacacgccca caagaagtac gcactacagg 1681 accaaaagaa ttttgatcca gttcaaattg agcaggagat gcagtccaag ttgccactgt 1741 gggaatttct tcaattccct ctacccccac catggaacaa cactaaacgt ctagctacaa 1801 ttcatgagct tatgcacttt tgtacgagtg atgtcttgag ctggaatgaa gtagaacgag 1861 ccttcaaggt gtttactttt gagagcctga agctctctga ggttgatgaa aaagggaaac 1921 tgaaaccttc tgggatgatg tgtgggtcag attctgaaat gttcaacata ccgtgggaca 1981 accctgccag atttgctaaa cagataaggc agcaatatgt catgaaaatg aatactcaag 2041 aggccaagca gaaagcagat attaaaatca aagacagaac actatttgtg gatcagaatt 2101 tgtcaatgtc tgtgcaagat aatgaaagca accgagaacc ttcagatcct agtcagtgtg 2161 atgctaacaa tatgaagcat tctgacttga ataatctcaa actctcagtc cctgataata 2221 gacagctgtt agagcaggag agcatcatga aggctcagcc ccaacatgag tctctggagc 2281 agaccacaaa caatgagatc aaagatgatg cagtcacaaa ggctgattct catgaaaaga 2341 aacccaagaa gatgatggtg gaagcagatt tagaggacat aaagaaaaca cagcagcgca 2401 gtctaatgga ctggagtttt actgaacatt ttaaaccgaa agtactgctt caggtccttc 2461 aagaagccca taagcaatat aggtgtgttg attcttacta ccacacccaa gacaactctt 2521 tacttttagt ctttcacaat ccaatgaata gacaacgttt gcattgtgaa tattggaaca 2581 ttgctctcca ctccaatgtt ggattcagga attatttgga acttgttgca aaatctattc 2641 aagattggat tacaaaagaa gaagctatat atcaggaatc taaaatgaat gagaaaatca 2701 tcaggaccag agctgagctg gaattgaaat cttctgctaa tgccaaactt acttctgcta 2761 gcaaaatttt ttccattaaa gaatctaaaa gtaacaaagg aatcagcaaa acagagatat 2821 cagatcaaga aaaagaaaaa gagaaggaaa agattccttt cattttagaa ggctctctca 2881 aggcatggaa agaagagcaa catcgattag cagaagagga gcgcttaagg gaagaaaaga 2941 aagcagagaa gaagggtaaa gaagctggta aaaagaaagg caaggataac gcagagaaag 3001 aggatagtag gtctttgaag aaaaaatcac cttacaagga gaaatctaaa gaagaacaag 3061 tcaagatcca agaagtaaca gaagagtccc cccaccaacc agaacctaag ataacttacc 3121 cgtttcacgg atacaatatg ggaaatatac ccactcaaat ctcagggtca aattactacc 3181 tgtatccttc tgatgggggg cagattgaag tggaaaagac aatgtttgaa aaaggcccaa 3241 cttttatcaa agtgagagtg gtaaaggaca accacaattt tatgattcat ttaaatgacc 3301 ctaaggaaat tgtgaaaaag gaagagaaag gggattatta tttagaagag gaagaagaag 3361 gagatgagga acaaagtctt gaaacggaag tatcagatgc aaagaataaa gctttcagca 3421 agtttggatc tttttctgcc accttagaaa atggaatctg cctctcgata agttactatg 3481 gatcaaatgg aatggcacca gaagataagg atcctgattt agaaacaata ttgaatatcc 3541 cttcagcact cactccaaca gtggttcctg ttatagtgac cgttcctcaa agcaaagcta 3601 aagggaaaat aaaaggcaaa gaaaaaccca aagaatccct taaagaagaa gaacacccaa 3661 aagaagaaga gaaaaaggaa gaagaagtag aaccagaacc tgttttacaa gagactttgg 3721 atgttcccac cttccagagc ctaaatgtgt cttgccccag tgggctcctg ttgactttca 3781 ttggacaaga atctacaggt caatatgtta tagatgagga acccacctgg gacatcatgg 3841 tccgtcagag ctacccccag agggtgaagc actatgagtt ctataaaacg gtgatgccac 3901 ccgcagagca ggaggcttca agggttatca ccagtcaagg cactgttgtc aaatatatgt 3961 tggatggatc cacacagatt ctctttgcag atggtgctgt gagcaggagt cccaattcag 4021 gtcttatttg tcctccttct gaaatgccag caacgcctca cagtggagat ttgatggact 4081 ctatttctca gcagaaatca gaaacgatac catctgagat taccaacaca aagaaaggaa 4141 aaagtcacaa aagtcagtca tcaatggccc ataagggtga aatccatgac cctcctccag 4201 aggcagttca aactgtaact cctgtggagg ttcacatagg cacctggttt acaaccacac 4261 ctgaaggaaa tcggatcggc accaaaggat tagaaagaat agcagacttg accccattgt 4321 tatcctttca ggccacagat cctgtcaatg gaacggttat gacaactcga gaagacaaag 4381 ttgtcatagt tgaaaggaaa gatggtactc ggatagtgga tcatgctgat ggtaccagaa1 gtggtagcgg ggacgcttag gcagggcctg cgcccagttt agaggccaat gcttctcccg 61 tcctttgcat ggcacccaag aaggagaaag gaggaactgt gaacaccagt tctaagatat 121 gggaaccctc gctcatagct gcacagttca atcagaacga ttggcaggcc tccattgctt 181 ttgtggttgg gaaccagatt gaagatgatc ttctcatcca agcccttacc gtggctgtcc 241 aggtccctca gcgtaaactc ttcagtatgg tgtcgtggca agacattctc cagcagatta 301 atgaaataaa tacacttgtt ggatctgctt catctaaaaa ggcaaaaaaa cctgtaggtg 361 gtaatgctcc tttatattat gaggtgttaa cggcagcaaa agcaattatg gatagtggag 421 agaaattaac cttaccactg atagggaaac tcttgaaatt tcaacttctc cagattaaat 481 ttaaggacca acagcgacgg gaaaatgaaa agaaggtaat agaagacaaa cctaagttag 541 aaaaggataa agggaaagca aaatctccca aggagaaaaa ggctccaagt gccaagcctg 601 ccaaaggaaa gggaaaggat cagcctgagg caaatgcacc agtgaaaaag accacccagt 661 taaagcggag aggagaagac gaccacacca atcgttacat tgacgatgag ccagatgatg 721 gtgcccaaca ttacattata gttgtgggct ttaacaatcc tcagctatta gcaattatgg 781 ctgagcttgg cattcctata accagcgtga ttaaaatatc ttcagagaat tatgaacctc 841 tgcagacaca cctggcagca gttaaccagc agcaggaagt tcttcttcag tcagaagatc 901 tagaagcaga aaaattgaag aaagaaaatg ccataaaaga gcttaaaact ttctggaagt 961 acttggaacc agtcctgaat aatgagaaac ctgaaacaaa tctctttgat gttgctcgac 1021 ttgagtacat ggtcaaagca gctgattttc cttctgactg gtcagatggt gagatgatgc 1081 tgaaattggg cactgatatt tttgaaaata ttgcctgctt gatgtatgac atcctggatt 1141 ggaaaaggca gcaccagcac tatttggaaa gcatgcagct tattaatgtt ccacaagtgg 1201 ttaatgagaa acctgtatta gaagccatgc caacttcaga ggctccacaa cctgctgtac 1261 cagctcctgg aaagaagaaa gcacagtatg aagaaccgca agctccacca ccagtgactt 1321 cagtcatcac aactgaagta gacatgagat attacaatta tttgctgaat ccaattcgag 1381 aggaattcat ttctgtgccc ctgatactgc attgtatgct ggaacaggtt gttgcaactg 1441 aagaagatct cgtcccaccc agtctgcggg agccatcccc cagagcagac gggctagacc 1501 acagaatcgc agctcacatt gtgtcccttc tgccctcact ctgtctctca gagagggaga 1561 aaaaga ATCT tcatgacata tttttatctg aagaagaaaa tgaaagcaaa gcagtgccca 1621 aaggccccct cctactgaac tatcatgatg cacacgccca caagaagtac gcactacagg 1681 accaaaagaa ttttgatcca gttcaaattg agcaggagat gcagtccaag ttgccactgt 1741 gggaatttct tcaattccct ctacccccac catggaacaa cactaaacgt ctagctacaa 1801 ttcatgagct tatgcacttt tgtacgagtg atgtcttgag ctggaatgaa gtagaacgag 1861 ccttcaaggt gtttactttt gagagcctga agctctctga ggttgatgaa aaagggaaac 1921 tgaaaccttc tgggatgatg tgtgggtcag attctgaaat gttcaacata ccgtgggaca 1981 accctgccag atttgctaaa cagataaggc agcaatatgt catgaaaatg aatactcaag 2041 aggccaagca gaaagcagat attaaaatca aagacagaac actatttgtg gatcagaatt 2101 tgtcaatgtc tgtgcaagat aatgaaagca accgagaacc ttcagatcct agtcagtgtg 2161 atgctaacaa tatgaagcat tctgacttga ataatctcaa actctcagtc cctgataata 2221 gacagctgtt agagcaggag agcatcatga aggctcagcc ccaacatgag tctctggagc 2281 agaccacaaa caatgagatc aaagatgatg cagtcacaaa ggctgattct catgaaaaga 2341 aacccaagaa gatgatggtg gaagcagatt tagaggacat aaagaaaaca cagcagcgca 2401 gtctaatgga c tggagtttt actgaacatt ttaaaccgaa agtactgctt caggtccttc 2461 aagaagccca taagcaatat aggtgtgttg attcttacta ccacacccaa gacaactctt 2521 tacttttagt ctttcacaat ccaatgaata gacaacgttt gcattgtgaa tattggaaca 2581 ttgctctcca ctccaatgtt ggattcagga attatttgga acttgttgca aaatctattc 2641 aagattggat tacaaaagaa gaagctatat atcaggaatc taaaatgaat gagaaaatca 2701 tcaggaccag agctgagctg gaattgaaat cttctgctaa tgccaaactt acttctgcta 2761 gcaaaatttt ttccattaaa gaatctaaaa gtaacaaagg aatcagcaaa acagagatat 2821 cagatcaaga aaaagaaaaa gagaaggaaa agattccttt cattttagaa ggctctctca 2881 aggcatggaa agaagagcaa catcgattag cagaagagga gcgcttaagg gaagaaaaga 2941 aagcagagaa gaagggtaaa gaagctggta aaaagaaagg caaggataac gcagagaaag 3001 aggatagtag gtctttgaag aaaaaatcac cttacaagga gaaatctaaa gaagaacaag 3061 tcaagatcca agaagtaaca gaagagtccc cccaccaacc agaacctaag ataacttacc 3121 cgtttcacgg atacaatatg ggaaatatac ccactcaaat ctcagggtca aattactacc 3181 tgtatccttc tgatgggggg cagattgaag tggaaaagac aatgtttgaa aaaggcccaa 3241 cttttatcaa agtgaga gtg gtaaaggaca accacaattt tatgattcat ttaaatgacc 3301 ctaaggaaat tgtgaaaaag gaagagaaag gggattatta tttagaagag gaagaagaag 3361 gagatgagga acaaagtctt gaaacggaag tatcagatgc aaagaataaa gctttcagca 3421 agtttggatc tttttctgcc accttagaaa atggaatctg cctctcgata agttactatg 3481 gatcaaatgg aatggcacca gaagataagg atcctgattt agaaacaata ttgaatatcc 3541 cttcagcact cactccaaca gtggttcctg ttatagtgac cgttcctcaa agcaaagcta 3601 aagggaaaat aaaaggcaaa gaaaaaccca aagaatccct taaagaagaa gaacacccaa 3661 aagaagaaga gaaaaaggaa gaagaagtag aaccagaacc tgttttacaa gagactttgg 3721 atgttcccac cttccagagc ctaaatgtgt cttgccccag tgggctcctg ttgactttca 3781 ttggacaaga atctacaggt caatatgtta tagatgagga acccacctgg gacatcatgg 3841 tccgtcagag ctacccccag agggtgaagc actatgagtt ctataaaacg gtgatgccac 3901 ccgcagagca ggaggcttca agggttatca ccagtcaagg cactgttgtc aaatatatgt 3961 tggatggatc cacacagatt ctctttgcag atggtgctgt gagcaggagt cccaattcag 4021 gtcttatttg tcctccttct gaaatgccag caacgcctca cagtggagat ttgatggact 4081 ctatttctca gcagaaatca ga aacgatac catctgagat taccaacaca aagaaaggaa 4141 aaagtcacaa aagtcagtca tcaatggccc ataagggtga aatccatgac cctcctccag 4201 aggcagttca aactgtaact cctgtggagg ttcacatagg cacctggttt acaaccacac 4261 ctgaaggaaa tcggatcggc accaaaggat tagaaagaat agcagacttg accccattgt 4321 tatcctttca ggccacagat cctgtcaatg gaacggttat gacaactcga gaagacaaag 4381 ttgtcatagt tgaaaggaaa gatggtactc ggatagtgga tcatgctgat ggtaccagaa
4441 tcacaacctt ttatcaagtt tatgaagatc aaattattct gccagatgat caagaaacaa4441 tcacaacctt ttatcaagtt tatgaagatc aaattattct gccagatgat caagaaacaa
4501 ccgagggtcc tcggactgtc accaggcagg tgaagtgtat gcgggtagaa agctcacgct4501 ccgagggtcc tcggactgtc accaggcagg tgaagtgtat gcgggtagaa agctcacgct
4561 atgccactgt tatcgccaac tgtgaggaca gtagctgctg tgccaccttt ggagatggaa4561 atgccactgt tatcgccaac tgtgaggaca gtagctgctg tgccaccttt ggagatggaa
4621 caactattat tgcaaagcca cagggaacat accaggtgtt acctccaaac acaggctctc 4681 tttatattga caaggattgt tcagctgtgt actgccatga gtcaagcagt aatatatact4621 caactattat tgcaaagcca cagggaacat accaggtgtt acctccaaac acaggctctc 4681 tttatattga caaggattgt tcagctgtgt actgccatga gtcaagcagt aatatatact
4741 atccttttca aaagcgtgag cagctgcgag ctggcaggta catcatgagg catacttcag4741 atccttttca aaagcgtgag cagctgcgag ctggcaggta catcatgagg catacttcag
4801 aggttatctg tgaggttctg gatcctgagg gaaacacttt tcaggtcatg gctgatggta4801 aggttatctg tgaggttctg gatcctgagg gaaacacttt tcaggtcatg gctgatggta
4861 gcatatcaac tatattacct gaaaaaaaat tggaagatga tttaaatgag aaaactgagg4861 gcatatcaac tatattacct gaaaaaaaat tggaagatga tttaaatgag aaaactgagg
4921 gctatgatag tctgtcctct atgcaccttg aaaagaatca tcagcaaatc tatggtgaac 4981 atgtccccag gttttttgtt atgtatgctg atggatcagg aatggaactt cttcgagaca4921 gctatgatag tctgtcctct atgcaccttg aaaagaatca tcagcaaatc tatggtgaac 4981 atgtccccag gttttttgtt atgtatgctg atggatcagg aatggaactt cttcgagaca
5041 gtgacataga agaatatcta tctttggcat ataaagaatc aaatactgtt gttctccaag5041 gtgacataga agaatatcta tctttggcat ataaagaatc aaatactgtt gctctccaag
5101 agccagtgca ggaacagcca ggcaccctaa ccatcacagt ccttcgccct ttccatgaag5101 agccagtgca ggaacagcca ggcaccctaa ccatcacagt ccttcgccct ttccatgaag
5161 catcaccatg gcaagtaaaa aaggaagata caattgtccc tcctaatctc cggtcaaggt5161 catcaccatg gcaagtaaaa aaggaagata caattgtccc tcctaatctc cggtcaaggt
5221 catgggaaac atttccctca gttgagaaaa aaactccagg acctccgttt ggtactcaga 5281 tttggaaagg cctttgcatt gagtccaaac agctagtgag tgccccgggt gccatactca5221 catgggaaac atttccctca gttgagaaaa aaactccagg acctccgttt ggtactcaga 5281 tttggaaagg cctttgcatt gagtccaaac agctagtgag tgccccgggt gccatactca
5341 agagccccag tgtgctacag atgcgccaat tcattcagca tgaggtcata aagaatgagg5341 agagccccag tgtgctacag atgcgccaat tcattcagca tgaggtcata aagaatgagg
5401 tgaaactgag gctgcaggtt tcccttaagg attacataaa ctatattcta aagaaagaag5401 tgaaactgag gctgcaggtt tcccttaagg attacataaa ctatattcta aagaaagaag
5461 atgagctgca ggaaatgatg gttaaagatt ccagaactga ggaggagaga ggcaatgctg5461 atgagctgca ggaaatgatg gttaaagatt ccagaactga ggaggagaga ggcaatgctg
5521 ctgatctcct caagctggtt atgtctttcc ctaaaatgga ggaaactaca aaaagtcatg 5581 ttactgaagt tgcagctcac ctaactgatt tattcaagca gtctttggct acgcctccaa5521 ctgatctcct caagctggtt atgtctttcc ctaaaatgga ggaaactaca aaaagtcatg 5581 ttactgaagt tgcagctcac ctaactgatt tattcaagca gtctttggct acgctcta
5641 aatgcccacc agacacattt ggtaaagatt tctttgaaaa gacatggaga cacacagcat5641 aatgcccacc agacacattt ggtaaagatt tctttgaaaa gacatggaga cacacagcat
5701 cctcaaaacg ctggaaagaa aagatagaca aaacgaggaa ggaaattgag acaacacaga5701 cctcaaaacg ctggaaagaa aagatagaca aaacgaggaa ggaaattgag acaacacaga
5761 attacctaat ggatattaag aaccgcataa taccaccctt ttttaaatct gaattgaacc5761 attacctaat ggatattaag aaccgcataa taccaccctt ttttaaatct gaattgaacc
5821 agttatatca gtctcagtat aatcacctgg acagtctttc caaaaaactg ccttctttta 5881 caaagaaaaa tgaagatgca aacgaaacag ctgttcaaga tacatctgat cttaatctag5821 agttatatca gtctcagtat aatcacctgg acagtctttc caaaaaactg ccttctttta 5881 caaagaaaaa tgaagatgca aacgaaacag ctgttcaaga tacatctgat cttaatctag
5941 atttcaagcc acataaggtt tcagaacaga aatcctcaag tgtgcctagt cttccaaaac5941 atttcaagcc acataaggtt tcagaacaga aatcctcaag tgtgcctagt cttccaaaac
6001 cagagatttc tgcagataag aaggatttca ctgctcagaa ccaaactgaa aatttaacaa6001 cagagatttc tgcagataag aaggatttca ctgctcagaa ccaaactgaa aatttaacaa
6061 aatctcctga agaagcagaa tcttatgagc ccgtgaaaat tccaacccag tccttgctgc6061 actctcctga agaagcagaa tcttatgagc ccgtgaaaat tccaacccag tccttgctgc
6121 aggatgttgc gggacaaaca agaaaagaaa aagtgaagtt gcctcattat ttgctgagtt 6181 ccaagcctaa gtctcaacct cttgcaaagg tgcaagattc tgttggagga aaagtgaaca6121 aggatgttgc gggacaaaca agaaaagaaa aagtgaagtt cctcattat ttgctgagtt 6181 ccaagcctaa gtctcaacct cttgcaaagg tgcaagattc tgttggagga aaagtgaaca
6241 catcctctgt tgcatctgct gccattaata atgcaaagtc atcccttttt gggttccatc6241 catcctctgt tgcatctgct gccattaata atgcaaagtc atcccttttt gggttccatc
6301 ttctcccatc atcagtcaag tttggagtgc ttaaggaagg acatacctat gccacagttg6301 ttctcccatc atcagtcaag tttggagtgc ttaaggaagg acatacctat gccacagttg
6361 taaagctcaa gaatgttgga gtggacttct gcaggtttaa agtaaagcag cccccaccca6361 taaagctcaa gaatgttgga gtggacttct gcaggtttaa agtaaagcag cccccaccca
6421 gcacaggact gaaagtgact tacaaacctg gacctgtggc agctggtatg cagacagaac 6481 tgaatataga gttatttgcc acagctgttg gagaggatgg ggccaaggga tcagcacaca6421 gcacaggact gaaagtgact tacaaacctg gacctgtggc agctggtatg cagacagaac 6481 tgaatataga gttatttgcc acagctgttg gagaggatgg ggccaaggga tcagcacaca
6541 tctctcacaa tatcgagatt atgacagagc atgaggttct gttcctacct gtggaagcaa6541 tctctcacaa tatcgagatt atgacagagc atgaggttct gttcctacct gtggaagcaa
6601 ctgttttaac aagcagcaat tatgataaac gaccaaaaga ctttccccag ggaaaagaaa6601 ctgttttaac aagcagcaat tatgataaac gaccaaaaga ctttccccag ggaaaagaaa
6661 atccaatggt ccagagaact tctacaattt attcctccac acttggagtc ttcatgtctc6661 atccaatggt ccagagaact tctacaattt attcctccac acttggagtc ttcatgtctc
6721 gtaaagtttc tccacattag tttcttctcg gtacaactca atagcctcca taatcctctc 6781 agcctacaga ggatgagaaa ggaaagaagt catcacaaca tactccatca tcccaggaca6721 gtaaagtttc tccacattag tttcttctcg gtacaactca atagcctcca taatcctctc 6781 agcctacaga ggatgagaaa ggaaagaagt catcacaaca tactccatca tcccaggaca
6841 ctgaaactgg aagaactgac cagaaatttg ccaaatgaaa tagcttcaat ctgtttaata6841 ctgaaactgg aagaactgac cagaaatttg ccaaatgaaa tagcttcaat ctgtttaata
6901 aagacgtgcg aatagagtgc caaaaagcat ttaaagacat ttttggtttt cttatttttt6901 aagacgtgcg aatagagtgc caaaaagcat ttaaagacat ttttggtttt cttatttttt
6961 aatgtacagg gaagagactg agtgtcatgg actcaggtgg gatgatatct agacactctg6961 aatgtacagg gaagagactg agtgtcatgg actcaggtgg gatgatatct agacactctg
7021 aatagggcag gtcccaggaa cacctgaaag gagcacatat tgatcaaaga gattcaggac 7081 tactcccatc tttggttaca agagaaggaa acaggttata atccc 7021 aatagggcag gtcccaggaa cacctgaaag gagcacatat tgatcaaaga gattcaggac 7081 tactcccatc tttggttaca agagaaggaa acaggttata atccc
<210> 23 <210> 23
<211 > 6911  <211> 6911
<212> DNA  <212> DNA
<213> Homo Sapiens  <213> Homo Sapiens
<400> 23  <400> 23
Dysferlin (DYSP) 1 tcgaccgccc agccaggtgc aaaatgccgt gtcattggga gactccgcag ccggagcattDysferlin (DYSP) 1 tcgaccgccc agccaggtgc aaaatgccgt gtcattggga gactccgcag ccggagcatt
61 agattacagc tcgacggagc tcgggaaggg cggcgggggt ggaagatgag cagaagcccc61 agattacagc tcgacggagc tcgggaaggg cggcgggggt ggaagatgag cagaagcccc
121 tgttctcgga acgccggctg acaagcgggg tgagcgcagg cggggcgggg acccagccta121 tgttctcgga acgccggctg acaagcgggg tgagcgcagg cggggcgggg acccagccta
181 gcccactgga gcagccgggg gtggcccgtt cccctttaag agcaactgct ctaagccagg181 gcccactgga gcagccgggg gtggcccgtt cccctttaag agcaactgct ctaagccagg
241 agccagagat tcgagccggc ctcgcccagc cagccctctc cagcgagggg acccacaagc 301 ggcgcctcgg ccctcccgac ctttccgagc cctctttgcg ccctgggcgc acggggccct241 agccagagat tcgagccggc ctcgcccgc cagccctctc cagcgagggg acccacaagc 301 ggcgcctcgg ccctcccgac ctttccgagc cctctttgcg ccctgggcgc acggggccct
361 acacgcgcca agcatgctga gggtcttcat cctctatgcc gagaacgtcc acacacccga361 acacgcgcca agcatgctga gggtcttcat cctctatgcc gagaacgtcc acacacccga
421 caccgacatc agcgatgcct actgctccgc ggtgtttgca ggggtgaaga agagaaccaa421 caccgacatc agcgatgcct actgctccgc ggtgtttgca ggggtgaaga agagaaccaa
481 agtcatcaag aacagcgtga accctgtatg gaatgaggga tttgaatggg acctcaaggg481 agtcatcaag aacagcgtga accctgtatg gaatgaggga tttgaatggg acctcaaggg
541 catccccctg gaccagggct ctgagcttca tgtggtggtc aaagaccatg agacgatggg 601 gaggaacagg ttcctggggg aagccaaggt cccactccga gaggtcctcg ccacccctag541 catccccctg gaccagggct ctgagcttca tgtggtggtc aaagaccatg agacgatggg 601 gaggaacagg ttcctggggg aagccaaggt cccactccga gaggtcctcg ccacccctag
661 tctgtccgcc agcttcaatg cccccctgct ggacaccaag aagcagccca caggggcctc661 tctgtccgcc agcttcaatg cccccctgct ggacaccaag aagcagccca caggggcctc
721 gctggtcctg caggtgtcct acacaccgct gcctggagct gtgcccctgt tcccgccccc721 gctggtcctg caggtgtcct acacaccgct gcctggagct gtgcccctgt tcccgccccc
781 tactcctctg gagccctccc cgactctgcc tgacctggat gtagtggcag acacaggagg781 tactcctctg gagccctccc cgactctgcc tgacctggat gtagtggcag acacaggagg
841 agaggaagac acagaggacc agggactcac tggagatgag gcggagccat tcctggatca 901 aagcggaggc ccgggggctc ccaccacccc aaggaaacta ccttcacgtc ctccgcccca841 agaggaagac acagaggacc agggactcac tggagatgag gcggagccat tcctggatca 901 aagcggaggc ccgggggctc ccaccacccc aaggaaacta ccttcacgtc ctccgcccca
961 ctaccccggg atcaaaagaa agcgaagtgc gcctacatct agaaagctgc tgtcagacaa961 ctaccccggg atcaaaagaa agcgaagtgc gcctacatct agaaagctgc tgtcagacaa
1021 accgcaggat ttccagatca gggtccaggt gatcgagggg cgccagctgc cgggggtgaa1021 accgcaggat ttccagatca gggtccaggt gatcgagggg cgccagctgc cgggggtgaa
1081 catcaagcct gtggtcaagg ttaccgctgc agggcagacc aagcggacgc ggatccacaa1081 catcaagcct gtggtcaagg ttaccgctgc agggcagacc aagcggacgc ggatccacaa
1141 gggaaacagc ccactcttca atgagactct tttcttcaac ttgtttgact ctcctgggga 1201 gctgtttgat gagcccatct ttatcacggt ggtagactct cgttctctca ggacagatgc1141 gggaaacagc ccactcttca atgagactct tttcttcaac ttgtttgact ctcctgggga 1201 gctgtttgat gagcccatct ttatcacggt ggtagactct cgttctctca ggacagatgc
1261 tctcctcggg gagttccgga tggacgtggg caccatttac agagagcccc ggcacgccta1261 tctcctcggg gagttccgga tggacgtggg caccatttac agagagcccc ggcacgccta
1321 tctcaggaag tggctgctgc tctcagaccc tgatgacttc tctgctgggg ccagaggcta1321 tctcaggaag tggctgctgc tctcagaccc tgatgacttc tctgctgggg ccagaggcta
1381 cctgaaaaca agcctttgtg tgctggggcc tggggacgaa gcgcctctgg agagaaaaga1381 cctgaaaaca agcctttgtg tgctggggcc tggggacgaa gcgcctctgg agagaaaaga
1441 cccctctgaa gacaaggagg acattgaaag caacctgctc cggcccacag gcgtagccct 1501 gcgaggagcc cacttctgcc tgaaggtctt ccgggccgag gacttgccgc agatggacga1441 cccctctgaa gacaaggagg acattgaaag caacctgctc cggcccacag gcgtagccct 1501 gcgaggagcc cacttctgcc tgaaggtctt ccgggccgag gacttgccgc agatggacga
1561 tgccgtgatg gacaacgtga aacagatctt tggcttcgag agtaacaaga agaacttggt1561 tgccgtgatg gacaacgtga aacagatctt tggcttcgag agtaacaaga agaacttggt
1621 ggaccccttt gtggaggtca gctttgcggg gaaaatgctg tgcagcaaga tcttggagaa1621 ggaccccttt gtggaggtca gctttgcggg gaaaatgctg tgcagcaaga tcttggagaa
1681 gacggccaac cctcagtgga accagaacat cacactgcct gccatgtttc cctccatgtg1681 gacggccaac cctcagtgga accagaacat cacactgcct gccatgtttc cctccatgtg
1741 cgaaaaaatg aggattcgta tcatagactg ggaccgcctg actcacaatg acatcgtggc 1801 taccacctac ctgagtatgt cgaaaatctc tgcccctgga ggagaaatag aagaggagcc1741 cgaaaaaatg aggattcgta tcatagactg ggaccgcctg actcacaatg acatcgtggc 1801 taccacctac ctgagtatgt cgaaaatctc tgcccctgga ggagaaatag aagaggagcc
1861 tgcaggtgct gtcaagcctt cgaaagcctc agacttggat gactacctgg gcttcctccc1861 tgcaggtgct gtcaagcctt cgaaagcctc agacttggat gactacctgg gcttcctccc
1921 cacttttggg ccctgctaca tcaacctcta tggcagtccc agagagttca caggcttccc1921 cacttttggg ccctgctaca tcaacctcta tggcagtccc agagagttca caggcttccc
1981 agacccctac acagagctca acacaggcaa gggggaaggt gtggcttatc gtggccggct1981 agacccctac acagagctca acacaggcaa gggggaaggt gtggcttatc gtggccggct
2041 tctgctctcc ctggagacca agctggtgga gcacagtgaa cagaaggtgg aggaccttcc 2101 tgcggatgac atcctccggg tggagaagta ccttaggagg cgcaagtact ccctgtttgc2041 tctgctctcc ctggagacca agctggtgga gcacagtgaa cagaaggtgg aggaccttcc 2101 tgcggatgac atcctccggg tggagaagta ccttaggagg cgcaagtact ccctgtttgc
2161 ggccttctac tcagccacca tgctgcagga tgtggatgat gccatccagt ttgaggtcag2161 ggccttctac tcagccacca tgctgcagga tgtggatgat gccatccagt ttgaggtcag
2221 catcgggaac tacgggaaca agttcgacat gacctgcctg ccgctggcct ccaccactca2221 catcgggaac tacgggaaca agttcgacat gacctgcctg ccgctggcct ccaccactca
2281 gtacagccgt gcagtctttg acgggtgcca ctactactac ctaccctggg gtaacgtgaa2281 gtacagccgt gcagtctttg acgggtgcca ctactactac ctaccctggg gtaacgtgaa
2341 acctgtggtg gtgctgtcat cctactggga ggacatcagc catagaatcg agactcagaa 2401 ccagctgctt gggattgctg accggctgga agctggcctg gagcaggtcc acctggccct2341 acctgtggtg gtgctgtcat cctactggga ggacatcagc catagaatcg agactcagaa 2401 ccagctgctt gggattgctg accggctgga agctggcctg gagcaggtcc acctggccct
2461 gaaggcgcag tgctccacgg aggacgtgga ctcgctggtg gctcagctga cggatgagct2461 gaaggcgcag tgctccacgg aggacgtgga ctcgctggtg gctcagctga cggatgagct
2521 catcgcaggc tgcagccagc ctctgggtga catccatgag acaccctctg ccacccacct2521 catcgcaggc tgcagccagc ctctgggtga catccatgag acaccctctg ccacccacct
2581 ggaccagtac ctgtaccagc tgcgcaccca tcacctgagc caaatcactg aggctgccct 2641 ggccctgaag ctcggccaca gtgagctccc tgcagctctg gagcaggcgg aggactggct2581 ggaccagtac ctgtaccagc tgcgcaccca tcacctgagc caaatcactg aggctgccct 2641 ggccctgaag ctcggccaca gtgagctccc tgcagctctg gagcaggcgg aggactggct
2701 cctgcgtctg cgtgccctgg cagaggagcc ccagaacagc ctgccggaca tcgtcatctg 2761 gatgctgcag ggagacaagc gtgtggcata ccagcgggtg cccgcccacc aagtcctctt 2821 ctcccggcgg ggtgccaact actgtggcaa gaattgtggg aagctacaga caatctttct 2881 gaaatatccg atggagaagg tgcctggcgc ccggatgcca gtgcagatac gggtcaagct 2941 gtggtttggg ctctctgtgg atgagaagga gttcaaccag tttgctgagg ggaagctgtc2701 cctgcgtctg cgtgccctgg cagaggagcc ccagaacagc ctgccggaca tcgtcatctg 2761 gatgctgcag ggagacaagc gtgtggcata ccagcgggtg cccgcccacc aagtcctctt 2821 ctcccggcgg ggtgccaact actgtggcaa gaattgtggg aagctacaga caatctttct 2881 gaaatatccg atggagaagg tgcctggcgc ccggatgcca gtgcagatac gggtcaagct 2941 gtggtttggg ctctctgtgg atgagaagga gttcaaccag tttgctgagg ggaagctgtc
3001 tgtctttgct gaaacctatg agaacgagac taagttggcc cttgttggga actggggcac 3061 aacgggcctc acctacccca agttttctga cgtcacgggc aagatcaagc tacccaagga 3121 cagcttccgc ccctcggccg gctggacctg ggctggagat tggttcgtgt gtccggagaa 3181 gactctgctc catgacatgg acgccggtca cctgagcttc gtggaagagg tgtttgagaa 3241 ccagacccgg cttcccggag gccagtggat ctacatgagt gacaactaca ccgatgtgaa3001 tgtctttgct gaaacctatg agaacgagac taagttggcc cttgttggga actggggcac 3061 aacgggcctc acctacccca agttttctga cgtcacgggc aagatcaagc tacccaagga 3121 cagcttccgc ccctcggccg gctggacctg ggctggagat tggttcgtgt gtccggagaa 3181 gactctgctc catgacatgg acgccggtca cctgagcttc gtggaagagg tgtttgagaa 3241 ccagacccgg cttcccggag gccagtggat ctacatgagt gacaactaca ccgatgtgaa
3301 cggggagaag gtgcttccca aggatgacat tgagtgccca ctgggctgga agtgggaaga 3361 tgaggaatgg tccacagacc tcaaccgggc tgtcgatgag caaggctggg agtatagcat 3421 caccatcccc ccggagcgga agccgaagca ctgggtccct gctgagaaga tgtactacac 3481 acaccgacgg cggcgctggg tgcgcctgcg caggagggat ctcagccaaa tggaagcact 3541 gaaaaggcac aggcaggcgg aggcggaggg cgagggctgg gagtacgcct ctctttttgg3301 cggggagaag gtgcttccca aggatgacat tgagtgccca ctgggctgga agtgggaaga 3361 tgaggaatgg tccacagacc tcaaccgggc tgtcgatgag caaggctggg agtatagcat 3421 caccatcccc ccggagcgga agccgaagca ctgggtccct gctgagaaga tgtactacac 3481 acaccgacgg cggcgctggg tgcgcctgcg caggagggat ctcagccaaa tggaagcact 3541 gaaaaggcac aggcaggcgg aggcggaggg cgagggctgg gagtacgcct ctctttttgg
3601 ctggaagttc cacctcgagt accgcaagac agatgccttc cgccgccgcc gctggcgccg 3661 tcgcatggag ccactggaga agacggggcc tgcagctgtg tttgcccttg agggggccct 3721 gggcggcgtg atggatgaca agagtgaaga ttccatgtcc gtctccacct tgagcttcgg 3781 tgtgaacaga cccacgattt cctgcatatt cgactatggg aaccgctacc atctacgctg 3841 ctacatgtac caggcccggg acctggctgc gatggacaag gactcttttt ctgatcccta3601 ctggaagttc cacctcgagt accgcaagac agatgccttc cgccgccgcc gctggcgccg 3661 tcgcatggag ccactggaga agacggggcc tgcagctgtg tttgcccttg agggggccct 3721 gggcggcgtg atggatgaca agagtgaaga ttccatgtcc gtctccacct tgagcttcgg 3781 tgtgaacaga cccacgattt cctgcatatt cgactatggg aaccgctacc atctacgctg 3841 ctacatgtac caggcccggg acctggctgc gatggacaag gactcttttt ctgatcccta
3901 tgccatcgtc tccttcctgc accagagcca gaagacggtg gtggtgaaga acacccttaa3901 tgccatcgtc tccttcctgc accagagcca gaagacggtg gtggtgaaga acacccttaa
3961 ccccacctgg gaccagacgc tcatcttcta cgagatcgag atctttggcg agccggccac3961 ccccacctgg gaccagacgc tcatcttcta cgagatcgag atctttggcg agccggccac
4021 agttgctgag caaccgccca gcattgtggt ggagctgtac gaccatgaca cttatggtgc 4081 agacgagttt atgggtcgct gcatctgtca accgagtctg gaacggatgc cacggctggc 4141 ctggttccca ctgacgaggg gcagccagcc gtcgggggag ctgctggcct cttttgagct4021 agttgctgag caaccgccca gcattgtggt ggagctgtac gaccatgaca cttatggtgc 4081 agacgagttt atgggtcgct gcatctgtca accgagtctg gaacggatgc cacggctggc 4141 ctggttccca ctgacgaggg gcagccagcc gtcgggggg ctgctggcct cttttgagct
4201 catccagaga gagaagccgg ccatccacca tattcctggt tttgaggtgc aggagacatc 4261 aaggatcctg gatgagtctg aggacacaga cctgccctac ccaccacccc agagggaggc 4321 caacatctac atggttcctc agaacatcaa gccagcgctc cagcgtaccg ccatcgagat 4381 cctggcatgg ggcctgcgga acatgaagag ttaccagctg gccaacatct cctcccccag 4441 cctcgtggta gagtgtgggg gccagacggt gcagtcctgt gtcatcagga acctccggaa4201 catccagaga gagaagccgg ccatccacca tattcctggt tttgaggtgc aggagacatc 4261 aaggatcctg gatgagtctg aggacacaga cctgccctac ccaccacccc agagggaggc 4321 caacatctac atggttcctc agaacatcaa gccagcgctc cagcgtaccg ccatcgagat 4381 cctggcatgg ggcctgcgga acatgaagag ttaccagctg gccaacatct cctcccccag 4441 cctcgtggta gagtgtgggg gccagacggt gcagtcctgt gtcatcagga acctccggaa
4501 gaaccccaac tttgacatct gcaccctctt catggaagtg atgctgccca gggaggagct 4561 ctactgcccc cccatcaccg tcaaggtcat cgataaccgc cagtttggcc gccggcctgt 4621 ggtgggccag tgtaccatcc gctccctgga gagcttcctg tgtgacccct actcggcgga 4681 gagtccatcc ccacagggtg gcccagacga tgtgagccta ctcagtcctg gggaagacgt 4741 gctcatcgac attgatgaca aggagcccct catccccatc caggaggaag agttcatcga4501 gaaccccaac tttgacatct gcaccctctt catggaagtg atgctgccca gggaggagct 4561 ctactgcccc cccatcaccg tcaaggtcat cgataaccgc cagtttggcc gccggcctgt 4621 ggtgggccag tgtaccatcc gctccctgga gagcttcctg tgtgacccct actcggcgga 4681 gagtccatcc ccacagggtg gcccagacga tgtgagccta ctcagtcctg gggaagacgt 4741 gctcatcgac attgatgaca aggagcccct catccccatc caggaggaag agttcatcga
4801 ttggtggagc aaattctttg cctccatagg ggagagggaa aagtgcggct cctacctgga 4861 gaaggatttt gacaccctga aggtctatga cacacagctg gagaatgtgg aggcctttga 4921 gggcctgtct gacttttgta acaccttcaa gctgtaccgg ggcaagacgc aggaggagac 4981 agaagatcca tctgtgattg gtgaatttaa gggcctcttc aaaatttatc ccctcccaga 5041 agacccagcc atccccatgc ccccaagaca gttccaccag ctggccgccc agggacccca4801 ttggtggagc aaattctttg cctccatagg ggagagggaa aagtgcggct cctacctgga 4861 gaaggatttt gacaccctga aggtctatga cacacagctg gagaatgtgg aggcctttga 4921 gggcctgtct gacttttgta acaccttcaa gctgtaccgg ggcaagacgc aggaggagac 4981 agaagatcca tctgtgattg gtgaatttaa gggcctcttc aaaatttatc ccctcccaga 5041 agacccagcc atccccatgc ccccaagaca gttccaccag ctggccgccc agggacccca
5101 ggagtgcttg gtccgtatct acattgtccg agcatttggc ctgcagccca aggaccccaa 5161 tggaaagtgt gatccttaca tcaagatctc catagggaag aaatcagtga gtgaccagga 5221 taactacatc ccctgcacgc tggagcccgt atttggaaag atgttcgagc tgacctgcac 5281 tctgcctctg gagaaggacc taaagatcac tctctatgac tatgacctcc tctccaagga5101 ctgcagccca aggaccccaa 5151 tggaaagtgt gatccttaca tcaagatctc catagggaag aaatcagtga gtgaccagga 5221 taactacatc ccctgcacgc tggagcccgt atttggaaag atgttcgagc tgacctgcac 5281 tctgcctctg gagaaggacc taaagatcac tctctatgac tatgacctcc tctccaagga
5341 cgaaaagatc ggtgagacgg tcgtcgacct ggagaacagg ctgctgtcca agtttggggc5341 cgaaaagatc ggtgagacgg tcgtcgacct ggagaacagg ctgctgtcca agtttggggc
5401 tcgctgtgga ctcccacaga cctactgtgt ctctggaccg aaccagtggc gggaccagct5401 tcgctgtgga ctcccacaga cctactgtgt ctctggaccg aaccagtggc gggaccagct
5461 ccgcccctcc cagctcctcc acctcttctg ccagcagcat agagtcaagg cacctgtgta5461 ccgcccctcc cagctcctcc acctcttctg ccagcagcat agagtcaagg cacctgtgta
5521 ccggacagac cgtgtaatgt ttcaggataa agaatattcc attgaagaga tagaggctgg 5581 caggatccca aacccacacc tgggcccagt ggaggagcgt ctggctctgc atgtgcttca5521 ccggacagac cgtgtaatgt ttcaggataa agaatattcc attgaagaga tagaggctgg 5581 caggatccca aacccacacc tgggcccagt ggaggagcgt ctggctctgc atgtgcttca
5641 gcagcagggc ctggtcccgg agcacgtgga gtcacggccc ctctacagcc ccctgcagcc5641 gcagcagggc ctggtcccgg agcacgtgga gtcacggccc ctctacagcc ccctgcagcc
5701 agacatcgag caggggaagc tgcagatgtg ggtcgaccta tttccgaagg ccctggggcg5701 agacatcgag caggggaagc tgcagatgtg ggtcgaccta tttccgaagg ccctggggcg
5761 gcctggacct cccttcaaca tcaccccacg gagagccaga aggtttttcc tgcgttgtat5761 gcctggacct cccttcaaca tcaccccacg gagagccaga aggtttttcc tgcgttgtat
5821 tatctggaat accagagatg tgatcctgga tgacctgagc ctcacggggg agaagatgag 5881 cgacatttat gtgaaaggtt ggatgattgg ctttgaagaa cacaagcaaa agacagacgt5821 tatctggaat accagagatg tgatcctgga tgacctgagc ctcacggggg agaagatgag 5881 cgacatttat gtgaaaggtt ggatgattgg ctttgaagaa cacaagcaaa agacagacgt
5941 gcattatcgt tccctgggag gtgaaggcaa cttcaactgg aggttcattt tccccttcga5941 gcattatcgt tccctgggag gtgaaggcaa cttcaactgg aggttcattt tccccttcga
6001 ctacctgcca gctgagcaag tctgtaccat tgccaagaag gatgccttct ggaggctgga6001 ctacctgcca gctgagcaag tctgtaccat tgccaagaag gatgccttct ggaggctgga
6061 caagactgag agcaaaatcc cagcacgagt ggtgttccag atctgggaca atgacaagtt6061 caagactgag agcaaaatcc cagcacgagt ggtgttccag atctgggaca atgacaagtt
6121 ctcctttgat gattttctgg gctccctgca gctcgatctc aaccgcatgc ccaagccagc 6181 caagacagcc aagaagtgct ccttggacca gctggatgat gctttccacc cagaatggtt6121 ctcctttgat gattttctgg gctccctgca gctcgatctc aaccgcatgc ccaagccagc 6181 caagacagcc aagaagtgct ccttggacca gctggatgat gctttccacc cagaatggtt
6241 tgtgtccctt tttgagcaga aaacagtgaa gggctggtgg ccctgtgtag cagaagaggg6241 tgtgtccctt tttgagcaga aaacagtgaa gggctggtgg ccctgtgtag cagaagaggg
6301 tgagaagaaa atactggcgg gcaagctgga aatgaccttg gagattgtag cagagagtga6301 tgagaagaaa atactggcgg gcaagctgga aatgaccttg gagattgtag cagagagtga
6361 gcatgaggag cggcctgctg gccagggccg ggatgagccc aacatgaacc ctaagcttga6361 gcatgaggag cggcctgctg gccagggccg ggatgagccc aacatgaacc ctaagcttga
6421 ggacccaagg cgccccgaca cctccttcct gtggtttacc tccccataca agaccatgaa 6481 gttcatcctg tggcggcgtt tccggtgggc catcatcctc ttcatcatcc tcttcatcct6421 ggacccaagg cgccccgaca cctccttcct gtggtttacc tccccataca agaccatgaa 6481 gttcatcctg tggcggcgtt tccggtgggc catcatcctc ttcatcatcc tcttcatcct
6541 gctgctgttc ctggccatct tcatctacgc cttcccgaac tatgctgcca tgaagctggt6541 gctgctgttc ctggccatct tcatctacgc cttcccgaac tatgctgcca tgaagctggt
6601 gaagcccttc agctgaggac tctcctgccc tgtagaaggg gccgtggggt cccctccagc6601 gaagcccttc agctgaggac tctcctgccc tgtagaaggg gccgtggggt cccctccagc
6661 atgggactgg cctgcctcct ccgcccagct cggcgagctc ctccagacct cctaggcctg6661 atgggactgg cctgcctcct ccgcccagct cggcgagctc ctccagacct cctaggcctg
6721 attgtcctgc cagggtgggc agacagacag atggaccggc ccacactccc agagttgcta 6781 acatggagct ctgagatcac cccacttcca tcatttcctt ctcccccaac ccaacgcttt6721 attgtcctgc cagggtgggc agacagacag atggaccggc ccacactccc agagttgcta 6781 acatggagct ctgagatcac cccacttcca tcatttcctt ctcccccaac ccaacgcttt
6841 tttggatcag ctcagacata tttcagtata aaacagttgg aaccacaaaa aaaaaaaaaa6841 tttggatcag ctcagacata tttcagtata aaacagttgg aaccacaaaa aaaaaaaaaa
6901 aaaaaaaaaa a 6901 aaaaaaaaaa a
<210> 24 <210> 24
<211> 1972 <211> 1972
<212> DNA <212> DNA
<213> Homo Sapiens <213> Homo Sapiens
<400> 24 <400> 24
Zona pellucida-protein 1 (ZP1)  Zona pellucida protein 1 (ZP1)
1 gggtgtgtct gtggcgtctc atggcaggag gctcagccac gacctggggt taccctgtgg 1 gggtgtgtct gtggcgtctc atggcaggag gctcagccac gacctggggt taccctgtgg
61 ccctgctact gctggttgcc accctggggc tgggtaggtg gctccagccc gaccctggcc 121 tcccaggcct ccggcacagc tacgactgtg ggatcaaggg aatgcagctg ctggtgttcc 181 ccaggccagg ccagactctc cgcttcaagg tggtggatga atttgggaac cgatttgatg 241 tcaacaactg ctccatctgc taccactggg tcacctccag gccgcaggag cctgcagtct 301 tctcggccga ttacagaggc tgccacgtgc tggagaagga tgggcgtttc cacctgaggg61 ccctgctact gctggttgcc accctggggc tgggtaggtg gctccagccc gaccctggcc 121 tcccaggcct ccggcacagc tacgactgtg ggatcaaggg aatgcagctg ctggtgttcc 181 ccaggccagg ccagactctc cgcttcaagg tggtggatga atttgggaac cgatttgatg 241 tcaacaactg ctccatctgc taccactggg tcacctccag gccgcaggag cctgcagtct 301 tctcggccga ttacagaggc tgccacgtgc tggagaagga tgggcgtttc cacctgaggg
361 tgttcatgga ggctgtgctg cccaatggtc gtgtggatgt ggcacaagac gctactctga 421 tctgtcccaa acctgacccc tcccggactc tggactccca gctggcacca cccgccatgt 481 tctctgtctc aaccccacaa accctttcct tcctccccac ctctggccat acctcccaag 541 gctctggcca tgcctttccc agcccactgg acccagggca cagctctgtc cacccaaccc 601 ctgctttacc atcccctgga cctggaccta ccctcgccac cctggctcaa ccccactggg 661 gcaccttgga acactgggat gtgaacaaac gagattacat aggtacccac ctgagccagg 721 agcagtgcca ggtggcctca gggcacctcc cctgcatcgt gagaagaact tcaaaagaag 781 cctgtcagca ggctggctgc tgctatgaca acaccagaga ggttccctgt tactatggca 841 acacagctac tgtccagtgc ttcagagatg gctacttcgt cctcgtggtg tcccaagaaa 901 tggccttgac acacaggatc acactggcca acatccacct ggcctatgcc cccaccagct 961 gctccccaac acagcacacg gaagctttcg tggtcttcta cttccctctc acccactgtg 1021 gaaccacaat gcaggtggct ggcgaccagc tcatctatga gaactggctg gtgtctggca 1081 tccacatcca aaaggggcca cagggttcca tcacgcggga cagcaccttc cagcttcatg 1141 tgcgctgtgt cttcaacgcc agtgacttcc tgcccattca ggcatccatt ttcccacccc 1201 catcgcctgc tcctatgacc cagcccggcc ccctgcggct tgagctgcgg attgccaaag 1261 acgagacctt cagctcgtac tatggggagg atgactatcc catcgtgagg ctgctccgag 1321 aaccagtcca tgtggaggtc cggcttctgc agaggacaga ccccaacctg gtcctgctgc 1381 tgcaccagtg ctggggcgct cccagtgcca accccttcca gcagccccag tggcccatcc 1441 tgtcagacgg atgccctttc aagggcgaca gctacagaac ccaaatggta gccttggacg 1501 gggccacacc tttccagtcg cactaccagc gattcactgt tgctaccttc gccctcctgg 1561 actcaggctc ccagagagcc ctcagaggac tggtttactt gttctgcagc acctctgcct 1621 gccacacctc agggctggag acttgctcca ctgcatgtag cactggcact acaagacagc 1681 gacgatcctc aggtcaccgt aatgacactg ccaggcccca ggacatcgtg agctctccgg 1741 ggccagtggg ctttgaggat tcttatgggc aggagcccac acttgggccc acagactcca 1801 atgggaactc cagcctgaga cctctccttt gggcggtcct tttgctgcca gctgttgccc 1861 tggtccttgg gtttggtgtc tttgtgggcc tgagccagac ctgggcccag aagctctggg 1921 aaagcaacag acagtgaatg ggcccaataa acaatcattt caaacctact ga 361 tgttcatgga ggctgtgctg cccaatggtc gtgtggatgt ggcacaagac gctactctga 421 tctgtcccaa acctgacccc tcccggactc tggactccca gctggcacca cccgccatgt 481 tctctgtctc aaccccacaa accctttcct tcctccccac ctctggccat acctcccaag 541 gctctggcca tgcctttccc agcccactgg acccagggca cagctctgtc cacccaaccc 601 ctgctttacc atcccctgga cctggaccta ccctcgccac cctggctcaa ccccactggg 661 gcaccttgga acactgggat gtgaacaaac gagattacat aggtacccac ctgagccagg 721 agcagtgcca ggtggcctca gggcacctcc cctgcatcgt gagaagaact tcaaaagaag 781 cctgtcagca ggctggctgc tgctatgaca acaccagaga ggttccctgt tactatggca 841 acacagctac tgtccagtgc ttcagagatg gctacttcgt cctcgtggtg tcccaagaaa 901 tggccttgac acacaggatc acactggcca acatccacct ggcctatgcc cccaccagct 961 gctccccaac acagcacacg gaagctttcg tggtcttcta cttccctctc acccactgtg 1021 gaaccacaat gcaggtggct ggcgaccagc tcatctatga gaactggctg gtgtctggca 1081 tccacatcca aaaggggcca cagggttcca tcacgcggga cagcaccttc cagcttcatg 1141 tgcgctgtgt cttcaacgcc agtgacttcc tgcccattca ggcatccatt ttcccacccc 1201 catcgcctgc tcctatgacc cagcccggcc ccctgcggct tgagctgcgg attgccaaag 1261 acgagacctt cagctcgtac tatggggagg atgactatcc catcgtgagg ctgctccgag 1321 aaccagtcca tgtggaggtc cggcttctgc agaggacaga ccccaacctg gtcctgctgc 1381 tgcaccagtg ctggggcgct cccagtgcca accccttcca gcagccccag tggcccatcc 1441 tgtcagacgg atgccctttc aagggcgaca gctacagaac ccaaatggta gccttggacg 1501 gggccacacc tttccagtcg cactaccagc gattcactgt tgctaccttc gccctcctgg 1561 actcaggctc ccagagagcc ctcagaggac tggtttactt gttctgcagc acctctgcct 1621 gccacacctc agggctggag acttgctcca ctgcatgtag cactggcact acaagacagc 1681 gacgatcctc aggtcaccgt aatgacactg ccaggcccca ggacatcgtg agctctccgg 1741 ggccagtggg ctttgaggat tcttatgggc aggagcccac acttgggccc acagactcca 1801 atgggaactc cagcctgaga cctctctct gggcggtcct tttgctgcca gctgttgccc 1861 tggtccttgg gtttggtgtc tttgtgggcc tgagccagac ctgggcccag aagctctggg 1921 aaagcaacag acagtgaatg ggcccaataa acaatcattt caaacctact ga
<210> 25 <210> 25
<21 1 > 2266  <21 1> 2266
<212> DNA  <212> DNA
<213> Homo Sapiens <213> Homo Sapiens
<400> 25  <400> 25
Zona pellucida-protein 2 (ZP2) Zona pellucida protein 2 (ZP2)
1 atggcgtgca ggcagagagg aggctcttgg agtccctcag gctggttcaa tgcaggctgg 1 atggcgtgca ggcagagagg aggctcttgg agtccctcag gctggttcaa tgcaggctgg
61 agcacctaca ggtcgatttc tctcttcttc gcccttgtga cttcagggaa ctccatagat61 agcacctaca ggtcgatttc tctcttcttc gcccttgtga cttcagggaa ctccatagat
121 gtttctcagt tggtaaatcc tgcctttcca ggcactgtca cttgcgatga aagggaaata121 gtttctcagt tggtaaatcc tgcctttcca ggcactgtca cttgcgatga aagggaaata
181 acagtggagt tcccaagcag tcctggcacc aagaaatggc atgcatctgt ggtggatcct183 acagtggagt tcccaagcag tcctggcacc aagaaatggc atgcatctgt ggtggatcct
241 cttggtctcg acatgccgaa ctgcacttac atcctggacc cagaaaagct caccctgagg 301 gctacctatg ataactgtac caggagagtg catggtggac accagatgac catcagagtc241 cttggtctcg acatgccgaa ctgcacttac atcctggacc cagaaaagct caccctgagg 301 gctacctatg ataactgtac caggagagtg catggtggac accagatgac catcagagtc
361 atgaacaaca gtgctgcctt aagacacgga gctgtcatgt atcagttctt ctgtccagct361 atgaacaaca gtgctgcctt aagacacgga gctgtcatgt atcagttctt ctgtccagct
421 atgcaagtag aagagaccca ggggctttca gcatctacaa tctgccagaa ggatttcatg421 atgcaagtag aagagaccca ggggctttca gcatctacaa tctgccagaa ggatttcatg
481 tctttttcct tgccacgggt cttctctggc ttggctgacg acagtaaggg gaccaaagtt481 tctttttcct tgccacgggt cttctctggc ttggctgacg acagtaaggg gaccaaagtt
541 cagatgggat ggagcattga ggttggtgat ggtgcaagag ccaaaactct gaccctgcca 601 gaggccatga aggaaggctt cagcctcttg attgacaacc acaggatgac cttccatgtg541 cagatgggat ggagcattga ggttggtgat ggtgcaagag ccaaaactct gaccctgcca 601 gaggccatga aggaaggctt cagcctcttg attgacaacc acaggatgac cttccatgtg
661 ccattcaatg ccactggagt gactcactat gtgcaaggta acagtcatct ctacatggtg661 ccattcaatg ccactggagt gactcactat gtgcaaggta acagtcatct ctacatggtg
721 tctctgaagc ttacatttat atctcctgga cagaaggtga tcttctcttc acaagctatt721 tctctgaagc ttacatttat atctcctgga cagaaggtga tcttctcttc acaagctatt
781 tgtgcaccag atcctgtgac ctgcaatgcc acacacatga ctctcaccat accagagttt781 tgtgcaccag atcctgtgac ctgcaatgcc acacacatga ctctcaccat accagagttt
841 cctgggaagc ttaagtctgt gagctttgaa aaccagaaca ttgatgtgag ccagctgcat 901 gacaatggaa ttgatctaga agcaacaaat ggcatgaaat tgcatttcag caaaactctg841 cctgggaagc ttaagtctgt gagctttgaa aaccagaaca ttgatgtgag ccagctgcat 901 gacaatggaa ttgatctaga agcaacaaat ggcatgaaat tgcatttcag caaaactctg
961 ctcaaaacga aattatctga aaaatgccta ctccatcagt tctacttagc ttcactcaag 1021 ctgacctttc tccttcggcc agagacagta tccatggtga tctatcctga gtgtctctgt961 ctcaaaacga aattatctga aaaatgccta ctccatcagt tctacttagc ttcactcaag 1021 ctgacctttc tccttcggcc agagacagta tccatggtga tctatcctga gtgtctctgt
1081 gagtcacccg tttctatagt tacaggggag ctgtgcaccc aggatgggtt tatggacgtc1081 gagtcacccg tttctatagt tacaggggag ctgtgcaccc aggatgggtt tatggacgtc
1141 gaggtctaca gctaccaaac acaaccagct cttgacctgg gtactctgag ggtgggaaac1141 gaggtctaca gctaccaaac acaaccagct cttgacctgg gtactctgag ggtgggaaac
1201 tcatcctgcc agcctgtctt tgaggctcag tctcaggggc tggtacggtt ccacataccc1201 tcatcctgcc agcctgtctt tgaggctcag tctcaggggc tggtacggtt ccacataccc
1261 ctgaatggat gtggaacgag atataagttc gaagatgata aagtcgtcta tgaaaacgaa 1321 atacatgctc tctggacgga ttttcctcca agcaaaatat ctagagacag tgagttcaga1261 ctgaatggat gtggaacgag atataagttc gaagatgata aagtcgtcta tgaaaacgaa 1321 atacatgctc tctggacgga ttttcctcca agcaaaatat ctagagacag tgagttcaga
1381 atgacagtga agtgttctta tagcaggaat gacatgctac taaacatcaa cgttgaaagc1381 atgacagtga agtgttctta tagcaggaat gacatgctac taaacatcaa cgttgaaagc
1441 cttactcctc cagtggcctc agtgaagttg ggtccattta ccttgatcct gcaaagctac1441 cttactcctc cagtggcctc agtgaagttg ggtccattta ccttgatcct gcaaagctac
1501 ccagataatt cctaccaaca accttatggg gaaaacgagt accctctagt gagattcctc1501 ccagataatt cctaccaaca accttatggg gaaaacgagt accctctagt gagattcctc
1561 cgccaaccaa tttacatgga agtgagagtc ctaaacaggg atgaccccaa catcaagctg 1621 gtcttagatg actgctgggc gacgtccacc atggatccag actctttccc ccagtggaac1561 cgccaaccaa tttacatgga agtgagagtc ctaaacaggg atgaccccaa catcaagctg 1621 gtcttagatg actgctgggc gacgtccacc atggatccag actctttccc ccagtggaac
1681 gttgtcgtgg atggctgtgc atatgacctg gacaactacc agaccacctt ccatccagtc1681 gttgtcgtgg atggctgtgc atatgacctg gacaactacc agaccacctt ccatccagtc
1741 ggctcctctg tgacccatcc tgatcactat cagaggtttg acatgaaggc ttttgccttt1741 ggctcctctg tgacccatcc tgatcactat cagaggtttg acatgaaggc ttttgccttt
1801 gtatcagaag cccacgtgct ctctagcctg gtctacttcc actgcagtgc cttaatctgt1801 gtatcagaag cccacgtgct ctctagcctg gtctacttcc actgcagtgc cttaatctgt
1861 aatcgactct cccctgactc cccactgtgt tctgtgacct gccctgtgtc ctctaggcac 1921 aggcgagcca caggggccac tgaagcagag aaaatgacag tcagcctccc aggacccatt1861 aatcgactct cccctgactc cccactgtgt tctgtgacct gccctgtgtc ctctaggcac 1921 aggcgagcca caggggccac tgaagcagag aaaatgacag tcagcctccc aggacccatt
1981 ctcctgttgt cagatgactc ctcattcaga ggtgtcggct catctgatct aaaagcaagt1981 ctcctgttgt cagatgactc ctcattcaga ggtgtcggct catctgatct aaaagcaagt
2041 gggagcagtg gggagaagag taggagtgaa acaggggagg aggttggctc acgaggtgct2041 gggagcagtg gggagaagag taggagtgaa acaggggagg aggttggctc acgaggtgct
2101 atggacacca aagggcacaa gactgctgga gatgttggtt ccaaagctgt ggctgctgtg2101 atggacacca aagggcacaa gactgctgga gatgttggtt ccaaagctgt ggctgctgtg
2161 gctgcctttg caggtgtggt ggcaactcta ggcttcatct actacctgta cgagaaaagg 2221 actgtgtcaa atcactaaat gggcttctaa ataaagcagt caaaat 2161 gctgcctttg caggtgtggt ggcaactcta ggcttcatct actacctgta cgagaaaagg 2221 actgtgtcaa atcactaaat gggcttctaa ataaagcagt caaaat
<210> 26 <210> 26
<211 > 1494 <211> 1494
<212> DNA <212> DNA
<213> Homo Sapiens <213> Homo Sapiens
<400> 26 <400> 26
Zona pellucida-protein 3 (ZP3) Zona pellucida protein 3 (ZP3)
1 agagcgcgcc cgcgtcctcg tggtggccgc agttgtgcac accccagccc aggctctggc 1 agagcgcgcc cgcgtcctcg tggtggccgc agttgtgcac accccagccc aggctctggc
61 aggctgccag gcggggctcg ccgccttcgc agtgcacgtt gtccagcagg atgtgtccgg61 aggctgccag gcggggctcg ccgccttcgc agtgcacgtt gtccagcagg atgtgtccgg
121 tgccatagcc gaagaaggcg ttggtggtgg cggccatggc cgccccgcag cccagctgac121 tgccatagcc gaagaaggcg ttggtggtgg cggccatggc cgccccgcag cccagctgac
181 gacagaccac agcggcatcc ggcagccccc agtcgtcgtc acacacggtg ccccacaggc181 gacagaccac agcggcatcc ggcagccccc agtcgtcgtc acacacggtg ccccacaggc
241 cactgtgcag gatctccact cggccctgac acagggtgga gccagccatc ctgagacgtc 301 cgtacagccc gtactggtgg agtgtcagga ggccactctg atggtcatgg tcagcaaaga241 cactgtgcag gatctccact cggccctgac acagggtgga gccagccatc ctgagacgtc 301 cgtacagccc gtactggtgg agtgtcagga ggccactctg atggtcatgg tcagcaaaga
361 cctttttggc accgggaagc tcatcagggc tgctgacctc accttgggcc cagaggcctg361 cctttttggc accgggaagc tcatcagggc tgctgacctc accttgggcc cagaggcctg
421 tgagcctctg gtctccatgg acacagaaga tgtggtcagg tttgaggttg gactccacga421 tgagcctctg gtctccatgg acacagaaga tgtggtcagg tttgaggttg gactccacga
481 gtgtggcaac agcatgcagg taactgacga tgccctggtg tacagcacct tcctgctcca481 gtgtggcaac agcatgcagg taactgacga tgccctggtg tacagcacct tcctgctcca
541 tgacccccgc cccgtgggaa acctgtccat cgtgaggact aaccgcgcag agattcccat 601 cgagtgccgc taccccaggc agggcaatgt gagcagccag gccatcctgc ccacctggtt541 tgacccccgc cccgtgggaa acctgtccat cgtgaggact aaccgcgcag agattcccat 601 cgagtgccgc taccccaggc agggcaatgt gagcagccag gccatcctgc ccacctggtt
661 gcccttcagg accacggtgt tctcagagga gaagctgact ttctctctgc gtctgatgga661 gcccttcagg accacggtgt tctcagagga gaagctgact tctctctgc gtctgatgga
721 ggagaactgg aacgctgaga agaggtcccc caccttccac ctgggagatg cagcccacct721 ggagaactgg aacgctgaga agaggtcccc caccttccac ctgggagatg cagcccacct
781 ccaggcagaa atccacactg gcagccacgt gccactgcgg ttgtttgtgg accactgcgt781 ccaggcagaa atccacactg gcagccacgt gccactgcgg ttgtttgtgg accactgcgt
841 ggccacaccg acaccagacc agaatgcctc cccttatcac accatcgtgg acttccatgg 901 ctgtcttgtc gacggtctca ctgatgcctc ttctgcattc aaagttcctc gacccgggcc841 ggccacaccg acaccagacc agaatgcctc cctctacac accatcgtgg acttccatgg 901 ctgtcttgtc gacggtctca ctgatgcctc ttctgcattc aaagttcctc gacccgggcc
961 agatacactc cagttcacag tggatgtctt ccactttgct aatgactcca gaaacatgat961 agatacactc cagttcacag tggatgtctt ccactttgct aatgactcca gaaacatgat
1021 atacatcacc tgccacctga aggtcaccct agctgagcag gacccagatg aactcaacaa1021 atacatcacc tgccacctga aggtcaccct agctgagcag gacccagatg aactcaacaa
1081 ggcctgttcc ttcagcaagc cttccaacag ctggttccca gtggaaggct cggctgacat1081 ggcctgttcc ttcagcaagc cttccaacag ctggttccca gtggaaggct cggctgacat
1141 ctgtcaatgc tgtaacaaag gtgactgtgg cactccaagc cattccagga ggcagcctca 1201 tgtcatgagc cagtggtcca ggtctgcttc ccgtaaccgc aggcatgtga cagaagaagc1141 ctgtcaatgc tgtaacaaag gtgactgtgg cactccaagc cattccagga ggcagcctca 1201 tgtcatgagc cagtggtcca ggtctgcttc ccgtaaccgc aggcatgtga cagaagaagc
1261 agatgtcacc gtggggccac tgatcttcct ggacaggagg ggtgaccatg aagtagagca 1321 gtgggctttg ccttctgaca cctcagtggt gctgctgggc gtaggcctgg ctgtggtggt 1381 gtccctgact ctgactgctg ttatcctggt tctcaccagg aggtgtcgca ctgcctccca 1441 ccctgtgtct gcttccgaat aaaagaagaa agcaataaaa aaaaaaaaaa aaaa 1261 agatgtcacc gtggggccac tgatcttcct ggacaggagg ggtgaccatg aagtagagca 1321 gtgggctttg ccttctgaca cctcagtggt gctgctgggc gtaggcctgg ctgtggtggt 1381 gtccctgact ctgactgctg ttatcctggt tctcaccagg aggtgtcgca ctgcctccca 1441 ccctgtgtct gcttccgaat aaaagaagaa agcaataaaaaaaaaaaaaaaaa
<210> 27 <210> 27
<211 > 1892  <211> 1892
<212> DNA  <212> DNA
<213> Homo Sapiens  <213> Homo Sapiens
<400> 27  <400> 27
CRISPl CRISPl
1 ttaaaagcac aaatacacta catagagaaa ggcttggttc ttatcaggac acaaatttaa 1 ttaaaagcac aaatacacta catagagaaa ggcttggttc ttatcaggac acaaatttaa
61 aggctgtgtg gacttgggga tggaaattaa acacctcttg tttttggttg ctgctgcttg61 aggctgtgtg gacttgggga tggaaattaa acacctcttg tttttggttg ctgctgcttg
121 cttactgcct atgttgtcca tgaaaaagaa atcagctaga gaccaattta ataagctcgt 181 caccgacttg ccaaatgtac aagaagagat cgttaatata cacaacgccc tcaggagaag121 cttactgcct atgttgtcca tgaaaaagaa atcagctaga gaccaattta ataagctcgt 181 caccgacttg ccaaatgtac aagaagagat cgttaatata cacaacgccc tcaggagaag
241 agtagttcca ccagccagca acatgctgaa gatgagttgg agtgaagagg ctgcacaaaa241 agtagttcca ccagccagca acatgctgaa gatgagttgg agtgaagagg ctgcacaaaa
301 tgccagaatt ttttcaaagt attgtgatat gacagagagc aacccccttg agaggagact301 tgccagaatt ttttcaaagt attgtgatat gacagagagc aacccccttg agaggagact
361 tccaaatacc ttttgtggag aaaatatgca tatgacatct tatcctgtat catggtcaag361 tccaaatacc ttttgtggag aaaatatgca tatgacatct tatcctgtat catggtcaag
421 tgtaattgga gtctggtaca gtgagtctac aagtttcaaa catggagaat ggacaacaac 481 ggatgatgac ataactactg accactacac tcagattgtt tgggccacat cttacctgat421 tgtaattgga gtctggtaca gtgagtctac aagtttcaaa catggagaat ggacaacaac 481 ggatgatgac ataactactg accactacac tcagattgtt tgggccacat cttacctgat
541 tggctgtgcc attgcatctt gccgccaaca aggatcacct cgatatctct acgtttgtca541 tggctgtgcc attgcatctt gccgccaaca aggatcacct cgatatctct acgtttgtca
601 ctattgtcat gagggaaatg atcctgaaac aaagaatgaa ccttataaga caggcgtccc601 ctattgtcat gagggaaatg atcctgaaac aaagaatgaa ccttataaga caggcgtccc
661 atgtgaagcc tgcccaagta actgtgaaga caaactttgc actaacccct gcatctacta661 atgtgaagcc tgcccaagta actgtgaaga caaactttgc actaacccct gcatctacta
721 tgatgaatac ttcgactgtg acatacaagt ccattatctg ggatgcaacc actcaacaac 781 tatcctattc tgtaaagcca cttgtctgtg tgacactgag ataaaatagg tctttgttat721 tgatgaatac ttcgactgtg acatacaagt ccattatctg ggatgcaacc actcaacaac 781 tatcctattc tgtaaagcca cttgtctgtg tgacactgag ataaaatagg tctttgttat
841 tttcaactgt tctatgctgt gacgatgagg aggagatgtc tgttggattc atgtcttttg841 tttcaactgt tctatgctgt gacgatgagg aggagatgtc tgttggattc atgtcttttg
901 ctatagttca gtagcttctg ctaaatttca ctgattttaa tcatgctgga gaccttaact901 ctatagttca gtagcttctg ctaaatttca ctgattttaa tcatgctgga gaccttaact
961 cccatcctga tacatcctga agtaacactg ttttaaactt tcttagtgct ggagtaaaag961 cccatcctga tacatcctga agtaacactg ttttaaactt tcttagtgct ggagtaaaag
1021 gtcaagtcca acacctgcct taaatttaaa tcatgtgatt tatagttttt aagttggcat 1081 aattcaactt atggtataac tgggtccctc aacagtaacc tgggctaaaa taggtcttat1021 gtcaagtcca acacctgcct taaatttaaa tcatgtgatt tatagttttt aagttggcat 1081 aattcaactt atggtataac tgggtccctc aacagtaacc tgggctaaa taggtcttat
1141 gtggttcaac tcccaccccc gccttcccca tattttcaac cactctgatt atcttccctg1141 gtggttcaac tcccaccccc gccttcccca tattttcaac cactctgatt atcttccctg
1201 cacaactaac atccagtaat aattcttcac ttttaaaatt ttacttctac tttaaatcaa1201 cacaactaac atccagtaat aattcttacac ttttaaaatt ttacttctac tttaaatcaa
1261 tcattaaagg aatccacaaa gcaaacagag ttcagtctca tcttgcaagg taaatatcat1261 tcattaaagg aatccacaaa gcaaacagag ttcagtctca tcttgcaagg taaatatcat
1321 ttaattggaa gtagtttaaa tgtctcattg ttttattgac acatctatat atacatttgt 1381 gaagcaagaa acaataaaaa agcttcgtat gccattaatt taacaaaata tgtattcagt1321 ttaattggaa gtagtttaaa tgtctcattg ttttattgac acatctatat atacatttgt 1381 gaagcaagaa acaataaaaa agcttcgtat gccattaatt taacaaaata tgtattcagt
1441 actgattgca tacaagatgc atgtttatat atatggaagg aatatagttt catttcattg1441 actgattgca tacaagatgc atgtttatat atatggaagg aatatagttt catttcattg
1501 caaaggcagt ataaaagata tataaaatag cataatatga gaaattaagt ccctaaagac1501 caaaggcagt ataaaagata tataaaatag cataatatga gaaattaagt ccctaaagac
1561 atataggtca catattatta ttgccagatg agcataaata gcttctgttt ggagattcag1561 atataggtca catattatta ttgccagatg agcataaata gcttctgttt ggagattcag
1621 gaaagcctta gggtggaatg aggaacatct tctgagtaaa cagggttgca aaggttatga 1681 ttatttcaac acaatggaag agcacagtta aggccaacta acgtaaaatg cactgaagcc 1741 ttagggaata ttgaagggcc tgacatgggg aaagggaagg ctaaaaatac ttggtcaaat1621 gaaagcctta gggtggaatg aggaacatct tctgagtaaa cagggttgca aaggttatga 1681 ttatttcaac acaatggaag agcacagtta aggccaacta acgtaaaatg cactgaagcc 1741 ttagggaata ttgaagggcc tgacatgggg aaagggaagg ctaaaaatac ttggtcaaat
1801 tttaacatta taccaaagtt atacccagtt ctacctactt gtatatttct ttactcattt 1861 caataaagtg tttgaaaaaa aaaaaaaaaa aa 1801 tttaacatta taccaaagtt atacccagtt ctacctactt gtatatttct ttactcattt 1861 caataaagtg tttgaaaaaa aaaaaaaaaa aa
<210> 28 <210> 28
<211> 1413 <211> 1413
<212> DNA <212> DNA
<213> Homo Sapiens <213> Homo Sapiens
<400> 28 <400> 28
CRISP2 CRISP2
1 acacgtggcg cctggcaagt gaacaatcgc ggtgagaggg gcgcgccgca gctcctcaac 1 acacgtggcg cctggcaagt gaacaatcgc ggtgagaggg gcgcgccgca gctcctcaac
61 gccgcaacgc gccggcccaa ctgcaggaag gtctgtgctc tggagccagg gtaaatggtt61 gccgcaacgc gccggcccaa ctgcaggaag gtctgtgctc tggagccagg gtaaatggtt
121 ataaaattat acaccatggc cctcctaaag acactctagg aaaaccatgt catcctgatc121 ataaaattat acaccatggc cctcctaaag acactctagg aaaaccatgt catcctgatc
181 ttaaaacacc tgcaagaaag agcacagtac ttcaccatta ataaagtaga tatttcatcc181 ttaaaacacc tgcaagaaag agcacagtac ttcaccatta ataaagtaga tatttcatcc
241 tgctcagaaa accaacattt ccagcaatgg ctttactacc ggtgttgttt ctggttactg241 tgctcagaaa accaacattt ccagcaatgg ctttactacc ggtgttgttt ctggttactg
301 tgctgcttcc atctttacct gcagaaggaa aggatcccgc ttttactgct ttgttaacca301 tgctgcttcc atctttacct gcagaaggaa aggatcccgc ttttactgct ttgttaacca
361 cccagttgca agtgcaaagg gagattgtaa ataaacacaa tgaactaagg aaagcagtct361 cccagttgca agtgcaaagg gagattgtaa ataaacacaa tgaactaagg aaagcagtct
421 ctccacctgc cagtaacatg ctaaagatgg aatggagcag agaggtaaca acgaatgccc421 ctccacctgc cagtaacatg ctaaagatgg aatggagcag agaggtaaca acgaatgccc
481 aaaggtgggc aaacaagtgc actttacaac atagtgatcc agaggaccgc aaaaccagta481 aaaggtgggc aaacaagtgc actttacaac atagtgatcc agaggaccgc aaaaccagta
541 caagatgtgg tgagaatctc tatatgtcaa gtgaccctac ttcctggtct tctgcaatcc541 caagatgtgg tgagaatctc tatatgtcaa gtgaccctac ttcctggtct tctgcaatcc
601 aaagctggta tgacgagatc ctagattttg tctatggtgt aggaccaaag agtcccaatg601 aaagctggta tgacgagatc ctagattttg tctatggtgt aggaccaaag agtcccaatg
661 cagttgttgg acattatact cagcttgttt ggtactcgac ttaccaggta ggctgtggaa661 cagttgttgg acattatact cagcttgttt ggtactcgac ttaccaggta ggctgtggaa
721 ttgcctactg tcccaatcaa gatagtctaa aatactacta tgtttgccaa tattgtcctg721 ttcctactg tcccaatcaa gatagtctaa aatactacta tgtttgccaa tattgtcctg
781 ctggtaataa tatgaataga aagaataccc cgtaccaaca aggaacacct tgtgccggtt781 ctggtaataa tatgaataga aagaataccc cgtaccaaca aggaacacct tgtgccggtt
841 gccctgatga ctgtgacaaa ggactatgca ccaatagttg ccagtatcaa gatctcctaa841 gccctgatga ctgtgacaaa ggactatgca ccaatagttg ccagtatcaa gatctcctaa
901 gtaactgtga ttccttgaag aatacagctg gctgtgaaca tgagttactc aaggaaaagt901 gtaactgtga ttcttgaag aatacagctg gctgtgaaca tgagttactc aaggaaaagt
961 gcaaggctac ttgcctatgt gagaacaaaa tttactgatt tacctagtga gcattgtgca961 gcaaggctac ttgcctatgt gagaacaaaa tttactgatt tacctagtga gcattgtgca
1021 agactgcatg gataagggct gcatcattta attgcgacat accagtggaa attgtatgta1021 agactgcatg gataagggct gcatcattta attgcgacat accagtggaa attgtatgta
1081 tgttagtgac aaatttgatt tcaaagagca atgcatcttc tcccccagat catcacagaa1081 tgttagtgac aaatttgatt tcaaagagca atgcatcttc tcccccagat catcacagaa
1141 atcactttca ggcaatgatt tacaaaagta gcatagtaga tgatgacaac tgtgaactct1141 atcactttca ggcaatgatt tacaaaagta gcatagtaga tgatgacaac tgtgaactct
1201 gacataaatt tagtgcttta taacgaactg aatcaggttg aggattttga aaactgtata1201 gacataaatt tagtgcttta taacgaactg aatcaggttg aggattttga aaactgtata
1261 accataggat ttaggtcact aggactttgg atcaaaatgg tgcattacgt atttcctgaa1261 accataggat ttaggtcact aggactttgg atcaaaatgg tgcattacgt atttcctgaa
1321 acatgctaaa gaagaagact gtaacatcat tgccattcct actacctgag tttttacttg1321 acatgctaaa gaagaagact gtaacatcat tgccattcct actacctgag tttttacttg
1381 cataaacaat aaattcaaag ctttacatct gcc 1381 cataaacaat aaattcaaag ctttacatct gcc
<210> 29 <210> 29
<211> 6837 <211> 6837
<212> DNA <213> Homo Sapiens <212> DNA <213> Homo Sapiens
<400> 29 <400> 29
Myoferlin (MYOF) Myoferlin (MYOF)
1 ggcacgagct tctctcccag ggcggtgcga cccggagctc cagcgcccga gtctccactt 1 ggcacgagct tctctcccag ggcggtgcga cccggagctc cagcgcccga gtctccactt
61 cgtttgctga aacttgcttt ctaccagcta agaaccatgc tgcgagtgat tgtggaatct61 cgtttgctga aacttgcttt ctaccagcta agaaccatgc tgcgagtgat tgtggaatct
121 gccagcaata tccctaaaac gaaatttggc aagccggatc ctattgtttc tgtcattttt121 gccagcaata tccctaaaac gaaatttggc aagccggatc ctattgtttc tgtcattttt
181 aaggatgaga aaaagaaaac aaagaaagtt gataatgaat tgaaccctgt ctggaatgag181 aaggatgaga aaaagaaaac aaagaaagtt gataatgaat tgaaccctgt ctggaatgag
241 attttggagt ttgacttgag gggtatacca ctggactttt catcttccct tgggattatt241 attttggagt ttgacttgag gggtatacca ctggactttt catcttccct tgggattatt
301 gtgaaagatt ttgagacaat tggacaaaat aaattaattg gcacggcgac tgtagccctg301 gtgaaagatt ttgagacaat tggacaaaat aaattaattg gcacggcgac tgtagccctg
361 aaggacctga ctggtgacca gagcagatcc ctgccgtaca agctgatctc cctgctaaat361 aaggacctga ctggtgacca gagcagatcc ctgccgtaca agctgatctc cctgctaaat
421 gaaaaagggc aagatactgg ggccaccatt gacttggtga tcggctatga tccgccttct421 gaaaaagggc aagatactgg ggccaccatt gacttggtga tcggctatga tccgccttct
481 gctccacatc caaatgacct gagcgggccc agcgtgccag gcatgggagg agatggggaa481 gctccacatc caaatgacct gagcgggccc agcgtgccag gcatgggagg agatggggaa
541 gaagatgaag gtgatgaaga caggttggac aatgcagtca ggggccctgg gcccaagggg541 gaagatgaag gtgatgaaga caggttggac aatgcagtca ggggccctgg gcccaagggg
601 ccagttggga cggtgtcgga agctcagctt gctcggaggc tcaccaaagt aaagaacagc601 ccagttggga cggtgtcgga agctcagctt gctcggaggc tcaccaaagt aaagaacagc
661 cggcggatgc tgtcaaataa gccacaggac ttccagatcc gcgtccgagt gattgagggc661 cggcggatgc tgtcaaataa gccacaggac ttccagatcc gcgtccgagt gattgagggc
721 cgacagttaa gtggtaacaa cataaggcct gtggtcaaag ttcacgtctg tggccagaca721 cgacagttaa gtggtaacaa cataaggcct gtggtcaaag ttcacgtctg tggccagaca
781 caccgaacaa gaatcaagag aggaaacaac cctttttttg atgagttgtt tttctacaat781 caccgaacaa gaatcaagag aggaaacaac cctttttttg atgagttgtt tttctacaat
841 gtcaacatga ccccttctga attgatggat gagatcatca gcatccgggt ttataattct841 gtcaacatga ccccttctga attgatggat gagatcatca gcatccgggt ttataattct
901 cactctctgc gggcagattg tctgatgggg gaatttaaga ttgatgttgg atttgtttat901 cactctctgc gggcagattg tctgatgggg gaatttaaga ttgatgttgg atttgtttat
961 gatgaacctg gccatgctgt catgagaaag tggcttcttc tcaatgaccc ggaagatacc961 gatgaacctg gccatgctgt catgagaaag tggcttcttc tcaatgaccc ggaagatacc
1021 agttcaggtt ctaaaggtta tatgaaagtc agcatgtttg tcctgggaac cggagatgag1021 agttcaggtt ctaaaggtta tatgaaagtc agcatgtttg tcctgggaac cggagatgag
1081 cctcctcctg agagacgaga tcgtgataat gacagtgatg atgtggagag taatttgtta1081 cctcctcctg agagacgaga tcgtgataat gacagtgatg atgtggagag taatttgtta
1141 ctccctgctg gcattgccct ccggtgggtg accttcttgc tgaaaatcta ccgagctgag1141 ctccctgctg gcattgccct ccggtgggtg accttcttgc tgaaaatcta ccgagctgag
1201 gacatccccc agatggatga tgccttctca cagacagtaa aggaaatatt tggaggcaat1201 gacatccccc agatggatga tgccttctca cagacagtaa aggaaatatt tggaggcaat
1261 gcagataaga aaaatctcgt ggatcctttt gtagaagttt cctttgctgg aaaaaaggtt1261 gcagataaga aaaatctcgt ggatcctttt gtagaagttt cctttgctgg aaaaaaggtt
1321 tgtacaaaca taattgagaa aaatgcaaac ccagagtgga atcaggtcgt caatcttcag1321 tgtacaaaca taattgagaa aaatgcaaac ccagagtgga atcaggtcgt caatcttcag
1381 atcaagtttc cttcagtgtg tgaaaaaata aaactaacaa tatatgactg ggaccgtctt1381 atcaagtttc cttcagtgtg tgaaaaaata aaactaacaa tatatgactg ggaccgtctt
1441 actaaaaatg atgtagttgg aacaacatat ctacacctct ctaaaattgc tgcctctggt1441 actaaaaatg atgtagttgg aacaacatat ctacacctct ctaaaattgc tgctctggt
1501 ggggaagtgg aagatttctc atcttcggga actggggctg catcatatac agtaaacaca1501 ggggaagtgg aagatttctc atcttcggga actggggctg catcatatac agtaaacaca
1561 ggagaaacag aggtaggctt tgttccaacg tttggacctt gttacctgaa tctttatgga1561 ggagaaacag aggtaggctt tgttccaacg tttggacctt gttacctgaa tctttatgga
1621 agccccaggg agtacacggg attcccagac ccctatgatg agctgaatac tggaaagggg1621 agccccaggg agtacacggg attcccagac cctctgatg agctgaatac tggaaagggg
1681 gaaggagttg cctacagagg caggatcttg gttgaattag ccacttttct tgagaagaca1681 gaaggagttg cctacagagg caggatcttg gttgaattag ccacttttct tgagaagaca
1741 ccaccagata aaaagcttga gcccatttca aatgatgacc tgctggttgt tgagaaatac1741 ccaccagata aaaagcttga gcccatttca aatgatgacc tgctggttgt tgagaaatac
1801 cagcgaaggc ggaagtacag cctgtctgcc gtgtttcatt cagccaccat gttgcaagat1801 cagcgaaggc ggaagtacag cctgtctgcc gtgtttcatt cagccaccat gttgcaagat
1861 gttggtgagg ccattcagtt tgaagtcagc attgggaact atggcaacaa gtttgacacc1861 gttggtgagg ccattcagtt tgaagtcagc attgggaact atggcaacaa gtttgacacc
1921 acctgtaagc ctttggcatc aacaactcag tacagccgtg ctgtatttga tggcaactac1921 acctgtaagc ctttggcatc aacaactcag tacagccgtg ctgtatttga tggcaactac
1981 tattattact tgccttgggc ccacaccaag ccagttgtta ccctgacttc atactgggag1981 tattattact tgccttgggc ccacaccaag ccagttgtta ccctgacttc atactgggag
2041 gatattagtc atcgcctgga tgcggtgaac actctcctag ctatggcaga acggctgcaa2041 gatattagtc atcgcctgga tgcggtgaac actctcctag ctatggcaga acggctgcaa
2101 acaaatatag aagctctaaa atcagggata caaggtaaaa ttcctgcaaa ccagctggct2101 acaaatatag aagctctaaa atcagggata caaggtaaaa tctctgcaaa ccagctggct
2161 gaattgtggc tgaagctgat agatgaagtt atagaagaca cgagatacac gttgcctctc2161 gaattgtggc tgaagctgat agatgaagtt atagaagaca cgagatacac gttgctctc
2221 acagaaggaa aagccaacgt cacagttctc gatactcaga tccgaaagct gcggtccagg2221 acagaaggaa aagccaacgt cacagttctc gatactcaga tccgaaagct gcggtccagg
2281 tctctctccc aaatacatga ggcggctgtg aggatgaggt cggaagccac agatgtgaag2281 tctctctccc aaatacatga ggcggctgtg aggatgaggt cggaagccac agatgtgaag
2341 tccacactgg cagaaattga ggactggctt gataaattaa tgcagctgac tgaagagcca 2401 cagaacagca tgcctgacat catcatctgg atgatccggg gagagaagag actggcctat2341 tccacactgg cagaaattga ggactggctt gataaattaa tgcagctgac tgaagagcca 2401 cagaacagca tgcctgacat catcatctgg atgatccggg gagagaagag actggctct
2461 gcacgaattc ccgcacatca ggtcttgtac tccaccagtg gtgagaatgc atctggaaaa 2521 tactgtggga aaacccaaac catctttctg aagtatccac aggagaaaaa caacgggcca 2581 aaggtgcctg tggagttgcg agtgaacatc tggctaggct taagtgctgt ggagaagaag 2641 tttaacagct tcgcagaagg aactttcacc gtctttgctg aaatgtatga aaatcaagct 2701 ctcatgtttg gaaaatgggg tacttctgga ttagtaggac gtcataagtt ttctgatgtc2461 gcacgaattc ccgcacatca ggtcttgtac tccaccagtg gtgagaatgc atctggaaaa 2521 tactgtggga aaacccaaac catctttctg aagtatccac aggagaaaaa caacgggcca 2581 aaggtgcctg tggagttgcg agtgaacatc tggctaggct taagtgctgt ggagaagaag 2641 tttaacagct tcgcagaagg aactttcacc gtctttgctg aaatgtatga aaatcaagct 2701 ctcatgtttg gaaaatgggg tacttctgga ttagtaggac gtcataagtt ttctgatgtc
2761 acaggaaaaa taaaactcaa gagggaattt tttctgcctc caaaaggctg ggaatgggaa 2821 ggagagtgga tagttgatcc tgaaagaagc ttgctgactg aggcagatgc aggtcacacg 2881 gagttcactg atgaagtcta tcagaacgag agccgctacc ccgggggcga ctggaagccg2761 acaggaaaaa taaaactcaa gagggaattt tttctgcctc caaaaggctg ggaatgggaa 2821 ggagagtgga tagttgatcc tgaaagaagc ttgctgactg aggcagatgc aggtcacacg 2881 gagttcactg atgaagtcta tcagaacgag agccgctacc ccgggggcga ctggaagccg
2941 gccgaggaca cctacacgga tgcgaacggc gataaagcag catcacccag cgagttgact 3001 tgtcctccag gttgggaatg ggaagatgat gcatggtctt atgacataaa tcgagcggtg2941 gccgaggaca cctacacgga tgcgaacggc gataaagcag catcacccag cgagttgact 3001 tgtcctccag gttgggaatg ggaagatgat gcatggtctt atgacataaa tcgagcggtg
3061 gatgagaaag gctgggaata tggaatcacc attcctcctg atcataagcc caaatcctgg 3121 gttgcagcag agaaaatgta ccacactcat agacggcgaa ggctggtccg aaaacgcaag 3181 aaagatttaa cacagactgc ttcaagcacc gcaagggcca tggaggaatt gcaagaccaa 3241 gagggctggg aatatgcttc tctaattggc tggaaatttc actggaaaca acgtagttca 3301 gataccttcc gccgcagacg ctggaggaga aaaatggctc cttcagaaac acatggtgca3061 gatgagaaag gctgggaata tggaatcacc attcctcctg atcataagcc caaatcctgg 3121 gttgcagcag agaaaatgta ccacactcat agacggcgaa ggctggtccg aaaacgcaag 3181 aaagatttaa cacagactgc ttcaagcacc gcaagggcca tggaggaatt gcaagaccaa 3241 gagggctggg aatatgcttc tctaattggc tggaaatttc actggaaaca acgtagttca 3301 gataccttcc gccgcagacg ctggaggaga aaaatggctc cttcagaaac acatggtgca
3361 gctgccatct ttaaacttga aggtgccctt ggggcagaca ctaccgaaga tggggatgag 3421 aagagcctgg agaaacagaa gcacagtgcc accactgtgt tcggagcaaa cacccccatt 3481 gtttcctgca attttgacag agtctacatc taccatctgc gctgctatgt ctatcaagcc 3541 agaaacctct tggctttaga taaggatagc ttttcagatc catatgctca tatctgtttc 3601 ctccatcgga gcaaaaccac tgagatcatc cattcaaccc tgaatcccac gtgggaccaa3361 gctgccatct ttaaacttga aggtgccctt ggggcagaca ctaccgaaga tggggatgag 3421 aagagcctgg agaaacagaa gcacagtgcc accactgtgt tcggagcaaa cacccccatt 3481 gtttcctgca attttgacag agtctacatc taccatctgc gctgctatgt ctatcaagcc 3541 agaaacctct tggctttaga taaggatagc ttttcagatc catatgctca tatctgtttc 3601 ctccatcgga gcaaaaccac tgagatcatc cattcaaccc tgaatcccac gtgggaccaa
3661 acaattatat tcgatgaagt tgaaatctat ggggaacccc aaacagttct acagaatcca3661 acaattatat tcgatgaagt tgaaatctat ggggaacccc aaacagttct acagaatcca
3721 cccaaagtta tcatggaact ttttgacaat gaccaagtgg gcaaagatga atttttagga 3781 cgaagcattt tctctcctgt ggtgaaactg aactcagaaa tggacatcac acccaaactt 3841 ctctggcacc cagtaatgaa tggagacaaa gcctgcgggg atgttcttgt aactgcagag 3901 ctgattctga ggggcaagga tggctccaac cttcccattc ttccccctca aagggcgcca3721 cccaaagtta tcatggaact ttttgacaat gaccaagtgg gcaaagatga atttttagga 3781 cgaagcattt tctctcctgt ggtgaaactg aactcagaaa tggacatcac acccaaactt 3841 ctctggcacc cagtaatgaa tggagacaaa gcctgcgggg atgttcttgt aactgcagag 3901 ctgattctga ggggcaagga tggctccaac cttcccattc ttccccctca aagggcgcca
3961 aatctataca tggtccccca ggggatcagg cctgtggtcc agctcactgc cattgagatt 4021 ctagcttggg gcttaagaaa tatgaaaaac ttccagatgg cttctatcac atcccccagt 4081 cttgttgtgg agtgtggagg agaaagggtg gaatcggtgg tgatcaaaaa ccttaagaag 4141 acacccaact ttccaagttc tgttctcttc atgaaagtgt tcttgcccaa ggaggaattg 4201 tacatgcccc cactggtgat caaggtcatc gaccacaggc agtttgggcg gaagcctgtc3961 aatctataca tggtccccca ggggatcagg cctgtggtcc agctcactgc cattgagatt 4021 ctagcttggg gcttaagaaa tatgaaaaac ttccagatgg cttctatcac atcccccagt 4081 cttgttgtgg agtgtggagg agaaagggtg gaatcggtgg tgatcaaaaa ccttaagaag 4141 acacccaact ttccaagttc tgttctcttc atgaaagtgt tcttgcccaa ggaggaattg 4201 tacatgcccc cactggtgat caaggtcatc gaccacaggc agtttgggcg gaagcctgtc
4261 gtcggccagt gcaccatcga gcgcctggac cgctttcgct gtgaccctta tgcagggaaa 4321 gaggacatcg tcccacagct caaagcctcc cttctgtctg ccccaccatg ccgggacatc 4381 gttatcgaaa tggaagacac caaaccatta ctggcttcta agctgacaga aaaggaggaa 4441 gaaatcgtgg actggtggag taaattttat gcttcctcag gggaacatga aaaatgcgga 4501 cagtatattc agaaaggcta ttccaagctc aagatatata attgtgaact agaaaatgtagtcggccagt 4261 gcaccatcga gcgcctggac cgctttcgct gtgaccctta tgcagggaaa 4321 gaggacatcg tcccacagct caaagcctcc cttctgtctg ccccaccatg ccgggacatc 4381 gttatcgaaa tggaagacac caaaccatta ctggcttcta agctgacaga aaaggaggaa 4441 gaaatcgtgg actggtggag taaattttat gcttcctcag gggaacatga aaaatgcgga 4501 cagtatattc agaaaggcta ttccaagctc aagatatata attgtgaact agaaaatgta
4561 gcagaatttg agggcctgac agacttctca gatacgttca agttgtaccg aggcaagtcg 4621 gatgaaaatg aagatccttc tgtggttgga gagtttaagg gctcctttcg gatctaccct 4681 ctgccggatg accccagcgt gccagcccct cccagacagt ttcgggaatt acctgacagc 4741 gtcccacagg aatgcacggt taggatttac attgttcgag gcttagagct ccagccccag 4801 gacaacaatg gcctgtgtga cccttacata aaaataacac tgggcaaaaa agtcattgaa4561 gcagaatttg agggcctgac agacttctca gatacgttca agttgtaccg aggcaagtcg 4621 gatgaaaatg aagatccttc tgtggttgga gagtttaagg gctcctttcg gatctaccct 4681 ctgccggatg accccagcgt gccagcccct cccagacagt ttcgggaatt acctgacagc 4741 gtcccacagg aatgcacggt taggatttac attgttcgag gcttagagct ccagccccag 4801 gacaacaatg gcctgtgtga cccttacata aaaataacac tgggcaaaaa agtcattgaa
4861 gaccgagatc actacattcc caacactctc aacccagtct ttggcaggat gtacgaactg 4921 agctgctact tacctcaaga aaaagacctg aaaatttctg tctatgatta tgacaccttt 4981 acccgggatg aaaaagtagg agaaacaatt attgatctgg aaaaccgatt cctttcccgc 5041 tttgggtccc actgcggcat accagaggag tactgtgttt ctggagtcaa tacctggcga4861 gaccgagatc actacattcc caacactctc aacccagtct ttggcaggat gtacgaactg 4921 agctgctact tacctcaaga aaaagacctg aaaatttctg tctatgatta tgacaccttt 4981 acccgggatg aaaaagtagg agaaacaatt attgatctgg aaaaccgatt cctttcccgc 5041 tttgggtccc actgcggcat accagaggag tactgtgttt ctggagtcaa tacctggcga
5101 gatcaactga gaccaacaca gctgcttcaa aatgtcgcca gattcaaagg cttcccacaa 5161 cccatccttt ccgaagatgg gagtagaatc agatatggag gacgagacta cagcttggat 5221 gaatttgaag ccaacaaaat cctgcaccag cacctcgggg cccctgaaga gcggcttgct 5281 cttcacatcc tcaggactca ggggctggtc cctgagcacg tggaaacaag gactttgcac 5341 agcaccttcc agcccaacat ttcccaggga aaacttcaga tgtgggtgga tgttttcccc5101 gatcaactga gaccaacaca gctgcttcaa aatgtcgcca gattcaaagg cttcccacaa 5161 cccatccttt ccgaagatgg gagtagaatc agatatggag gacgagacta cagcttggat 5221 gaatttgaag ccaacaaaat cctgcaccag cacctcgggg cccctgaaga gcggcttgct 5281 cttcacatcc tcaggactca ggggctggtc cctgagcacg tggaaacaag gactttgcac 5341 agcaccttcc agcccaacat ttcccaggga aaacttcaga tgtgggtgga tgttttcccc
5401 aagagtttgg ggccaccagg ccctcctttc aacatcacac cccggaaagc caagaaatac 5461 tacctgcgtg tgatcatctg gaacaccaag gacgttatct tggacgagaa aagcatcaca 5521 ggagaggaaa tgagtgacat ctacgtcaaa ggctggattc ctggcaatga agaaaacaaa 5581 cagaaaacag atgtccatta cagatctttg gatggtgaag ggaattttaa ctggcgattt 5641 gttttcccgt ttgactacct tccagccgaa caactctgta tcgttgcgaa aaaagagcat5401 aagagtttgg ggccaccagg ccctcctttc aacatcacac cccggaaagc caagaaatac 5461 tacctgcgtg tgatcatctg gaacaccaag gacgttatct tggacgagaa aagcatcaca 5521 ggagaggaaa tgagtgacat ctacgtcaaa ggctggattc ctggcaatga agaaaacaaa 5581 cagaaaacag atgtccatta cagatctttg gatggtgaag ggaattttaa ctggcgattt 5641 gttttcccgt ttgactacct tccagccgaa caactctgta tcgttgcgaa aaaagagcat
5701 ttctggagta ttgaccaaac ggaatttcga atcccaccca ggctgatcat tcagatatgg 5761 gacaatgaca agttttctct ggatgactac ttgggtttcc tagaacttga cttgcgtcac 5821 acgatcattc ctgcaaaatc accagagaaa tgcaggttgg acatgattcc ggacctcaaa 5881 gccatgaacc cccttaaagc caagacagcc tccctctttg agcagaagtc catgaaagga 5941 tggtggccat gctacgcaga gaaagatggc gcccgcgtaa tggctgggaa agtggagatg5701 ttctggagta ttgaccaaac ggaatttcga atcccaccca ggctgatcat tcagatatgg 5761 gacaatgaca agttttctct ggatgactac ttgggtttcc tagaacttga cttgcgtcac 5821 acgatcattc ctgcaaaatc accagagaaa tgcaggttgg acatgattcc ggacctcaaa 5881 gccatgaacc cccttaaagc caagacagcc tccctctttg agcagaagtc catgaaagga 5941 tggtggccat gctacgcaga gaaagatggc gcccgcgtaa tggctgggaa agtggagatg
6001 acattggaaa tcctcaacga gaaggaggcc gacgagaggc cagccgggaa ggggcgggac 6061 gaacccaaca tgaaccccaa gctggactta ccaaatcgac cagaaacctc cttcctctgg 6121 ttcaccaacc catgcaagac catgaagttc atcgtgtggc gccgctttaa gtgggtcatc 6181 atcggcttgc tgttcctgct tatcctgctg ctcttcgtgg ccgtgctcct ctactctttg 6241 ccgaactatt tgtcaatgaa gattgtaaag ccaaatgtgt aacaaaggca aaggcttcat6001 acattggaaa tcctcaacga gaaggaggcc gacgagaggc cagccgggaa ggggcgggac 6061 gaacccaaca tgaaccccaa gctggactta ccaaatcgac cagaaacctc cttcctctgg 6121 ttcaccaacc catgcaagac catgaagttc atcgtgtggc gccgctttaa gtgggtcatc 6181 atcggcttgc tgttcctgct tatcctgctg ctcttcgtgg ccgtgctcct ctactctttg 6241 ccgaactatt tgtcaatgaa gattgtaaag ccaaatgtgt aacaaaggca aaggcttcat
6301 ttcaagagtc atccagcaat gagagaatcc tgcctctgta gaccaacatc cagtgtgatt 6361 ttgtgtctga gaccacaccc cagtagcagg ttacgccatg tcaccgagcc ccattgattc 6421 ccagagggtc ttagtcctgg aaagtcaggc caacaagcaa cgtttgcatc atgttatctc 6481 ttaagtatta aaagttttat tttctaaagt ttaaatcatg tttttcaaaa tatttttcaa 6541 ggtggctggt tccatttaaa aatcatcttt ttatatgtgt cttcggttct agacttcagc6301 ttcaagagtc atccagcaat gagagaatcc tgcctctgta gaccaacatc cagtgtgatt 6361 ttgtgtctga gaccacaccc cagtagcagg ttacgccatg tcaccgagcc ccattgattc 6421 ccagagggtc ttagtcctgg aaagtcaggc caacaagcaa cgtttgcatc atgttatctc 6481 ttaagtatta aaagttttat tttctaaagt ttaaatcatg tttttcaaaa tatttttcaa 6541 ggtggctggt tccatttaaa aatcatcttt ttatatgtgt cttcggttct agacttcagc
6601 ttttggaaat tgctaaatag aattcaaaaa tctctgcatc ctgaggtgat atacttcata 6661 tttgtaatca actgaaagag ctgtgcatta taaaatcagt tagaatagtt agaacaattc 6721 ttatttatgc ccacaaccat tgctatattt tgtatggatg tcataaaagt ctatttaacc 6781 tctgtaatga aactaaataa aaatgtttca cctttaaaaa aaaaaaaaaa aaaaaaa 6601 ttttggaaat tgctaaatag aattcaaaaa tctctgcatc ctgaggtgat atacttcata 6661 tttgtaatca actgaaagag ctgtgcatta taaaatcagt tagaatagtt agaacaattc 6721 ttatttatgc ccacaaccat tgctatattt tgtatggatg tcataaaagt ctatttaacc 6781 tctgtaatga aactaaataa aaatgtttca cctttaaaaa aaaaaaaaaa aaaaaaa
<210> 30 <210> 30
<21 1 > 4969  <21 1> 4969
<212> DNA  <212> DNA
<213> Homo Sapiens  <213> Homo Sapiens
<400> 30 <400> 30
Otoferlin (OTOP) Otoferlin (OTOP)
1 ccgtgagttc tgcccaggcc ctgtgagctc accagagcca cagactcaca gcccagaggt 61 ggcttcttcc ttcaggaact gaagaacccc catgaacacc aacatctcca ggttctgaga1 ccgtgagttc tgcccaggcc ctgtgagctc accagagcca cagactcaca gcccagaggt 61 ggcttcttcc ttcaggaact gaagaacccc catgaacacc aacatctcca ggttctgaga
121 acagaacctg ggaaattgat gacttcctca tgatgaccga tactcaggat ggccctagcg 181 agagctccca gatcatgagg aagaaggcct gaacgacata caggagatga tcaaaacgga 241 gaagtcctac cctgagcgtc gcctgcgggg cgtcctggag gagctgagct gtggctgctg 301 ccgcttcctc tccctcgctg acaaggacca gggccactca tcccgcacca ggcttgaccg 361 ggagcgcctc aagtcctgca tgagggagct ggaaaacatg gggcagcagg ccaggatgct121 acagaacctg ggaaattgat gacttcctca tgatgaccga tactcaggat ggccctagcg 181 agagctccca gatcatgagg aagaaggcct gaacgacata caggagatga tcaaaacgga 241 gaagtcctac cctgagcgtc gcctgcgggg cgtcctggag gagctgagct gtggctgctg 301 ccgcttcctc tccctcgctg acaaggacca gggccactca tcccgcacca ggcttgaccg 361 ggagcgcctc aagtcctgca tgagggagct ggaaaacatg gggcagcagg ccaggatgct
421 gcgggcccag gtgaagcggc acacggtgcg ggacaagctg aggctgtgcc agaacttcct 481 gcagaagctg cgcttcctgg cggacgagcc ccagcacagc attcccgaca tcttcatctg 541 gatgatgagc aacaacaagc gtgtcgccta tgcccgtgtg ccctccaagg acctgctctt 601 ctccatcgtg gaggaggaga ctggcaagga ctgcgccaag gtcaagacgc tcttccttaa 661 gctgccaggg aagcggggct tcggctcggc aggctggaca gtgcaggcca aggtggagct421 gcgggcccag gtgaagcggc acacggtgcg ggacaagctg aggctgtgcc agaacttcct 481 gcagaagctg cgcttcctgg cggacgagcc ccagcacagc attcccgaca tcttcatctg 541 gatgatgagc aacaacaagc gtgtcgccta tgcccgtgtg ccctccaagg acctgctctt 601 ctccatcgtg gaggaggaga ctggcaagga ctgcgccaag gtcaagacgc tcttccttaa 661 gctgccaggg aagcggggct tcggctcggc aggctggaca gtgcaggcca aggtggagct
721 gtacctgtgg ctgggcctca gcaaacagcg caaggagttc ctgtgcggcc tgccctgtgg 781 cttccaggag gtcaaggcag cccagggcct gggcctgcat gccttcccac ccgtcagcct 841 ggtctacacc aagaagcagg cgttccagct ccgagcgcac atgtaccagg cccgcagcct 901 ctttgccgcc gacagcagcg gactctcaga cccctttgcc cgcgtcttct tcatcaatca 961 gagtcagtgc acagaggtgc tgaatgagac cctgtgtccc acctgggacc agatgctggt721 gtacctgtgg ctgggcctca gcaaacagcg caaggagttc ctgtgcggcc tgccctgtgg 781 cttccaggag gtcaaggcag cccagggcct gggcctgcat gccttcccac ccgtcagcct 841 ggtctacacc aagaagcagg cgttccagct ccgagcgcac atgtaccagg cccgcagcct 901 ctttgccgcc gacagcagcg gactctcaga cccctttgcc cgcgtcttct tcatcaatca 961 gagtcagtgc acagaggtgc tgaatgagac cctgtgtccc acctgggacc agatgctggt
1021 gttcgacaac ctggagctct atggtgaagc tcatgagctg agggacgatc cgcccatcat 1081 tgtcattgaa atctatgacc aggattccat gggcaaagct gacttcatgg gccggacctt 1141 cgccaaaccc ctggtgaaga tggcagacga ggcgtactgc ccaccccgct tcccacctca 1201 gctcgagtac taccagatct accgtggcaa cgccacagct ggagacctgc tggcggcctt 1261 cgagctgctg cagattggac cagcagggaa ggctgacctg ccccccatca atggcccggt1021 gttcgacaac ctggagctct atggtgaagc tcatgagctg agggacgatc cgcccatcat 1081 tgtcattgaa atctatgacc aggattccat gggcaaagct gacttcatgg gccggacctt 1141 cgccaaaccc ctggtgaaga tggcagacga ggcgtactgc ccaccccgct tcccacctca 1201 gctcgagtac taccagatct accgtggcaa cgccacagct ggagacctgc tggcggcctt 1261 cgagctgctg cagattggac cagcagggaa ggctgacctg ccccccatca atggcccggt
1321 ggacgtggac cgaggtccca tcatgcccgt gcccatgggc atccggcccg tgctcagcaa 1381 gtaccgagtg gaggtgctgt tctggggcct acgggaccta aagcgggtga acctggccca 1441 ggtggaccgg ccacgggtgg acatcgagtg tgcagggaag ggggtgcagt cgtccctgat 1501 ccacaattat aagaagaacc ccaacttcaa caccctcgtc aagtggtttg aagtggacct 1561 cccagagaac gagctgctgc acccgccctt gaacatccgt gtggtggact gccgggcctt1321 ggacgtggac cgaggtccca tcatgcccgt gcccatgggc atccggcccg tgctcagcaa 1381 gtaccgagtg gaggtgctgt tctggggcct acgggaccta aagcgggtga acctggccca 1441 ggtggaccgg ccacgggtgg acatcgagtg tgcagggaag ggggtgcagt cgtccctgat 1501 ccacaattat aagaagaacc ccaacttcaa caccctcgtc aagtggtttg aagtggacct 1561 cccagagaac gagctgctgc acccgccctt gaacatccgt gtggtggact gccgggcctt
1621 cggtcgctac acactggtgg gctcccatgc cgtcagctcc ctgcgacgct tcatctaccg 1681 gcccccagac cgctcggccc ccagctggaa caccacgggg gaggttgtgg tgactatgga 1741 gccagaggta cccatcaaga aactggagac catggtgaag ctggacgcga cttctgaagc 1801 tgttgtcaag gtggatgtgg ctgaggagga gaaggagaag aagaagaaga agaagggcac 1861 tgcggaggag ccagaggagg aggagccaga cgagagcatg ctggactggt ggtccaagta1621 cggtcgctac acactggtgg gctcccatgc cgtcagctcc ctgcgacgct tcatctaccg 1681 gcccccagac cgctcggccc ccagctggaa caccacgggg gaggttgtgg tgactatgga 1741 gccagaggta cccatcaaga aactggagac catggtgaag ctggacgcga cttctgaagc 1801 tgttgtcaag gtggatgtgg ctgaggagga gaaggagaag aagaagaaga agaagggcac 1861 tgcggaggag ccagaggagg aggagccaga cgagagcatg ctggactggt ggtccaagta
1921 ctttgcctcc attgacacca tgaaggagca acttcgacaa caagagccct ctggaattga 1981 cttggaggag aaggaggaag tggacaatac cgagggcctg aaggggtcaa tgaagggcaa 2041 ggagaaggca agggctgcca aagaggagaa gaagaagaaa actcagagct ctggctctgg 2101 ccaggggtcc gaggcccccg agaagaagaa acccaagatt gatgagctta aggtataccc 2161 caaagagctg gagtccgagt ttgataactt tgaggactgg ctgcacactt tcaacttgct1921 ctttgcctcc attgacacca tgaaggagca acttcgacaa caagagccct ctggaattga 1981 cttggaggag aaggaggaag tggacaatac cgagggcctg aaggggtcaa tgaagggcaa 2041 ggagaaggca agggctgcca aagaggagaa gaagaagaaa actcagagct ctggctctgg 2101 ccaggggtcc gaggcccccg agaagaagaa acccaagatt gatgagctta aggtataccc 2161 caaagagctg gagtccgagt ttgataactt tgaggactgg ctgcacactt tcaacttgct
2221 tcggggcaag accggggatg atgaggatgg ctccaccgag gaggagcgca ttgtgggacg 2281 cttcaagggc tccctctgcg tgtacaaagt gccactccca gaggacgtgt cccgggaagc 2341 cggctacgac tccacctacg gcatgttcca gggcatcccg agcaatgacc ccatcaatgt 2401 gctggtccga gtctatgtgg tccgggccac ggacctgcac cctgctgaca tcaacggcaa 2461 agctgacccc tacatcgcca tccggctagg caagactgac atccgcgaca aggagaacta2221 tcggggcaag accggggatg atgaggatgg ctccaccgag gaggagcgca ttgtgggacg 2281 cttcaagggc tccctctgcg tgtacaaagt gccactccca gaggacgtgt cccgggaagc 2341 cggctacgac tccacctacg gcatgttcca gggcatcccg agcaatgacc ccatcaatgt 2401 gctggtccga gtctatgtgg tccgggccac ggacctgcac cctgctgaca tcaacggcaa 2461 agctgacccc tacatcgcca tccggctagg caagactgac atccgcgaca aggagaacta
2521 catctccaag cagctcaacc ctgtctttgg gaagtccttt gacatcgagg cctccttccc 2581 catggaatcc atgctgacgg tggctgtgta tgactgggac ctggtgggca ctgatgacct 2641 cattggggaa accaagatcg acctggagaa ccgcttctac agcaagcacc gcgccacctg 2701 cggcatcgcc cagacctact ccacacatgg ctacaatatc tggcgggacc ccatgaagcc2521 catctccaag cagctcaacc ctgtctttgg gaagtccttt gacatcgagg cctccttccc 2581 catggaatcc atgctgacgg tggctgtgta tgactgggac ctggtgggca ctgatgacct 2641 cattggggaa accaagatcg acctggagaa ccgcttctac agcaagcacc gcgccacctg 2701 cggcatcgcc cagacctact ccacacatgg ctacaatatc tggcgggacc ccatgaagcc
2761 cagccagatc ctgacccgcc tctgcaaaga cggcaaagtg gacggccccc actttgggcc2761 cagccagatc ctgacccgcc tctgcaaaga cggcaaagtg gacggccccc actttgggcc
2821 ccctgggaga gtgaaggtgg ccaaccgcgt cttcactggg ccctctgaga ttgaggacga2821 ccctgggaga gtgaaggtgg ccaaccgcgt cttcactggg ccctctgaga ttgaggacga
2881 gaacggtcag aggaagccca cagacgagca tgtggcgctg ttggccctga ggcactggga2881 gaacggtcag aggaagccca cagacgagca tgtggcgctg ttggccctga ggcactggga
2941 ggacatcccc cgcgcaggct gccgcctggt gccagagcat gtggagacga ggccgctgct 3001 caaccccgac aagccgggca tcgagcaggg ccgcctggag ctgtgggtgg acatgttccc2941 ggacatcccc cgcgcaggct gccgcctggt gccagagcat gtggagacga ggccgctgct 3001 caaccccgac aagccgggca tcgagcaggg ccgcctggag ctgtgggtgg acatgttccc
3061 catggacatg ccagcccctg ggacgcctct ggacatctca cctcggaagc ccaagaagta3061 catggacatg ccagcccctg ggacgcctct ggacatctca cctcggaagc ccaagaagta
3121 cgagctgcgg gtcatcatct ggaacacaga tgaggtggtc ttggaggacg acgacttctt3121 cgagctgcgg gtcatcatct ggaacacaga tgaggtggtc ttggaggacg acgacttctt
3181 cacaggggag aagtccagtg acatcttcgt gagggggtgg ctgaagggcc agcaggagga3181 cacaggggag aagtccagtg acatcttcgt gagggggtgg ctgaagggcc agcaggagga
3241 caagcaggac acagacgtcc actaccactc cctcactggc gagggcaact tcaactggcg 3301 ctacctgttc cccttcgact acctggcggc ggaggagaag atcgtcatct ccaagaagga3241 caagcaggac acagacgtcc actaccactc cctcactggc gagggcaact tcaactggcg 3301 ctacctgttc cctctcgact acctggcggc ggaggagaag atcgtcatct ccaagaagga
3361 gtccatgttc tcctgggacg agaccgagta caagatcccc gcgcggctca ccctgcagat3361 gtccatgttc tcctgggacg agaccgagta caagatcccc gcgcggctca ccctgcagat
3421 ctgggatgcg gaccacttct ccgctgacga cttcctgggg gccatcgagc tggacctgaa3421 ctgggatgcg gaccacttct ccgctgacga cttcctgggg gccatcgagc tggacctgaa
3481 ccggttcccg cggggcgcaa agacagccaa gcagtgcacc atggagatgg ccaccgggga3481 ccggttcccg cggggcgcaa agacagcaa gcagtgcacc atggagatgg ccaccgggga
3541 ggtggacgtg cccctcgtgt ccatcttcaa gcaaaagcgc gtcaaaggct ggtggcccct 3601 cctggcccgc aatgagaacg atgagtttga gctcacgggc aaggtggagg ctgagctgca3541 ggtggacgtg cccctcgtgt ccatcttcaa gcaaaagcgc gtcaaaggct ggtggcccct 3601 cctggcccgc aatgagaacg atgagtttga gctcacgggc aaggtggagg ctgagctgca
3661 tttactgaca gcagaggagg cagagaagaa cccagtgggc ctggcccgca atgaacctga3661 tttactgaca gcagaggagg cagagaagaa cccagtgggc ctggcccgca atgaacctga
3721 ccccctagag aaacccaacc ggcccgacac gagcttcatc tggttcctga accctctcaa 3781 gtcggctcgc tacttcttgt ggcacacgta tcgctggctg ctcctcaaac tgttgctgct 3841 cctgctgctg ctcctcctcc tcgccctgtt cctctactct gtgcctggct acctggtcaa 3901 gaaaatcctc ggggcctgag cccagtggcc tcctggccgg cccgacacgg ccttcgtctg3721 ccccctagag aaacccaacc ggcccgacac gagcttcatc tggttcctga accctctcaa 3781 gtcggctcgc tacttcttgt ggcacacgta tcgctggctg ctcctcaaac tgttgctgct 3841 cctgctgctg ctcctcctcc tcgccctgtt cctctactct gtgcctggct acctggtcaa 3901 gaaaatcctc ggggcctgag cccagtggcc tcctggccgg cccgacacgg ccttcgtctg
3961 gttcctcaac cctctcaagt ccatcaagta cctcatctgc acccggtaca agtggctcat3961 gttcctcaac cctctcaagt ccatcaagta cctcatctgc acccggtaca agtggctcat
4021 catcaagatc gtgctggcgc tgttggggct gctcatgttg gggctcttcc tctacagcct4021 catcaagatc gtgctggcgc tgttggggct gctcatgttg gggctcttcc tctacagcct
4081 ccctggctac atggtcaaaa agctccttgg ggcatgaagg ccgccagctc ccgccagccg4081 ccctggctac atggtcaaaa agctccttgg ggcatgaagg ccgccagctc ccgccagccg
4141 ctccccagcc ctgccgcatt tcctttcagt ggcttggact ctttcccatc tcccctgggg 4201 agcctgagga gcccagcgtc cactcttcat gccttgggcc gagcctgcct cctgcttgcg4141 ctccccagcc ctgccgcatt tcctttcagt ggcttggact ctttcccatc tcccctgggg 4201 agcctgagga gcccagcgtc cactcttcat gccttgggcc gagcctgcct cctgcttgcg
4261 ggggccgcct gtcctcactg ccccaggctg cggcttgccc agtcccgccc ctctgacccc4261 ggggccgcct gctctcactg ccccaggctg cggcttgccc agtcccgccc ctctgacccc
4321 tgcctgtggg ctggggagcc ttggatgggg tggggacctg gaatgggtct ctcttgcccc4321 tgcctgtggg ctggggagcc ttggatgggg tggggacctg gaatgggtct ctcttgcccc
4381 acctggctga ggcgccaccc ttcttcaggc ccaggctcca gaggaagact cctgaaaccc4381 acctggctga ggcgccaccc ttcttcaggc ccaggctcca gaggaagact cctgaaaccc
4441 tccccaggtc ttccaagtac aggattgaag ctttagtgaa attaaccaag gaccatgggt 4501 cagtgcccag ggctttaaaa agaatgaacg agcaaaaggt atccccgccg tgacccctgc4441 tccccaggtc ttccaagtac aggattgaag ctttagtgaa attaaccaag gaccatgggt 4501 cagtgcccag ggctttaaaa agaatgaacg agcaaaaggt atccccgccg tgacccctgc
4561 agatagcacc ggtctttgat ccgcagcagg ggccagaccc tgcccacaag tcccagcgcg4561 agatagcacc ggtctttgat ccgcagcagg ggccagaccc tgcccacaag tcccagcgcg
4621 gctgcttctg ccactgctgg gctccacttg gctcctctca cttcccaggg ggtcgcctgt4621 gctgcttctg ccactgctgg gctccacttg gctcctctca cttcccaggg ggtcgcctgt
4681 cctgcctgtg ggtttccatg gcttcccaga gctccctctg ccccagccag cgcctccagg4681 cctgcctgtg ggtttccatg gcttcccaga gctccctctg ccccagccag cgcctccagg
4741 cccagctgag gagctgtgag aagcagcaga ggggactccc catcccgggc acaccctgtc 4801 ctcccacccc tgcccccttg cccttccagc cctttcagct gcagctggga gctggcccgt4741 cccagctgag gagctgtgag aagcagcaga ggggactccc catcccgggc acaccctgtc 4801 ctcccacccc tgcccccttg cccttccagc cctttcagct gcagctggga gctggcccgt
4861 caagtgctgc ccctgcctgt gtctgggttt ctgttggctg tttttctttt cttgagtggt4861 caagtgctgc ccctgcctgt gtctgggttt ctgttggctg tttttctttt cttgagtggt
4921 gatttttctc taaataaaag aagtcaagca ctgaaaaaaa aaaaaaaaa 4921 gatttttctc taaataaaag aagtcaagca ctgaaaaaaaaaaaaaaa
<210> 31 <210> 31
<21 1 > 1849 <21 1> 1849
<212> DNA <213> Homo Sapiens <212> DNA <213> Homo Sapiens
<400> 31 <400> 31
SED-l SED-l
1 agtgggaggt gctgagccgc ctgatttatt ccggtcccag aggagaaggc gccagaaccc 61 cgcggggtct gagcagccca gcgtgcccat tccagcgccc gcgtccccgc agcatgccgc 1 agtgggaggt gctgagccgc ctgatttatt ccggtcccag aggagaaggc gccagaaccc 61 cgcggggtct gagcagccca gcgtgcccat tccagcgccc gcgtccccgc agcatgccgc
121 gcccccgcct gctggccgcg ctgtgcggcg cgctgctctg cgcccccagc ctcctcgtcg 181 ccctggatat ctgttccaaa aacccctgcc acaacggtgg tttatgcgag gagatttccc 241 aagaagtgcg aggagatgtc ttcccctcgt acacctgcac gtgccttaag ggctacgcgg 301 gcaaccactg tgagacgaaa tgtgtcgagc cactgggcct ggagaatggg aacattgcca 361 actcacagat cgccgcctcg tctgtgcgtg tgaccttctt gggtttgcag cattgggtcc121 gcccccgcct gctggccgcg ctgtgcggcg cgctgctctg cgcccccagc ctcctcgtcg 181 ccctggatat ctgttccaaa aacccctgcc acaacggtgg tttatgcgag gagatttccc 241 aagaagtgcg aggagatgtc ttcccctcgt acacctgcac gtgccttaag ggctacgcgg 301 gcaaccactg tgagacgaaa tgtgtcgagc cactgggcct ggagaatggg aacattgcca 361 actcacagat cgccgcctcg tctgtgcgtg tgaccttctt gggtttgcag cattgggtcc
421 cggagctggc ccgcctgaac cgcgcaggca tggtcaatgc ctggacaccc agcagcaatg 481 acgataaccc ctggatccag gtgaacctgc tgcggaggat gtgggtaaca ggtgtggtga 541 cgcagggtgc cagccgcttg gccagtcatg agtacctgaa ggccttcaag gtggcctaca 601 gccttaatgg acacgaattc gatttcatcc atgatgttaa taaaaaacac aaggagtttg 661 tgggtaactg gaacaaaaac gcggtgcatg tcaacctgtt tgagacccct gtggaggctc421 cggagctggc ccgcctgaac cgcgcaggca tggtcaatgc ctggacaccc agcagcaatg 481 acgataaccc ctggatccag gtgaacctgc tgcggaggat gtgggtaaca ggtgtggtga 541 cgcagggtgc cagccgcttg gccagtcatg agtacctgaa ggccttcaag gtggcctaca 601 gccttaatgg acacgaattc gatttcatcc atgatgttaa taaaaaacac aaggagtttg 661 tgggtaactg gaacaaaaac gcggtgcatg tcaacctgtt tgagacccct gtggaggctc
721 agtacgtgag attgtacccc acgagctgcc acacggcctg cactctgcgc tttgagctac 781 tgggctgtga gctgaacgga tgcgccaatc ccctgggcct gaagaataac agcatccctg 841 acaagcagat cacggcctcc agcagctaca agacctgggg cttgcatctc ttcagctgga 901 acccctccta tgcacggctg gacaagcagg gcaacttcaa cgcctgggtt gcggggagct 961 acggtaacga tcagtggctg cagatcttcc ctggcaactg ggacaaccac tcccacaaga721 agtacgtgag attgtacccc acgagctgcc acacggcctg cactctgcgc tttgagctac 781 tgggctgtga gctgaacgga tgcgccaatc ccctgggcct gaagaataac agcatccctg 841 acaagcagat cacggcctcc agcagctaca agacctgggg cttgcatctc ttcagctgga 901 acccctccta tgcacggctg gacaagcagg gcaacttcaa cgcctgggtt gcggggagct 961 acggtaacga tcagtggctg cagatcttcc ctggcaactg ggacaaccac tcccacaaga
1021 agaacttgtt tgagacgccc atcctggctc gctatgtgcg catcctgcct gtagcctggc 1081 acaaccgcat cgccctgcgc ctggagctgc tgggctgtta gtggccacct gccaccccca 1141 ggtcttcctg ctttccatgg gcccgctgcc tcttggcttc tcagcccctt taaatcacca 1201 tagggctggg gactggggaa ggggagggtg ttcagaggca gcaccaccac acagtcaccc 1261 ctccctccct ctttcccacc ctccacctct cacgggccct gccccagccc ctaagccccg1021 agaacttgtt tgagacgccc atcctggctc gctatgtgcg catcctgcct gtagcctggc 1081 acaaccgcat cgccctgcgc ctggagctgc tgggctgtta gtggccacct gccaccccca 1141 ggtcttcctg ctttccatgg gcccgctgcc tcttggcttc tcagcccctt taaatcacca 1201 tagggctggg gactggggaa ggggagggtg ttcagaggca gcaccaccac acagtcaccc 1261 ctccctccct ctttcccacc ctccacctct cacgggccct gccccagccc ctaagccccg
1321 tcccctaacc cccagtcctc actgtcctgt tttcttaggc actgagggat ctgagtaggt 1381 ctgggatgga caggaaaggg caaagtaggg cgtgtggttt ccctgcccct gtccggaccg 1441 ccgatcccag gtgcgtgtgt ctctgtctct cctagcccct ctctcacaca tcacattccc 1501 atggtggcct caagaaaggc ccggaagcgc caggctggag ataacagcct cttgcccgtc 1561 ggccctgcgt cggccctggg gtaccatgtg gccacaactg ctgtggcccc ctgtccccaa1321 tcccctaacc cccagtcctc actgtcctgt tttcttaggc actgagggat ctgagtaggt 1381 ctgggatgga caggaaaggg caaagtaggg cgtgtggttt ccctgcccct gtccggaccg 1441 ccgatcccag gtgcgtgtgt ctctgtctct cctagcccct ctctcacaca tcacattccc 1501 atggtggcct caagaaaggc ccggaagcgc caggctggag ataacagcct cttgcccgtc 1561 ggccctgcgt cggccctggg gtaccatgtg gccacaactg ctgtggcccc ctgtccccaa
1621 gacacttccc cttgtctccc tggttgcctc tcttgcccct tgtcctgaag cccagcgaca 1681 cagaaggggg tggggcgggt ctatggggag aaagggagcg aggtcagagg agggcatggg 1741 ttggcagggt gggcgtttgg ggccctctat gctggctttt caccccagag gacacaggca 1801 gcttccaaaa tatatttatc ttcttcacgg gaaaaaaaaa aaaaaaaaa 1621 gacacttccc cttgtctccc tggttgcctc tcttgcccct tgtcctgaag cccagcgaca 1681 cagaaggggg tggggcgggt ctatggggag aaagggagcg aggtcagagg agggcatggg 1741 ttggcagggt gggcgtttgg ggccctctat gctggctttt caccccagag gacacaggca 1801 gcttccaaaa tatatttatc ttcttcacgg gaaaaaaaaa aaaaaaaaa
<210> 32 <210> 32
<211> 8689  <211> 8689
<212> DNA  <212> DNA
<213> Homo Sapiens <213> Homo Sapiens
<400> 32  <400> 32
Zonad esin (ZAN) Zonad esin (ZAN)
1 gccatgttga tttctgatcc ttgagctttt ctgtgcttct ctgttcattc ttcatggcat 61 ccttggaagg atgccaagct aaggaggcca ggggggaata aaaggagtcc aggctcccaa 121 ctgtgccctt cccctctccc ctgggagcaa ccacttaggg tcctcatggt tcctccagtc1 gccatgttga tttctgatcc ttgagctttt ctgtgcttct ctgttcattc ttcatggcat 61 ccttggaagg atgccaagct aaggaggcca ggggggaata aaaggagtcc aggctcccaa 121 ctgtgccctt cccctctccc ctgggagcaa ccacttaggg tcctcatggt tcctccagtc
181 tggactctgc tgcttctggt gggggctgcc cttttcagga aagagaagcc tccggaccag 241 aagctggttg ttcgcagctc tagggacaac tatgtcctca cccagtgtga ttttgaggat 301 gacgccaaac ccctctgtga ctggtcccaa gtgtccgcag acgatgaaga ctgggttcga 361 gccagtgggc cctctcccac cggctccacc ggggcccccg gggggtaccc taacggagag 421 ggcagctatc tgcatatgga atcgaacagc ttccaccgtg ggggagtggc ccgcctgctc181 tggactctgc tgcttctggt gggggctgcc cttttcagga aagagaagcc tccggaccag 241 aagctggttg ttcgcagctc tagggacaac tatgtcctca cccagtgtga ttttgaggat 301 gacgccaaac ccctctgtga ctggtcccaa gtgtccgcag acgatgaaga ctgggttcga 361 gccagtgggc cctctcccac cggctccacc ggggcccccg gggggtaccc taacggagag 421 ggcagctatc tgcatatgga atcgaacagc ttccaccgtg ggggagtggc ccgcctgctc
481 agccccgacc tatgggagca aggccccctc tgtgtgcact ttgcccacca catgttcggg 541 ctgtcttggg gcgcccagct caggctgctg ctgctctcgg gtgaagaggg ccgccgcccc 601 gatgtgctct ggaaacactg gaacacccag agaccctcct ggatgctcac caccgtcact 661 gtgcccgcag ggttcaccct gcccacccgg ctgatgtttg agggaacacg gggtagcact 721 gcctacctgg acatcgccct ggatgccctc tctatccgcc ggggctcctg taatcgcgtc481 agccccgacc tatgggagca aggccccctc tgtgtgcact ttgcccacca catgttcggg 541 ctgtcttggg gcgcccagct caggctgctg ctgctctcgg gtgaagaggg ccgccgcccc 601 gatgtgctct ggaaacactg gaacacccag agaccctcct ggatgctcac caccgtcact 661 gtgcccgcag ggttcaccct gcccacccgg ctgatgtttg agggaacacg gggtagcact 721 gcctacctgg acatcgccct ggatgccctc tctatccgcc ggggctcctg taatcgcgtc
781 tgtatgatgc aaacatgcag ctttgacatt ccaaatgacc tctgtgactg gacctggatc 841 ccaactgcct ccggggccaa gtggactcag aagaaagggt catcaggaaa gccaggcgtg 901 gggcctgatg gcgacttctc tagccctggt agtggctgct acatgctcct ggaccccaag 961 aatgcaagac ctgggcagaa agctgtcctc ctgagccccg tgagcctgtc ctctggctgt 1021 ctgagctttt ccttccacta catcctccgg ggccagtctc ctggtgcagc cctccacatt781 tgtatgatgc aaacatgcag ctttgacatt ccaaatgacc tctgtgactg gacctggatc 841 ccaactgcct ccggggccaa gtggactcag aagaaagggt catcaggaaa gccaggcgtg 901 gggcctgatg gcgacttctc tagccctggt agtggctgct acatgctcct ggaccccaag 961 aatgcaagac ctgggcagaa agctgtcctc ctgagccccg tgagcctgtc ctctggctgt 1021 ctgagctttt ccttccacta catcctccgg ggccagtctc ctggtgcagc cctccacatt
1081 tatgcttcag tcttggggag tatccggaaa cacactctct tctcaggaca acctgggccc 1141 aactggcagg ctgtttctgt caattacaca gccgtgggac ggatacagtt tgccgtggta 1201 ggcgtttttg gaaagacccc agagccagct gtggcagttg atgcaaccag cattgctcct 1261 tgtggggagg gttttcctca gtgtgacttt gaagacaacg cccatccctt ctgtgactgg 1321 gtccagactt ccggggatgg tggacactgg gccctcggac ataaaaatgg acccgtccat1081 tatgcttcag tcttggggag tatccggaaa cacactctct tctcaggaca acctgggccc 1141 aactggcagg ctgtttctgt caattacaca gccgtgggac ggatacagtt tgccgtggta 1201 ggcgtttttg gaaagacccc agagccagct gtggcagttg atgcaaccag cattgctcct 1261 tgtggggagg gttttcctca gtgtgacttt gaagacaacg cccatccctt ctgtgactgg 1321 gtccagactt ccggggatgg tggacactgg gccctcggac ataaaaatgg acccgtccat
1381 ggcatgggcc ctgcgggagg tttccctaat gcagggggtc actatatcta ccttgaggct 1441 gacgagttct cccaggcagg ccagtcagtc agactggtga gccggccctt ctgcgcccca 1501 ggtgacatct gcgtggagtt cgcataccac atgtatggcc ttggggaggg tactatgctc 1561 gaactcctcc tgggaagtcc tgcggggagt cccccgattc ctctctggaa acgcgtgggg 1621 tctcagcgcc cttactggca gaacacctcc gtcaccgtcc cctcaggaca ccaacagccc1381 ggcatgggcc ctgcgggagg tttccctaat gcagggggtc actatatcta ccttgaggct 1441 gacgagttct cccaggcagg ccagtcagtc agactggtga gccggccctt ctgcgcccca 1501 ggtgacatct gcgtggagtt cgcataccac atgtatggcc ttggggaggg tactatgctc 1561 gaactcctcc tgggaagtcc tgcggggagt cccccgattc ctctctggaa acgcgtgggg 1621 tctcagcgcc cttactggca gaacacctcc gtcaccgtcc cctcaggaca ccaacagccc
1681 atgcagctta ttttcaaggg catccaggga agcaacacgg cctctgtggt tgctatgggt 1741 ttcatcttga tcaatcctgg gacttgtcca gtaaaagtgc taccagagct tcctcccgta 1801 tctccagttt cttccactgg cccttctgaa accactggcc tcacagaaaa ccctacaatc 1861 tccaccaaga aacctacagt ttccatagaa aaacccagtg tcaccacaga aaagcccaca 1921 gtccccaaag aaaagcccac cattcccaca gaaaaaccca ccatctccac agaaaaaccc1681 atgcagctta ttttcaaggg catccaggga agcaacacgg cctctgtggt tgctatgggt 1741 ttcatcttga tcaatcctgg gacttgtcca gtaaaagtgc taccagagct tcctcccgta 1801 tctccagttt cttccactgg cccttctgaa accactggcc tcacagaaaa ccctacaatc 1861 tccaccaaga aacctacagt ttccatagaa aaacccagtg tcaccacaga aaagcccaca 1921 gtccccaaag aaaagcccac cattcccaca gaaaaaccca ccatctccac agaaaaaccc
1981 accattcctt cagaaaaacc caacatgccc tcagaaaaac ccaccattcc ctcagaaaaa 2041 cccaccatcc tcacagaaaa acccaccatt ccctcagaaa aacccaccat tccctcagaa 2101 aaacccacca tttccacaga aaaacccacc gtccccacag aagagcccac cacccccact 2161 gaggagacca ccacctccat ggaagagcct gtcatcccta cagaaaaacc cagcatccct 2221 acagaaaaac ccagcatccc cacggaaaaa cccaccatct ccatggaaga gactatcatc1981 accattcctt cagaaaaacc caacatgccc tcagaaaaac ccaccattcc ctcagaaaaa 2041 cccaccatcc tcacagaaaa acccaccatt ccctcagaaa aacccaccat tccctcagaa 2101 aaacccacca tttccacaga aaaacccacc gtccccacag aagagcccac cacccccact 2161 gaggagacca ccacctccat ggaagagcct gtcatcccta cagaaaaacc cagcatccct 2221 acagaaaaac ccagcatccc cacggaaaaa cccaccatct ccatggaaga gactatcatc
2281 tccacagaaa aacccaccat ctccccagaa aaacccacca tccccacaga aaaacccacc 2341 atccccacag aaaaatccac catctcccca gaaaaaccca ccacccccac agaaaaaccc 2401 accatcccca cagaaaaacc caccatctcc ccagaaaaac ccaccacccc cacagaaaaa 2461 cccaccatct ccccagaaaa actcaccatc cccacagaaa aacccaccat ccccacagaa 2521 aaacccacca ttcccacaga aaaacccacc atctccacag aagagcccac cacccccact2281 tccacagaaa aacccaccat ctccccagaa aaacccacca tccccacaga aaaacccacc 2341 atccccacag aaaaatccac catctcccca gaaaaaccca ccacccccac agaaaaaccc 2401 accatcccca cagaaaaacc caccatctcc ccagaaaaac ccaccacccc cacagaaaaa 2461 cccaccatct ccccagaaaa actcaccatc cccacagaaa aacccaccat ccccacagaa 2521 aaacccacca ttcccacaga aaaacccacc atctccacag aagagcccac cacccccact
2581 gaggagacca ccatctccac agaaaaaccc agcatcccca tggaaaaacc cactctcccc 2641 actgaagaaa ccaccacctc tgttgaagag actaccatct ctacagaaaa actcaccatc 2701 cccatggaaa aacccaccat ctccacagaa aaacccacca tccccacaga aaaacccacc 2761 atctccccag aaaaactcac catccccacg gaaaaactca ccatccccac ggaaaaaccc2581 gaggagacca ccatctccac agaaaaaccc agcatcccca tggaaaaacc cactctcccc 2641 actgaagaaa ccaccacctc tgttgaagag actaccatct ctacagaaaa actcaccatc 2701 cccatggaaa aacccaccat ctccacagaa aaacccacca tccccacaga aaaacccacc 2761 atctccccag aaaaactcac catccccacg gaaaaactca ccatccccac ggaaaaaccc
2821 accatcccca ttgaagagac taccatctcc acagaaaaac tcaccatccc cacagaaaaa 2881 cccaccatct ccccagaaaa acccaccatc tccacggaaa aacccaccat ccccacggaa 2941 aaacccacca tccccactga agagactacc atctccacag aaaaactcac catccccaca 3001 gaaaaaccca ccatctcccc agaaaaactc accatcccca cagaaaaacc caccatctcc 3061 acggaaaaac ccaccatccc cacggaaaaa cttaccatcc ccacggaaaa acccaccatc2821 accatcccca ttgaagagac taccatctcc acagaaaaac tcaccatccc cacagaaaaa 2881 cccaccatct ccccagaaaa acccaccatc tccacggaaa aacccaccat ccccacggaa 2941 aaacccacca tccccactga agagactacc atctccacag aaaaactcac catccccaca 3001 gaaaaaccca ccatctcccc agaaaaactc accatcccca cagaaaaacc caccatctcc 3061 acggaaaaac ccaccatccc cacggaaaaa cttaccatcc ccacggaaaa acccaccatc
3121 cccacagaaa aacccaccat tcccacagag aagctcacag ccctgaggcc accccatccc 3181 agccccacag ccactgggct ggcagccttg gtgatgtctc cacatgctcc aagtacccct 3241 atgaccagtg tgattctggg cactaccaca acctccagat ccagtacaga gcgctgccct 3301 ccaaatgccc gctacgaatc ctgtgcttgt cctgcttcgt gcaagagccc caggcctagc 3361 tgtgggcccc tctgtcggga gggctgtgtc tgcaaccctg gctttttgtt tagtgacaac3121 cccacagaaa aacccaccat tcccacagag aagctcacag ccctgaggcc accccatccc 3181 agccccacag ccactgggct ggcagccttg gtgatgtctc cacatgctcc aagtacccct 3241 atgaccagtg tgattctggg cactaccaca acctccagat ccagtacaga gcgctgccct 3301 ccaaatgccc gctacgaatc ctgtgcttgt cctgcttcgt gcaagagccc caggcctagc 3361 tgtgggcccc tctgtcggga gggctgtgtc tgcaaccctg gctttttgtt tagtgacaac
3421 cactgcatcc aggcctcttc ctgcaattgc ttctacaaca acgactacta tgagcctggg 3481 gcagagtggt tcagccccaa ctgcacagaa cattgccgct gctggcccgg cagtcgggtc 3541 gagtgccaga tctctcagtg tgggacacac accgtgtgcc agcttaagaa tggccagtat 3601 ggatgccacc cctacgcagg cactgccacc tgcttggtct acggagaccc tcattatgtc 3661 acctttgacg ggaggcactt tggcttcatg ggcaagtgca cttacatctt ggcccagccc3421 cactgcatcc aggcctcttc ctgcaattgc ttctacaaca acgactacta tgagcctggg 3481 gcagagtggt tcagccccaa ctgcacagaa cattgccgct gctggcccgg cagtcgggtc 3541 gagtgccaga tctctcagtg tgggacacac accgtgtgcc agcttaagaa tggccagtat 3601 ggatgccacc cctacgcagg cactgccacc tgcttggtct acggagaccc tcattatgtc 3661 acctttgacg ggaggcactt tggcttcatg ggcaagtgca cttacatctt ggcccagccc
3721 tgtggcaact caacagaccc attcttcagg gtgacagcca agaatgagga gcagggacag 3781 gaaggcgtgt cctgcctgag caaagtctac gtgaccctgc ccgagagcac cgtcaccctg 3841 cttaagggca gacgcactct ggttgggggt cagcaagtta ctctcccagc cataccctct 3901 aaaggcgtct tcctgggtgc aagcgggcgg tttgtggagc tgcagacgga gttcggtttg 3961 cgggtgagat gggatggtga ccagcagctg tatgttactg tgtccagcac atactctggc3721 tgtggcaact caacagaccc attcttcagg gtgacagcca agaatgagga gcagggacag 3781 gaaggcgtgt cctgcctgag caaagtctac gtgaccctgc ccgagagcac cgtcaccctg 3841 cttaagggca gacgcactct ggttgggggt cagcaagtta ctctcccagc cataccctct 3901 aaaggcgtct tcctgggtgc aagcgggcgg tttgtggagc tgcagacgga gttcggtttg 3961 cgggtgagat gggatggtga ccagcagctg tatgttactg tgtccagcac atactctggc
4021 aaactctgtg gtttgtgtgg gaactatgac ggcaacagtg acaatgacca cctgaagttg 4081 gacggcagcc cagcaggaga caaggaggag ctggggaaca gctggcagac ggaccaggac 4141 gaggaccagg agtgtcagaa gtaccaggtg gtgaattccc cgtcttgtga ttcatctctg 4201 cagagcagca tgtcggggcc agggttctgt ggacggctgg tcgacactca tggcccattt 4261 gagacatgcc tgctgcacgt gaaggccgct tccttcttcg acagctgcat gcttgatatg4021 aaactctgtg gtttgtgtgg gaactatgac ggcaacagtg acaatgacca cctgaagttg 4081 gacggcagcc cagcaggaga caaggaggag ctggggaaca gctggcagac ggaccaggac 4141 gaggaccagg agtgtcagaa gtaccaggtg gtgaattccc cgtcttgtga ttcatctctg 4201 cagagcagca tgtcggggcc agggttctgt ggacggctgg tcgacactca tggcccattt 4261 gagacatgcc tgctgcacgt gaaggccgct tccttcttcg acagctgcat gcttgatatg
4321 tgcggattcc aggggctgca gcacctgctg tgcacacaca tgtccaccat gaccaccacc 4381 tgccaggacg caggccacgc tgtgaagccc tggagggaac cccacttctg cccaatggcc 4441 tgcccgccca acagcaagta ctccctgtgt gcgaagccat gccctgacac ctgccattca 4501 ggattctccg gcatgttctg ctcagaccgg tgcgtggagg cctgtgaatg caatccgggc 4561 ttcgtcctca gtggcctcga gtgcatacct cgctcccagt gtgggtgcct ccaccctgca4321 tgcggattcc aggggctgca gcacctgctg tgcacacaca tgtccaccat gaccaccacc 4381 tgccaggacg caggccacgc tgtgaagccc tggagggaac cccacttctg cccaatggcc 4441 tgcccgccca acagcaagta ctccctgtgt gcgaagccat gccctgacac ctgccattca 4501 ggattctccg gcatgttctg ctcagaccgg tgcgtggagg cctgtgaatg caatccgggc 4561 ttcgtcctca gtggcctcga gtgcatacct cgctcccagt gtgggtgcct ccaccctgca
4621 ggcagctact tcaaggtagg ggagcggtgg tacaagccag gctgcaaaga gttgtgcgtc 4681 tgtgaaagca acaacagaat tcgctgccag ccctggaggt gtagggccca ggagttctgt 4741 ggccaacagg atggtatcta tggctgccat gcccaaggtg ccgccacctg cacagcctcg 4801 ggtgaccccc actacctgac cttcgatggc gccttgcacc acttcatggg cacctgcacc 4861 tatgtcctga cccggccttg ctggtccagg tcccaagaca gctattttgt tgtgagcgcc4621 ggcagctact tcaaggtagg ggagcggtgg tacaagccag gctgcaaaga gttgtgcgtc 4681 tgtgaaagca acaacagaat tcgctgccag ccctggaggt gtagggccca ggagttctgt 4741 ggccaacagg atggtatcta tggctgccat gcccaaggtg ccgccacctg cacagcctcg 4801 ggtgaccccc actacctgac cttcgatggc gccttgcacc acttcatggg cacctgcacc 4861 tatgtcctga cccggccttg ctggtccagg tcccaagaca gctattttgt tgtgagcgcc
4921 accaacgaga accgcggggg gatcctggag gtctcctaca tcaaagccgt ccacgtgaca 4981 gtctttgacc tcagcatctc actgctcaga ggctgtaagg tcatgctgaa tggccatcgg 5041 gtggccctac ctgtgtggct tgcacaaggc cgggtgacca taaggctcag cagcaacctc 5101 gtcctcctct acacgaactt tgggctccaa gttcgctacg acgggagcca cttggtggaa 5161 gtgacagtcc cctcctccta tggcggccag ctctgtgggc tgtgtgggaa ctacaacaac4921 accaacgaga accgcggggg gatcctggag gtctcctaca tcaaagccgt ccacgtgaca 4981 gtctttgacc tcagcatctc actgctcaga ggctgtaagg tcatgctgaa tggccatcgg 5041 gtggccctac ctgtgtggct tgcacaaggc cgggtgacca taaggctcag cagcaacctc 5101 gtcctcctct acacgaactt tgggctccaa gttcgctacg acgggagcca cttggtggaa 5161 gtgacagtcc cctcctccta tggcggccag ctctgtgggc tgtgtgggaa ctacaacaac
5221 aacagcttgg atgacaacct gcgccccgac agaaagcttg caggcgattc catgcagctg 5281 ggggccgcct ggaagttacc tgaatcctct gaacctggct gtttccttgt gggtggcaag 5341 ccctccagct gccaggagaa cagcatggca gacgcctgga acaagaactg tgcgatctta 5401 ataaaccctc agggaccctt ctctcaatgt caccaggtgg tgcctcccca gtccagcttt5221 aacagcttgg atgacaacct gcgccccgac agaaagcttg caggcgattc catgcagctg 5281 ggggccgcct ggaagttacc tgaatcctct gaacctggct gtttccttgt gggtggcaag 5341 ccctccagct gccaggagaa cagcatggca gacgcctgga acaagaactg tgcgatctta 5401 ataaaccctc agggaccctt ctctcaatgt caccaggtgg tgcctcccca gtccagcttt
5461 gccagttgcg tgcatggtca gtgtgggacc aagggcgaca ccacagccct gtgccgctcc 5521 ctgcaggcct acgcgtccct gtgtgcccag gctggccagg cccctgcctg gcggaacaga 5581 accttctgcc ctatgaggtg cccacctggc agcagctaca gcccctgcag cagcccctgc 5641 ccagacacct gcagcagcat aaacaacccg agggactgcc ccaaagcact gccctgtgct 5701 gagagctgtg aatgtcagaa aggccacatc ttgagtggaa cctcctgcgt gccccttggc5461 gccagttgcg tgcatggtca gtgtgggacc aagggcgaca ccacagccct gtgccgctcc 5521 ctgcaggcct acgcgtccct gtgtgcccag gctggccagg cccctgcctg gcggaacaga 5581 accttctgcc ctatgaggtg cccacctggc agcagctaca gcccctgcag cagcccctgc 5641 ccagacacct gcagcagcat aaacaacccg agggactgcc ccaaagcact gccctgtgct 5701 gagagctgtg aatgtcagaa aggccacatc ttgagtggaa cctcctgcgt gccccttggc
5761 cagtgtggct gcactgaccc agcgggctcc taccacccgg tcggggagcg ctggtacaca 5821 gagaacacct gcaccaggct ctgcacctgc tccgtccaca acaacatcac ctgcttccag 5881 agcacctgca aacccaacca gatatgctgg gccctggatg ggctgctccg ttgtcgggcc 5941 tcaggtgtgg gagtgtgtca gctcccaggg gagtcccact acgtgagctt tgatggtagt 6001 aaccattcta tcccggacgc ctgcactctt gtcctggtga aagtgtgcca ccccgccatg5761 cagtgtggct gcactgaccc agcgggctcc taccacccgg tcggggagcg ctggtacaca 5821 gagaacacct gcaccaggct ctgcacctgc tccgtccaca acaacatcac ctgcttccag 5881 agcacctgca aacccaacca gatatgctgg gccctggatg ggctgctccg ttgtcgggcc 5941 tcaggtgtgg gagtgtgtca gctcccaggg gagtcccact acgtgagctt tgatggtagt 6001 aaccattcta tcccggacgc ctgcactctt gtcctggtga aagtgtgcca ccccgccatg
6061 gccttgccct tcttcaagat cagtgccaag catgagaagg aggaaggtgg aactgaggct 6121 ttccgccttc atgaggtcta cattgacatc tacgatgccc aggtcaccct gcagaagggc 6181 caccgtgtgc taatcaacag caaacaggtc accctccccg ccatctccca gatccctggg 6241 gtcagtgtca agtccagcag catctacagc attgttaaca tcaagatcgg ggtgcaagtc 6301 aagtttgacg ggaatcatct cttagagatt gaaatcccca caacctacta tggaaaggtc6061 gccttgccct tcttcaagat cagtgccaag catgagaagg aggaaggtgg aactgaggct 6121 ttccgccttc atgaggtcta cattgacatc tacgatgccc aggtcaccct gcagaagggc 6181 caccgtgtgc taatcaacag caaacaggtc accctccccg ccatctccca gatccctggg 6241 gtcagtgtca agtccagcag catctacagc attgttaaca tcaagatcgg ggtgcaagtc 6301 aagtttgacg ggaatcatct cttagagatt gaaatcccca caacctacta tggaaaggtc
6361 tgcggcatgt gtgggaactt caatgatgag gaagaggacg aactaatgat gcccagcgat 6421 gaagtagcaa atagtgacag tgaatttgtg aacagttgga aagataagga cattgaccca 6481 agttgtcaga gtctcctggt agatgagcag cagattccag cggaacagca ggagaacccg 6541 agtggaaact gcagggcggc cgacctccgc agggcgcggg aaaagtgcga ggcagcgctc 6601 cgggctcctg tgtgggccca gtgcgcctcc cgcatagacc tcacgccctt cctggtggac6361 tgcggcatgt gtgggaactt caatgatgag gaagaggacg aactaatgat gcccagcgat 6421 gaagtagcaa atagtgacag tgaatttgtg aacagttgga aagataagga cattgaccca 6481 agttgtcaga gtctcctggt agatgagcag cagattccag cggaacagca ggagaacccg 6541 agtggaaact gcagggcggc cgacctccgc agggcgcggg aaaagtgcga ggcagcgctc 6601 cgggctcctg tgtgggccca gtgcgcctcc cgcatagacc tcacgccctt cctggtggac
6661 tgtgcaaaca ccctctgtga gttcggaggt ctctaccagg ccctctgcca ggctctgcaa 6721 gccttcgggg ccacctgcca gagccagggg ctcaagcccc cactctggag aaacagcagc 6781 ttctgccctc tggaatgccc tgcctacagc agctacacca actgccttcc ctcctgctca 6841 ccctcctgct gggacctgga tggccggtgt gagggcgcca aagtcccctc tgcctgcgct 6901 gagggctgca tttgtcagcc cggctatgtg ctgagtgaag acaagtgtgt ccccagaagt6661 tgtgcaaaca ccctctgtga gttcggaggt ctctaccagg ccctctgcca ggctctgcaa 6721 gccttcgggg ccacctgcca gagccagggg ctcaagcccc cactctggag aaacagcagc 6781 ttctgccctc tggaatgccc tgcctacagc agctacacca actgccttcc ctcctgctca 6841 ccctcctgct gggacctgga tggccggtgt gagggcgcca aagtcccctc tgcctgcgct 6901 gagggctgca tttgtcagcc cggctatgtg ctgagtgaag acaagtgtgt ccccagaagt
6961 cagtgtggct gcaaggatgc ccatggtggc tccatccctc tgggcaagag ctgggtctcc 7021 agcggttgca cggagaagtg tgtctgcacg ggaggagcca ttcagtgcgg ggacttccga 7081 tgcccctctg ggtcccactg ccagctcact tccgacaaca gcaacagcaa ttgtgtctca 7141 gacaagtctg aacaatgctc agtctatggc gacccccgtt acctcacatt tgacggcttc 7201 agctaccgct tgcaaggccg catgacctat gttctgatca agactgtgga cgtactgcct6961 cagtgtggct gcaaggatgc ccatggtggc tccatccctc tgggcaagag ctgggtctcc 7021 agcggttgca cggagaagtg tgtctgcacg ggaggagcca ttcagtgcgg ggacttccga 7081 tgcccctctg ggtcccactg ccagctcact tccgacaaca gcaacagcaa ttgtgtctca 7141 gacaagtctg aacaatgctc agtctatggc gacccccgtt acctcacatt tgacggcttc 7201 agctaccgct tgcaaggccg catgacctat gttctgatca agactgtgga cgtactgcct
7261 gagggggtgg agcccctcct cgtggaagga cgcaacaaga tggatccgcc caggagctcc 7321 atcttcttgc aggaagtgat taccaccgtc tacggctata aagtgcagct ccaagctggt 7381 ctggagcttg tggtcaacaa ccagaagatg gccgtcccct acaggccaaa tgaacacctg 7441 cgggtcaccc tgtggggcca acggctctac ctggtcaccg actttgagct ggtcgtcagc 7501 tttggtggaa ggaaaaatgc agtgatctcc ctacccagca tgtacgaggg gcttgtgagt7261 gagggggtgg agcccctcct cgtggaagga cgcaacaaga tggatccgcc caggagctcc 7321 atcttcttgc aggaagtgat taccaccgtc tacggctata aagtgcagct ccaagctggt 7381 ctggagcttg tggtcaacaa ccagaagatg gccgtcccct acaggccaaa tgaacacctg 7441 cgggtcaccc tgtggggcca acggctctac ctggtcaccg actttgagct ggtcgtcagc 7501 tttggtggaa ggaaaaatgc agtgatctcc ctacccagca tgtacgaggg gcttgtgagt
7561 ggcctgtgcg gaaactacga caagaaccgc aagaatgaca tgatgctgcc cagtggcgcc 7621 ctgacccaga acctcaacac ctttggcaac agctgggagg tgaagaccga ggacgcactc 7681 ctgcgcttcc ccagggctat accagcggag gaggagggac aaggggcgga gctgggcctc 7741 cgcacgggcc tccaagtgtc cgaatgtagc ccggagcagc tggcgagcaa cagcacccag 7801 gcctgtaggg tgctggcaga cccccagggc ccctttgctg cctgtcacca gacggtggcc7561 ggcctgtgcg gaaactacga caagaaccgc aagaatgaca tgatgctgcc cagtggcgcc 7621 ctgacccaga acctcaacac ctttggcaac agctgggagg tgaagaccga ggacgcactc 7681 ctgcgcttcc ccagggctat accagcggag gaggagggac aaggggcgga gctgggcctc 7741 cgcacgggcc tccaagtgtc cgaatgtagc ccggagcagc tggcgagcaa cagcacccag 7801 gcctgtaggg tgctggcaga cccccagggc ccctttgctg cctgtcacca gacggtggcc
7861 ccagagccct tccaagagca ctgcgtgctg gatctgtgct ctgctcagga cccaagagag 7921 caagaggagc tgcgttgcca ggtcctcagt ggccatggag tgtccagcag gtaccatata 7981 tcagagctgt atgacaccct gcccagcatc ctgtgccaac ctggcagacc ccggggactg 8041 cgagggcccc tgcgtggaag gctgcgccag catcccaggc tatgcctaca gtggcaccca7861 ccagagccct tccaagagca ctgcgtgctg gatctgtgct ctgctcagga cccaagagag 7921 caagaggagc tgcgttgcca ggtcctcagt ggccatggag tgtccagcag gtaccatata 7981 tcagagctgt atgacaccct gcccagcatc ctgtgccaac ctggcagacc ccggggactg 8041 cgagggcccc tgcgtggaag gctgcgccag catcccaggc tatgcctaca gtggcaccca
8101 gagcctcccc tggctgactg tggctgcacc agcaatggca tctactacca gctgggcagc8101 gagcctcccc tggctgactg tggctgcacc agcaatggca tctactacca gctgggcagc
8161 agctttctga ctgaggactg ctctcagcgg tgcacctgtg ccagctcacg gatcctgctg8161 agctttctga ctgaggactg ctctcagcgg tgcacctgtg ccagctcacg gatcctgctg
8221 tgtgagccct tcagctgcag agcgggggag gtctgcaccc tggggaacca cacccaaggc8221 tgtgagccct tcagctgcag agcgggggag gtctgcaccc tggggaacca cacccaaggc
8281 tgctttccag aaagcccgtg tctgcagaac ccctgtcaga atgacgggca gtgtcgggag8281 tgctttccag aaagcccgtg tctgcagaac ccctgtcaga atgacgggca gtgtcgggag
8341 cagggagcca ccttcacctg cgagtgtgaa gttggttacg ggggaggcct gtgtatggag8341 cagggagcca ccttcacctg cgagtgtgaa gttggttacg ggggaggcct gtgtatggag
8401 cctcgagatg cgccacctcc cagaaagcca gcatctaacc tggtggccgt cctactggga8401 cctcgagatg cgccacctcc cagaaagcca gcatctaacc tggtggccgt cctactggga
8461 ctgctggtgc ctgtggtggt cgtactactg gccgtgacca gagagtgcat ttacagaacg8461 ctgctggtgc ctgtggtggt cgtactactg gccgtgacca gagagtgcat ttacagaacg
8521 aggaggaaga gagagaaaac gcaggaggga gacagactgg ccaggctggt ggacacagat8521 aggaggaaga gagagaaaac gcaggaggga gacagactgg ccaggctggt ggacacagate
8581 actgttctgg actgtgcctg ttaagttgct cagttttgag ctgtcttcag acaagaagat 8641 taaataaatt tatatattta tttatttgaa aaaaaaaaaa aaaaaaaaa 8581 actgttctgg actgtgcctg ttaagttgct cagttttgag ctgtcttcag acaagaagat 8641 taaataaatt tatatattta tttatttgaa aaaaaaaaaaaaaaaaaa
<210> 33 <210> 33
<211 > 4456  <211> 4456
<212> DNA <212> DNA
<213> Homo Sapiens  <213> Homo Sapiens
<400> 33 <400> 33
MMP15  MMP15
1 acgactcttt gatccctccc ctaagacctc cttcccgtcc gcctaggcct cggtatcccc 61 caccaggtat gagaaggagg agtcttcatt cttcccaggc ggggagacca cgccttccct 121 gcctcctccc tccgcggggg gtcgcgttgg aggtcacccc cgccccctag gcgctgggtt 181 gggagtgacg cggggtgggc tggagaggtt tcctgccgtc tgggaagcgt aaacggaccg 241 cccacctgtc gggcctcggc cgcccgcacc tgcttgtgag aagcctgcgg ctggggcacc 301 gcccccggtc cccgcccggg tccgcgcatt gggagcacac tggcccttta agagcgcggc 361 ggccgcggcg cgcggggagg agggctggga gcgcccggag ccgcgctgaa ctcgccgggg 421 acgtcgggcg cccgctcctt ggctggctcg cttgctctct cgctcgctct ctcgggtcgg 481 ctccctgcgc ctcctcccgg gactgcttgg ggacccgggc ccggtcgggc gcggcggcga 541 gcagaatccc cgtgcaggag gcgcgcgctc cgggcagcgc ccggccccgg gcatggacag 601 agggagctgg gcgcgcaggg agcgccgcgg gaccgggcgg ccggagcgct gagccagaca 661 aaggctccgg agttgcgctt gctctcggga gccgggcccc aggcgctggg cgccgaggct 721 gcggaacctc gccgggggca gctccggtcg gccccctttc ccgccggctg gttccgagct 781 cccggacctg ccctgcccgc ttctcctcgg gcttgggaat ttgccgaggc gacctaggcg 841 gctccggcgg ggaccgggag cccgaggtcc gcggcgcgcc tgccgggcca ggagccaggg 901 agcgtcgcaa gtttccaagg cgcgtgcgag gatccggcgt gcagtgttcc gagctgggct 961 gggcgccgag agcatgggca gcgacccgag cgcgcccgga cggccgggct ggacgggcag 1021 cctcctcggc gaccgggagg aggcggcgcg gccgcgactg ctgccgctgc tcctggtgct 1081 tctgggctgc ctgggccttg gcgtagcggc cgaagacgcg gaggtccatg ccgagaactg 1141 gctgcggctt tatggctacc tgcctcagcc cagccgccat atgtccacca tgcgttccgc 1201 ccagatcttg gcctcggccc ttgcagagat gcagcgcttc tacgggatcc cagtcaccgg 1261 tgtgctcgac gaagagacca aggagtggat gaagcggccc cgctgtgggg tgccagacca 1321 gttcggggta cgagtgaaag ccaacctgcg gcggcgtcgg aagcgctacg ccctcaccgg 1381 gaggaagtgg aacaaccacc atctgacctt tagcatccag aactacacgg agaagttggg 1441 ctggtaccac tcgatggagg cggtgcgcag ggccttccgc gtgtgggagc aggccacgcc 1501 cctggtcttc caggaggtgc cctatgagga catccggctg cggcgacaga aggaggccga 1561 catcatggta ctctttgcct ctggcttcca cggcgacagc tcgccgtttg atggcaccgg 1621 tggctttctg gcccacgcct atttccctgg ccccggccta ggcggggaca cccattttga 1681 cgcagatgag ccctggacct tctccagcac tgacctgcat ggaaacaacc tcttcctggt 1741 ggcagtgcat gagctgggcc acgcgctggg gctggagcac tccagcaacc ccaatgccat 1801 catggcgccg ttctaccagt ggaaggacgt tgacaacttc aagctgcccg aggacgatct 1861 ccgtggcatc cagcagctct acggtacccc agacggtcag ccacagccta cccagcctct1 acgactcttt gatccctccc ctaagacctc cttcccgtcc gcctaggcct cggtatcccc 61 caccaggtat gagaaggagg agtcttcatt cttcccaggc ggggagacca cgccttccct 121 gcctcctccc tccgcggggg gtcgcgttgg aggtcacccc cgccccctag gcgctgggtt 181 gggagtgacg cggggtgggc tggagaggtt tcctgccgtc tgggaagcgt aaacggaccg 241 cccacctgtc gggcctcggc cgcccgcacc tgcttgtgag aagcctgcgg ctggggcacc 301 gcccccggtc cccgcccggg tccgcgcatt gggagcacac tggcccttta agagcgcggc 361 ggccgcggcg cgcggggagg agggctggga gcgcccggag ccgcgctgaa ctcgccgggg 421 acgtcgggcg cccgctcctt ggctggctcg cttgctctct cgctcgctct ctcgggtcgg 481 ctccctgcgc ctcctcccgg gactgcttgg ggacccgggc ccggtcgggc gcggcggcga 541 gcagaatccc cgtgcaggag gcgcgcgctc cgggcagcgc ccggccccgg gcatggacag 601 agggagctgg gcgcgcaggg agcgccgcgg gaccgggcgg ccggagcgct gagccagaca 661 aaggctccgg agttgcgctt gctctcggga gccgggcccc aggcgctggg cgccgaggct 721 gcggaacctc gccgggggca gctccggtcg gccccctttc ccgccggctg gttccgagct 781 cccggacctg ccctgcccgc ttctcctcgg gcttgggaat ttgccgaggc gacctaggcg 841 gctccggcgg ggaccggg ag cccgaggtcc gcggcgcgcc tgccgggcca ggagccaggg 901 agcgtcgcaa gtttccaagg cgcgtgcgag gatccggcgt gcagtgttcc gagctgggct 961 gggcgccgag agcatgggca gcgacccgag cgcgcccgga cggccgggct ggacgggcag 1021 cctcctcggc gaccgggagg aggcggcgcg gccgcgactg ctgccgctgc tcctggtgct 1081 tctgggctgc ctgggccttg gcgtagcggc cgaagacgcg gaggtccatg ccgagaactg 1141 gctgcggctt tatggctacc tgcctcagcc cagccgccat atgtccacca tgcgttccgc 1201 ccagatcttg gcctcggccc ttgcagagat gcagcgcttc tacgggatcc cagtcaccgg 1261 tgtgctcgac gaagagacca aggagtggat gaagcggccc cgctgtgggg tgccagacca 1321 gttcggggta cgagtgaaag ccaacctgcg gcggcgtcgg aagcgctacg ccctcaccgg 1381 gaggaagtgg aacaaccacc atctgacctt tagcatccag aactacacgg agaagttggg 1441 ctggtaccac tcgatggagg cggtgcgcag ggccttccgc gtgtgggagc aggccacgcc 1501 cctggtcttc caggaggtgc cctatgagga catccggctg cggcgacaga aggaggccga 1561 catcatggta ctctttgcct ctggcttcca cggcgacagc tcgccgtttg atggcaccgg 1621 tggctttctg gcccacgcct atttccctgg ccccggccta ggcggggaca cccattttga 1681 cgcagatgag ccctggacct tctcc agcac tgacctgcat ggaaacaacc tcttcctggt 1741 ggcagtgcat gagctgggcc acgcgctggg gctggagcac tccagcaacc ccaatgccat 1801 catggcgccg ttctaccagt ggaaggacgt tgacaacttc aagctgcccg aggacgatct 1861 ccgtggcatc cagcagctct acggtacccc agacggtcag ccacagccta cccagcctct
1921 ccccactgtg acgccacggc ggccaggccg gcctgaccac cggccgcccc ggcctcccca 1981 gccaccaccc ccaggtggga agccagagcg gcccccaaag ccgggccccc cagtccagcc 2041 ccgagccaca gagcggcccg accagtatgg ccccaacatc tgcgacgggg actttgacac 2101 agtggccatg cttcgcgggg agatgttcgt gttcaagggc cgctggttct ggcgagtccg 2161 gcacaaccgc gtcctggaca actatcccat gcccatcggg cacttctggc gtggtctgcc1921 ccccactgtg acgccacggc ggccaggccg gcctgaccac cggccgcccc ggcctcccca 1981 gccaccaccc ccaggtggga agccagagcg gcccccaaag ccgggccccc cagtccagcc 2041 ccgagccaca gagcggcccg accagtatgg ccccaacatc tgcgacgggg actttgacac 2101 agtggccatg cttcgcgggg agatgttcgt gttcaagggc cgctggttct ggcgagtccg 2161 gcacaaccgc gtcctggaca actatcccat gcccatcggg cacttctggc gtggtctgcc
2221 cggtgacatc agtgctgcct acgagcgcca agacggtcgt tttgtctttt tcaaaggtga 2281 ccgctactgg ctctttcgag aagcgaacct ggagcccggc tacccacagc cgctgaccag 2341 ctatggcctg ggcatcccct atgaccgcat tgacacggcc atctggtggg agcccacagg 2401 ccacaccttc ttcttccaag aggacaggta ctggcgcttc aacgaggaga cacagcgtgg 2461 agaccctggg taccccaagc ccatcagtgt ctggcagggg atccctgcct cccctaaagg2221 cggtgacatc agtgctgcct acgagcgcca agacggtcgt tttgtctttt tcaaaggtga 2281 ccgctactgg ctctttcgag aagcgaacct ggagcccggc tacccacagc cgctgaccag 2341 ctatggcctg ggcatcccct atgaccgcat tgacacggcc atctggtggg agcccacagg 2401 ccacaccttc ttcttccaag aggacaggta ctggcgcttc aacgaggaga cacagcgtgg 2461 agaccctggg taccccaagc ccatcagtgt ctggcagggg atccctgcct cccctaaagg
2521 ggccttcctg agcaatgacg cagcctacac ctacttctac aagggcacca aatactggaa 2581 attcgacaat gagcgcctgc ggatggagcc cggctacccc aagtccatcc tgcgggactt 2641 catgggctgc caggagcacg tggagccagg cccccgatgg cccgacgtgg cccggccgcc 2701 cttcaacccc cacgggggtg cagagcccgg ggcggacagc gcagagggcg acgtggggga 2761 tggggatggg gactttgggg ccggggtcaa caaggacggg ggcagccgcg tggtggtgca2521 ggccttcctg agcaatgacg cagcctacac ctacttctac aagggcacca aatactggaa 2581 attcgacaat gagcgcctgc ggatggagcc cggctacccc aagtccatcc tgcgggactt 2641 catgggctgc caggagcacg tggagccagg cccccgatgg cccgacgtgg cccggccgcc 2701 cttcaacccc cacgggggtg cagagcccgg ggcggacagc gcagagggcg acgtggggga 2761 tggggatggg gactttgggg ccggggtcaa caaggacggg ggcagccgcg tggtggtgca
2821 gatggaggag gtggcacgga cggtgaacgt ggtgatggtg ctggtgccac tgctgctgct 2881 gctctgcgtc ctgggcctca cctacgcgct ggtgcagatg cagcgcaagg gtgcgccacg 2941 tgtcctgctt tactgcaagc gctcgctgca ggagtgggtc tgaccaccca gcgctcctgc 3001 taacggtgct cagggggcgc ctgtggttct gagatggctc ccaggggctc cctccgcccc 3061 caggtagggg cccctctcag ccctcacaca ccctgtctgc cccgccctca ttatttatgt2821 gatggaggag gtggcacgga cggtgaacgt ggtgatggtg ctggtgccac tgctgctgct 2881 gctctgcgtc ctgggcctca cctacgcgct ggtgcagatg cagcgcaagg gtgcgccacg 2941 tgtcctgctt tactgcaagc gctcgctgca ggagtgggtc tgaccaccca gcgctcctgc 3001 taacggtgct cagggggcgc ctgtggttct gagatggctc ccaggggctc cctccgcccc 3061 caggtagggg cccctctcag ccctcacaca ccctgtctgc cccgccctca ttatttatgt
3121 ccaggtgttt gttttgtttt gtttttggca ccttacttga ccatttgttt ctgtttcccc 3181 gactggggca gggtgtttag aattttctaa atgtagttct gctccagaca gggaattagg 3241 cccccatcat cctctggctt ggccacagcc aggggagcag aggggcagag gcccacattg 3301 gaagagcagc acctcctcag cctgaacccc agggctgtaa ctgccaggct ctctttgccc 3361 agttggagac tgtctggccc ccctggtccc ctccttccca agtgagtctc tctgggcctt3121 ccaggtgttt gttttgtttt gtttttggca ccttacttga ccatttgttt ctgtttcccc 3181 gactggggca gggtgtttag aattttctaa atgtagttct gctccagaca gggaattagg 3241 cccccatcat cctctggctt ggccacagcc aggggagcag aggggcagag gcccacattg 3301 gaagagcagc acctcctcag cctgaacccc agggctgtaa ctgccaggct ctctttgccc 3361 agttggagac tgtctggccc ccctggtccc ctccttccca agtgagtctc tctgggcctt
3421 aggaagagcc ttccacccag gggcagcccc aggccaaagg ggacctggaa gggaggtggg 3481 ccgtggccct tgagtcccca ttgaggcttg gttccttccc aatccagtgg acttcgcagt 3541 ccacttctga cagcctcagt gaccctggct ccttgtgcca gagaacccag cccacccccg 3601 gcagcagccc ccagctccca cctccccttg ggcccacacc tccttccctc tctggagaaa 3661 gggccctggg cctgcctcac cacggaccaa agggagtctg ccagggcccc tctccccagg3421 gggcagcccc aggaagagcc ttccacccag aggccaaagg ggacctggaa gggaggtggg 3481 ccgtggccct tgagtcccca ttgaggcttg gttccttccc aatccagtgg acttcgcagt 3541 ccacttctga cagcctcagt gaccctggct ccttgtgcca gagaacccag cccacccccg 3601 gcagcagccc ccagctccca cctccccttg ggcccacacc tccttccctc tctggagaaa 3661 gggccctggg cctgcctcac cacggaccaa agggagtctg ccagggcccc tctccccagg
3721 gaagcagcag cctcgcccct ggcagagatg cctccctgag ctagaaccct ctgttccttc 3781 cctgtgcctc ctccctccct ctccgactca caccactagc ctcaggggtc tgagctccag 3841 ctcctttggg cttcagctgc cagtgtcctg agccccaggg agagggggct ggtgggtgcc 3901 taggcctggg cagtggatgg ccgtgaatgg gtgcccacag tgtcaggcac tgggcatgag 3961 gggttcctcc cctccagctc cctgtgcccc cagggtcctg ggaggagaga cactggtggg3721 gaagcagcag cctcgcccct ggcagagatg cctccctgag ctagaaccct ctgttccttc 3781 cctgtgcctc ctccctccct ctccgactca caccactagc ctcaggggtc tgagctccag 3841 ctcctttggg cttcagctgc cagtgtcctg agccccaggg agagggggct ggtgggtgcc 3901 taggcctggg cagtggatgg ccgtgaatgg gtgcccacag tgtcaggcac tgggcatgag 3961 gggttcctcc cctccagctc cctgtgcccc cagggtcctg ggaggagaga cactggtggg
4021 gataggccag ccgcgcatca gactgtgaac cccacgaagg agcccattgt ggcctaagag 4081 gctgccctcc tgtgctcagc cctgaggaca gatgcctcct tcctcttttc cttcccaaag 4141 caagcaagag gccgtggctg ctgtgggaaa tggtactgta cagctggctc tacttcccca 4201 tggccctgag cgagtggagt ctgccaccca ggatccccaa ggcacttgag ggggaaggat 4261 tctgctggcc tctgcgagtg gtttcttgtg cactggcacc aagtgcgggt ccggcagctt4021 gataggccag ccgcgcatca gactgtgaac cccacgaagg agcccattgt ggcctaagag 4081 gctgccctcc tgtgctcagc cctgaggaca gatgcctcct tcctcttttc cttcccaaag 4141 caagcaagag gccgtggctg ctgtgggaaa tggtactgta cagctggctc tacttcccca 4201 tggccctgag cgagtggagt ctgccaccca ggatccccaa ggcacttgag ggggaaggat 4261 tctgctggcc tctgcgagtg gtttcttgtg cactggcacc aagtgcgggt ccggcagctt
4321 ctgccccctg cagaaccgga gagccagcta aggggtgggg ctgcgggggt tccgtgtcca 4381 cccccataca tttatttctg taaataatgt gcactgaata aattgtacag ccggcaaaaa 4441 aaaaaaaaaa aaaaaa 4321 ctgccccctg cagaaccgga gagccagcta aggggtgggg ctgcgggggt tccgtgtcca 4381 cccccataca tttatttctg taaataatgt gcactgaata aattgtacag ccggcaaaa 4441 aaaaaaaaaa aaaaaa
<210> 34 <210> 34
<211> 6347 <211> 6347
<212> DNA  <212> DNA
<213> Homo Sapiens  <213> Homo Sapiens
<400> 34  <400> 34
MMP16 MMP16
1 tctttgagcc ggaaccgccg gtgaacttag gcgccacgtt cccggtgact gaccccggag 61 gatggtgaac aggaactact gctgaccctg tcttcgccgc tgcctctcgg gggctgccga1 tctttgagcc ggaaccgccg gtgaacttag gcgccacgtt cccggtgact gaccccggag 61 gatggtgaac aggaactact gctgaccctg tcttcgccgc tgcctctcgg gggctgccga
121 gcgcggggcc cctgtctcct ccccttgccc ggctgtgggt gaacctgcag gctccttacc121 gcgcggggcc cctgtctcct ccccttgccc ggctgtgggt gaacctgcag gctccttacc
181 cacccggagg actttttttt gaaaggaaac gagggaggga gggagaggga gagagggaga181 cacccggagg actttttttt gaaaggaaac gagggaggga gggagaggga gagagggaga
241 aaacgaaggg gagctcgtcc atccattgaa gcacagttca ctatgatctt actcacattc241 aaacgaaggg gagctcgtcc atccattgaa gcacagttca ctatgatctt actcacattc
301 agcactggaa gacggttgga tttcgtgcat cattcggggg tgtttttctt gcaaaccttg 361 ctttggattt tatgtgctac agtctgcgga acggagcagt atttcaatgt ggaggtttgg301 agcactggaa gacggttgga tttcgtgcat cattcggggg tgtttttctt gcaaaccttg 361 ctttggattt tatgtgctac agtctgcgga acggagcagt atttcaatgt ggaggtttgg
421 ttacaaaagt acggctacct tccaccgact gaccccagaa tgtcagtgct gcgctctgca421 ttacaaaagt acggctacct tccaccgact gaccccagaa tgtcagtgct gcgctctgca
481 gagaccatgc agtctgccct agctgccatg cagcagttct atggcattaa catgacagga481 gagaccatgc agtctgccct agctgccatg cagcagttct atggcattaa catgacagga
541 aaagtggaca gaaacacaat tgactggatg aagaagcccc gatgcggtgt acctgaccag541 aaagtggaca gaacacaat tgactggatg aagaagcccc gatgcggtgt acctgaccag
601 acaagaggta gctccaaatt tcatattcgt cgaaagcgat atgcattgac aggacagaaa 661 tggcagcaca agcacatcac ttacagtata aagaacgtaa ctccaaaagt aggagaccct601 acaagaggta gctccaaatt tcatattcgt cgaaagcgat atgcattgac aggacagaaa 661 tggcagcaca agcacatcac ttacagtata aagaacgtaa ctccaaaagt aggagaccct
721 gagactcgta aagctattcg ccgtgccttt gatgtgtggc agaatgtaac tcctctgaca721 gagactcgta aagctattcg ccgtgccttt gatgtgtggc agaatgtaac tcctctgaca
781 tttgaagaag ttccctacag tgaattagaa aatggcaaac gtgatgtgga tataaccatt781 tttgaagaag ttccctacag tgaattagaa aatggcaaac gtgatgtgga tataaccatt
841 atttttgcat ctggtttcca tggggacagc tctccctttg atggagaggg aggatttttg841 atttttgcat ctggtttcca tggggacagc tctccctttg atggagaggg aggatttttg
901 gcacatgcct acttccctgg accaggaatt ggaggagata cccattttga ctcagatgag 961 ccatggacac taggaaatcc taatcatgat ggaaatgact tatttcttgt agcagtccat901 gcacatgcct acttccctgg accaggaatt ggaggagata cccattttga ctcagatgag 961 ccatggacac taggaaatcc taatcatgat ggaaatgact tatttcttgt agcagtccat
1021 gaactgggac atgctctggg attggagcat tccaatgacc ccactgccat catggctcca1021 gaactgggac atgctctggg attggagcat tccaatgacc ccactgccat catggctcca
1081 ttttaccagt acatggaaac agacaacttc aaactaccta atgatgattt acagggcatc1081 ttttaccagt acatggaaac agacaacttc aaactaccta atgatgattt acagggcatc
1141 cagaagatat atggtccacc tgacaagatt cctccaccta caagacctct accgacagtg1141 cagaagatat atggtccacc tgacaagatt cctccaccta caagacctct accgacagtg
1201 cccccacacc gctctattcc tccggctgac ccaaggaaaa atgacaggcc aaaacctcct 1261 cggcctccaa ccggcagacc ctcctatccc ggagccaaac ccaacatctg tgatgggaac1201 cccccacacc gctctattcc tccggctgac ccaaggaaaa atgacaggcc aaaacctcct 1261 cggctctaa ccggcagacc ctcctatccc ggagccaaac ccaacatctg tgatgggaac
1321 tttaacactc tagctattct tcgtcgtgag atgtttgttt tcaaggacca gtggttttgg1321 tttaacactc tagctattct tcgtcgtgag atgtttgttt tcaaggacca gtggttttgg
1381 cgagtgagaa acaacagggt gatggatgga tacccaatgc aaattactta cttctggcgg1381 cgagtgagaa acaacagggt gatggatgga tacccaatgc aaattactta cttctggcgg
1441 ggcttgcctc ctagtatcga tgcagtttat gaaaatagcg acgggaattt tgtgttcttt1441 ggcttgcctc ctagtatcga tgcagtttat gaaaatagcg acgggaattt tgtgttcttt
1501 aaaggtaaca aatattgggt gttcaaggat acaactcttc aacctggtta ccctcatgac 1561 ttgataaccc ttggaagtgg aattccccct catggtattg attcagccat ttggtgggag1501 aaaggtaaca aatattgggt gttcaaggat acaactcttc aacctggtta ccctcatgac 1561 ttgataaccc ttggaagtgg aattccccct catggtattg attcagccat ttggtgggag
1621 gacgtcggga aaacctattt cttcaaggga gacagatatt ggagatatag tgaagaaatg1621 gacgtcggga aaacctattt cttcaaggga gacagatatt ggagatatag tgaagaaatg
1681 aaaacaatgg accctggcta tcccaagcca atcacagtct ggaaagggat ccctgaatct1681 aaaacaatgg accctggcta tcccaagcca atcacagtct ggaaagggat ccctgaatct
1741 cctcagggag catttgtaca caaagaaaat ggctttacgt atttctacaa aggaaaggag1741 cctcagggag catttgtaca caaagaaaat ggctttacgt atttctacaa aggaaaggag
1801 tattggaaat tcaacaacca gatactcaag gtagaacctg gatatccaag atccatcctc 1861 aaggatttta tgggctgtga tggaccaaca gacagagtta aagaaggaca cagcccacca1801 tattggaaat tcaacaacca gatactcaag gtagaacctg gatatccaag atccatcctc 1861 aaggatttta tgggctgtga tggaccaaca gacagagtta aagaaggaca cagcccacca
1921 gatgatgtag acattgtcat caaactggac aacacagcca gcactgtgaa agccatagct1921 gatgatgtag acattgtcat caaactggac aacacagcca gcactgtgaa agccatagct
1981 attgtcattc cctgcatctt ggccttatgc ctccttgtat tggtttacac tgtgttccag1981 attgtcattc cctgcatctt ggccttatgc ctccttgtat tggtttacac tgtgttccag
2041 ttcaagagga aaggaacacc ccgccacata ctgtactgta aacgctctat gcaagagtgg2041 ttcaagagga aaggaacacc ccgccacata ctgtactgta aacgctctat gcaagagtgg
2101 gtgtgatgta gggttttttc ttctttcttt cttttgcagg agtttgtggt aacttgagat 2161 tcaagacaag agctgttatg ctgtttccta gctaggagca ggcttgtggc agcctgattc2101 gtgtgatgta gggttttttc ttctttcttt cttttgcagg agtttgtggt aacttgagat 2161 tcaagacaag agctgttatg ctgtttccta gctaggagca ggcttgtggc agcctgattc
2221 ggggctgacc tttcaaaccc agagggttgc tggtcctgca catgagtgga aatacactca2221 ggggctgacc tttcaaaccc agagggttgc tggtcctgca catgagtgga aatacactca
2281 tggggaagct tccatgatgc acagtatctg ctgttcttca gtcctttgtc tttctttgtc2281 tggggaagct tccatgatgc acagtatctg ctgttcttca gtcctttgtc tttctttgtc
2341 attcagttct aggcctttcc tctgcacgct caatgcccag taaaatttca ggattaacta2341 attcagttct aggcctttcc tctgcacgct caatgcccag taaaatttca ggattaacta
2401 aagaagagga gaaaaagaag aaaagattct tcttaaaagt ttctaatgtt attttccttc 2461 tgaagtctga gcccatttct ggggggagaa aaaaaaagca aatcagaaaa cccacggttt2401 aagaagagga gaaaaagaag aaaagattct tcttaaaagt ttctaatgtt attttccttc 2461 tgaagtctga gcccatttct ggggggagaa aaaaaaagca aatcagaaaa cccacggttt
2521 ttcttttttt ctttttttct ttttttcttt ttttgcttta aaacaaaggg aaaaaagagt2521 ttcttttttt ctttttttct ttttttcttt ttttgcttta aaacaaaggg aaaaaagagt
2581 ttaaacaaaa aacccacaat tgaacttcca ggaaagtgtg aagacccaaa acagctttgt2581 ttaaacaaaa aacccacaat tgaacttcca ggaaagtgtg aagacccaaa acagctttgt
2641 ctccaaagaa gatagctctc tgactgcttt ggatagtctc ctacgcacca ttttgtcagg2641 ctccaaagaa gatagctctc tgactgcttt ggatagtctc ctacgcacca ttttgtcagg
2701 tgggagattt ggaatacaca tgcaggacgt tagactgttg ggacagccat tttccaacaa 2761 ccaaggggcc aaaatatctg caatatagta acagccttaa taatacatcc atttttcgtt2701 tgggattattt ggaatacaca tgcaggacgt tagactgtg ggacagccat tttccaacaa 2761 ccaaggggcc aaaatatctg caatatagta acagccttaa taatacatcc atttttcgtt
2821 ttatacagct gttctcagct atgtcctcag tgtttcatcg catttatatt catagctatt2821 ttatacagct gttctcagct atgtcctcag tgtttcatcg catttatatt catagctatt
2881 ttcaaacacg accttttaat tgtttttgaa gtatttctaa accccttctt tccaccttac2881 ttcaaacacg accttttaat tgtttttgaa gtatttctaa accccttctt tccaccttac
2941 tcctccatca ttgtgataat cttcccaagt tgtattaggc cattgcccca ggccttccat2941 tcctccatca ttgtgataat cttcccaagt tgtattaggc cattgcccca ggccttccat
3001 gggtctgtca ggaatattcg ttacaaagca gagcaagaag cagtatgtct ctgaagtgga 3061 ttacagtggc agttatttta caaggatttg tgacactagt aacatacccg tgtaaccctt3001 gggtctgtca ggaatattcg ttacaaagca gagcaagaag cagtatgtct ctgaagtgga 3061 ttacagtggc agttatttta caaggatttg tgacactagt aacatacccg tgtaaccctt
3121 tgagaactat cagaccagct ttcagagtct taggattgtc ggtcttgcga tctgataaat3121 tgagaactat cagaccagct ttcagagtct taggattgtc ggtcttgcga tctgataaat
3181 tatagaactg ggcaatggta aaaacagtca caagttcaag aagttcaggt ttttaaaaca3181 tatagaactg ggcaatggta aaaacagtca caagttcaag aagttcaggt ttttaaaaca
3241 gatatcctat aatgtcatat aatttttaaa tgatttacaa gactacataa atgtgtttat3241 gatatcctat aatgtcatat aatttttaaa tgatttacaa gactacataa atgtgtttat
3301 aacaaacaga aatgatgtta cttgccaaaa tttttctggc aaataaaaaa ggtattttat 3361 taagattctc ataaatctga aattttattt gaaaaactga taatagccta agtcttcttt 3421 tctttttttt aggcatactg aatttctgtt ttaaaatcca ttgcatgaaa attcaatttg 3481 ccttggtata tgcagttagc attgccattt taaaaatgaa ttaaaacggt gactctgaag 3541 ttgcatgaat atcctccagt gcattaccta ttgcatgtcc accatagttc tcaaagggtt 3601 agtgtggctt ctggcattta gccgtccatt tgatcactga cagagccaag agaccaccaa 3661 agcatttcat tgttgagtgt aatttgtcct aacagcagta ttgtcatttt catgtgacct 3721 gcagagcagg tttgtatcaa tatttttttc ctagagaaaa gtcagcaact gacagacctc3301 aacaaacaga aatgatgtta cttgccaaaa tttttctggc aaataaaaaa ggtattttat 3361 taagattctc ataaatctga aattttattt gaaaaactga taatagccta agtcttcttt 3421 tctttttttt aggcatactg aatttctgtt ttaaaatcca ttgcatgaaa attcaatttg 3481 ccttggtata tgcagttagc attgccattt taaaaatgaa ttaaaacggt gactctgaag 3541 ttgcatgaat atcctccagt gcattaccta ttgcatgtcc accatagttc tcaaagggtt 3601 agtgtggctt ctggcattta gccgtccatt tgatcactga cagagccaag agaccaccaa 3661 agcatttcat tgttgagtgt aatttgtcct aacagcagta ttgtcatttt catgtgacct 3721 gcagagcagg tttgtatcaa tatttttttc ctagagaaaa gtcagcaact gacagacctc
3781 tttattgatt tttaggagct gcttcttgca gtgaaaggct ttacagccac tgggctgtga 3841 acttattaga gatggtcaga atgaatgcac cccatgagtc agacattggc tttgtgtgaa 3901 agccagcttt gaggggatta gcttttgaaa caatgaacag cttgccttga acttgattat 3961 tgatctattg actgtcatta acaacaactt aaacattgtc ttctgtgaaa attttccttg 4021 aagagtcctg ttctatgtct ttgccctttg acctttaact tgcaaactgg cacaaactga3781 tttattgatt tttaggagct gcttcttgca gtgaaaggct ttacagccac tgggctgtga 3841 acttattaga gatggtcaga atgaatgcac cccatgagtc agacattggc tttgtgtgaa 3901 agccagcttt gaggggatta gcttttgaaa caatgaacag cttgccttga acttgattat 3961 tgatctattg actgtcatta acaacaactt aaacattgtc ttctgtgaaa attttccttg 4021 aagagtcctg ttctatgtct ttgccctttg acctttaact tgcaaactgg cacaaactga
4081 aggaaatctg gtgttgcttc tccattggat tagttgttct ctaaaaccta gtaagcatga 4141 gctgtttcct tagagtggag agagtggtga tggcagatct gcagatggac actttgctct 4201 ttacatgcac actctgaaaa tgccctatag gtagaagtga attttaattt cattttaata 4261 taatttcaag tctaaattca tcattttagt acaaattaca aaaactatag gaaaaaaaaa 4321 acctcaaata cttgaatggc cagtgtggct tttatataaa gcaggaattt tatactagta4081 aggaaatctg gtgttgcttc tccattggat tagttgttct ctaaaaccta gtaagcatga 4141 gctgtttcct tagagtggag agagtggtga tggcagatct gcagatggac actttgctct 4201 ttacatgcac actctgaaaa tgccctatag gtagaagtga attttaattt cattttaata 4261 taatttcaag tctaaattca tcattttagt acaaattaca aaaactatag gaaaaaaaaa 4321 acctcaaata cttgaatggc cagtgtggct tttatataaa gcaggaattt tatactagta
4381 aaaatttctt actcatttgc taatacacat ttccagatga tttttaatga gtgtaggtat 4441 acattcttat ttggaaatgg atagtttggc tgccttgaat ttatatttat actcaacgta 4501 gcatgaaaat tagaatgcct tttggttaaa ctacatgttt atgatttggt tggggaaaat 4561 attttataat tgtgggtggc atgctgcaaa gccttgcaga ttgttatttc ttacaacctg 4621 agcgtatata gtatgagcct aagaaaaaag aagagtaaga aaagaagaat ggctttacag4381 aaaatttctt actcatttgc taatacacat ttccagatga tttttaatga gtgtaggtat 4441 acattcttat ttggaaatgg atagtttggc tgccttgaat ttatatttat actcaacgta 4501 gcatgaaaat tagaatgcct tttggttaaa ctacatgttt atgatttggt tggggaaaat 4561 attttataat tgtgggtggc atgctgcaaa gccttgcaga ttgttatttc ttacaacctg 4621 agcgtatata gtatgagcct aagaaaaaag aagagtaaga aaagaagaat ggctttacag
4681 taaaatatca tacaatgcag acaatatttt aagaggatat tggagattat gtacgcaagg 4741 gccaagaaag caagaaatga gaaccagagt cagccctgta gctttacttc agtgcttcca 4801 ttctagatga tgctgatatt ataaagagtt agtcactgct gctaagcatg gaggactata 4861 tacataagct cgtttataca gtgtttgctt gtgggagggt ttaatccttt tagggccttg 4921 atgtcaagaa aaaaataact ggaaactata ttttgctaaa gatagaaatg aggaactgtg4681 taaaatatca tacaatgcag acaatatttt aagaggatat tggagattat gtacgcaagg 4741 gccaagaaag caagaaatga gaaccagagt cagccctgta gctttacttc agtgcttcca 4801 ttctagatga tgctgatatt ataaagagtt agtcactgct gctaagcatg gaggactata 4861 tacataagct cgtttataca gtgtttgctt gtgggagggt ttaatccttt tagggccttg 4921 atgtcaagaa aaaaataact ggaaactata ttttgctaaa gatagaaatg aggaactgtg
4981 tcattttggg acatgtgcaa atcattgagg aactccatca ccctgcattg aaaattgatt 5041 tttttttcct ctaaaatgag aaagaaactg aataagcaat ctgttgcctc tttactcatt 5101 catcacaata tcctgattcg tcataaggct atcagtatat aagggctaga aaataatcat 5161 agcattaaga aggaaggagt ctatcattat gcttgaattc tggcaaatgt catgaataag 5221 ggttgggtca tatttacttt aatatgagac aagatttatg tgataagcaa aggcatataa4981 tcattttggg acatgtgcaa atcattgagg aactccatca ccctgcattg aaaattgatt 5041 tttttttcct ctaaaatgag aaagaaactg aataagcaat ctgttgcctc tttactcatt 5101 catcacaata tcctgattcg tcataaggct atcagtatat aagggctaga aaataatcat 5161 agcattaaga aggaaggagt ctatcattat gcttgaattc tggcaaatgt catgaataag 5221 ggttgggtca tatttacttt aatatgagac aagatttatg tgataagcaa aggcatataa
5281 ggctgctctt ttgaacagaa catttcagtt atcaggctgt actattacaa gagataagaa 5341 gacaataagg acaatgtaat cacaaacagt gggattccat ttgtttattg tacaccagct 5401 actttgtggg tatggttcct gactcctctt ctacatgagg tttgggaaaa aagtctcaaa 5461 ccaaatggaa cagtgaaagg gaaagtaatt catctagcac ataagaatag tgattcaaaa 5521 ccaatgcaga ataaatttcc atgggtcaat aacataaggt gtcagttcag tgttactaga5281 ggctgctctt ttgaacagaa catttcagtt atcaggctgt actattacaa gagataagaa 5341 gacaataagg acaatgtaat cacaaacagt gggattccat ttgtttattg tacaccagct 5401 actttgtggg tatggttcct gactcctctt ctacatgagg tttgggaaaa aagtctcaaa 5461 ccaaatggaa cagtgaaagg gaaagtaatt catctagcac ataagaatag tgattcaaaa 5521 ccaatgcaga ataaatttcc atgggtcaat aacataaggt gtcagttcag tgttactaga
5581 gatatgcaag gcataaaata ttttcatcac cccatcacta ataacatgaa aagctcagac 5641 ataggatttc ccaaattgaa atgaaaacac attcatgcct gcaaaaataa ttctccttct 5701 gcttcatttc tcattacttt atctaatata aacacaaatg taaacaaggt aatggtcttc 5761 atgtaaaatg accatatagt taagaatttt agtaaaatat tgttgttctg tgtattatta 5821 aacaaatgca atgaagtatt aaaatagctg atcagtttga atttcctgta aagcagtaat5581 gatatgcaag gcataaaata ttttcatcac cccatcacta ataacatgaa aagctcagac 5641 ataggatttc ccaaattgaa atgaaaacac attcatgcct gcaaaaataa ttctccttct 5701 gcttcatttc tcattacttt atctaatata aacacaaatg taaacaaggt aatggtcttc 5761 atgtaaaatg accatatagt taagaatttt agtaaaatat tgttgttctg tgtattatta 5821 aacaaatgca atgaagtatt aaaatagctg atcagtttga atttcctgta aagcagtaat
5881 tccgcatcag aattgtagat aaggttgtga atttattgac tcatttcaga acagtgtctg 5941 ttgacatggc agtcagagca ggtgaataca gatgctcttt ctgattgcaa aggttataga 6001 gctaaattag acagcattat gtgatactag caaagacaac ttctgttata aatcagaggg 6061 caaggctttt ctgaatcgat gtgataaatt actaagtaat gattaccaaa aataattact 6121 aagtaataaa agatacagac tggtttactg aaataagcaa gtgttacatt taataattac5881 tccgcatcag aattgtagat aaggttgtga atttattgac tcatttcaga acagtgtctg 5941 ttgacatggc agtcagagca ggtgaataca gatgctcttt ctgattgcaa aggttataga 6001 gctaaattag acagcattat gtgatactag caaagacaac ttctgttata aatcagaggg 6061 caaggctttt ctgaatcgat gtgataaatt actaagtaat gattaccaaa aataattact 6121 aagtaataaa agatacagac tggtttactg aaataagcaa gtgttacatt taataattac
6181 ctataatctt tttttgttaa cacataagca agtgttacct ttaataatta cctataatct 6241 ttttttgtta acacataatt tggccatttc atatactgtg tacctatttt cattccctct 6301 ctgtgggtca ttaaaaaaca caatgtggtg gataaaaaaa aaaaaaa 6181 ctataatctt tttttgttaa cacataagca agtgttacct ttaataatta cctataatct 6241 ttttttgtta acacataatt tggccatttc atatactgtg tacctatttt cattccctct 6301 ctgtgggtca ttaaaaaaca caatgtggtg gataaaaaa aaaaaaa
<210> 35 <210> 35
<211> 2429  <211> 2429
<212> DNA  <212> DNA
<213> Homo Sapiens  <213> Homo Sapiens
<400> 35 ccggcggggg cgccgcggag agcggagggc gccgggctgc ggaacgcgaa gcggagggcg cgggaccctg cacgccgccc gcgggcccat gtgagcgcca tgcggcgccg cgcagcccgg 121 ggacccggcc cgccgccccc agggcccgga ctctcgcggc tgccgctgcc gctgctgctg<400> 35 ccggcggggg cgccgcggag agcggagggc gccgggctgc ggaacgcgaa gcggagggcg cgggaccctg cacgccgccc gcgggcccat gtgagcgcca tgcggcgccg cgcagcccgg 121 ggacccggcc cgccgccccc agggcccgga ctctcgcggc tgccgctgcc gctgctgctg
181 ctgctggcgc tggggacccg cgggggctgc gccgcgcccg cacccgcgcc gcgcgccgag181 ctgctggcgc tggggacccg cgggggctgc gccgcgcccg cacccgcgcc gcgcgccgag
241 gacctcagcc tgggagtgga gtggctaagc aggttcggtt acctgccccc ggctgacccc241 gacctcagcc tgggagtgga gtggctaagc aggttcggtt acctgccccc ggctgacccc
301 acaacagggc agctgcagac gcaagaggag ctgtctaagg ccatcacagc catgcagcag301 acaacagggc agctgcagac gcaagaggag ctgtctaagg ccatcacagc catgcagcag
361 tttggtggcc tggaggccac cggcatcctg gacgaggcca ccctggccct gatgaaaacc 421 ccacgctgct ccctgccaga cctccctgtc ctgacccagg ctcgcaggag acgccaggct361 tttggtggcc tggaggccac cggcatcctg gacgaggcca cctctggccct gatgaaaacc 421 ccacgctgct ccctgccaga cctccctgtc ctgacccagg ctcgcaggag acgccaggct
481 ccagccccca ccaagtggaa caagaggaac ctgtcgtgga gggtccggac gttcccacgg 541 gactcaccac tggggcacga cacggtgcgt gcactcatgt actacgccct caaggtctgg 601 agcgacattg cgcccctgaa cttccacgag gtggcgggca gcgccgccga catccagatc 661 gacttctcca aggccgacca taacgacggc taccccttcg acggccccgg cggcaccgtg 721 gcccacgcct tcttccccgg ccaccaccac accgccgggg acacccactt tgacgatgac481 ccagccccca ccaagtggaa caagaggaac ctgtcgtgga gggtccggac gttcccacgg 541 gactcaccac tggggcacga cacggtgcgt gcactcatgt actacgccct caaggtctgg 601 agcgacattg cgcccctgaa cttccacgag gtggcgggca gcgccgccga catccagatc 661 gacttctcca aggccgacca taacgacggc taccccttcg acggccccgg cggcaccgtg 721 gcccacgcct tcttccccgg ccaccaccac accgccgggg acacccactt tgacgatgac
781 gaggcctgga ccttccgctc ctcggatgcc cacgggatgg acctgtttgc agtggctgtc781 gaggcctgga ccttccgctc ctcggatgcc cacgggatgg acctgtttgc agtggctgtc
841 cacgagtttg gccacgccat tgggttaagc catgtggccg ctgcacactc catcatgcgg841 cacgagtttg gccacgccat tgggttaagc catgtggccg ctgcacactc catcatgcgg
901 ccgtactacc agggcccggt gggtgacccg ctgcgctacg ggctccccta cgaggacaag901 ccgtactacc agggcccggt gggtgacccg ctgcgctacg ggctccccta cgaggacaag
961 gtgcgcgtct ggcagctgta cggtgtgcgg gagtctgtgt ctcccacggc gcagcccgag 1021 gagcctcccc tgctgccgga gcccccagac aaccggtcca gcgccccgcc caggaaggac961 gtgcgcgtct ggcagctgta cggtgtgcgg gagtctgtgt ctcccacggc gcagcccgag 1021 gagcctcccc tgctgccgga gcccccagac aaccggtcca gcgccccgcc caggaaggac
1081 gtgccccaca gatgcagcac tcactttgac gcggtggccc agatccgggg tgaagctttc1081 gtgccccaca gatgcagcac tcactttgac gcggtggccc agatccgggg tgaagctttc
1141 ttcttcaaag gcaagtactt ctggcggctg acgcgggacc ggcacctggt gtccctgcag1141 ttcttcaaag gcaagtactt ctggcggctg acgcgggacc ggcacctggt gtccctgcag
1201 ccggcacaga tgcaccgctt ctggcggggc ctgccgctgc acctggacag cgtggacgcc1201 ccggcacaga tgcaccgctt ctggcggggc ctgccgctgc acctggacag cgtggacgcc
1261 gtgtacgagc gcaccagcga ccacaagatc gtcttcttta aaggagacag gtactgggtg 1321 ttcaaggaca ataacgtaga ggaaggatac ccgcgccccg tctccgactt cagcctcccg1261 gtgtacgagc gcaccagcga ccacaagatc gtcttcttta aaggagacag gtactgggtg 1321 ttcaaggaca ataacgtaga ggaaggatac ccgcgccccg tctccgactt cagcctcccg
1381 cctggcggca tcgacgctgc cttctcctgg gcccacaatg acaggactta tttctttaag1381 cctggcggca tcgacgctgc cttctcctgg gcccacaatg acaggactta tttctttaag
1441 gaccagctgt actggcgcta cgatgaccac acgaggcaca tggaccccgg ctaccccgcc1441 gaccagctgt actggcgcta cgatgaccac acgaggcaca tggaccccgg ctaccccgcc
1501 cagagccccc tgtggagggg tgtccccagc acgctggacg acgccatgcg ctggtccgac1501 cagagccccc tgtggagggg tgtccccagc acgctggacg acgccatgcg ctggtccgac
1561 ggtgcctcct acttcttccg tggccaggag tactggaaag tgctggatgg cgagctggag 1621 gtggcacccg ggtacccaca gtccacggcc cgggactggc tggtgtgtgg agactcacag1561 ggtgcctcct acttcttccg tggccaggag tactggaaag tgctggatgg cgagctggag 1621 gtggcacccg ggtacccaca gtccacggcc cgggactggc tggtgtgtgg agactcacag
1681 gccgatggat ctgtggctgc gggcgtggac gcggcagagg ggccccgcgc ccctccagga1681 gccgatggat ctgtggctgc gggcgtggac gcggcagagg ggccccgcgc ccctccagga
1741 caacatgacc agagccgctc ggaggacggt tacgaggtct gctcatgcac ctctggggca1741 caacatgacc agagccgctc ggaggacggt tacgaggtct gctcatgcac ctctgggggca
1801 tcctctcccc cgggggcccc aggcccactg gtggctgcca ccatgctgct gctgctgccg1801 tcctctcccc cgggggcccc aggcccactg gtggctgcca ccatgctgct gctgctgccg
1861 ccactgtcac caggcgccct gtggacagcg gcccaggccc tgacgctatg acacacagcg 1921 cgagcccatg agaggacaga ggcggtggga cagcctggcc acagagggca aggactgtgc1861 ccactgtcac caggcgccct gtggacagcg gcccaggccc tgacgctatg acacacagcg 1921 cgagcccatg agaggacaga ggcggtggga cagcctggcc acagagggca aggactgtgc
1981 cggagtccct gggggaggtg ctggcgcggg atgaggacgg gccaccctgg caccggaagg1981 cggagtccct gggggaggtg ctggcgcggg atgaggacgg gccaccctgg caccggaagg
2041 ccagcagagg gcactgcccg ccagggctgg gcaggctcag gtggcaagga cggagctgtc2041 ccagcagagg gcactgcccg ccagggctgg gcaggctcag gtggcaagga cggagctgtc
2101 ccctagtgag ggactgtgtt gactgacgag ccgaggggtg gccgctccag aagggtgccc2101 ccctagtgag ggactgtgtt gactgacgag ccgaggggtg gccgctccag aagggtgccc
2161 agtcaggccg caccgccgcc agcctcctcc ggccctggag ggagcatctc gggctggggg 2221 cccacccctc tctgtgccgg cgccaccaac cccacccaca ctgctgcctg gtgctcccgc2161 agtcaggccg caccgccgcc agcctcctcc ggccctggag ggagcatctc gggctggggg 2221 cccacccctc tctgtgccgg cgccaccaac cccacccaca ctgctgcctg gtgctcccgc
2281 cggcccacag ggcctccgtc cccaggtccc cagtggggca gccctcccca cagacgagcc2281 cggcccacag ggcctccgtc cccaggtccc cagtggggca gccctcccca cagacgagcc
2341 ccccacatgg tgccgcggca cgtcccccct gtgacgcgtt ccagaccaac atgacctctc2341 ccccacatgg tgccgcggca cgtcccccct gtgacgcgtt ccagaccaac atgacctctc
2401 cctgctttgt aaaaaaaaaa aaaaaaaaa 2401 cctgctttgt aaaaaaaaaa aaaaaaaaa
<210> 36 <210> 36
<211 > 1956 <211> 1956
<212> DNA <212> DNA
<213> Homo Sapiens <213> Homo Sapiens
<400> 36 <400> 36
MMP20  MMP20
1 ctactgtgag gggatgaagg tgctccctgc atctggcctt gctgtcttcc tcatcatggc 61 tttgaagttt tccactgcag ccccctccct agttgcagcc tcccccagga cctggaggaa 121 caactaccgc ctcgcacagg cgtatcttga caaatattac acaaataaag aaggacacca 181 gattggtgag atggttgcaa gaggaagcaa ttccatgata aggaagatta aggagctaca 241 agcgttcttt ggcctccaag tcaccgggaa gttagaccag accacaatga acgtgatcaa 301 gaagcctcgc tgtggagttc ctgatgtggc caattatcgc ctcttccctg gtgaacccaa 361 atggaaaaaa aatactttga catacagaat atctaaatac acaccttcca tgagttctgt1 ctactgtgag gggatgaagg tgctccctgc atctggcctt gctgtcttcc tcatcatggc 61 tttgaagttt tccactgcag ccccctccct agttgcagcc tcccccagga cctggaggaa 121 caactaccgc ctcgcacagg cgtatcttga caaatattac acaaataaag aaggacacca 181 gattggtgag atggttgcaa gaggaagcaa ttccatgata aggaagatta aggagctaca 241 agcgttcttt ggcctccaag tcaccgggaa gttagaccag accacaatga acgtgatcaa 301 gaagcctcgc tgtggagttc ctgatgtggc caattatcgc ctcttccctg gtgaacccaa 361 atggaaaaaa aatactttga catacagaat atctaaatac acaccttcca tgagttctgt
421 cgaggtggac aaagcagtgg agatggcctt gcaggcctgg agtagcgccg tccctctgag421 cgaggtggac aaagcagtgg agatggcctt gcaggcctgg agtagcgccg tccctctgag
481 ctttgtcaga ataaactcag gagaagcgga tattatgata tcttttgaaa atggagatca481 ctttgtcaga ataaactcag gagaagcgga tattatgata tcttttgaaa atggagatca
541 cggggattcc tatccattcg atgggcctcg ggggactcta gcccatgcat ttgctcctgg541 cggggattcc tatccattcg atggcctcg ggggactcta gcccatgcat ttgctcctgg
601 agaaggcctg ggaggagata cacatttcga caatgctgag aagtggacta tgggaacgaa 661 tggttttaat ttgtttaccg ttgctgctca tgaatttggc catgccctgg gcctggccca601 agaaggcctg ggaggagata cacatttcga caatgctgag aagtggacta tgggaacgaa 661 tggttttaat ttgtttaccg ttgctgctca tgaatttggc catgccctgg gcctggccca
721 ttccacagac ccatcagcac tgatgtaccc aacttataag tacaagaatc cctatggatt721 ttccacagac ccatcagcac tgatgtaccc aacttataag tacaagaatc cctatggatt
781 ccacctcccc aaagatgatg tgaaagggat ccaggcatta tacggacctc ggaaagtatt781 ccacctcccc aaagatgatg tgaaagggat ccaggcatta tacggacctc ggaaagtatt
841 cctggggaag cccactctgc cccatgcccc ccatcacaag ccatccatcc ctgacctctg841 cctggggaag cccactctgc cccatgcccc ccatcacaag ccatccatcc ctgacctctg
901 tgactccagc tcatcctttg acgctgtgac aatgctgggg aaggagctcc tgctcttcaa 961 ggaccggatt ttctggagac ggcaggttca cttgcggaca ggaattcggc ccagcactat901 tgactccagc tcatcctttg acgctgtgac aatgctgggg aaggagctcc tgctcttcaa 961 ggaccggatt ttctggagac ggcaggttca cttgcggaca ggaattcggc ccagcactat
1021 taccagctcc ttcccccagc tcatgtccaa tgtggatgca gcttacgaag tggctgagag1021 taccagctcc ttcccccagc tcatgtccaa tgtggatgca gcttacgaag tggctgagag
1081 gggcactgct tacttcttca aaggtcccca ctactggata acaagaggat tccaaatgca1081 gggcactgct tacttcttca aaggtcccca ctactggata acaagaggat tccaaatgca
1141 aggtcctcct cggactattt atgactttgg atttccaagg cacgtgcagc aaatagatgc1141 aggtcctcct cggactattt atgactttgg atttccaagg cacgtgcagc aaatagatgc
1201 tgctgtctac ctcagggagc cacagaagac ccttttcttt gtgggagatg aatactacag 1261 ctacgacgaa aggaaaagga aaatggaaaa agactatcca aagaatactg aagaagaatt1201 tgctgtctac ctcagggagc cacagaagac ccttttcttt gtgggagatg aatactacag 1261 ctacgacgaa aggaaaagga aaatggaaaa agactatcca aagaatactg aagaagaatt
1321 ttcaggagta aatggccaaa tcgatgctgc tgtagaatta aatggctaca tttacttctt1321 ttcaggagta aatggccaaa tcgatgctgc tgtagaatta aatggctaca tttacttctt
1381 ttcaggacca aaaacataca agtatgacac agagaaggaa gatgtggtta gtgtggtgaa1381 ttcaggacca aaacacaca agtatgacac agagaaggaa gatgtggtta gtgtggtgaa
1441 atctagttcc tggattggtt gctaaataga aaagcctagt cttctcaagc aatgaggatg1441 atctagttcc tggattggtt gctaaataga aaagcctagt cttctcaagc aatgaggatg
1501 actacaagca gcctctaact ggatcttaag gactaaagca gaatgtagga gagggattct 1561 tccaaaggcc ttcaaatcaa attagaattc actgagaata ataatacttc caattttttt1501 actacaagca gctctaact ggatcttaag gactaaagca gaatgtagga gagggattct 1561 tccaaaggcc ttcaaatcaa attagaattc actgagaata ataatacttc caattttttt
1621 catagttgta taatcagaat ttcaatccac attagaaaag tttttatatg ggcaacttta1621 catagttgta taatcagaat ttcaatccac attagaaaag tttttatatg ggcaacttta
1681 tgcgaaatcc aaatcaacac aatgcactct gcagttagac accattattt tttcttacct1681 tgcgaaatcc aaatcaacac aatgcactct gcagttagac accattattt tttcttacct
1741 aatatactga agcagattga tccgtttgat ttttatttcc aggaggaaga ctagtggtgg1741 aatatactga agcagattga tccgtttgat ttttatttcc aggaggaaga ctagtggtgg
1801 attccatgac atatattgta attcttttca taggaaatgt cattacagta tgaattataa 1861 ttatttacaa gcaatggctt ttgtggccat catttggcca tcatttgtta taataaatat1801 attccatgac atatattgta attcttttca taggaaatgt cattacagta tgaattataa 1861 ttatttacaa gcaatggctt ttgtggccat catttggcca tcatttgtta taataaatat
1921 aaatttccca atttttactt aaaagacatc acaaca 1921 aaatttccca atttttactt aaaagacatc acaaca

Claims

Patentansprüche claims
1 . Pharmazeutische Zusammensetzung, umfassend ein Mittel, das die 1 . A pharmaceutical composition comprising an agent containing the
Expression oder Aktivität eines Tumor-assoziierten Antigens nachweist oder hemmt, wobei das Mittel oder Antigen eine Sequenz aufweist, die aus der Gruppe ausgewählt ist, bestehend aus:  Detecting or inhibiting expression or activity of a tumor-associated antigen, wherein the agent or antigen has a sequence selected from the group consisting of:
(a) einer Nukleinsäure, die eine Nukleinsäuresequenz umfasst, die aus der Gruppe SEQ ID NO: 1 bis 36, einem Teil oder einem Derivat davon (a) a nucleic acid comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 36, a part or a derivative thereof
(b) einer Nukleinsäure, die unter stringenten Bedingungen mit der (B) a nucleic acid which under stringent conditions with the
Nukleinsäure unter (a) hybridisiert,  Nucleic acid hybridized under (a),
(c) einer Nukleinsäure, die in Bezug auf die Nukleinsäure unter (a) oder (b) degeneriert ist und (c) a nucleic acid which is degenerate with respect to the nucleic acid under (a) or (b), and
(d) einer Nukleinsäure, die zu der Nukleinsäure unter (a), (b) oder (c) (d) a nucleic acid which can be added to the nucleic acid under (a), (b) or (c)
komplementär ist.  is complementary.
2. Pharmazeutische Zusammensetzung nach Anspruch 1 , wobei das Mittel die Induktion des Zelltods, die Reduktion der Zellentwicklung, die Reduktion der Zelteilung, die Reduktion der Zellmigration, eine Schädigung der The pharmaceutical composition of claim 1, wherein the agent is the induction of cell death, the reduction of cell development, the reduction of cell division, the reduction of cell migration, damage to the cells
Zellmembran, eine Sekretion von Zytokinen oder eine Neutralisation des Antigens bewirkt.  Cell membrane, secretion of cytokines or neutralization of the antigen causes.
3. Pharmazeutische Zusammensetzung nach einem der voranstehenden 3. Pharmaceutical composition according to one of the preceding
Ansprüche, wobei das Mittel ein komplementaktivierender Antikörper ist, ein ADCC aktivierender Antikörper, ein Antikörper-ähnliches Molekül oder ein Antikörper der weitere humorale oder zelluläre Immunantworten auslöst, insbesondere eine Anti-Zytokin Antikörper. Claims, wherein the agent is a complement-activating antibody, an ADCC-activating antibody, an antibody-like molecule or an antibody that elicits further humoral or cellular immune responses, in particular an anti-cytokine antibody.
4. Pharmazeutische Zusammensetzung nach einem der voranstehenden 4. Pharmaceutical composition according to one of the preceding
Ansprüche, wobei an den modifizierten Antikörper mindestens ein  Claims, wherein at least one of the modified antibodies
therapeutisches oder diagnostisches Mittel gebunden ist.  therapeutic or diagnostic agent is bound.
5. Pharmazeutische Zusammensetzung nach einem der voranstehenden 5. Pharmaceutical composition according to one of the preceding
Ansprüche, wobei an das Mittel Nanopartikel oder radioaktive Isotope zur Claims, wherein the agent nanoparticles or radioactive isotopes for
Visualisierung in der CT und MRT aufweist. Visualization in CT and MRI.
6. Pharmazeutische Zusammensetzung nach einem der voranstehenden 6. Pharmaceutical composition according to one of the preceding
Ansprüche, wobei das Mittel ausgewählt ist aus der Gruppe bestehend aus Taxinen, Alkylantien, Colchicin, Vincristin, Vinblastin, Bleomycin,  Claims, wherein the agent is selected from the group consisting of taxanes, alkylating agents, colchicine, vincristine, vinblastine, bleomycin,
Combretastatin, Podophyllotoxin, Angiostatin, Endostatin, Vasculostatin und Interleukinen, Radionukliden, nicht-radioaktiven Isotopen, Photosensitizer, Nanopartikel.  Combretastatin, podophyllotoxin, angiostatin, endostatin, vasculostatin and interleukins, radionuclides, non-radioactive isotopes, photosensitizers, nanoparticles.
7. Pharmazeutische Zusammensetzung nach einem der voranstehenden 7. Pharmaceutical composition according to one of the preceding
Ansprüche zur Bekämpfung von Tumoren zusammen mit einem oder mehreren pharmakologisch unbedenklichen Hilfs- oder Trägerstoffen.  Claims for controlling tumors together with one or more pharmacologically acceptable excipients or carriers.
8. Pharmazeutische Zusammensetzung nach Anspruch 7, wobei der Tumor ausgewählt ist aus der Liste: 8. A pharmaceutical composition according to claim 7, wherein the tumor is selected from the list:
Blasen-, Gastrointestinal-, Haut-, Hirn-, Knochen-, Lungen-, Mamma-, Nieren-, Schilddrüsen-, Ovarien-, Pankreas-, Prostata-, Lebertumore, Lymphome und Tumorarten des blutbildenden Systems, Seminome, Melanome, Teratome, Tumore des Nervensystems (wie Gliome, Meningiome, Neuroblastome,Bladder, gastrointestinal, skin, brain, bone, lung, mammary, kidney, thyroid, ovarian, pancreatic, prostate, liver tumors, lymphomas and tumor types of the hematopoietic system, seminomas, melanomas, teratomas , Tumors of the nervous system (such as gliomas, meningiomas, neuroblastomas,
Medulloblastome, Schwannome, neuroendokrine Tumore), Gastrointestinal-, Pankreas-, Hals-, Nasen-, Ohren- (HNO)-, Blasen-, Brust, Knochen-, Leber-, Nieren-, Prostata-, Gebärmutter-, Ovarial-, Lungen- und Schilddrüsentumore, Lymphome, sowie Tumorarten des blutbildenden Systems (Leukämien etc.). Medulloblastomas, schwannomas, neuroendocrine tumors), gastrointestinal, pancreatic, ear, nose, throat (ENT), bladder, breast, bone, liver, kidney, prostate, uterine, ovarian, Pulmonary and thyroid tumors, lymphomas, as well as tumor types of the blood-forming system (leukemia, etc.).
9. Verfahren zur Behandlung und/oder Diagnose einer Tumorerkrankung, umfassend 9. A method for the treatment and / or diagnosis of a tumor disease, comprising
a. in Kontaktbringen einer Gewebe- oder Flüssigkeitsprobe eines zu  a. in contacting a tissue or fluid sample one to
untersuchenden Individuums mit einem Mittel, das die Expression oder Aktivität eines Tumor-assoziierten Antigens nachweist oder hemmt, wobei das Mittel oder Antigen eine Sequenz aufweist, die aus der Gruppe ausgewählt ist, bestehend aus:  examining individual with an agent that detects or inhibits the expression or activity of a tumor-associated antigen, wherein the agent or antigen has a sequence selected from the group consisting of:
(a) einer Nukleinsäure, die eine Nukleinsäuresequenz umfasst, die aus der (a) a nucleic acid comprising a nucleic acid sequence derived from the
Gruppe SEQ ID NO: 1 bis 36, einem Teil oder einem Derivat davon (b) einer Nukleinsäure, die unter stringenten Bedingungen mit der Nukleinsäure unter (a) hybridisiert,  Group SEQ ID NO: 1 to 36, a part or a derivative thereof (b) of a nucleic acid which hybridizes under stringent conditions with the nucleic acid under (a),
(c) einer Nukleinsäure, die in Bezug auf die Nukleinsäure unter (a) oder (b) degeneriert ist und (c) a nucleic acid which is degenerate with respect to the nucleic acid under (a) or (b), and
(d) einer Nukleinsäure, die zu der Nukleinsäure unter (a), (b) oder (c) (d) a nucleic acid which can be added to the nucleic acid under (a), (b) or (c)
komplementär ist,  is complementary,
b. Nachweis der Bindung des Antigens oder Mittels an Bestandteile der Probe, umfassend PCR, ELISA, Northern-, Southern-, Western-Blot, Immuncyto- und Immunhistologie, MRT, CT, PET, LC/MS. b. Detection of binding of the antigen or agent to components of the sample, including PCR, ELISA, Northern, Southern, Western blot, immunocytochemistry and immunohistology, MRI, CT, PET, LC / MS.
10. Verfahren zur Behandlung und/oder Diagnose eines Patienten, umfassend die Verabreichung einer pharmazeutischen Zusammensetzung gemäß einem der voranstehenden Ansprüche. A method of treating and / or diagnosing a patient comprising administering a pharmaceutical composition according to any one of the preceding claims.
PCT/DE2015/000077 2014-02-20 2015-02-19 Tumour-associated antigens and gene products in diagnosis and treatment WO2015124138A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102014002256.0A DE102014002256A1 (en) 2014-02-20 2014-02-20 Gene products for diagnosis and therapy
DE102014002256.0 2014-02-20
DE102014011258.6A DE102014011258A1 (en) 2014-07-30 2014-07-30 Tumor associated antigens for diagnosis and therapy
DE102014011258.6 2014-07-30

Publications (1)

Publication Number Publication Date
WO2015124138A1 true WO2015124138A1 (en) 2015-08-27

Family

ID=52779439

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2015/000077 WO2015124138A1 (en) 2014-02-20 2015-02-19 Tumour-associated antigens and gene products in diagnosis and treatment

Country Status (1)

Country Link
WO (1) WO2015124138A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002086071A2 (en) * 2001-04-20 2002-10-31 Ludwig Institute For Cancer Research Cancer-testis antigens
WO2004047863A2 (en) * 2002-11-22 2004-06-10 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002086071A2 (en) * 2001-04-20 2002-10-31 Ludwig Institute For Cancer Research Cancer-testis antigens
WO2004047863A2 (en) * 2002-11-22 2004-06-10 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof

Non-Patent Citations (55)

* Cited by examiner, † Cited by third party
Title
A. W. WHITEHURST ET AL: "Tumor Antigen Acrosin Binding Protein Normalizes Mitotic Spindle Function to Promote Cancer Cell Proliferation", CANCER RESEARCH, vol. 70, no. 19, 28 September 2010 (2010-09-28), pages 7652 - 7661, XP055193483, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-10-0840 *
AHMED D; EIDE PW; EILERTSEN IA; DANIELSEN SA; EKNAES M; HEKTOEN M; LIND GE; LOTHE RA: "Epigenetic and genetic features of 24 colon cancer cell lines", ONCOGENESIS, vol. 2, 2013, pages E71
BARTLETT JD; SIMMER JP: "Proteinases in developing dental enamel", CRIT REV ORAL BIOL MED., vol. 10, 1999, pages 425 - 4
BIANCHI E; DOE B; GOULDING D; WRIGHT GJ: "Juno is the egg Izumo receptor and is essential for mammalian fertilization", NATURE, vol. 508, 2014, pages 483 - 7
BIRNIE GD: "The HL60 cell line: a model system for studying human myeloid cell differentiation", BR J CANCER, vol. 9, 1988, pages 41 - 5
BU HF; ZUO XL; WANG X; ENSSLIN MA; KOTI V; HSUEH W; RAYMOND AS; SHUR BD; TAN XD: "Milk fat globule-EGF factor 8/lactadherin plays a crucial role in maintenance and repair of murine intestinal epithelium", J CLIN INVEST., vol. 117, 2007, pages 3673 - 83
CAMOLOTTO SA; RACCA AC; RIDANO ME; GENTI-RAIMONDI S; PANZETTA-DUTARI GM: "PSG gene expression is up-regulated by lysine acetylation involving histone and nonhistone proteins", PLOS ONE, vol. 8, no. 2, 2013, pages E55992
CARR DW; FUJITA A; STENTZ CL; LIBERTY GA; OLSON GE; NARUMIYA S: "Identification of sperm-specific proteins that interact with A-kinase anchoring proteins in a manner similar to the type 11 regulatory subunit of PKA", J BIOL CHEM., vol. 276, no. 20, 7 February 2001 (2001-02-07), pages 17332 - 8
CHEN ET AL., ANTICANCER RES., vol. 30, 2010, pages 4363
CHUNG JJ; NAVARRO B; RAPIVINSKY G; KRAPIVINSKY L; CLAPHAM DE: "A novel gene required for male fertility and functional CATSPER channel formation in spermatozoa", NAT COMMUN., vol. 2, 11 January 2011 (2011-01-11), pages 153
DARRAH C; DONELL ST; SHEPSTONE L; PORTER S; BROCKBANK SM; EDWARDS DR; PARKER AE; CLARK IM: "Expression profiling of metalloproteinases and their inhibitors in cartilage", ARTHRITIS RHEUM., vol. 50, 2004, pages 131 - 141
ELLERMAN DA; PEI J; GUPTA S; SNELL WJ; MYLES D; PRIMAKOFF P: "Izumo is part of a multiprotein family whose members form large complexes on mammalian sperm", MOL REPROD DEV., vol. 76, 2009, pages 1188 - 99
GAUTHIER MC; RACINE C; FERLAND C; FLAMAND N; CHAKIR J; TREMBLAY GM; LAVIOLETTE: "Expression of membrane type-4 matrix metalloproteinase (metalloproteinase-17) by human eosinophils", INT J BIOCHEM CELL BIOL., vol. 35, 2003, pages 1667 - 73
GIBBS GM; ROELANTS K; O'BRYAN MK: "The CAP superfamily: cysteine-rich secretory proteins, antigen 5, and pathogenesis-related 1 proteins--roles in reproduction, cancer, and immune defense", ENDOCR REV., vol. 29, 2008, pages 865 - 97
GOLDBERG GS; BECHBERGER JF; TAJIMA Y; MERRITT M; OMORI Y; GAWINOWICZ MA; NARAYANAN R; TAN Y; SANAI Y; YAMASAKI H: "Connexin43 suppresses MFG-E8 while inducing contact growth inhibition of glioma cells", CANCER RES., vol. 60, no. 21, 1 November 2000 (2000-11-01), pages 6018 - 26
GRANT GM; GIAMBERNARDI TA; GRANT AM; KLEBE RJ: "Overview of expression of ; matrix metalloproteinases (MMP-17, MMP-18, and MMP-20) in cultured human cells", MATRIX BIOL., vol. 18, 1999, pages 145 - 8
GRANT GM; GIAMBERNARDI TA; GRANT AM; KLEBE RJ: "Overview of expression of matrix metalloproteinases (MMP-1 7, MMP-18, and MMP-20) in cultured human cells", MATRIX BIOL, vol. 18, 1999, pages 145 - 8
GRUPP K; KOHL S; SIRMA H; SIMON R; STEURER S; BECKER A; ADAM M; IZBICKI J; SAUTER G; MINNER S: "Cysteine-rich secretory protein 3 overexpression is linked to a subset of P EN-deleted. ERG fusion-positive prostate cancers with early biochemical recurrence", MOD PATHOL., vol. 26, no. 5, 30 November 2012 (2012-11-30), pages 733 - 42
GUPTA SK; BHANDARI B; SHRESTHA A; BISWAL BK; PALANIAPPAN C; MALHOTRA SS; GUPTA N: "Mammalian zona pellucida glycoproteins: structure and function during fertilization", CELL TISSUE RES., vol. 349, 2012, pages 665 - 78
HERLYN H; ZISCHLER H: "The molecular evolution of sperm zonadhesin", INT J DEV BIOL., vol. 52, 2008, pages 781 - 90
INABA N; RENK T; WURSTER K; RAPP W; BOHN H: "Ectopic synthesis of pregnancy specific beta 1 - glycoprotein (SP1) and placental specific tissue proteins (PP5, PP10, PP11, PP12) in nontrophoblastic malignant tumours. Possible markers in oncology", KLIN WOCHENSCHR., vol. 58, 1980, pages 789 - 91
JAMSAI D; BIANCO DM; SMITH SJ; MERRINER DJ; LY-HUYNH JD; HERLIHY A; NIRANJAN B; GIBBS GM; O'BRYAN MK: "Characterization of gametogenetin 1 (GGN1) and its potential role in male fertility through the interaction with the ion channel regulator, cysteine-rich secretory protein 2 (CRISP2) in the sperm tail", REPRODUCTION, vol. 135, no. 6, June 2008 (2008-06-01), pages 751 - 9
KRÄTZSCHMAR J; HAENDLER B; EBERSPAECHER U; ROOSTERMAN D; DONNER P; SCHLEUNING WD: "The human cysteine-rich secretory protein (CRISP) family. Primary structure and tissue distribution of CRISP-1, CRISP-2 and CRISP-3", EUR J BIOCHEM., vol. 236, no. 3, 15 March 1996 (1996-03-15), pages 827 - 36
KUKLINSKI S; PESHEVA P; HEIMANN C; URSCHEL S; GLOOR S; GRAEBER S; HERZOG V; PIETSCH T; WIESTLER OD; PROBSTMEIER R: "Expression pattern of galectin-3 in neural tumor cell lines", J NEUROSCI RES., vol. 60, 2000, pages 45 - 57
LANDRY JJ; PYL PT; RAUSCH T; ZICHNER T; TEKKEDIL MM; STÜTZ AM; JAUCH A; AIYAR RS; PAU G; DELHOMME N: "The genomic and transcriptomic landscape of a HeLa cell line", G3 (BETHESDA, vol. 3, 2013, pages 1213 - 24
LEDIG S; RÖPKE A; WIEACKER P: "Copy number variants in premature ovarian failure and ovarian dysgenesis", SEX DEV., vol. 4, no. 4-5, 3 July 2010 (2010-07-03), pages 225 - 32
LEUNG C; SHAHEEN F; BERNATCHEZ P; HACKETT TL: "Expression of myoferlin in human airway epithelium and its role in cell adhesion and zonula occludens-1 expression", PLOS ONE, vol. 7, no. 7, 2012, pages E40478
LEUNG C; YU C; LIN MI; TOGNON C; BERNATCHEZ P: "Expression of myoferlin in human and murine carcinoma tumors: role in membrane repair; cell proliferation, and tumorigenesis", AM J PATHOL., vol. 182, 2013, pages 1900 - 9
LIU J; XIA J; CHO KH; CLAPHAM DE; REN D: "CatSperbeta, a novel transmembrane protein in the CatSper channel complex", J BIOL CHEM., vol. 282, no. 26, 3 May 2007 (2007-05-03), pages 18945 - 52
LIU Y; YANG X; GUO C; NIE P; LIU Y; MA J: "Essential role of MFG-E8 for phagocytic properties of microglial cells", PLOS ONE, vol. 8, no. 2, 2013, pages E55754
LOBLEY A; PIERRON V; REYNOLDS L; ALLEN L; MICHALOVICH D: "Identification of human and mouse CatSper3 and CatSper4 genes: characterisation of a common interaction domain and evidence for expression in testis", REPROD BIOL ENDOCRINO, vol. 1, 2003, pages 53
MURMANN T; CARRILLO-GARCIA C; VEIT N; COURTS C; GLASSMANN A; JANZEN V; MADEA B; REINARTZ M; HARZEN A; NOWAK M: "Staurosporine and extracellular matrix proteins mediate the differentiation of small cell lung carcinoma cells into a neuron-like phenotype", PLOSONE, 2014
NEILSON LI; SCHNEIDER PA; VAN DEERLIN, PG; KIRIAKIDOU M; DRISCOLL DA; PELLEGRINI MC; MILLINDER S; YAMAMOTO KK; FRENCH CK; STRAUSS: "cDNA cloning and characterization of a human sperm antigen (SPAG6) with homology to the product of the Chlamydomonas PF16 locus", GENOMICS, vol. 60, no. 3, 15 September 1999 (1999-09-15), pages 272 - 80
ONO T; KURASHIGE T; HARADA N; NOGUCHI Y; SAIKA T; NIIKAWA N; AOE M; NAKAMURA S; HIGASHI T; HIRAKI A: "Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen", PROC NATL ACAD SCI USA., vol. 98, no. 6, 13 March 2001 (2001-03-13), pages 3282 - 7
PAN CJ; CHAMBERLIN ME; WU SM; CHAN WY; CHOU JY: "Pregnancy-specific glycoprotein gene expression and the induction by 5-bromo-2'-deoxyuridine", BIOCHEMISTRY, vol. 33, no. 23, 14 June 1994 (1994-06-14), pages 7260 - 6
POSEY AD JR; PYTEL P; GARDIKIOTES K; DEMONBREUN AR; RAINEY M; GEORGE M; BAND H; MCNALLY EM: "Endocytic recycling proteins EHD1 and EHD2 interact with fer-1-like-5 (Fer1 L5) and mediate myoblast fusion", J BIOL CHEM., vol. 286, no. 9, 22 December 2010 (2010-12-22), pages 7379 - 88
QUILL TA; REN D; CLAPHAM DE; GARBERS DL: "A voltage-gated ion channei, expressed specifically in spermatozoa", PROC NATL ACAD SCI USA., vol. 98, no. 22, 23 October 2001 (2001-10-23), pages 12527 - 31
RAHMAN N ET AL.: "A novel treatment strategy for ovarian cancer based on immunization against zona pellucida protein (ZP) 3", FASEB J., vol. 26, 2012, pages 324 - 33
REN D; NAVARRO B; PEREZ G; JACKSON AC; HSU S; SHI Q; TILLY JL; CLAPHAM DE: "A sperm ion channel required for sperm motility and male fertility", NATURE, vol. 413, no. 6856, 11 October 2001 (2001-10-11), pages 603 - 9
SCHUG N; BRAIG C; ZIMMERMANN U; ENGEL J; WINTER H; RUTH P; BLIN N; PFISTER M; KALBACHER H; KNIPPER M: "Differential expression of otoferlin in brain, vestibuiar system, immature and mature cochlea of the rat", EUR J NEUROSCI., vol. 24, 2006, pages 3372 - 80
SCHWEPPE RE; KLOPPER JP; KORCH C; PUGAZHENTHI U; BENEZRA M; KNAUF JA; FAGIN JA; MARLOW LA; COPLAND JA; SMALLRIDGE RC: "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification", J CLIN ENDOCRINOL METAB., vol. 93, 2008, pages 4331 - 41
SEHRAWAT B; SRIDHARAN M; GHOSH S; ROBSON P; CASS CE; MACKEY JR; GREINER R; DAMARAJU S: "Potential novel candidate polymorphisms identified in genome-wide association study for breast cancer susceptibility", HUM GENET., vol. 130, no. 4, 19 March 2011 (2011-03-19), pages 529 - 37
SHABANOWITZ RB; O'RAND MG: "Molecular changes in the human zona pellucida associated with fertilization and human sperm-zona interactions", ANN N Y ACAD SCI., vol. 541, 1988, pages 621 - 32
SILI A K; ZAYAKIN P; KALNINA Z; IVANOVA L; MEISTERE I; ENDZELINS E; ABOLS A; STENGREVICS A; LEJA M; DUCENA K: "Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients", J IMMUNOTHER., vol. 34, no. 1, January 2011 (2011-01-01), pages 28 - 44
SILINA K; ZAYAKIN P; KALNINA Z; IVANOVA L; MEISTERE I; ENDZETINš E; ABOLS A; STENGREVICS A; LEJA M; DUCENA K: "Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients", J LMMUNOTHER., vol. 34, no. 1, January 2011 (2011-01-01), pages 28 - 44
SILINA K; ZAYAKIN P; KALNINA Z; IVANOVA L; MEISTERE; ENDZELINS E; ABOLS A; STENGREVICS A; LEJA M; DUCENA K: "Sperm-associated antigens as targets for cancer immunotherapy: expression pattem and humoral immune response in cancer patients", J IMMUNOTHER., vol. 34, no. 1, January 2011 (2011-01-01), pages 28 - 44
SPIEGELSTEIN O; EUDY JD; FINNELL RH: "Identification of two putative novel folate receptor genes in humans and mouse", GENE, vol. 258, 2000, pages 117 - 25
VÄÄNÄNEN A; SRINIVAS R; PARIKKA M; PALOSAARI H; BARTLETT JD; IWATA K; GRENMAN R; STENMAN UH; SORSA T; SALO T: "Expression an regulation of MMP-20 in human tongue carcinoma cells", J DENT RES., vol. 80, 2001, pages 1884 - 9
WANG H; LIU J; CHO KH; REN D: "A novel, single, transmembrane protein CATSPERG is associated with CATSPER1 channel protein", BIOL REPROD., vol. 81, no. 3, 10 June 2009 (2009-06-10), pages 539 - 44
WATANABE T; MIURA T; DEGAWA Y; FUJITA Y; INOUE M; KAWAGUCHI M; FURIHATA C: "Comparison of lung cancer cell lines representing four histopathological subtypes with gene expression profiling using quantitative real-time PCR", CANCER CELL INT., vol. 10, 2010, pages 2
YAN-HO CHENG ET AL: "Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis", SPERMATOGENESIS, vol. 1, no. 3, 1 July 2011 (2011-07-01), pages 209 - 220, XP055193493, DOI: 10.4161/spmg.1.3.17990 *
ZHANG J; WANG Y; ZHOU Y; CAO Z; HUANG P; LU B: "Yeast two-hybrid screens imply that GGNBP1, GGNBP2 and OAZ3 are potential interaction partners of testicular germ cell-specific protein GGN1", FEBS LETT., vol. 579, no. 2, 2005, pages 559 - 66
ZHANG XD; MIAO SY; WANG LF; LI Y; ZONG SD; YAN YC; KOIDE SS: "Human sperm membrane protein (hSMP-1): a developmental testis-specific component during germ cell differentiation", ARCH ANDROL., vol. 45, no. 3, November 2000 (2000-11-01), pages 239 - 46
ZHANG Z; JONES BH; TANG W; MOSS SB; WEI Z; HO C; POLLACK M; HOROWITZ E; BENNETT J; BAKER ME: "Dissecting the axoneme interactome: the mammalian orthologue of Chlamydomonas PF6 interacts with sperm-associated antigen 6, the mammalian' orthologue of Chlamydomonas PF16", MOL CELL PROTEOMICS, vol. 4, no. 7, 12 April 2005 (2005-04-12), pages 914 - 23
ZHAO Q; ZHOU Y; CAO Z; ZHU H; HUANG P; LU B: "Germ-cell specific protein gametogenetin protein 2 (GGN2), expression in the testis, and association with intracellular membrane", MOL REPROD DEV., vol. 72, no. 1, September 2005 (2005-09-01), pages 31 - 9

Similar Documents

Publication Publication Date Title
AU2020270508B2 (en) C/EBP alpha short activating RNA compositions and methods of use
AU2022201307B2 (en) Genetically modified cells, tissues, and organs for treating disease
AU2017267184B2 (en) Method for assessing a prognosis and predicting the response of patients with malignant diseases to immunotherapy
US6262333B1 (en) Human genes and gene expression products
KR101234281B1 (en) Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
US11103538B2 (en) Targeting epigenetic regulators using a bacterial delivery system
KR20190017985A (en) Genetically modified cells, tissues, and organs for treating diseases
KR20120082906A (en) Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
US20220389519A1 (en) Biomarkers predictive of anti-immune checkpoint response
KR20180093902A (en) Detection of fetal chromosomal anomalies using differentially methylated diene regions between fetuses and pregnant women
CN101258249A (en) Methods and reagents for the detection of melanoma
CN109863251A (en) To the method for squamous cell lung carcinoma subtype typing
KR20110015409A (en) Gene expression markers for inflammatory bowel disease
KR20200123450A (en) Prostate cancer detection and treatment method
JP2003304888A (en) Method for toxicity prediction of compound
WO2021183218A1 (en) Compositions and methods for modulating the interaction between ss18-ssx fusion oncoprotein and nucleosomes
KR20070099564A (en) Methods for assessing patients with acute myeloid leukemia
KR20040065524A (en) Method for assessing and treating leukemia
KR20140113021A (en) Biomarkers for confirmation of drug addiction and dependence
US20020137077A1 (en) Genes regulated in activated T cells
JP2003259877A (en) Marker for hepatic fibrosis disease and application of the same
KR20190126812A (en) Biomarkers for Disease Diagnosis
US20220265798A1 (en) Cancer vaccine compositions and methods for using same to prevent and/or treat cancer
CN100516876C (en) Methods for diagnosing RCC and other solid tumors
KR100877554B1 (en) A marker for predicting survival period of a hepatocellular carcinoma patient, a kit and microarray comprising the same and method for predicting survival period of a hepatocellular carcinoma patient using the marker

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15713128

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 15713128

Country of ref document: EP

Kind code of ref document: A1